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Abstract  
Introduction 
Dementia and pain are common in older adults. Clinical features of dementia such as 
communication difficulties may complicate the identification, assessment, and management 
of pain. This thesis therefore aimed to investigate pain identification, assessment, and 
management for community-dwelling people with dementia.  
Methods 
A systematic review was conducted to describe and synthesise existing evidence on pain 
assessment and pain treatment for community-dwelling people with dementia. The review 
then informed on a convergent mixed methods strategy; using quantitative and qualitative 
methods. Quantitative methods utilised the Clinical Practice Research Datalink (a UK wide 
database of primary care health records) to examine the incidence and prevalence of 
musculoskeletal consultations and analgesic prescriptions for people with dementia. 
Qualitative semi-structured interviews were conducted with people with dementia (n=8), 
family caregivers (n=9), general practitioners (n=9), and old age psychiatrists (n=5) to 
explore their perspectives of pain identification, assessment, and management for 
community-dwelling people with dementia. 
Results 
The systematic review identified 32 studies and highlighted a dearth of high quality evidence 
in community settings.  
With regards to pain identification and assessment, quantitative findings show that people 
with dementia had consistently lower incidence and prevalence of musculoskeletal 
consultations than older adults. Qualitative findings highlighted the unique challenges of pain 
identification and assessment; including the complexity of untangling the self-reported pain, 
and the importance of observing behavioural, psychological, and physical changes. 
Participants also reflected upon the importance of familiarity and the use of pain assessment 
tools to identify and assess pain.  
Quantitative findings exploring pain management show that people with dementia had 
consistently lower prevalence of analgesic prescription compared to older adults, with the 
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discrepancy between people with and without dementia increasing over time. Qualitative 
findings revealed many potential explanations for this discrepancy, with concerns relating to 
side effects, illness burden, and treatment burden. Alternatively, many participants supported 
the use of non-drug strategies to manage pain. Regardless of the pain management 
strategy, family caregivers were often responsible to manage pain in the community. 
Conclusion 
This thesis provides a novel and in-depth investigation of pain identification, assessment, 
and management for community-dwelling people with dementia by integrating quantitative 
and qualitative data. Implications for practice, policy, and future research are described.
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1 Chapter One: Introduction 
1.1 Dementia 
The word ‘dementia’ describes a syndrome or common set of symptoms that may include 
memory loss and difficulties with thinking, problem-solving or language (Harwood & 
McCulloch, 2017). It is an ‘umbrella’ term that encompasses over 200 neurodegenerative 
conditions, usually of a chronic or progressive nature (Brooker & Lillyman, 2013).  
The most common type of dementia is Alzheimer’s disease (AD) which accounts for 
approximately one half of all people diagnosed, followed by vascular dementia, and dementia 
with Lewy bodies (Livingston et al., 2017). Importantly, mixed dementia with features of more 
than one cause is also common (Livingston et al., 2017).  
1.1.1 Dementia: a paradigm shift 
The conceptualisation of dementia was often based upon biomedical models of disease and 
illness due to the neurological changes associated with dementia (Kitwood, 1997). The 
biomedical model or the ‘standard paradigm’ (as named by Kitwood, 1997) assumes a linear 
causal relationship between neuropathology and dementia. The neurological understanding 
of dementia led to a focus upon ‘treatments’ and a ‘cure’ for the dementia patient. In more 
recent years, however, the biomedical model has been criticised for having an oversimplified 
view of dementia. A focus upon neuropathology in isolation has neglected the highly 
individual, subjective and variable nature of dementia. Additionally, the standard paradigm 
has failed to provide insights into care for people with dementia. Ultimately, the biomedical 
model has fed into the deterministic view that dementia is the ‘death that leaves the body 
behind’ (Kitwood, 1997, p. 37).  
In relatively recent years, there has been a shift away from the ‘standard paradigm’ to an 
Enriched Model of dementia (Brooker, 2007). Dementia has been reconceptualised as a 
subjective and individual experience greatly influenced by a number of factors, including 
neurological impairment, but also physical health, personality, and the social environment. 
The conceptual lens of dementia has widened to consider the unique identity of the person 
with dementia; often referred to as ‘personhood’. Kitwood (1997) defined personhood as ‘a 
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position or social relationship that is bestowed on one human being by ‘others’, in the context 
of relationship and social being. It implies recognition, respect and trust’ (p. 8). Person-
centred care is important to support personhood for people with dementia in the face of 
cognitive decline. Person-centred care encompasses four key elements, known as the VIPS 
framework (Brooker, 2004): 
 Valuing people with dementia and people who care for them (V) 
 Treating people with dementia as individuals (I) 
 Looking at the world from the perspective of the person with dementia (P) 
 A positive social environment in which the person living with dementia can 
experience relative wellbeing (S) 
The concepts of ‘personhood’ and person-centred care have placed the person with 
dementia at ‘centre stage’; shifting the focus from the person with dementia to the person 
with dementia. 
1.1.2 Dementia as a holistic concept 
In this thesis, I use the term dementia in a broad and descriptive way, acknowledging the 
‘whole person’ (rather than just the brain) with a clinically identified condition. By using 
‘dementia’ as a holistic concept, the ‘whole person’ and all dementia conditions can be 
observed in their entirety. 
1.2 Symptoms of dementia 
1.2.1 Cognitive symptoms 
Cognitive symptoms such memory loss and difficulties with thinking, problem-solving, 
orientation or language are clinical hallmark features of dementia (Herr, Bjoro & Decker, 
2006a). Cognitive symptoms are a primary disease characteristic associated with dementia, 
however such symptoms are not clinical features of dementia independently, and may 
present in a variety of disease profiles.  
1.2.2 Activities of Daily Living 
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One of the most common symptoms of dementia is the difficulty, or inability to complete 
activities of daily living, such as organising finances, medication management, washing, and 
eating (Giebel, Sutcliffe & Challis, 2015). 
1.2.3 Behavioural and Psychological Symptoms 
Behavioural and psychological symptoms of dementia (BPSD; or otherwise known as 
neuropsychiatric symptoms, Cummings, 1994; Cerejeira, Lagarto & Mukaetova-Ladinska, 
2012) are defined as ‘signs and symptoms of disturbed perception, thought content, mood, or 
behavior that frequently occur in patients with dementia’ (Finkel et al., 1996, p. 498). In other 
words, BPSD is an umbrella term that encompasses many non-cognitive symptoms 
associated with dementia, such as aggression, ‘wandering’, sexual disinhibition, agitation, 
and psychological symptoms such as anxiety, depression, and delusions (Jennings et al., 
2018a), often categorised into three main syndromes: agitation, psychosis, and mood 
disorders (Cohen-Mansfield & Libin, 2004). The aetiology of BPSD is complex and poorly 
understood. It is often unclear if behavioural or psychological symptoms can be directly 
attributed as a symptom of dementia, or if behavioural and psychological symptoms are an 
expression of an alternative underlying cause (Flo, Gulla & Husebo, 2014). The perspective 
that BPSD may be an expression of an unmet need is discussed in Section 1.14. 
Epidemiological evidence suggests that the point prevalence of BPSD ranges from 60% to 
80%, with a cumulative risk that 90% of people with dementia experience one or more 
clinically significant behavioural and psychological symptom throughout the course of their 
condition (Norton, Allen, Snow, Hardin & Burgio, 2010; Steinberg et al., 2008; LoGiudice, 
2002; Kales, Gitlin & Lyketsos, 2015). BPSD often becomes more severe as dementia 
progresses (Kazui et al., 2016), increasing the rate of nursing home admission, longer 
hospital stays, and decreased quality of life for the person with dementia (Lichtner et al., 
2014; Kales et al., 2015; Forester & Vahia, 2019; Ballard, Corbett, Chitramohan & Aarsland, 
2009). In addition, a breadth of literature highlights the negative impact of BPSD upon family 
caregivers and care providers; including increased distress (Feast, Orrell, Russell, 
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Charlesworth & Moniz‐Cook, 2016), increased burden (Rosdinom, Zarina, Zanariah, Marhani 
& Suzaily, 2013), and decreased quality of life (Feast et al., 2016). 
1.3 Preventable, modifiable yet incurable 
Pharmacological treatments are available to slow the disease progression for certain 
dementia conditions (e.g. cholinesterase inhibitors including donepezil, rivastigmine and 
galantamine). Dementia as a condition has been typically considered as neither preventable 
nor treatable, however, a recent Lancet commission by Livingston et al. (2017) identified a 
number of preventable or modifiable risk factors for dementia. The research identified that an 
increase in childhood education and exercise, maintaining social engagements, reducing or 
stopping smoking, and management of hearing loss, depression, diabetes, hypertension, and 
obesity could all contribute to the prevention or delay of dementia (Livingston et al., 2017). 
These preventable or modifiable risk factors have the potential to prevent one-third of 
dementia cases (Livingston et al., 2017). Despite necessary progression in our 
understanding about preventable and modifiable risk factors, age remains the largest risk 
factor for dementia, which is not modifiable nor preventable.  
1.4 Epidemiology of dementia 
1.4.1 Incidence of dementia 
Dementia is often perceived as the greatest global challenge for health and social care in the 
21st century (Livingston et al., 2017). The incidence of dementia increases with age, from 3.1 
per 1000 person-years at age 60 to 64, to 175 per 1000 person-years at age 95+ (World 
Health Organisation [WHO], 2015). In accordance with these findings, previous studies 
suggest a higher incidence of dementia in female populations due to longer life expectancy 
increasing the likelihood that females reach the typical age of dementia onset (Mielke, 
Vemuri & Rocca, 2014; Hebert, Scherr, McCann, Beckett & Evans, 2001). Recent evidence, 
however, suggests that the incidence of dementia is beginning to fall in high-income 
countries (Prince et al., 2014; 2016; Livingston et al., 2017). The lowering incidence in these 
settings seems to be associated with the preventable and modifiable factors outlined 
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previously (see Section 1.3), such as higher education standards, activity levels, and 
improved cardiovascular health (Grasset et al., 2016; Livingston et al., 2017).  
1.4.2 Prevalence of dementia 
Despite the incidence of dementia lowering in high-income countries, the world’s population 
is ageing. Dementia is not an inevitable part of ageing; however, ageing is the largest risk 
factor for dementia. This means that the prevalence of dementia continues to increase, 
irrespective of the lowering dementia incidence in high-income countries (Livingston et al., 
2017; Prince et al., 2016). Approximately 47 million people were living with dementia 
worldwide in 2015, with 850,000 people living with dementia in the United Kingdom (UK), 
equating to 1.3% of the entire UK population. The prevalence of dementia in the UK rises to 
7.1% for people over the age of 65 (Prince et al., 2014). Based on the current estimated 
prevalence rate, the amount of people with dementia in the UK will rise to over one million by 
2025, and over two million by 2051 (Prince et al., 2014).  
1.5 Progression of dementia symptoms 
Symptoms of dementia are typically persistent and progressive. This means that, generally 
speaking, cognitive ability gradually and progressively deteriorates over time with the 
condition (Duong, Patel & Chang, 2017). Many cognitive screening instruments have been 
developed to assess the severity of cognitive impairment for people with dementia (Ismail, 
Rajji & Shulman, 2009), including The Mini Mental State Examination (MMSE; Folstein, 
Folstein & McHigh, 1975), Montreal Cognitive Assessment Scale (MoCA; Nasreddine et al., 
2005), Mini-Cog, the General Practitioner Assessment of Cognition (GPCOG), and the 
Memory Impairment Screen (MIS). Importantly, each of these tools in isolation are not 
diagnostic tools for dementia (Tombaugh & McIntyre, 1992). 
The MMSE remains the best known and most commonly used brief cognitive screening tool 
to determine an overall measure of cognitive impairment in healthcare and research settings 
(Ismail et al., 2009; Arevalo-Rodriguez et al., 2015). Therefore, an MMSE score is frequently 
used in the following chapters to depict the severity of cognitive impairment for people with 
dementia. The MMSE has a maximum score of 30 (Tombaugh & McIntyre, 1992). Research 
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evidence has developed a range of standard ‘cut-points’ to classify and conceptualise the 
severity of cognitive impairment (a score of 24 to 30 means no cognitive impairment; 18 to 23 
means mild cognitive impairment; and 0 to 17 denoting severe cognitive impairment; 
Tombaugh & McIntyre, 1992). Although there are limitations to classifying people with 
dementia as ‘mild’, ‘moderate’ or ‘severe’ based upon a cognitive screening test (e.g. buying 
into neurological determinism; Kitwood, 1997), classification based on severity of the 
condition can be useful for clinical and research purposes. 
1.6 Cost of dementia   
Dementia is recognised as a ‘public health priority’ (WHO, 2017) and has received extensive 
research interest worldwide. Despite research, there is currently no cure (see Section 1.3), 
therefore dementia continues to have a significant economic impact (Annear, Tierney, 
Vickers & Palmer, 2016). The overall annual economic impact of dementia in the UK is 
approximately £25 billion (Prince et al., 2014; Wittenberg et al., 2019), including social care, 
health care costs, and contributed work from unpaid caregivers. The average cost of 
dementia is estimated at £32,250 per person per year (Prince et al., 2014), with the cost of 
dementia in England rising from mild, to moderate, to severe dementia (£24,400, £27,450, 
and £46,050, respectively; Wittenberg et al., 2019). The Alzheimer’s Society Dementia UK 
report found that supporting people with dementia to continue living in the community (thus 
reducing the rate of preventable hospital admissions and early care home admission) would 
reduce the economic cost of dementia upon society (Prince et al., 2014). 
1.7 Dementia in the community 
Community-dwelling is defined as people with dementia living in private residences or non-
nursing home settings (Hunt et al., 2015). Community-dwelling people with dementia may 
live in their own home alone, with family members, in an assisted living facility, retirement 
community, or residential home. Two-thirds of people with dementia live in the community 
(Prince et al., 2014; Knapp et al., 2007; Jones et al., 2009; Magaziner et al., 2000). Of this 
population, two-thirds live with a family caregiver (often a spouse; Banerjee, 2009), with one-
third living alone (Lakey, Chandaria, Quince, Kane, & Saunders, 2012). An estimated 
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670,000 people act as primary caregivers for people with dementia in the UK, estimated to 
save the state £8 billion per year (Lakey et al., 2012). In addition to the importance of family 
caregivers, general practitioners (GPs) play an important role as the first point of contact for 
ongoing care and support (Jennings, Linehan & Foley, 2018b; Lakey et al., 2012), especially 
for people living in the community whom (unlike nursing home residents) may not have 
regular contact with qualified healthcare professionals. Remaining in the community is 
important to people with dementia (Alzheimer’s Society, 2011; Lakey et al., 2012). Research 
and care that continues to support people with dementia to live independently in their own 
homes is essential to avoid preventable or early nursing home admission (Alzheimer’s 
Society, 2011).  
1.8 The concept of pain 
Pain is a complex and multi-factorial symptom derived from sensory stimuli or neurologic 
injury and modified by individual memory, expectations, and emotions (Corbett et al., 2014; 
American Geriatric Society [AGS] Panel, 2002). The task force on taxonomy of the 
International Association for the Study of Pain (IASP) defined pain as: 
an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage  
Merskey and Bogduk, 1994, p. 210  
The accompanying notes for this definition highlight the subjectivity of pain and that ‘the 
inability to communicate verbally does not negate the possibility that an individual is 
experiencing pain and is in need of appropriate pain-relieving treatment’ (Merskey & Bogduk, 
1994, p. 210). However, researchers have continued to criticise the definition, as the 
definition is often presented without the accompanying notes (Kaasalainen, 2007). The 
definition in isolation fails to illuminate the subjectivity of pain and places too much emphasis 
upon the ‘description’ of pain, when many populations may be unable to verbally describe 
their subjective experience. An alternative definition of pain is:  
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whatever the experiencing person says it is, existing whenever the experiencing 
person says it does  
McCaffery, 1968 p. 95 
This definition acknowledges the subjectivity of pain, however alike to other definitions does 
not consider the pain experienced by people with dementia that may have difficulty verbally 
communicating their pain experience. To acknowledge the limitations of previous definitions 
of pain, a recent definition describes pain as:  
an unpleasant subjective experience that can be communicated to others either through 
self-report when possible or through a set of pain-related behaviours  
Kaasalainen, 2007, p. 7 
This definition provides a basis to understand the subjective pain experienced by people with 
dementia who may not have the ability to verbally communicate, or self-report their pain, 
illuminating the importance of non-verbal means of pain communication.  
1.9 Theories of pain 
Many theoretical frameworks have been proposed to understand the physiological basis of 
pain (Moayedi & David, 2013). For many years our understanding of pain was based upon 
René Descartes’ description of the pain system. Descartes described pain as a biomedical 
concept; the experience of pain is produced by a direct, straight-through transmission system 
from injured tissues in the body to a pain centre in the brain (Melzack, 1996). The first theory 
to move away from the biomedical model was the Gate Control Theory (Melzack & Wall, 
1965). This theory proposed that a mechanism or ‘gate’ in the spinal cord inhibits or 
facilitates the transmission of pain. Importantly, this theory illuminated the modulation of 
inputs in the spinal dorsal horn and the dynamic role of the brain in pain processes. When 
nociceptive information reaches a threshold it ‘opens the gate’ and activates pathways that 
lead to the experience of pain. Since the development of the Gate Control Theory, many 
limitations have been noted, including the inability to identify a ‘gate’, and the limits of the 
theory to explain painful conditions such as phantom limb pain for people with paraplegia 
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who do not have a connection between the brain and the spinal gate, yet continue to 
experience pain (Melzack 1996). Despite limitations, the Gate Control Theory had a major 
influence on the direction of pain research (Sufka & Price, 2002). Importantly, the Gate 
Control Theory moved away from the traditional biomedical perspective that had dominated 
our understanding of pain, viewing pain as a perception rather than a sensation, and 
acknowledging individuals’ active rather than passive influence on pain experience. In recent 
years, research has identified the importance of biopsychosocial factors in pain; with pain for 
people with dementia being conceptualised as an interaction between predisposing, lifelong, 
and current biological, psychological, and social factors (Gagliese, Gauthier, Narain & 
Freedman, 2018).  
1.10 Persistent and acute pain 
The terms persistent and chronic pain are often used interchangeably. Recent guidance, 
however, recommends the use of persistent pain due to patients’ and healthcare 
professionals’ negative connotations towards chronic pain (AGS Panel, 2009). The term 
chronic pain is associated with negative images and stereotypes that may alter perspectives 
towards treatment options (AGS Panel, 2009). In accordance with this guidance, this thesis 
uses the term persistent pain from this point forwards. 
There remains no universally accepted definition for persistent pain (Reid, Eccleston & 
Pillemer, 2015), with researchers and healthcare professionals debating the most 
appropriate duration of time to classify pain as being persistent in nature. Definitions classify 
pain as persistent if it lasts longer than 3 months, 6 months, or more (AGS Panel, 2009; 
Schofield, 2018). Other researchers have argued that the time frame is only one element of 
persistent pain, and definitions need to take into account the physical, psychological, social 
and spiritual dimensions of pain (Ong, Dunn & Croft, 2006).  
Alternatively, acute pain is typically associated with trauma or injury (Schofield, 2018). Older 
adults frequently undergo medical or surgical treatments that result in acute pain (Ardey et 
al., 2003).  
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1.11 Nociceptive pain and neuropathic pain 
Nociceptive pain describes pain in a normally functioning somatosensory nervous system 
(Merskey & Bogduk, 1994). Nociceptive pain is commonly derived from the stimulation of 
pain receptors caused by actual tissue damage or potentially tissue-damaging stimuli 
(Nicholson, 2006). Alternatively, neuropathic pain syndromes develop after a lesion or 
disease affecting the somatosensory nervous system (Finnerup et al., 2016; Treede et al., 
2008). Neuropathic pain can arise from a variety of conditions that affect the peripheral 
and/or central nervous system (Nicholson, 2006). Painful neuropathic conditions include 
diabetic neuropathy, herpes zoster (shingles), and post-stroke central or thalamic pain. 
People experiencing neuropathic pain may describe their symptoms as spontaneous 
electrical attack-like pain, pins and needles, or a loss a function (Finnerup et al., 2016; Baron 
et al., 2017). Nociceptive and neuropathic pain often co-exist, meaning that the presence of 
one type of pain does not mean the absence of the other type of pain.  
1.12 Epidemiology of pain 
1.12.1 Incidence of pain 
The incidence of pain for older adults is yet to be widely investigated (Shi, Hooten, Roberts, 
& Warner, 2010), with a gap in the evidence examining the incidence of pain for people with 
dementia. The minimal evidence suggests that the annual incidence of pain for older adults 
ranged from 3.3% to 16% (Elliott, Smith, Hannaford, Smith & Chambers, 2002; Thomas, 
Mottram, Peat, Wilkie & Croft, 2007; Jordan, Thomas, Peat, Wilkie & Croft, 2008; Magni et 
al., 1993). Research investigating the incidence of pain found that 4.7 older adults per 100-
person years reported pain (Shi et al., 2010).  
1.12.2 Prevalence of pain 
Age is a risk factor for pain, with prevalence estimates suggesting that half of older adults 
living in the community experience pain (AGS Panel, 2002; Corbett et al., 2012; Donald & 
Foy, 2004; Jakobsson Klevsgård, Westergren, & Hallberg, 2003; Herr, 2002; Patel, Guralnik, 
Dansie & Turk, 2014; Zarit, Griffiths & Berg, 2004). The prevalence of pain increases to 
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approximately 80% in nursing home settings (Hadjistavropoulos, Fitzgerald, & Marchildon, 
2010). 
In addition to pain, age is also a common risk factor for dementia (Reid et al., 2015; Malec & 
Shega, 2015). This means that as people get older, their risk of dementia and pain 
increases. Many older adults with dementia are therefore likely to concurrently have a painful 
condition (Frampton, 2003). Cross-sectional studies suggest that the point prevalence rate of 
pain for people with dementia living in the community ranges from 16.7% to 87.5% (Jensen-
Dahm et al., 2012; Krulewitch et al., 2000; Gilmartin et al., 2015; Barry, Parsons, Passmore, 
& Hughes, 2016; Shega, Hougham, Stocking, Cox-Hayley & Sachs, 2004; Mäntyselkä, 
Hartikainen, Louhivuori-Laako, & Sulkava, 2004). The prevalence of pain for people with 
dementia living in nursing homes is similar to community estimates and ranges from 17% to 
83% (Ferrell, Ferrell & Rivera, 1995; McClean & Higginbotham, 2002; Lin, Lum, Mehr & 
Kane, 2006; Parmelee, Smithy & Katz, 1993; Fisher et al., 2002; Sengupta, Bercovitz, & 
Harris-kojetin, 2010; Barry, Parsons, Passmore, & Hughes, 2015; Kooten et al., 2017; Chen 
et al., 2010). Studies estimating the prevalence of pain for people with dementia used a 
variety of pain assessment methods; including but not limited to self-report, staff report 
(observation or documentation in medical records), family caregiver report, or a combination 
of methods. The variety of methods used to estimate the prevalence of pain, in addition to 
the heterogeneous settings and sample characteristics are likely to contribute to the wide 
prevalence estimates (Chen, Lin & Watson, 2010; Bjorkman et al., 2008). A critique of the 
methods used to assess pain are discussed in Section 2.3. 
Musculoskeletal conditions, such as osteoarthritis, lower back pain, and pain from healed 
bones and fractures are the most common cause of persistent pain for people with dementia 
(and older adults generally) (Schofield, 2018; Herr, Coyne, McCaffery, Manworren & Merkel, 
2011). The annual prevalence of musculoskeletal consultation within primary care ranged 
from 33% to 41% for people aged over 65 years old in the UK (Jordan et al., 2010), making 
musculoskeletal pain one of the most common reasons for people to access healthcare 
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services (Briggs et al., 2016), and the leading cause of disability worldwide (Blyth & Noguchi, 
2017). 
1.13 Neurodegeneration and pain  
A number of experimental studies have investigated if the neurodegenerative changes 
associated with dementia implicate the experience of pain. This exploration is based upon 
the idea that the neurodegenerative changes may affect pain processing pathways 
(depending upon the type, extent, and location of the lesions). A systematic review and 
meta-analysis conducted by Stubbs et al. (2016) examined if the sensory aspect of pain was 
altered for people with dementia. Thirteen studies were identified, including 256 people with 
dementia and 260 healthy controls. Results of the meta-analysis found no significant 
difference in pain threshold, pain tolerance, pain intensity ratings, or heart rate response to 
pain. In fact, the review by Stubbs et al. identified that people with dementia had significantly 
raised facial expression scores in response to pain compared with healthy controls. This 
finding is in accordance with other studies that suggest a potential amplified experience of 
pain for people with dementia (De Tommaso et al., 2016; De Tommaso, Kunz, & Valeriani, 
2017; Kunz, Mylius, Scharmann, Schepelman & Lautenbacher, 2009; Lautenbacher & Kunz, 
2017). Aside from the sensory component of pain, research investigating the affective and 
cognitive components of pain suggest subtle changes in the pain experience for people with 
dementia compared to people without dementia, however evidence is limited (Gagliese et al., 
2018).  
At present, many experimental studies continue to use self-report as an indication of 
tolerance and threshold, despite the unsuitability of this method for some people with 
dementia (see Section 2.3.1). Additionally, most experimental evidence to date include only a 
small sample of people with dementia, many of which have mild-to-moderate cognitive 
impairment and therefore may not be representative of the full range of condition severity. 
Furthermore, as pain processing may be implicated by neurodegenerative changes in the 
brain (in which the anatomical location is different depending upon the subtype of dementia) 
each dementia subtype may affect the pain experience differently (Álvaro González et al., 
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2015; De Tommaso et al., 2017), however at present, such experimental evidence is largely 
limited to people with AD (Defrin et al., 2015).  
On the basis of the current experimental findings, there is ‘no convincing evidence to suggest 
that the brain deterioration that occurs with dementia leads to clinically significant reductions 
in pain intensity’ (Hadjistavropoulos, Fitzgerald & Marchildon, 2010, p. 105). In fact, recent 
research suggests that pain perception may be enhanced for people with dementia (De 
Tommaso et al., 2017; Stubbs et al., 2016).  
1.14 Pain as an unmet need  
Earlier in this chapter, BPSD was introduced as a symptom of dementia (alongside cognitive 
symptoms, and difficulties performing activities of daily living; see Section 1.2.3). The 
neurological cause of dementia meant that the understanding of behavioural and 
psychological changes were largely based upon biomedical models of disease and illness 
(see Section 1.1.1; Kitwood, 1997). Therefore, behavioural and psychological changes were 
conceptualised and researched as direct ‘symptoms’ of dementia.  
Contrary to the biomedical model, the unmet needs model (Algase et al., 1996; Cohen-
Mansfield, 2000) provides an alternate view of behavioural and psychological changes for 
people with dementia. This model postulates that so-called ‘challenging behaviour’ is a 
response to the individual social and/or physical needs of the person with dementia. In other 
words, ‘challenging’ or ‘problematic’ behaviours are attempts for the person with dementia to 
communicate distress when unmet needs arise (Kovach, Noonan, Schlidt & Wells, 2005, 
p.135). This position is aligned to a person-centred framework of care in which all ‘behaviour 
has meaning’ (Brooker, 2007, p. 16) and that ‘problem behaviours’ should be seen primarily 
as attempts to communicate. Common unmet needs that may lead to ‘challenging behaviour’ 
include pain, boredom, fatigue, a noisy environment, or uncomfortable room temperature 
(Algase et al., 1996; Cohen-Mansfield, 2000; Kovach et al., 2005). The unmet needs model 
therefore shifts the reference from the person with dementia; in which ‘challenging behaviour’ 
is attributed to neuropathological changes associated with dementia (biomedical approach), 
to the person with dementia; exploring the individual needs, social environment, and 
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perspective of the person with dementia to understand why their behaviour may have 
become ‘challenging’. This shift allows focus upon the person rather than the illness 
(Kitwood, 1997).  
One of the most popular unmet needs models is the need-driven, dementia-compromised 
behavior model (Kovach et al., 2005). This model highlights the cascading nature of unmet 
needs when the behavioural or psychological symptom is misinterpreted as a symptom of 
dementia (Kovach et al., 2005). A good example of this cascading effect is the presence of 
pain. Pain results in a need for pain relief (e.g. analgesic medication), which may result in 
agitation and ‘wandering’ if the person with dementia struggles to verbally express their pain. 
If the need for pain relief remains unmet, the primary BPSD (in this case, ‘wandering’) may 
continue or worsen, with the potential for negative outcomes (e.g. falling). The cascading 
impact continues, with the fall resulting in secondary BPSD (e.g. physical aggression, 
increased agitation).  
A review of the literature investigated the link between pain and BPSD, concluding that there 
is an association between unmet pain and BPSD in people with dementia (Flo, Gulla & 
Husebo, 2014). A number of studies have examined analgesic medication and the effects on 
BPSD (Blytt, Bjorvatn, Husebo & Flo, 2017; Husebo, Ballard, Sandvik, Nilsen & Aarsland, 
2011b; Husebo, Ballard, Fritze, Sandvik & Aarsland, 2014a; Manfredi et al., 2003; Cipher, 
Clifford, & Roper, 2007; Chibnall, Tait, Harman & Luebbert, 2005; Habiger, Flo, Achterberg & 
Husebo, 2016; Husebo, Ballard, Cohen-Mansfield, Seifert & Aarsland, 2014b), with the logic 
that if the unmet need was indeed pain, the initiation of analgesic medication (thus ‘meeting’ 
the need) would reduce BPSD. Two systematic reviews (Husebo, Ballard & Aarsland, 2011a; 
Pieper et al., 2013) and a perspective review (Tampi, Hassell, Pallavi & Tampi, 2017) 
concluded from the available evidence that analgesic medication appears to reduce BPSD. 
Whilst these findings show a promising link between BPSD and pain, the actual testing of 
this link to assess the benefit in the reduction of BPSD by the administration of analgesia has 
been restricted to pilot randomised control trials conducted solely within formal nursing home 
settings, with small sample sizes, and short duration follow up times (Bjorvatn, Husebo, & 
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Flo, 2017; 2018; Blytt, Husebo, Flo, & Bjorvatn, 2018). The findings of these trials however 
do show a beneficial effect, again reinforcing the link between pain and BPSD.  
Despite evidence of the link between BPSD and pain (and BPSD and other drivers) and the 
wider ‘unmet’ needs hypothesis, the current method often used to manage BPSD is the 
administration of anti-psychotics (Banerjee, 2009). Such treatment approaches target BPSD 
as a direct symptom of dementia (in line with a biomedical approach) rather than 
investigating the underlying cause of the presentation. Estimates suggest that only 20% of 
people with dementia prescribed anti-psychotics for BPSD derived some benefit from the 
treatment (Banerjee, 2009). Additionally, anti-psychotics increase the risk of cerebrovascular 
adverse events and avoidable mortality (Kales et al., 2012; Forester & Vahia, 2019; 
Banerjee, 2009). Given the inefficacy and risks associated with anti-psychotic medication for 
BPSD, several UK policies and guidance documents have called for the reduction of 
inappropriate antipsychotic prescription for people with dementia (Department of Health, 
2015; Napp Pharmaceuticals, 2014; Banerjee, 2009). Instead it is proposed that the 
underlying driver of the behavioural change should be investigated first (e.g. pain) in order to 
target appropriate treatments (Livingston et al., 2017). By identifying the cause of BPSD, 
effective treatments have the potential to manage BPSD, in turn reducing avoidable 
admissions to hospitals and nursing homes, allowing the person with dementia to continue 
living in the community (Department of Health, 2015). 
1.15 Impact of pain 
Pain has a detrimental impact for older adults with and without dementia (Reid et al., 2015). 
Pain is associated with an occurrence of falls (Stubbs et al., 2014; Crowe et al., 2017a), 
frailty (Saraiva et al., 2018), changes in mood (e.g. depression and anxiety) (AGS Panel, 
2002), increased emergency department visits (Hunt et al., 2018), delirium (Feast et al., 
2018), loss of ability to perform activities of daily living (Shega et al., 2010a), decreased 
quality of life (Rostad et al., 2017) and mortality (Rajkumar et al., 2017). In addition to these 
various negative implications of pain, research also suggests unique implications for people 
with dementia, with pain exacerbating cognitive impairment (Cook, Niven & Downs, 1999; 
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Buffum, Sands, Miaskowski, Brod & Washburn, 2004), and behavioural and psychological 
symptoms (Flo, Gulla & Husebo, 2014; see Section 1.14). The negative effects of pain 
extend beyond the person with dementia to disrupt family and social relationships, with a 
significant economic burden on society (Reid et al., 2015).  
1.16 The structure of the thesis 
This thesis is organised into ten chapters. The following chapter, Chapter Two, provides an 
overview of the literature into pain identification, assessment, and treatment for people with 
dementia, drawing upon the large body of evidence based from nursing homes. In Chapter 
Three, a systematic review was conducted to examine pain assessment and pain treatment 
for people with dementia who reside in the community. The literature review (Chapter Two) 
and the systematic review (Chapter Three) were conducted with a differing purpose. The 
literature review takes a more flexible and broad stance (due to the availability of pre-existing 
evidence) to allow key debates in the literature to be examined (Greenhalgh, Thorne & 
Malterud, 2018). The systematic review of Chapter Three builds upon the findings of the 
literature review but narrowing the focus to findings reported on people with dementia living 
in the community. Chapter Four provides a brief overview of the rationale, aim and research 
objectives of this thesis, reflecting on the gaps in evidence identified from the literature 
review (Chapter Two) and the systematic review (Chapter Three).  
Chapter Five provides an overview of the convergent mixed methods approach for this 
thesis; including the theoretical underpinning of critical realism. The quantitative and 
qualitative methods chosen to encapsulate the mixed methods design are described in 
Chapter Six. A descriptive overview of the populations (quantitative) and people (qualitative) 
is given in Chapter Seven to provide a contextual foundation prior to the findings. 
The findings are presented in Chapters Eight and Nine. Each findings chapter is based upon 
a conceptually distinct area. Chapter Eight draws upon quantitative and qualitative findings to 
investigate pain identification and pain assessment for community-dwelling people with 
dementia. Chapter Nine also draws upon quantitative and qualitative findings to investigate 
the management of pain for community-dwelling people with dementia. 
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The final chapter of this thesis, Chapter Ten, will summarise the thesis overall by providing 
an integrated summary of the quantitative and qualitative findings for each research 
objective, while reflecting upon findings from the existing literature. The thesis concludes by 
highlighting the implications of the research and suggestions for future research. 
1.17 The style of the thesis  
Traditionally, a formal, third person style is used to report scientific results. The third person 
allows scientific research to remain ‘objective’ rather than personal, moving the emphasis to 
the arguments made by the author, rather than the author themselves (Gillett, Hammond & 
Martala, 2013). The use of the third person may, however, ‘silence’ the author (Gilgun, 
2005), minimising the extent that the researcher influenced, interpreted, and made decisions 
about the direction and the conclusions of the research (Webb, 1992). In accordance with my 
theoretical approach (see Section 5.3.2), I have decided to take a balanced approach 
between third and first person. The use of both styles acknowledges my presence as part of 
the research, whilst keeping the focus on the research. 
1.18 Conclusion 
This chapter provided an introduction to the key tenants of this thesis; dementia and pain. 
Chapter Two (literature review) and Chapter Three (systematic review) build upon this 
chapter by critically reviewing the literature on pain identification, assessment, and 
management for people with dementia. 
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2 Chapter Two: Literature review 
2.1 Introduction 
This chapter provides a critical review of the literature to examine the current understanding 
of pain identification, assessment, and management for people with dementia. This review 
builds upon the previous chapter that provided an overview to dementia and pain (see 
Chapter One). This chapter begins by describing the aim and approach to the literature 
review. Following this, the key issues, debates, and concepts relating to pain identification, 
assessment and management for people with dementia are described sequentially.    
2.2 Aim of the literature review 
In the previous chapter, the prevalence of pain was found to be high for people with 
dementia (see Section 1.12.2). Most pain in people with dementia is due to musculoskeletal 
problems, and is most often persistent in nature (Pautex et al., 2005; Rubey, 2005; Scherder 
& Plooij, 2012; Corbett et al., 2012; Jørgensen, Thorleifsson, Selbæk, Benth & Helvik, 2018). 
As stated previously, pain has many negative implications for older adults with and without 
dementia (see Section 1.15).  
Research on pain for people with dementia has, to date, focused largely on formal settings, 
particularly nursing home (Tan et al., 2015; Chow et al., 2016), hospital (Closs et al., 2016), 
and palliative settings (Burns & McIlfatrick, 2015a). Pain in acute settings is often related to 
acute injury (e.g. long bone fractures; Arendts & Fry, 2006; Fry, Arendts, Chenoweth & 
MacGregor, 2015). Pain in palliative settings is complex, with a mix of acute and persistent 
pain within an end of life setting. Both of these settings therefore have numerous contextual 
differences that may not represent the broader population of people with dementia (Platt, 
2010; Coyne, Mulvenon & Paice, 2018). Therefore, in order to give a contextual foundation 
for this thesis, this literature review will draw largely upon the evidence from nursing home 
settings; with the systematic review (see Chapter Three) narrowing the focus to community-
dwelling people with dementia in order to generate novel research questions. 
Whilst this literature review was not a systematic review (in terms of the analytical approach), 
the search was conducted systematically using an iterative process. Searches were 
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conducted in a variety of electronic databases (EBSCO [including: CINAHL, Medline, 
PsycINFO, AgeLine], Web of Science, and PubMed) to identify relevant abstracts and full-
text articles. Firstly, a general search was conducted ((‘pain’ or ‘discomfort’) and (‘dementia’ 
or ‘cognitive impairment’)) to identify the breadth of core literature related to the topic of 
interest. Importantly, key researchers in the field were identified and their publications 
searched, along with the reference screening of published literature reviews and systematic 
reviews. The iterative nature of the literature review meant that additional searches were 
conducted before, during, and after the findings.  
This literature review will provide an overview of the evidence related to i) pain identification, 
and assessment, and ii) management of pain for people with dementia. A number of reviews 
and studies have identified barriers to optimal pain identification, assessment, and 
management for people with dementia in a variety of settings (McAuliffe, Nay, O’Donnell & 
Fetherstonhaugh, 2008; Zwakhalen et al., 2018; Geddis‐Regan, Stewart & Wassall, 2018; 
Rantala, Kankkunen, Kvist & Hartikainen, 2014). An overview of the barriers is provided in 
Table 2.1. Although each barrier is categorised into two conceptual domains i) pain 
identification and assessment and ii) management of pain, it is acknowledged that these 
barriers may cross each domain. Many of these barriers have been integrated and discussed 
throughout this chapter. 
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Table 2.1. Barriers to adequate pain identification, assessment and management for 
people with dementia 
Domain Barrier  
Pain identification and 
assessment 
 Lack of objectivitya 
 Lack of information or ‘evidence’a, b 
 Communication difficultiesa, d 
 Lack of education, knowledge and expertisea 
 Lack of recognition, misdiagnosis, or late diagnosisb, e 
 Lack of timea, b 
 Lack of interest and awarenessa 
 Lack of available assessment toolsa, b, d 
 Stoical attitudesb, e 
Management of pain  Difficulties in pain assessmentc, d 
 Reluctance to prescribe and take analgesic medicationc, e 
 Lack of familiarityd 
 Physiological changes associated with ageing (e.g. side 
effects, comorbidities)d, e 
aZwakhalen et al. (2018); bMcAuliffe et al. (2008); cRantala et al. (2014); dGeddis-Regan, Stewart 
and Wassall (2018); eVeal et al. (2018) 
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2.3 Pain identification and assessment 
People with dementia experience the same pain as older adults without dementia (see 
Section 1.13). It is important that pain is systematically and adequately assessed to ensure 
appropriate management (Pink, O’Brien, Robinson & Longson, 2018). This is all the more 
true for some people with dementia, where assessment can be problematic due to the 
symptoms of dementia (AGS Panel, 2002; Herr et al., 2011). Symptoms of dementia such as 
impaired reasoning, planning, memory, and communication may cause difficulty when 
recalling, and reporting physical conditions and pain (Kovach, Logan, Simpson & Reynolds, 
2010). Therefore, many guidance documents and clinical protocols have been developed to 
guide the systematic identification and assessment of pain for older adults 
(Hadjistavropoulos et al., 2007; Hadjistavropoulos, Fitzgerald & Marchildon, 2010), including 
people with dementia (Herr et al., 2011; Snow & Shuster, 2006). These guidelines, however, 
often do not critically examine the evidence that underpins their recommendations (Corbett et 
al., 2016). Recently, Schofield (2018) published UK national guidelines on the assessment of 
pain for older people (updated from the Royal College of Physicians, British Geriatrics 
Society and British Pain Society guidance published in 2007). Unlike previous guidelines, 
Schofield adopts a more critical and systematic approach to the current evidence, including a 
section dedicated to pain assessment for people with dementia. As part of the guidelines, 
Schofield (2018) acknowledges the need for a multifaceted approach to pain identification 
and assessment, in line with NICE (2018) guidelines, and as reported in research, protocols, 
and USA guidelines for non-verbal older adults (Herr et al., 2011; Pasero & McCaffery, 2011; 
Hadjistavropoulos et al., 2007; Snow & Shuster, 2006). Each element of the multifaceted 
approach to pain identification and assessment is displayed in Table 2.2.
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Table 2.2. A multifaceted approach to pain identification and assessment (adapted from 
Herr et al., 2011) 
Pain identification and 
assessment method 
Specific consideration for people with dementia 
Obtain self-report Self-report of pain is often possible in mild-to-moderate 
cognitive impairment, but ability to self-report decreases as 
dementia progresses 
Search for potential 
causes of pain 
Consider common chronic pain aetiologies. Musculoskeletal 
and neurologic disorders are the most common causes of 
pain in older adults 
Observe patient behaviour Observe facial expressions, verbalisations/vocalisations, 
body movements, changes in interactions, changes in activity 
patterns or routines, and mental status  
Informant reporting In long-term care settings, the certified nursing assistant is a 
key health care provider shown to be effective in recognising 
the presence of pain. Family are helpful if visit regularly 
Attempt an analgesic trial  Estimate the intensity of pain based on information obtained 
from prior assessment steps and select appropriate 
analgesic 
 
Despite recommendations, research continues to suggest that pain identification and 
assessment for people with dementia remains inadequate (Chen & Lin, 2016; Corbett et al., 
2012). The diagnosis of dementia may ‘overshadow’ other potentially painful comorbid 
conditions (Tolman & Dening, 2018). Research has found that the vast majority of nursing 
home managers (Barry, Parsons, Passmore & Hughes, 2012), nurses (Burns & McIlfatrick, 
2015b), and GPs (Jennings et al., 2018b) agree that the presence of dementia can make 
pain assessment difficult (91.7%, 91%, 98%, respectively). The difficulty of pain identification 
and assessment for people with dementia means that healthcare professionals are 
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concerned that pain remains inadequately identified and assessed (Kaasalainen et al., 
2007). This is illuminated by a systematic review and meta-analysis that found a lower 
identification of pain for people with dementia (using self-report and nurse observation) than 
older adults without dementia (OR 0.36, 95% CI 0.28 to 0.45), despite both groups having a 
similar prevalence of painful conditions (e.g. musculoskeletal conditions, fractures and 
cancer) (Tan et al., 2015). Similarly, recent research by Nakashima, Young and Hsu (2019) 
found that people with dementia in nursing home settings had significantly fewer pain 
assessments than people without dementia (74.3% vs 92.5%, p<0.001), negatively impacting 
the identification of pain. In an alternative nursing home study, people with dementia were 
less likely to have pain identified on their most recent pain assessment than people without 
dementia (Veal, Williams, Bereznicki, Cummings & Winzenberg, 2019). Such findings 
highlight the potential inadequacy of pain identification and assessment for people with 
dementia, which seems to incrementally lower with increasing cognitive impairment 
(Reynolds, Hanson, DeVellis, Henderson & Steinhauser, 2008).  
In accordance with these findings, a recent cross-sectional study by Jørgensen et al. (2018) 
examined the number of physical diagnoses recorded in the medical records of nursing 
home residents with (n=2470) and without dementia (n=513) at two time-points (2004/2005 
and 2010/2011). This study found that people with dementia had fewer physical diagnoses in 
their medical records than people without dementia (including potentially painful 
musculoskeletal conditions, 22.4% vs. 29.8%, respectively). Additionally, the number of 
recorded physical diagnoses lowered in line with increased severity of dementia. Such 
findings may suggest that people without dementia may live in nursing homes due to their 
physical morbidities (thus explaining the higher prevalence) whereas people with dementia 
may live in nursing homes due to their cognitive impairment. Alternatively, these findings may 
also infer that less attention is paid to the physical symptoms of people with dementia, 
especially as their severity of dementia increases and the symptoms associated with 
dementia (e.g. BPSD) become ‘clinically dominant’. Longitudinal research (rather than cross-
sectional) in community settings would overcome the distinct reasons that a person with and 
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without dementia may live in a nursing home (physical vs. cognitive morbidity), therefore 
providing greater confidence and direction when interpreting these findings. 
In contrast to this evidence, Hoffman et al. (2014) found that people with and without 
dementia had a similar prevalence rate of pain diagnosis (74.4% vs. 72.5%, respectively; 
p=0.11), indicating potentially adequate pain identification. This study, however, only 
examined pain diagnoses during the first year following dementia diagnosis. Therefore, this 
study did not examine pain-related diagnoses over time, and cannot provide insight into pain 
identification and assessment throughout the expected course of dementia progression.  
The following sections will provide an overview of the evidence into a variety of pain 
identification and assessment methods, as outlined by Herr et al. (2011; see Table 2.2). 
Throughout each section, the challenges and barriers specific to people with dementia are 
highlighted.   
2.3.1 Self-report 
The subjectivity of pain renders verbal self-report methods as the ‘gold standard’ assessment 
for typical populations (Horgas, Elliott & Marsiske, 2009; Schofield, 2018). Self-report allows 
the person to describe the location, intensity, type, frequency, and duration of the pain 
experienced (Kang & Demiris, 2018). The symptoms associated with dementia (i.e. 
communication difficulties, problems with abstract reasoning, decline in executive 
functioning; see Section 1.2) may impede the person with dementia’s ability to provide a 
verbal self-report that reflects their pain experience (Brennan & Soohoo, 2019), including the 
efficacy of pain treatments and potential side effects. Qualitative research has repeatedly 
illuminated reduced or altered verbal communication as a barrier to self-report for people with 
dementia (Geddis-Regan, Stewart & Wassall, 2018). Whilst self-report can be problematic, 
guidance suggests that self-report remains the most reliable and accurate pain assessment 
method for people with dementia, and therefore should be attempted, irrespective of the 
degree of cognitive impairment (Herr et al., 2006b; Schofield, 2018). In accordance, research 
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utilising focus groups of nursing home staff, and family caregivers perceived self-report as 
the ‘most meaningful assessment route’ for people with dementia (Corbett et al., 2016).  
The current UK guidelines for pain assessment for older adults suggest that there are a 
number of valid and reliable self-report measures suitable for use with people with mild-to-
moderate dementia, including Numerical Rating Scales and Verbal Descriptor Scales 
(Schofield, 2018).  
 Numerical Rating Scales (NRS); respondents pick a number (usually starting from 
zero indicating no pain), with higher numbers indicating increased pain intensity.  
 Verbal Rating/Descriptor Scale (VRS/VDS); respondents select a word descriptor that 
represents pain of progressive intensity (e.g. mild pain to excruciating pain).  
In accordance with these recommendations, many studies have found that the majority of 
people with mild-to-moderate dementia can provide a self-report of their pain experience 
(Ware, Epps, Herr & Packard, 2006; Kaasalainen & Crook, 2004; Chibnall & Tait, 2001; 
Chen & Lin, 2015). A review completed by Stolee et al. (2005) found that completion rates for 
self-report pain assessment tools varied from 20% to 100% depending upon the severity of 
cognitive impairment. This finding has been supported in a number of studies, which also 
found that as the severity of dementia increases, the percentage of people with dementia 
able to self-report pain or use a self-report measure reduces (Closs, Barr, Briggs, Cash & 
Seers, 2004; Kunz, Scharmann, Hemmeter, Schepelmann & Lautenbacher 2007; 2009; 
Lukas, Niederecker, Günther & Nikolaus, 2013a).  
Recommendations stress the potential need for individualised adaptations (e.g. simplified 
language, large fonts, involvement of a speech therapist), especially for people with 
moderate-to-severe cognitive impairment (AGS Panel, 2002; Schofield, 2018). Research 
suggests that simple dichotomous questions that require a concrete yes or no response such 
as ‘are you currently experiencing pain?’ may be useful for people with dementia 
(Hadjistavropoulos, Fitzgerald & Marchildon, 2010). When endorsing this method of pain 
assessment, Fisher, Burgio, Thorn and Hardin (2006) found that 81% of people with 
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dementia living in a nursing home had the ability to respond ‘yes’ or ‘no’ to a dichotomous 
question. Simple, dichotomous questions are therefore often used, with qualitative 
observation and interview studies showing that nurses used simple and direct questioning to 
assess their patient’s pain irrespective of their cognitive ability (Manias, 2012; Karlsson, 
Ernsth-Bravell, Ek & Bergh, 2014).  
Many studies investigating self-report pain assessment tools focus upon the percentage 
response or completion rate of people with dementia (Ware et al., 2006; Closs et al., 2004). 
However, many studies do not investigate the person with dementia’s comprehension of the 
self-report tool. Scherder and Bouma (2000) examined comprehension and understanding of 
the Faces Pain Scale by asking nursing home residents with and without dementia to choose 
which face indicated ‘most pain’ and ‘least pain’. This research found that even 25% of older 
adults without dementia, and 50% and 80% of older adults with early and mid-stage 
dementia, respectively misinterpreted the scale. These findings highlight the importance of 
considering the comprehension of self-report instruments, in addition to relying upon the 
completion rate for people with dementia.  
To further question the extent that self-reported pain reflects the pain experience, older 
adults, including people with dementia, may have a stoical attitude towards pain. Stoicism is 
defined as ‘illness behaviour characterised by silent endurance and lack of emotion’ (Moore, 
Grime, Campbell & Richardson, 2012, p.159), often colloquially described as a ‘stiff upper lip’ 
in the UK. Research suggests that a stoical attitude may stem from the acceptance of pain 
as a perceived inevitability in older age that cannot be alleviated (AGS Panel, 2009; 
McAuliffe et al., 2008; Barry, Parsons, Passmore & Hughes, 2013; Zwakhalen, Hamers, 
Peijnenburg & Berger, 2007; Makris et al., 2015; Crowe, Gillon, Jordan & McCall, 2017b). 
Additionally, a stoical attitude towards pain may be due to the perception that pain is a lower 
priority problem compared with other comorbidities (Makris et al., 2015). The stoical 
attitudes, beliefs and expectations held by older adults and healthcare professionals may 
impede care seeking, and accurate pain identification and assessment (Makris et al., 2015; 
AGS Panel, 2002; 2009). This is demonstrated in qualitative research including family 
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members of people with cognitive impairment living in nursing homes (Mentes, Teer & 
Cadogan, 2004) and older adults, family caregivers, and healthcare professionals (Martin, 
Williams, Hadjistavropoulos, Hadjistavropoulos & MacLean, 2005). In these qualitative 
studies, stoicism was perceived as a barrier to pain identification and assessment, with 
people with dementia denying or minimising their pain experience.  
In contrast to the stoical attitude, a minority of family members perceived their relative’s pain 
report as ‘dramatic’ as a means to get attention (Mentes et al., 2004). This finding again 
highlights the challenge of pain assessments for people with dementia, and in particular 
highlights the perceptions and interpretations of pain presence by others. In contrast, other 
studies have shown that nurses emphasise the importance of trusting the person with 
dementia’s self-report of pain (Karlsson et al., 2014). Multiple pain assessment methods may 
be used to support or refute self-report, and to determine if complaints or denials of pain can 
be taken ‘literally’ (Dowding et al., 2016). This multidimensional approach may help clarify if 
the self-report of pain reflects the pain experience (Gilmore-Bykovskyi & Bowers, 2013).  
Although guidance emphasises the importance of attempting to obtain a self-report for 
people with dementia (irrespective of cognitive ability), people with severe cognitive 
impairment may be unable to self-report pain, even with adaptation and full assistance 
(Schofield, 2018; Wynne, Ling & Remsburg, 2000; Closs et al., 2004; Barry et al., 2015). 
Therefore, although self-report is the preferential pain assessment method for people with 
dementia (Ngu et al., 2015; Pautex et al., 2005), self-report in isolation may not be 
appropriate nor sufficient to measure pain for people with dementia (Hadjistavropoulos et al., 
2007; Kaasalainen & Crook, 2004). Certainly, there are drawbacks to a reliance on self-
report alone, and research has suggested that healthcare professionals often rely upon self-
report to assess pain; inferring that a lack of self-report equates to no pain (McAuliffe et al., 
2009; Reynolds et al., 2008). A reliance upon self-report may contribute to the under-
detection of pain for people with dementia (Stubbs et al., 2016), especially so for people with 
advanced cognitive impairment. This reiterates the need for a multifaceted approach to pain 
identification and assessment, in which self-report is always attempted, but other pain 
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assessment techniques are used to build a complete picture of the pain experience (Cohen-
Mansfield, 2008; Herr et al., 2011; Schofield, 2018).  
2.3.2 Search for causes of pain 
The multifaceted approach to pain identification and assessment for people with dementia 
recommends the search for painful conditions (Herr et al., 2011; see Table 2.2). This ‘search’ 
may include an investigation into the patient’s medical and medication history, 
complemented by a physical examination (Hadjistavropoulos et al., 2007; Schofield, 2018). 
Searches for the potential source of physiological pain may identify a treatable cause to 
relieve pain. Importantly, guidelines emphasise that pain can exist even if physical 
examination is normal (Schofield, 2018). 
In recent questionnaire studies, the majority of GPs (91.7%) (Jennings et al., 2018b) and 
nursing home nurses (100%) (Burns & McIlfatrick, 2015b) agreed that physiological 
indicators of pain (e.g. heart rate, blood pressure, temperature) were an important aspect of 
pain assessment for people with dementia. Though worthy of note, the study by Burns and 
McIlfatrick report a low sample response rate of 33% (32/96) indicating potential under-
representation of the wider population of nurses, and it is not known whether an affirmative 
answer translated to actual practice. Interview studies with nursing assistants in nursing 
home settings show that regular physical examination of the person during daily care tasks 
was important to identify physiological changes that might be indicative of pain (Karlsson, 
Bravell, Ek & Bergh, 2012; De Witt Jansen et al., 2017a). Despite the potential usefulness of 
examination, Chang et al. (2009) illuminated the difficulty of physical examination for people 
with dementia due to their understanding of, and potential ‘lack of co-operation’ with the 
examination. This then highlights not only the potential for dementia (and linked severity) to 
affect self-report but also to affect physiological examination. 
2.3.3 Observation of changes in presentation  
Behavioural indicators, facial expressions, and changes in normal functioning may indicate 
that the person with dementia is experiencing pain (Schofield, 2018). Such indications of pain 
are especially important when the person with dementia can no longer verbally self-report 
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their experience. The AGS Panel (2002; 2009) identified six behavioural domains that are 
indicative of pain. The six domains are outlined in Table 2.3, and should be observed during 
activity if possible, as pain for people with dementia is often musculoskeletal in nature and 
initiated in response to motor activity (see Section 1.12.2). Despite the high profile of the 
AGS panel behavioural domains, the methodological development of the behavioural 
categories has been poorly documented.  
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Table 2.3. Pain related behaviours for people with dementia (adapted from AGS Panel, 
2002). 
Behaviour domain Example behaviour 
Facial expressions Slight frown, sad, frightened face 
Grimacing, wrinkled forehead, closed or tightened eyes 
Any distorted expression 
Rapid blinking 
Verbalisations, vocalisations Sighing, moaning, groaning 
Grunting, chanting, calling out 
Noisy breathing 
Asking for help 
Verbally abusive 
Body movements Rigid, tense body posture, guarding 
Fidgeting 
Increased pacing, rocking 
Restricted movement 
Gait or mobility changes 
Changes in interpersonal 
interactions 
Aggressive, combative, resisting care 
Decreased social interactions 
Socially inappropriate, disruptive 
Withdrawn 
Changes in activity patterns 
or routines 
Refusing food, appetite change 
Increase in rest periods 
Sleep, rest pattern changes 
Sudden cessation of common routines 
Increased wandering 
Mental status changes Crying or tears 
Increased confusion 
Irritability or distress 
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A recent systematic review by Strand et al. (2019) investigated the scientific basis for 
claiming that pain behaviours (such as facial expressions, vocalisations, and body 
movements) indicate an underlying pain experience for people with dementia. A total of 17 
quantitative, and 8 qualitative studies provided strong evidence that restlessness (agitation), 
rubbing, guarding, rigidity, and physical aggression were valid indicators of pain. Despite 
being strong indicators of pain, such pain behaviours are not necessarily pain-specific and 
may be indicative of other experiences. In a questionnaire study, Barry et al. (2012) found 
that ‘nearly all’ (percentage unknown) nursing home managers recognised the importance of 
delirium, confusion, or a marked change in the residents’ behaviour as a possible indication 
of pain. However, only 96 nursing home nurses responded to this survey (response rate of 
39%). The small sample limits generalisability to the wider nursing home nurse population, 
and also limited the statistical analysis beyond descriptive statistics. Qualitative studies offer 
support to these findings, with a recent meta-review showing that behavioural and 
psychological cues (e.g. irritability, vocalisation, grimacing, guarding, rubbing the affected 
area, physical withdrawal from touch) were important to identify and ‘build a picture’ of pain 
for the person with dementia (Geddis-Regan et al., 2018).  
Facial expressions are a key behavioural domain indicative of pain experience for people 
with dementia (see Table 2.3; AGS Panel, 2002; Sheu, Versloot, Nader, Kerr & Craig, 2011). 
Facial reactions are a reflexive response to pain, and therefore become increasingly 
important to identify pain for people with dementia, especially as the ability to provide a self-
report diminishes (Lints-Martindale, Hadjistavropoulos, Barber & Gibson, 2007; Browne, 
Hadjistavropoulos, Prkachin, Ashraf & Taati, 2019; Oosterman, Zwakhalen, Sampson & 
Kunz, 2016). Two studies examined which facial expressions were perceived by nurses (and 
‘non-professional’ observers) to be indicative of pain (Lautenbacher, Sampson, Pähl & Kunz, 
2016; Lautenbacher, Walz & Kunz, 2018). Both studies asked participants to observe people 
with dementia and to rate their pain using facial descriptors. Facial expressions that 
participants attributed to pain were ‘frowning’, ‘opened mouth’, ‘narrowed eyes’, ‘looking 
tense’, and ‘looking frightened’. However, identification of pain using facial descriptors was 
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only weakly correlated with the self-report of pain from the person with dementia 
(Lautenbacher et al., 2018) and ratings did not differ between nurses and ‘non-professional’ 
age-matched observers (Lautenbacher, Niewelt & Kunz, 2013). This finding may highlight the 
difficulty of using facial expressions to identify and assess pain in isolation. Despite these 
findings, qualitative evidence found that nursing assistants often used facial expressions 
(focusing upon the eyes and mouth) to identify pain and to examine the efficacy of pain relief 
for people with dementia in nursing home settings (Mentes et al., 2004). 
2.3.3.1 Observational tools to assess change  
The association between pain and a changed presentation, along with the need to assess 
pain for people with dementia without relying upon self-report has led to a proliferation of 
behavioural observation tools (Lichtner et al., 2014; AGS Panel, 2002). Recent UK pain 
assessment guidelines identified 16 behavioural pain assessment tools for people with 
dementia (Schofield, 2018). The most frequently reviewed behavioural observation tools to 
identify and assess pain are listed below (Lichtner et al., 2014):  
 Abbey Pain Scale  
 Non-Communicative Patient’s Pain Assessment Instrument (NOPPAIN) 
 Pain Assessment Checklist for Seniors with Limited Ability to Communicate 
(PACSLAC) 
 Pain Assessment in Dementing Elderly (PADE) 
 Checklist of Nonverbal Pain Indicator (CNPI)  
 Pain Assessment in Advanced Dementia (PAINAD)  
Many guidance documents recommend the Abbey Pain Scale to assess pain for people with 
advanced dementia (The Napp Pharmaceuticals, 2014; Social Care Institute for Excellence, 
2015), including the guidelines by the Royal College of Physicians, British Pain Society and 
British Geriatric Society in 2007. However, when these guidelines were updated in 2018, the 
Pain in Advanced Dementia (PAINAD) and Doloplus-2 were recommended, due to the lack 
of recent validation of the Abbey Pain Scale (Schofield, 2018). 
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A number of reviews have examined behavioural observation tools for people with dementia 
(Van Herk, Van Dijk, Baar, Tibboel & De Wit, 2007; Zwakhalen, Hamers, Abu-Saad, & 
Berger, 2006; Schofield et al., 2005; Stolee et al., 2005; Herr et al., 2006a; Smith, 2005; 
Park, Castellanos‐Brown & Belcher, 2010; Ng, Brammer & Creedy, 2012; Thuathail & 
Welford, 2011). When compiling the evidence as a meta-review, tools with the ‘most promise’ 
were the DS-DAT, Doloplus 2, Mahoney Pain Scale, PACSLAC, PAINAD, Abbey Pain Scale, 
and ECPA (Lichtner et al., 2014; Closs et al., 2016). However, the meta-review emphasised 
that the psychometric evidence of each tool was limited, with no one behavioural observation 
tool being more reliable or valid than the others (Lichtner et al., 2014).  
The proliferation of behavioural observation tools has led to the creation of a number of 
meta-tools, such as The Pain Assessment in Impaired Cognition scale (PAIC15) developed 
in Europe (Kunz et al., 2019), and the Pain Intensity Measure for Persons with Dementia 
(PIMD) developed in America (Ersek et al., 2018). These meta-tools used a Delphi-like 
consensus exercise and psychometric evaluation to identify and compile items from pre-
existing behavioural observation tools for people with dementia. Initial testing seems 
promising, however, further psychometric testing and investigation of clinical utility in a 
variety of settings and countries remains essential.  
Despite UK guidelines advising the use of behavioural observation tools to assess pain in 
people with dementia (NICE, 2018; Schofield, 2018), and many tools being available, only 
10% of GPs reported any knowledge of their existence (Jennings et al., 2018b). Unlike other 
studies of this kind (e.g. Barry et al., 2012), the response rate of GPs was modest (49%), yet 
remained underpowered. Qualitative studies have explored the perspective of nurses and 
physicians regarding the use of behavioural observation tools for people with dementia. De 
Witt Jansen and colleagues (2018) interviewed 23 physicians and 24 nurses providing end-
of-life care to people with advanced dementia in primary care, hospital, secondary care, and 
nursing homes settings. All participants recognised that their place of work mandated the use 
of behavioural observation for people with advanced dementia, however only 34% used a 
behavioural observation tool (often the Abbey Pain Scale) if self-report could not be obtained. 
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Similarly, interviews with nurses and formal caregivers in nursing home settings (Tordoff, Wei 
& Smith, 2017) and hospital settings (Lichtner, Dowding & Closs, 2015) discussed that 
behavioural observation tools were rarely used in their practice. Reasons for the lack of use 
may include the difficulty and subjectivity of interpreting pain behaviours, a lack of training, 
interest, and time to implement behavioural observation assessments in practice (Zwakhalen 
et al., 2018), and the opinion that behavioural observation tools ‘add no value’ (De Witt 
Jansen et al., 2018; McMahon, De Witt Jansen & Kernohan, 2019). 
Several intervention studies have investigated if systematic and regular use of behavioural 
observation pain tools improved pharmacological treatment initiation for people with 
dementia (Fry, Chenoweth & Arendts, 2018; Liu & Lai, 2017; Zwakhalen, van't Hof & 
Hamers, 2012). Despite systematic and regular use of behavioural observation tools, the 
initiation of pharmacological treatment for people with dementia did not improve. These 
findings indicate that even when a behavioural observation tool was systematically used to 
assess pain for people with dementia, there remains potential barriers to pharmacological 
treatment initiation. In these studies, the treatment protocol included an option to manage 
pain using non-pharmacological treatments. Non-pharmacological treatments were identified 
as the most common treatment approach following a positive pain score (Fry et al., 2018; 
Zwakhalen et al., 2012), with the use of non-pharmacological treatments being significantly 
higher in the intervention nursing homes (using the pain protocol) compared to control 
nursing homes (usual pain management strategies). This might reflect nurses’ and nurse 
assistants’ preference towards non-pharmacological options for people with dementia 
(Kovach, Griffie, Muchka, Noonan & Weissman, 2000; Mentes et al., 2004; Liu, 2014). Each 
of these findings highlight a dissonance between policy, protocol, or guidance and the 
challenge of translating research into practice to improve pain assessment and the 
management of pain for people with dementia (Cohen-Mansfield, 2012). 
Aside from their inclusion in behavioural observation tools, facial expressions have also 
received attention in their own right driven by the development of facial recognition 
technology, such as the Facial Action Coding System (FACS) (Oosterman et al., 2016), and 
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more recently, mobile applications such as PainChek™ (Atee, Hoti & Hughes, 2018). Facial 
recognition technology is a promising avenue for pain assessment for people with dementia 
who cannot verbally communicate, however more work is essential before such technologies 
can be implemented in everyday practice.  
2.3.3.2 Misattributing changes in presentation 
Despite the well-known link between pain and behavioural and psychological changes (see 
Section 1.14), such changes may also be indicative of many alternative unmet needs (e.g. 
hunger, fatigue, constipation, isolation, or urinary infection; Kovach et al., 2005). GPs 
participating in semi-structured interviews reflected upon the difficulty of assessing for the 
driver of behavioural and psychological symptoms (Jennings et al., 2017), with care home 
staff suggesting that behavioural changes may disguise the identification of pain for people 
with dementia (Veal et al., 2018). In support of these findings, caregivers of people with 
dementia and nurses discussed the challenge of determining if behavioural and 
psychological symptoms are driven by pain or if behavioural and psychological symptoms 
are driven by an alternate reason (Martin et al., 2005; Gilmore-Bykovskyi & Bowers, 2013). 
The ambiguity of pain-related behaviours contributes to uncertainty regarding the presence 
or absence of pain (Gilmore-Bykovskyi & Bowers, 2013; Zwakhalen et al., 2018). The 
challenge of determining the driver may contribute to the misattribution of pain behaviours; 
the idea that behavioural signs of pain are being incorrectly attributed to a psychological or 
psychiatric problem (McAuliffe et al., 2008). If behavioural changes are not recognised as an 
expression of an unmet need for pain relief, pain may remain inadequately identified, 
assessed, and suboptimally treated.  
In the alternate direction, behavioural observation tools may lead to behavioural changes 
being incorrectly attributed to pain. Research suggests that behaviours and facial 
expressions included in behavioural observation tools are not unique behavioural indicators 
of pain (Liu, Briggs & Closs, 2011), with research suggesting that others are not indicative of 
pain experience (e.g. ‘seeming disinterested’, ‘empty gaze’ from the Doloplus 2) 
(Lautenbacher et al., 2018). This increases the sensitivity of behavioural observation tools, 
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and thus may detect distress not caused by pain (Jordan, Regnard, O’Brien & Hughes, 2012; 
Feast et al., 2018). For example, a person with dementia with a urinary tract infection may 
show behaviours that are misinterpreted as pain behaviours. This misinterpretation may lead 
to inappropriate analgesic prescription when alternative treatments are more appropriate (i.e. 
an antibiotic prescription). Furthermore, many items included within behavioural observation 
tools require a degree of observer interpretation, heightening the subjectivity of the 
assessment and increasing variability (Lautenbacher & Kunz, 2017). Consequently, although 
behavioural observation tools may aid pain identification for people with dementia, a reliance 
upon behavioural observation tools in isolation may lead to false positives and false 
negatives (Lukas, Barber, Johnson & Gibson, 2013b); a high score on an observational pain 
tool is not diagnostic of pain. This may in turn impede accurate pain prevalence estimates 
(potentially leading to inflated prevalence, as false positives appear more likely), and 
ultimately leading to erroneous pain treatment.  
2.3.4 Informant assessment of pain 
Another key component to the multifaceted pain assessment, as outlined by Herr et al. 
(2011), is the informant assessment of pain (see Table 2.2). Informant assessments involve 
a person familiar with the person with dementia providing their perspective on the pain 
experienced by the person with dementia. The informant may include informal (family, 
friends, neighbours) or formal (nursing home staff) caregivers, depending upon the 
residential setting of the person with dementia. Informal and/or formal caregivers that are 
familiar with the person with dementia may provide in-depth insights into subtle individual 
pain behaviours, detecting and interpreting pain‐related changes, and a knowledge of pain 
history (Geddis-Regan et al., 2018). Qualitative research has identified that familiarity with 
the person with dementia allows for the identification of unusual or ‘out of character’ 
behaviour that may go unnoticed, especially when the baseline, or ‘usual behaviour’ of the 
person with dementia is unknown (Kovach et al., 2000; Liu, 2014; Mentes et al., 2004). The 
insights of informal and formal caregivers (who know the person with dementia well) are 
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particularly beneficial when the person with dementia is no longer able to verbally articulate 
their pain (Corbett et al., 2016; Geddis-Regan et al., 2018).  
Knowing the person well aids the identification and assessment of pain for people with 
dementia (Geddis-Regan et al., 2018). Therefore, continuity of care is beneficial for 
healthcare professionals to identify and assess pain for people with dementia. Continuity of 
care encompasses relationship continuity – ‘a continuous therapeutic relationship with a 
clinician’ and management continuity – ‘continuity and consistency of clinical management, 
including providing and sharing information and care planning, and any necessary co-
ordination of care required by the patient’ (Freeman & Hughes, 2010, p. 4). Continuity of care 
has been described as an essential feature of general practice in England (Freeman & 
Hughes, 2010), however, recent developments in primary care (e.g. increasing 
specialisation, changing professional work patterns) mean that relationship continuity with a 
GP is becoming more difficult to achieve. For example, the availability of appointments and 
staff could impede patients’ attempts to see the same GP – patients may sacrifice 
relationship continuity to get a quicker appointment. Research has found that poor continuity 
(and thus familiarity) with the person with dementia may make pain identification and 
assessment more challenging (Geddis-Regan et al., 2018). In circumstances where the 
healthcare professional is unfamiliar of the person with dementia, they may rely upon the 
perception and interpretation of the person that knows the person with dementia well, in 
addition to medical records, as a surrogate familiarity (Scherder & van Manen, 2005; 
Monroe, Parish & Mion 2015; Jennings et al., 2018b). Aside from pain identification and 
assessment, familiarity with the person with dementia is important to gauge the effectiveness 
of pain-related treatment and to facilitate optimum medication management (Barry et al., 
2019). 
2.3.4.1 Informant rating of pain 
Dementia-specific informant rating scales have been developed, including the Pain 
Assessment for the Dementing Elderly (PADE; Villanueva, Smith, Erickson, Lee & Singer, 
2003) and the Pain Assessment Instrument in Noncommunicative Elderly (PAINE; Cohen-
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Mansfield, 2006). In an intervention study conducted by Cohen-Mansfield and Lipson (2008), 
self-report, informant report (using the PADE and PAINE), and behavioural observation tools 
were used to assess pain for people with advanced dementia at each ‘step’ of a stepped 
analgesic trial. This study found that nursing staff informant ratings were the most sensitive 
method to identify pain, and to detect the effects of analgesic medication (reduction of pain) 
for people with dementia compared to self-report and behavioural observation tools. This 
study emphasised the importance of using multiple assessment methods, including informant 
reports, to assess and monitor a person with dementia’s response to pain treatment.   
Although informant specific pain assessment tools have been developed, such as PADE and 
PAINE, many studies have examined informant ratings of pain using common self-report 
tools described previously (see Section 2.3.1). When examining nursing home staff 
(informant) ratings of pain compared to self-reported pain ratings, many studies reported a 
degree of congruence between the two pain scores (Hemmingsson et al., 2017; Cohen-
Mansfield, 2005; Ersek, Polissar & Neradilek, 2011). However, the congruence between 
informant and independent measures of pain (e.g. self-report, Minimum Data Set) seemed to 
be negatively affected by the presence and severity of cognitive impairment (Ruben, van 
Osch & Blanch-Hartigan, 2015; Hemmingsson et al., 2017; Cohen-Mansfield, 2002; Scherder 
& van Manen, 2005; Fisher et al., 2002).  
All of these previous studies have focused on informant ratings of pain by nursing home staff 
with regular contact with people with dementia. However, the dynamic and relationship 
between the person with dementia and their family caregivers may influence the informant 
report of pain. Research by Santos and Castanho (2014) investigated family caregiver’s 
informant pain ratings using the Colour Analogue Scale (CAS) for their relative with dementia 
(residence unknown). They found that family caregivers rated the pain experienced by the 
person with dementia as significantly lower than the self-report of the person with dementia 
(mean CAS score: 1.2 vs. 4.7, respectively). Additionally, differences have been reported 
between family caregivers of people with dementia and family caregivers of people who do 
not have dementia; results have shown a lower report of pain from informant ratings for 
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people with dementia compared to people without dementia (mean CAS score: 1.2 vs. 6.2, 
respectively). Similarly, Cohen-Mansfield (2002) found that relatives were less likely to 
provide a pain rating for the person with dementia (i.e. respond ‘don’t know’) if they have 
more severe cognitive impairment, or longer duration living in a nursing home. These 
findings provide support to previous research, indicating that cognitive impairment may 
increase the difficulty for informants to provide an informant report of pain. Family caregivers’ 
informant reports of pain for community-dwelling people with dementia is explored in the 
systematic review (see Section 3.5.3.2).   
Each of these studies reported above commented upon the accuracy of informant reports of 
pain by determining the ‘congruence’ or ‘agreement’ between the self-report and informant 
report of pain. However, the self-report of the person with dementia may not reflect their pain 
experience for the many reasons outlined in section 2.3.1. Therefore, it is unknown if the 
informant truly ‘under-estimated’ pain, or whether this reflects an over-estimation of the self-
report (or vice versa). Furthermore, the accuracy of informant ratings of pain could only be 
investigated for people with dementia who could self-report their own pain (as used as the 
comparison). Therefore, and importantly, these findings do not provide insight into the utility 
of informant reports for people with advanced dementia unable to self-report their pain.  
To overcome these challenges, Eritz and Hadjistavropoulos (2011) compared self-reported 
(where possible), informant reported, and behavioural observation of pain (using the 
PACSLAC). This study found that the informant reports provided by family caregivers were 
able to distinguish between painful and non-painful states, and correlated well with self-
reported pain. This study also found a link to familiarity, the behavioural observation score of 
pain only predicted the informant report of pain successfully if the family caregiver spent 
more than 10 hours per week with the person with dementia (compared to family caregivers 
that spend less than 10 hours per week). These findings suggest that the informant report of 
pain is moderated in part by familiarity and regular contact with the person with dementia to 
provide an informant rating of pain that is informed by behavioural cues (see Section 2.3.4).  
Chapter Two: Literature Review 
40 
 
2.3.5 Response to analgesic medication 
The final aspect of the multidimensional pain identification and assessment for people with 
dementia is an analgesic trial (see Table 2.2; Herr et al., 2011). This would typically involve 
the examination of pain before and after the administration of analgesics (Hadjistavropoulos, 
Fitzgerald & Marchildon, 2010). This technique of pain assessment works on the premise 
that a reduction in pain assessment score or pain-related behaviour following the initiation of 
an analgesic trial is likely to reflect improved pain control (Hadjistavropoulos et al., 2007; De 
Witt Jansen et al., 2017b). In other words, the unmet need for pain relief now being met. 
Qualitative research found that nurses often approach pain management in a ‘trial and error’ 
manner; employing various pharmacological and non-pharmacological treatments while 
observing pain-related behaviours of the person with dementia as a means of pain 
assessment (Gilmore-Bykovskyi & Bowers, 2013; Monroe et al., 2015; Geddis‐Regan et al., 
2018; Dowding et al., 2016). 
In the previous chapter, randomised controlled trials (RCT) found that analgesic medication 
reduced behavioural indicators thought to be related to pain in people with dementia (Husebo 
et al., 2011a; Pieper et al., 2013; Tampi et al., 2017; see Section 1.2.3). However, many of 
these studies attributed lowering BPSD as an indication of lowering pain or addressing pain, 
rather than directly assessing pain pre-and-post administration. To build upon these findings, 
research has examined the effect of analgesic medication upon pain assessment scores. A 
systematic review and meta-analysis investigated the efficacy of analgesic treatments to 
reduce pain scores for nursing home residents with persistent pain (Knopp-Sihota, Patel & 
Estabrooks, 2016). Four studies were included in the meta-analysis (two RCTs; Corsinovi et 
al., 2009; Kovach et al., 2006, and two cluster RCTs; Sandvik et al., 2014; Husebo et al., 
2011b). Only one study was not focused upon people with dementia (Corsinovi et al., 2009) 
and so the evidence is useful for inclusion. The meta-analysis found that pain scores had 
shown statistically significant improvements at all-time points in the respective studies, with a 
reported clinically useful moderate to large treatment effect. To date however, there has 
been limited studies investigating the effectiveness of analgesics for people with dementia, 
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despite it being an area requiring urgent attention (Knopp-Sihota, Patel & Estabrooks, 2016; 
Achterberg et al., 2013). 
The systematic review and meta-analysis outlined directly above only included RCTs 
(Knopp-Sihota, Patel & Estabrooks, 2016). A randomised crossover trial examined if regular, 
scheduled administration of paracetamol (intervention phase) improved discomfort for people 
with dementia more than as-required administration of paracetamol (Buffum et al., 2004). 
This study found that there was no difference in discomfort score for people with dementia 
when taking scheduled versus as-required administration of paracetamol, despite only seven 
(out of 39) people taking the as-required paracetamol during the month long study period. 
Importantly, neither administration method of paracetamol reduced discomfort scores for 
people with dementia. These findings are discordant with the meta-analysis that found that 
analgesic medication reduced pain scores (Knopp-Sihota, Patel & Estabrooks, 2016). The 
discordance between these findings may be explained by the inefficacy of paracetamol to 
treat the pain experienced by participants. The RCTs included in the meta-analysis used a 
stepped analgesic treatment, meaning that the analgesic treatment in the intervention phase 
could escalate to opioid medications if required (Husebo et al., 2011a; Sandvik et al., 2014). 
However, in the study by Buffum et al. analgesic treatment was limited to paracetamol, which 
may not have been sufficient to reduce discomfort or demonstrate a detectable effect for 
people with dementia experiencing pain. These findings demonstrate the importance of 
individualised pain assessment and matched analgesic treatment, rather than a blanket 
administration of paracetamol.  
2.3.6 Key findings 
Each method of pain identification and assessment had its own challenges; meaning that no 
single method was deemed sufficient in isolation for people with dementia in the absence of 
self-report. Guidelines therefore recommend an individualised, multifaceted approach to pain 
identification and assessment, with each method comprising of a wider, comprehensive 
assessment (Herr et al., 2011; Pasero & McCaffery, 2011; Hadjistavropoulos et al., 2007; 
Horgas & Miller, 2008). Despite recommendations, the majority of research continues to 
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suggest that pain identification and assessment for people with dementia remains 
inadequate due to the complexity of the process (Chen & Lin, 2016; Corbett et al., 2012; 
Monroe et al., 2015), especially with increasing cognitive impairment. These findings are 
essential as pain identification and assessment is a precursor for optimal pain management 
(Godfrey, 2005). 
2.4 Management of pain 
The British Geriatric Society and British Pain Society collaborated to create the current UK 
pain management guidelines for older adults, including people with dementia (Abdulla et al., 
2013). The UK guidelines, along with the current American guidelines (AGS Panel, 2009) 
recommend a dual approach to manage pain; using a combination of non-pharmacological 
and pharmacological strategies (analgesic medications). Despite recommendations, 
research in nursing home settings has found that a dual approach for pain was only used for 
10% of people with dementia (Liu & Leung, 2016). This finding highlights a discordance 
between the guidance recommending dual approaches for pain treatment and the 
employment of approaches in practice. Alternatively, clinical pain management protocols 
developed for people with dementia (such as the Serial Trial Intervention; Kovach et al., 
2000; Snow & Shuster, 2006) advise that non-pharmacological approaches should be 
attempted prior to the use of analgesic medications. In agreement with these 
recommendations, family caregivers of people with dementia living in care homes perceived 
non-pharmacological strategies as an important first step of pain management (Corbett et al., 
2016). The following sections follow this guidance, by providing a sequential overview of non-
pharmacological approaches, followed by pharmacological treatments for pain.  
2.4.1 Non-pharmacological management 
Non-pharmacological or ‘non-drug’ interventions are broadly defined as an intervention not 
involving drugs or medications (McDermott et al., 2018). Non-pharmacological interventions 
for pain may range from simple measures to improve comfort (e.g. changing sitting position, 
distraction techniques) to psychosocial interventions which involve physical, cognitive, or 
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social activities that aim to improve wellbeing and functioning (Moniz-Cook, Vernooij-Dassen, 
Woods, Orrell & INTERDEM Network, 2011; Pu, Moyle, Jones & Todorovic, 2019). 
A review of the evidence was conducted by Abdulla et al. (2013) to inform the UK guidance 
on the management of pain for older adults. This review (and other reviews focused upon 
older adults; Park & Hughes, 2012) identified that a number of non-pharmacological 
strategies are effective for persistent pain (e.g. acupuncture, transcutaneous electrical nerve 
stimulation (TENS), and massage). However, these guidelines (as with almost all guidelines; 
Corbett et al., 2016) were for older adults rather than specific to people with dementia. 
Despite the recommendations, such non-pharmacological strategies may not be available, 
especially as part of the National Health Service (NHS, 2018). 
Pieper et al. (2013) conducted a comprehensive overview of the current evidence regarding 
the effectiveness of pain interventions targeting behaviour, and behavioural interventions 
targeting pain for people with dementia. The review concluded that rocking chair therapy, 
music therapy, Reiki (a biofield therapy; direct or indirect pressure is applied to affect the 
energy fields; Koithan, 2009), reflexology, person-centred showering or bathing (e.g. 
providing choices, towels for warmth, product recommendations from family caregivers; 
Sloane et al., 2004), and cognitive behavioural therapy can be effective in reducing pain and 
discomfort for people with dementia. However, the conclusions of this review are based upon 
a small number of studies, many of which had small sample sizes, which limit 
generalisability. To illustrate, the conclusion that Reiki improved pain and discomfort was 
based upon one case-series study including six people with dementia (Meland, 2009); 
questioning the reliability of this evidence. 
In line with these findings, a recent systematic review and meta-analysis investigated the 
effectiveness of psychosocial interventions on pain in people with dementia (Pu et al., 2018). 
Inclusion was restricted to RCTs, with eight low to moderate quality studies identified. Six 
studies focused on sensory stimulation – reflexology, massage, ear acupressure, music 
therapy, and person-centred showering or bathing – whereas two studies reported physical 
activity interventions, including Tai Chi and passive movement therapy. The meta-analysis 
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indicated that psychosocial interventions were beneficial for pain when assessed using a 
behavioural observation pain assessment. Conversely, there was no significant result found 
for self-reported pain. Although this systematic review provides preliminary evidence for the 
effectiveness of psychosocial interventions for people with dementia, alike to previous 
reviews (Pieper et al., 2013) there remains relatively limited high quality evidence. Most 
evidence to date is based on small samples meaning that the certainty of evidence is 
currently low. The uncertainty of evidence was illuminated as a sensitivity analysis found that 
the effectiveness of psychosocial interventions on pain no longer reached statistical 
significance when high-risk studies were omitted from the meta-analysis (Pu et al., 2018).  
Since the completion of the systematic reviews discussed above, Maltais et al. (2018) 
conducted a 24-week cluster RCT, in which people with dementia living in a nursing home 
were assigned to a moderate intensity exercise program (intervention), or a social interaction 
group (control). The intervention group exercised twice per week, for 60 minutes (n=44). The 
social interaction group did not involve physical activity (n=47). Pain was assessed using the 
Algoplus scale (a behavioural observation rating scale), at baseline and post-intervention. 
Findings suggest no difference in pain score between the exercise intervention and control 
group at post-intervention. There may be many reasons that no difference was evident 
between the intervention and control group. Participants had a relatively low pain score at 
baseline; leaving the intervention little scope to further decrease the pain score (floor effects). 
Additionally, although the social interaction group was intended to act as a control group, the 
activities involved (e.g. music meditation, drawing alone or in groups) may have improved the 
perception of pain experience for people with dementia, contributing to the lack of difference 
between the intervention and control group.  
In a recent qualitative meta-synthesis, non-drug pain management strategies were supported 
for people with dementia, largely due to their reluctance to use analgesic medications 
(Geddis-Regan et al., 2018). Non-pharmacological treatments may therefore play a role to 
reduce pharmacological burden (e.g. polypharmacy; defined as taking more than five 
prescription and over-the-counter medications at one time; Skinner, 2015). Questionnaire 
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studies suggest that the majority of nursing home managers (Barry et al., 2012), community 
pharmacists (Barry et al., 2013), and GPs (Jennings et al., 2018b) agree that non-
pharmacological methods are useful in the management of pain in people with dementia 
(51%, 59.9%, and 82.1%, respectively). In accordance, interviews with nurses (Kovach et al., 
2000), clinical nursing assistants, and family caregivers of people with dementia living in 
nursing homes (Mentes et al., 2004) found that they perceived a variety of non-
pharmacological approaches as effective for pain, including massage, one-to-one interaction, 
repositioning, lying down in a quiet room, relaxation, physical therapy, exercise and 
distraction techniques. In contrast to the generally positive opinion towards non-drug pain 
treatment, qualitative research with care assistants in a care home described non-drug 
treatments as ‘time consuming’ and ‘ineffective’ (Petyaeva et al., 2017). Studies have also 
noted that dementia (depending upon the severity) may impede the ability to self-manage 
pain using non-drug strategies (Bunn et al., 2016). This may mean that family or formal 
caregivers are relied upon to engage in non-pharmacological strategies to manage pain for 
the person with dementia.  
2.4.2 Pharmacological treatment 
The most common strategy to manage pain is to use analgesic medications (defined as 
drugs classified within the Anatomical Therapeutic Chemical (ATC) groups N02 or M01A), 
however, this is also the area of greatest risk (AGS Panel, 2009). The following sections will 
first discuss the physiological changes associated with ageing that increase the risk of 
analgesic treatment (see Section 2.4.2.1), and the stepwise treatment of analgesic 
medication (see Section 2.4.2.2). The literature review will then discuss analgesic medication 
use for people with dementia living in formal settings. 
2.4.2.1 Physiological changes associated with ageing 
Older adults have a higher risk of side effects due to the effects of ageing on the 
pharmacokinetics and pharmacodynamics of medications (McLachlan et al., 2011; Abdulla et 
al., 2013; AGS Panel, 2009). Older adults are more heterogeneous concerning morbidity and 
physiology, leading to less predictable responses to medications (McLachlan et al., 2011). 
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Research suggests that people with dementia may have unique physiological changes, 
above and beyond ageing alone, increasing their risk of side effects (Reeve, Trenaman, 
Rockwood & Hilmer, 2017), with healthcare professionals perceiving dementia as an 
additional risk factor for analgesic treatment (Jennings et al., 2018b). People with dementia 
are often excluded from medication trials meaning that safe and effective analgesic dosage 
regimes are often unknown (Erdal, Ballard, Vahia & Husebo, 2019). The specific side effects 
associated with each therapeutic classification of analgesic medication are discussed later in 
this chapter. 
As the population ages, the proportion of people with dementia and comorbidity increases 
(Bunn et al., 2016). In the UK, people with dementia have, on average, 4.6 comorbidities in 
addition to dementia, many of which require pharmacological treatment (Guthrie et al., 2012; 
Piccirillo et al., 2008). Comorbid conditions or their associated pharmacological treatments 
may contraindicate the use of analgesic medications. The amount of medications being 
taken by the person with dementia (due to their comorbidities) was perceived as a barrier to 
taking additional medications (Mentes et al., 2004; Kaasalainen et al., 2007). Research 
suggests that older adults accept pain because it is tolerable and not life threatening, with 
other ‘more important’ medications taking priority (Sale, Gignac & Hawker, 2006; Makris et 
al., 2015). This aligns with the perception of pain as a ‘lower priority’ condition, as described 
in section 2.3.1. 
Physiological changes associated with ageing (including side effects and comorbidities), 
along with the additional challenge of cognitive impairment means that pain management is 
perceived as complex and restricted for people with dementia (Corbett et al., 2016; Griffioen, 
Husebø, Achterberg, Willems & Husebo, 2017a). Despite the challenge, in qualitative 
research, healthcare professionals emphasised the importance of balancing the benefits of 
pain relief against the potential negatives (e.g. side effects) when prescribing analgesics to 
people with dementia (Kaasalainen et al., 2007), in line with NICE (2018) guidelines. 
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2.4.2.2 Stepwise treatment 
In 1986, the WHO developed a model for the slow introduction, and titration of analgesic 
medication (Ventafridda & Stjernsward, 1996). The model was developed to guide analgesic 
treatments for people with cancer (WHO, 1996). This model was named the ‘WHO analgesic 
pain stepladder’ (see Figure 2.1). The principle of this model included the slow incremental 
increase of analgesic medication, starting at simple non-opioid analgesics, with a 
progression to weak opioids, and then strong opioids guided by the patient’s pain 
experience. Although originally developed for cancer pain, the model has been widely 
adopted for persistent pain. In recent years, however, the use of the WHO analgesic pain 
stepladder for persistent pain has been criticised, as total alleviation from pain is often 
unrealistic (AGS Panel, 2009; Ballantyne, Kalso & Stannard, 2016). Therefore, escalation of 
analgesic medicating in line with pain intensity may lead to inappropriate prescribing for 
persistent pain (NICE, 2017). 
 
Figure 2.1. World Health Organisation (WHO) Analgesic Stepladder 
 
In line with the WHO analgesic pain stepladder, current management guidelines for 
persistent pain for older adults recommend the slow upwards titration of analgesic 
medication with frequent reassessment to adjust dosage and to determine optimum pain 
relief with minimal side effects (AGS Panel, 2009; Abdulla et al., 2013; NICE, 2018). This is 
especially recommended for older adults due to the physiological changes associated with 
ageing altering the efficacy, sensitivity, and toxicity of analgesic medication (see Section 
2.4.2.1; AGS Panel, 2009).  
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The preference towards a stepped approach to analgesic treatment is observed in many 
studies, with the majority of nursing home managers (Barry et al., 2012) and community 
pharmacists (Barry et al., 2013) included in a questionnaire study agreeing that analgesic 
medications should follow a stepped approach. Interviews (Kovach et al., 2000) and focus 
groups (Kaasalainen et al., 2007) with nurses, and interviews with physicians (Kaasalainen 
et al., 2007) found a preference towards the systematic escalation of analgesic medications, 
describing their approach using the phrase: ‘start low and go slow’. However, nurses 
participating in the interview study by Kovach et al. had received ‘extensive education in pain 
management’ one year before the interviews. Nurses included in this study may have an 
increased knowledge and understanding of pain management for people with dementia that 
may not be transferable to the wider nurse population. Despite the perceived positives of the 
‘start low and go slow’ approach to pain management, Hanlon, Backonja, Weiner and Argoff, 
(2009) highlighted that this risk management strategy is often misinterpreted as ‘start low and 
stay low’ leading to potentially inadequate pain relief as an attempt to minimise risk.   
2.4.2.3 Analgesic medications 
This section of the literature review provides an overview of analgesic use and prescription 
as a whole - irrespective of the type or strength of the analgesic. A systematic review 
conducted by La Frenais and colleagues (2017), along with evidence published since the 
completion of the review (Hemmingsson et al., 2017) found that the prevalence of analgesic 
prescription incrementally increased in nursing and residential home settings from 1995 to 
2015, many of which included a significant dementia population. Only one study in this 
systematic review examined the temporal trend of analgesic prescription, stratifying the 
sample into people with and without dementia living in nursing homes (Sandvik, Selbaek, 
Kirkevold, Husebo & Aarsland, 2016). People with dementia were prescribed less analgesic 
medication compared to older adults without dementia in 2000, 2004, and 2009 (p=0.002; 
p=0.008; p=0.002, respectively). However, there was no difference in analgesic prescription 
between older adults with and without dementia in the later year of 2011. These findings may 
indicate that in recent years, the prevalence of analgesic prescription in nursing home 
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settings has increased for people with dementia, in line with people without dementia. This 
study used a series of cross-sectional time points to investigate the temporal pattern of 
analgesic prescription. This method meant that the samples obtained at each time point were 
not the same, and in fact differed significantly concerning a number of demographic 
characteristics. The difference between samples may influence analgesic prescription, thus 
hinder the comparability of findings over time.   
When comparing the prevalence of analgesic prescription in nursing home settings, a 
systematic review and meta-analysis found that the overall prevalence of analgesic use in 
people with and without dementia ranged from 20.2% to 61.2% and 38.8% to 79.6%, 
respectively (Tan et al., 2015). Meta-analysis revealed that people with dementia had a 
significantly lower analgesic prevalence compared to people without dementia (OR 0.58, 
95% CI 0.41 to 0.82, p=0.002) (Tan et al., 2015). In line with these findings, Hoffmann, van 
den Bussche, Wiese, Glaeske and Kaduszkiewicz (2014) found that people with dementia 
were prescribed significantly less analgesics than age and sex matched older adults during 
the first year following dementia diagnosis (adjusted OR 0.78, 95% CI 0.68 to 0.88). In the 
Hoffman et al. study, paracetamol was not included as it was only available over-the-counter. 
Paracetamol is often the first-line treatment for musculoskeletal pain, and the preferred 
treatment for pain relief due to the good safety profile of the drug (see Section 2.4.2.4). The 
lack of inclusion of paracetamol may therefore influence the interpretation of these findings. 
Regardless, these findings question if people with dementia are inadequately treated for their 
pain. 
The potential under treatment of pain for people with dementia is reiterated as other studies 
identified that 34.2% to 38.4% of people with dementia in nursing homes did not receive an 
analgesic medication despite experiencing pain (Griffioen, Husebo, Flo, Caljouw & 
Achterberg, 2017b; de Souto Barreto, Lapeyre-Mestre, Vellas & Rolland, 2013). This 
percentage was higher than people without dementia, in which only 23% experiencing pain 
were not prescribed an analgesic medication (de Souto Barreto et al., 2013). In line with 
these findings, Hunnicutt, Ulbricht, Tjia and Lapane (2017) examined pain and 
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pharmacological pain treatments for 1,387,405 long-stay nursing home residents in the 
United States. This study found that people with severe cognitive impairment had an 
increased prevalence of untreated and undertreated pain compared to people with no/mild 
cognitive impairment. These findings appear to show that cognitive impairment (because of 
dementia) may be a potential barrier to adequate pain treatment. This evidence is in 
accordance with older studies also concluding that people with dementia are under treated 
for their pain (Horgas & Tsai, 1998). 
However, in discordance with the findings above, recent evidence indicates that people with 
and without dementia in nursing home settings were prescribed a similar amount of 
analgesic medication (Tan et al., 2016; Nakashima et al., 2019). However, Nakashima et al. 
found that people with dementia received fewer as-required analgesic medications than 
people without dementia. This discordance may again reflect that analgesic prescription for 
people with dementia has increased in nursing home settings, in line with people without 
dementia, but highlights that people with dementia may be suboptimally treated for their pain 
due to the lower administration of as-required analgesic medication.  
It is important to acknowledge that many of the studies investigating the prevalence of 
analgesic prescription are cross-sectional (Tan et al., 2015; Tan et al., 2016), or have a 
limited follow up period (i.e. one year; Hoffmann et al., 2014). These current approaches do 
not allow for the investigation of analgesic prescriptions throughout the course of dementia 
progression, and do not report on the prevalence of analgesic prescription stratified by 
different levels of cognitive impairment. Therefore, these studies do not examine increasing 
cognitive impairment and the potential effects this has on analgesic prescription.  
That said, a small number of studies have investigated analgesic prescription for people with 
dementia with varying severities of cognitive impairment. Studies have found that the 
prevalence of analgesic prescription incrementally lowered with increasing cognitive 
impairment (Neumann-Podczaska et al., 2016; Cornali, Franzoni, Gatti & Trabucchi, 2006; 
Bauer et al., 2016), with people with dementia that could no longer verbally communicate 
receiving even fewer analgesic medications (Bauer et al., 2016). Such findings show that the 
Chapter Two: Literature Review 
51 
 
symptoms associated with increased severity of cognitive impairment (such as lowered 
communicative ability) may not only act as a barrier to pain identification and assessment, 
but also limit the person with dementia’s ability to express their unmet need for pain relief 
(Corbett et al., 2016). It is important to consider that the stratification of participants (often by 
MMSE score) in each of these studies led to small samples within each stratum. For 
example, in the study by Cornali et al. (2006) only 17 participants contributed to the MMSE 0 
to 12 strata. The small samples reduce confidence in the findings. 
2.4.2.4 Paracetamol 
Paracetamol is a simple non-opioid analgesic medication. Recommendations unequivocally 
highlight paracetamol as the first-line treatment for many painful conditions due to the ‘good 
safety profile’ with minimal side effects and contraindications for older adults (AGS Panel, 
2009; Abdulla et al., 2013; McLachlan et al., 2011; Zhang et al., 2008; Jordan et al., 2003; 
NICE, 2015; Erdal et al., 2019; Girard, Sourdet, Cantet, de Souto Barreto & Rolland, 2019). 
However, recent studies have called the safety of paracetamol into question. A systematic 
review and meta-analysis of observational data found that paracetamol was associated with 
an increased number of cardiovascular and gastrointestinal adverse events, renal 
impairment, and mortality (Roberts et al., 2016). In recent years, NICE guidelines have also 
questioned the effectiveness of paracetamol to treat the pain caused by osteoarthritis (Wise, 
2014; NICE, 2014) and low back pain (NICE, 2016; Saragiotto et al., 2016). Despite 
concerns, paracetamol remains the most commonly prescribed analgesic for nursing home 
residents with and without dementia (McLachlan et al., 2011; La Frenais et al., 2017; 
Hemmingsson et al., 2017; Rajkumar et al., 2017). 
The prevalence of paracetamol use ranges from 45.2% to 71.0% for people with dementia in 
nursing home settings (Tan et al., 2015; Tan et al., 2016), with an increasing temporal trend 
of paracetamol from 1995 to 2015 for nursing home residents, many of which had dementia 
(La Frenais et al., 2017). When comparing paracetamol for nursing home residents with and 
without dementia, a systematic review found that people with dementia were more likely to 
use paracetamol than people without dementia (Tan et al., 2015). This finding has also been 
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identified for people with and without dementia living in a variety of settings (including nursing 
and residential homes, and in their own homes; Lövheim, Karlsson & Gustafson, 2008). 
Additional studies since the completion of the systematic review (Tan et al., 2015) indicate no 
significant difference between the prevalence of paracetamol use for people with and without 
dementia (Tan et al., 2016; Bauer et al., 2016). Although these findings indicate that a 
similar, if not greater proportion of people with dementia use paracetamol in nursing home 
settings, many epidemiological studies were unable to capture over-the-counter medications 
(Tan et al., 2015). This requires consideration as paracetamol is commonly obtained over-
the-counter (Hoffmann et al., 2014; Mentes et al., 2004). Therefore, it is important to remain 
mindful that these prevalence estimates may minimise the true extent of paracetamol use for 
people with and without dementia.  
Studies also investigated the prevalence of paracetamol use in nursing home residents, 
stratified by MMSE score (Bauer et al., 2016; Cornali et al., 2006). Both studies found that 
the prevalence of paracetamol remained stable, or increased in line with increasing cognitive 
impairment. These findings may reflect attempts to provide adequate pain relief for people 
with dementia using an analgesic with a good safety profile. 
In a qualitative study using semi-structured interviews to generate data, nurses perceived 
paracetamol as the analgesic of choice for mild-to-moderate pain, reflecting upon the low 
side effect profile for older adults (Kovach et al., 2000). The preference towards paracetamol 
for these reasons may explain the similar prevalence estimates for people with and without 
dementia. However, a questionnaire study with GPs (Jennings et al., 2018b), community 
pharmacists (Barry et al., 2013), and nursing home managers (Barry et al., 2012) found that 
many respondents neither agreed nor disagreed that ‘paracetamol is the best analgesic to 
use in people with dementia who are experiencing chronic pain’ (27.3%, 46.2%, 29.2%, 
respectively). These findings suggest that despite the preference towards paracetamol, many 
healthcare professionals are not convinced that paracetamol is always the best analgesic of 
choice. This may reflect the recent debates regarding the efficacy and safety of long-term 
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paracetamol use for persistent pain (Roberts et al., 2016; NICE, 2016; Saragiotto et al., 
2016). 
2.4.2.5 Non-steroidal anti-inflammatory drugs  
Non-steroidal anti-inflammatory drugs (NSAIDs) are valuable agents in the treatment of 
painful musculoskeletal conditions, due to their analgesic and anti-inflammatory properties. 
NSAIDs include ibuprofen, naproxen, and diclofenac. Older adults are at higher risk of 
NSAID related side effects (e.g. gastrointestinal, renal, and cardiovascular side effects) than 
adults of working age, with numerous absolute and relative contraindications to consider 
(AGS Panel, 2009). Recommendations suggest that NSAIDs should be considered rarely for 
older adults, and only if alternative therapies (i.e. non-pharmacological approaches and 
paracetamol) have failed to relieve pain (AGS Panel, 2009; Abdulla et al., 2013; McLachlan 
et al., 2011). Qualitative research with nursing assistants highlighted their concern relating to 
NSAID side effects for people with dementia, including possible bleeding problems and 
stomach upset (Kovach et al., 2000). 
A systematic review of cross-sectional studies (Tan et al., 2015), and cross-sectional studies 
conducted since the completion of the review (Tan et al., 2016; Bauer et al., 2016) have 
found that the prevalence of oral NSAID use ranges from 2.0% to 25.1% for people with 
dementia in nursing homes. When examining the temporal pattern of NSAID prescription, the 
prevalence lowered over time for nursing home residents (a large percentage of which had 
dementia), with a reduction from 6.8% in 2000 to 3.2% in 2011 (Sandvik et al., 2016), and 
4.7% in 2007 to 3.6% in 2013 (Hemmingsson et al., 2017). In nursing home and assisted 
living settings, the prevalence lowered from 13.0% in 2003 to 2.6% in 2011 (Pitkala et al., 
2015). These findings reflect the repeated national guidelines advising that NSAID use is 
reduced due to the complications associated with NSAIDs, especially for older adults (NICE, 
2015; AGS Panel, 2009; Abdulla et al., 2013; McLachlan et al., 2011; Cavalieri, 2007; 
MHRA, 2015; Bedson et al., 2013).  
In nursing home settings, people with dementia had a lower prevalence of oral NSAID 
prescription than people without dementia (2% vs. 3.9% de Souto Barreto et al., 2013; 2.4% 
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vs. 4.7% Tan et al., 2016). However, in multivariable analysis, following statistical 
adjustment, Haasum, Fastbom, Fratiglioni, Kareholt and Johnell (2011) found no difference 
between NSAID use for people with and without dementia in nursing home settings (adjusted 
OR 0.41, 95% CI 0.15 to 1.11).  
Studies also investigated the prevalence of NSAID use, stratified by MMSE score (Bauer et 
al., 2016; Neumann-Podczaska et al., 2016). Both studies found that the prevalence of 
NSAID prescription lowered with increasing cognitive impairment. Additionally, Bauer et al. 
found that when further stratifying people with cognitive impairment based upon their ability 
to verbally communicate (verbal and non-verbal), 28.9% of the cognitively impaired but 
verbal group, and 18.4% of the cognitively impaired but non-verbal group used NSAIDs. 
These studies suggest that NSAID use lowered in line with increased cognitive impairment, 
with the suggestion that limited verbal communication may act as a potential barrier to 
NSAID use.  
2.4.2.6 Opioids 
Opioid narcotic drugs are typically advocated for the effective treatment of acute pain (i.e. 
following injury or surgery), at the end of life, and for cancer-related pain. Opioids sit at the 
top of the WHO analgesic stepladder (see Figure 2.1). Opioids include Morphine, Fentanyl, 
and Oxycodone. In recent years, opioids have been recommended for persistent non-cancer 
pain if the pain is causing functional impairment or reducing quality of life (Abdulla et al., 
2013). In persistent pain, it is recommended that opioids should be prescribed to older adults 
on a trial basis with clearly defined therapeutic goals (AGS Panel, 2009). This is despite 
research highlighting the limited efficacy of opioids to treat persistent pain (NICE, 2017; 
Noble et al., 2010). In addition to the limited efficacy, the potential harms of opioids for older 
adults have been well documented (AGS Panel, 2002; Abdulla et al., 2013; McLachlan et al., 
2011). Opioids are associated with addiction, dependence, self-poisoning, confusion, 
gastrointestinal problems, daytime sedation, delirium, constipation, and falls for older adults 
(McLachlan et al., 2011; Tannenbaum, Paquette, Hilmer, Holroyd-Leduc & Carnahan, 2012; 
Clegg & Young, 2010). The potential side effects associated with opioids means that patients 
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should be regularly monitored to explore therapeutic goals, side effects, and safe and 
responsible medication use (AGS Panel, 2009).  
The prevalence of opioid use for people with dementia ranges from 13.8% to 30.1% (Tan et 
al., 2015; Tan et al., 2016). A systematic review identified 10 studies investigating the 
temporal pattern of opioid prescriptions for older adults (including people with dementia) in 
nursing home settings (La Frenais et al., 2017). This review found an increasing trend of 
opioid use from 1995 to 2015 (La Frenais et al., 2017). Since the completion of this review, 
studies continue to identify an increase prevalence of opioid use over time (from 2007 to 
2013) (Hemmingsson et al., 2017) for nursing home residents, a large percentage of which 
have dementia. A number of reasons may contribute to this increase: 
1. The epidemiological investigation of opioid use throughout this period (1995 to 2015) 
has found an increasing trend of prescriptions generally; often referred to as the 
‘opioid epidemic’ (Manchikanti et al., 2012; Basler, 2017).  
2. Studies that found NSAID use to be steadily decreasing over time also found an 
increase of opioid use over time (Sandvik et al., 2016; Hemmingsson et al., 2017; 
Pitkala et al., 2015). Such findings suggest that healthcare professionals may be 
increasingly cautious of NSAIDs (and their side effects; see Section 2.4.2.1), and may 
prescribe opioids as an alternative. 
3. The introduction of transdermal analgesic patches (e.g. buprenorphine and fentanyl) 
may have contributed to the use of strong opioids for people with dementia. The 
reasons healthcare professionals may use transdermal patches for people with 
dementia is multifaceted, including the perception that they are associated with a 
lower risk of side effects (such as constipation), and ease of administration and 
adherence, especially for people with dementia. Despite their use, research has 
highlighted that transdermal patches are not well tolerated by people with dementia 
(Erdal et al., 2018).  
A recent systematic review examined opioid prescription rates for people with and without 
dementia, irrespective of residential setting (Griffioen et al., 2017a). In total, 21 studies (out 
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of the total 24 identified, 87.5%) found that people with dementia use equal or less opioids 
than people without dementia. This review therefore concluded that people with dementia 
often have a lower use of opioids than people without dementia. None of the studies included 
in this review used a pain rating scale validated for people with dementia, therefore, it cannot 
be determined if the lower prevalence of opioid use truly reflects pain ‘under treatment’. 
A number of qualitative studies support these findings, with a recent meta-review suggesting 
that the side effects associated with opioids caused concern when treating the pain 
experienced by people with dementia (Geddis-Regan et al., 2018). The fear and concern of 
causing harm increased healthcare professionals’ reluctance to prescribe opioids to older 
adults (Spitz et al., 2011), with dementia being perceived as an additional complexity or ‘risk 
factor’ (Chang et al., 2009; Manias, 2012). Additionally, interviews with nursing home staff 
indicated a resistance (from family members, nurses, and care workers) for opioids to be 
used even when they are prescribed to the person with dementia (Peisah, Weaver, Wong & 
Strukovski, 2014). Resistance towards opioid medications remained even when alternative 
treatments (e.g. paracetamol) were not effective (Martin et al., 2005). These findings reflect 
the ‘negative social stigma’ towards opioid medications for people with dementia due to their 
potential harm (AGS Panel, 2009). 
2.4.3 Key findings 
This section of the literature review provided a critical summary of the evidence examining 
pain management for people with dementia, with a focus largely upon nursing home settings. 
Overall, the evidence concerning the management of pain for people with dementia has 
shown that there is limited high quality evidence investigating non-pharmacological 
approaches. Qualitative evidence, however, suggests that non-drug treatments are often 
viewed positively for people with dementia. Concerning pharmacological treatment, the 
temporal trend of analgesic use increased over time, however people with dementia 
continued to receive/use less analgesic medication than people without dementia. An 
increasing temporal trend was also evident for paracetamol use, with evidence suggesting 
that people with dementia used similar, if not more paracetamol than people without 
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dementia. This finding reflects the preference towards paracetamol due to its ‘good safety 
profile’ for older adults. Conversely, NSAID use lowered over time, with people with dementia 
having a lower prevalence of NSAID use compared to people without dementia. These 
findings reflect the repeated national guidelines to reduce NSAID prescribing, and the 
perceived caution surrounding NSAIDs due to their side effects for older adults. Finally, there 
was a general increasing temporal trend of opioid use in nursing homes, in line with the 
increasing prescription of opioids worldwide. Irrespective of this increasing trend, people with 
dementia used less opioids than people without dementia, highlighting the potential caution 
surrounding the side effects associated with opioids.    
2.5 Additional barriers to pain management 
The barriers to adequate pain identification, assessment, and management were outlined at 
the start of this chapter, in Table 2.1. Many of these barriers have been integrated and 
discussed throughout this chapter due to their close association with particular pain 
identification/assessment or management strategies. Barriers discussed so far include 
communication difficulties (see Section 2.3.1), lack of recognition or misdiagnosis of pain 
(see Section 2.3.3.2), stoical attitudes (see Section 2.3.1), lack of familiarity (or relationship 
continuity) (see Section 2.3.4), and the physiological changes associated with ageing (see 
Section 2.4.2.1). The following sections will provide an overview of additional barriers to pain 
identification, assessment, and management for people with dementia that could not be 
integrated during the review, including time pressures (see Section 2.5.1) and training, 
guidance, expertise and support (see Section 2.5.2). 
2.5.1 Time pressures 
Time is precious in healthcare settings, with a traditional 10-minute consultation model in UK 
general practice (The Royal College of General Practitioners, 2019). An in-depth assessment 
of pain using a multidimensional approach is often timely, especially with people with 
dementia where additional time and flexibility may be required to conduct an assessment 
(Chang et al., 2009). In a European survey, including healthcare professionals working in 
hospital settings, care home, and primary care settings, many respondents viewed 
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insufficient time as a key barrier to adequate pain identification and assessment for people 
with dementia (Zwakhalen et al., 2018).  
2.5.2 Training, guidance, expertise, and support 
The majority of nursing home managers (63.5%) had not received any recent training on pain 
in people with dementia (Barry et al., 2012), with the vast majority of community pharmacists 
also not receiving training in dementia (95.6%) or pain (93.4%) (Barry et al., 2013). In a 
questionnaire study across 13 care homes, the majority of nurses (66%) were unaware of 
any formal education programs exploring pain management for people with dementia that 
were adequate for their needs (Neville, McCarthy, Laurent, Creedy & Walker, 2006). In a 
cross European survey of healthcare professionals, respondents reported a lack of guidance, 
training, expertise, and awareness to adequately assess pain (Zwakhalen et al., 2018). In 
accordance with these survey/questionnaire studies, qualitative interviews with nurses in 
nursing home settings found that discomfort for people with dementia was not taught to them 
during their nursing training, with many conceptualising pain assessment as a ‘guessing 
game’ (Kovach et al., 2000; Dobbs, Baker, Carrion, Vongxaiburana & Hyer, 2014). Each of 
these findings highlight the gap in training, guidance and expertise for healthcare 
professionals; potentially contributing to the inadequate pain identification and assessment 
for people with dementia. 
Not only is training, guidance, and support essential for healthcare professionals to 
adequately identify and assess pain for people with dementia, but also for family caregivers. 
In a study by Maidment, Aston, Moutela, Fox and Hilton (2017) people with dementia and 
their family caregivers expressed their need for support to manage the person with 
dementia’s medications, especially as many family caregivers had their own comorbidities 
and medications to manage. Unlike all other qualitative studies discussed in this literature 
review, this research allowed people with dementia to contribute their perspective as part of 
a dyadic interview. However, this study focused upon ‘medication management’ generally, 
and therefore did not uncover their unique perspectives and experiences of pain 
management. 
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2.6 Conclusion 
This literature review provided an overview of pain identification, assessment, and 
management for people with dementia, with a particular focus primarily on nursing home 
settings as currently this is where the majority of research has been based. Overall, pain 
identification and assessment seems inadequate for people with dementia within nursing 
home settings. Evidence also suggests that, on a whole, people with dementia seem to 
receive suboptimal pain treatment, with limited research investigating non-drug strategies for 
people with dementia. The following chapter continues to build upon the findings of this 
literature review; narrowing the focus to pain assessment and treatment for community-
dwelling people with dementia.  
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3 Chapter Three: Systematic Review 
3.1 Introduction 
The previous chapter provided an overview of the large body of published literature 
examining pain identification, assessment and treatment for people with dementia living in 
nursing home settings. This research often found that people with dementia are suboptimally 
assessed and treated for their pain when compared to people without dementia.  
Despite evidence that people with dementia may be underserved in terms of pain 
(assessment, treatment) compared to people without dementia, randomised controlled trials 
(RCTs) in nursing home settings provide evidence that a stepped analgesic treatment can 
lead to a reduction in a range of behavioural and psychological symptoms (see Section 
1.2.3). Whilst evidence shows the benefits of assessment and treatment of pain for people 
with dementia, the focus of such research has been largely restricted to nursing home, 
hospital, and palliative settings, despite upwards of 60% of people with dementia living in the 
community in the UK (Prince et al., 2014). To date, a number of reviews (Corbett et al., 2012; 
Schofield et al., 2005; Stolee et al., 2005; Herr et al., 2006a; Smith, 2005; Park, Castellanos-
Brown & Belcher, 2010; Ng et al., 2012; While & Jocelyn, 2009) and a meta-review (Lichtner 
et al., 2014; Closs et al., 2016) have examined pain assessment and/or pain treatment for 
people with dementia. However, previous reviews have not taken account of the residential 
setting of the person with dementia, and the influence this may have on findings. Many of the 
reviews almost exclusively focus on people with dementia that can no longer verbally 
communicate their pain (Herr et al., 2006a; Smith; Park et al., 2010), or assessed 
observational pain tools specifically (Ng et al., 2012; Closs et al., 2016). 
Despite the abundance of systematic reviews, there has yet been a review to investigate 
pain assessment and pain treatment for people with dementia living in community settings. 
This highlights a significant knowledge gap in understanding the needs of community-
dwelling people with dementia. People with dementia living in the community have greater 
diversity in the capacity to self-report their pain; differences may exist in informant reports 
Chapter Three: Systematic Review 
 
 
61 
 
from family caregivers compared to formal caregivers who may have professional training in 
pain assessment. Finally, access to healthcare professionals may be different for people with 
dementia living in the community compared to people living in nursing home settings. This 
chapter builds upon the existing knowledge of pain assessment and pain treatment for 
people with dementia gained from the literature review, but narrowing the focus to people 
living in the community. An adapted version of this chapter has recently been published 
(Bullock et al., 2019). 
3.2 An overview of systematic reviews 
Systematic reviews summarise large bodies of evidence endorsing systematic strategies to 
limit bias, critically appraise, and to synthesise evidence to answer a specific research 
question (Cook, Mulrow & Haynes, 1997). Systematic reviews allow researchers, clinicians, 
consumers, and policy makers to keep up to date with the current evidence in their field 
without the need to allocate the time and resources to find, appraise, and interpret a large 
amount of primary research evidence (Higgins & Green, 2011). As a result, systematic 
reviews have become increasingly important in healthcare research (Moher, Liberati, Tetzlaff 
& Altman, 2010) to inform and influence healthcare management and policy making (Lavis, 
Posada, Haines & Osei, 2004).  
3.2.1 Strengths and limitations of systematic reviews 
By using replicable and transparent methods, an objective appraisal of the evidence means 
that potential biases can be minimised (Egger, Davey-Smith & Altman, 2001). Systematic 
strategies can identify, tabulate, and integrate evidence objectively, meaning that potential 
conflicts and disagreements between individual research papers are resolved (Egger et al., 
2001). Systematic reviews have the potential to identify gaps in the literature and 
methodological flaws to develop future research and intervention. When collating evidence 
for a systematic review and thus making the research evidence more accessible for a larger 
audience, the likelihood of unnecessary replication of research is minimised.  
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Despite the strengths of systematic reviews, it is also important to acknowledge the potential 
limitations associated with their conduct and interpretation. Systematic reviews often answer 
a relatively narrow question, with a primary focus on the extraction, tabulation and 
summation of empirical data. The narrow focus may limit the inclusion of relevant and 
informative evidence (Greenhalgh et al., 2018). To overcome this limitation, a narrative 
literature review was also conducted to provide a broader summary of the relevant literature 
with interpretation and critique (see Chapter Two). Furthermore, a critical phase of a 
systematic review is to conduct a ‘comprehensive search strategy with the ability to identify 
all studies applicable for the review’ (Higgins & Green, 2011), however this may be time 
consuming due to the high sensitivity of the screening strategies. The quality of the 
systematic review itself can be compromised by the inclusion of low quality papers leading to 
inaccurate conclusions. In addition, prior knowledge of the research field may influence 
alterations to the inclusion and exclusion criteria during the protocol development stages of 
the systematic review, leading to increased bias. 
3.3 Aim of the systematic review 
This review aims to provide a broad overview of the current literature examining pain 
assessment and pain treatment for community-dwelling people with dementia. Specific 
objectives of the systematic review were to: 
 Synthesise the evidence on the use of pain assessment tools and methods, and 
assess their utility for community-dwelling people with dementia 
  Synthesise the evidence on the use of pain treatments and evidence of efficacy for 
community-dwelling people with dementia 
3.4 Methods 
3.4.1 Search strategy 
I created a comprehensive search strategy with oversight from my supervisory team (PC, JB) 
and members of the systematic review team (JJ) within the School of Primary, Community 
and Social Care.  
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The search strategy was initially created and piloted using MEDLINE Ovid. Search terms 
were obtained from existing search strategies from systematic reviews in the field (see 
Section 3.1), with additional terms added as appropriate. The search strategy contained five 
filters, each of which included subject headings (e.g. MeSH headings), title and abstract in-
text terms (see Table 3.1).  
The search strategy was created to be highly sensitive. In this context, sensitivity refers to a 
‘search’s ability to correctly identify relevant articles’ (Higgins & Green, 2011). By using a 
highly sensitive and comprehensive search strategy in a number of medical and 
psychological databases with overlapping content, precision may be reduced. In this context, 
precision is defined as the amount ‘of relevant articles identified by a search strategy’ 
(Higgins & Green, 2011). A highly sensitive, yet low precision search strategy increased the 
amount of time taken to remove irrelevant and duplicate texts, however minimised the 
likelihood of missing potentially relevant articles (Montori, Wilczynski, Morgan & Haynes, 
2005).
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Table 3.1. Example of MEDLINE Ovid Search Filters and Terms 
Search Filter Example* of search terms 
Dementia exp Dementia/ dement*.ti,ab. (cognitive* adj3 impair*).ti,ab. 
Alzheimer*.ti,ab. lewy* bod*.ti,ab. pick* disease.ti,ab. creutzfeldt.ti,ab. 
huntington*.ti,ab. binswanger*.ti,ab. Wernicke Korsakoff.ti,ab. 
AND 
Community exp Primary Health Care/ exp General Practitioners/ exp Community 
Health Services/ communit*.ti,ab. community?dwelling.ti,ab. 
domestic.ti,ab. (home adj3 dwelling).ti,ab. general practi*.ti,ab. family 
practi*.ti,ab. family doctor.ti,ab. GP.ti,ab. GPs.ti,ab. doctor*.ti,ab. 
outpatient*.ti,ab. 
AND 
Pain exp Pain/ discomfort.ti,ab. nociception.ti,ab. pain*.ti,ab. 
AND 
Pain 
assessment 
(pain adj3 tool).ti,ab. (rating adj3 pain).ti,ab. (scale* adj3 pain).ti,ab. 
(measur* adj3 pain).ti,ab. (assess* adj3 pain).ti,ab. (pain adj3 
behavio?r).ti,ab. (observat* adj3 pain).ti,ab. (identif* adj3 pain).ti,ab. 
OR 
Pharmacological exp Analgesics/ analgesi*.ti,ab. drug*.ti,ab. (‘drug*’ adj3 ‘trial’).ti,ab. 
medication*.ti,ab. prescription*.ti,ab. pharmacolog*.ti,ab. (‘pain’ adj3 
‘manag*’).ti,ab. assess*.ti,ab. treat*.ti,ab. opioid*.ti,ab. 
paracetamol.ti,ab. acetaminophen.ti,ab. tylenol.ti,ab. panadol.ti,ab. 
NSAIDS.ti,ab. 
OR 
Non-
pharmacological 
exp Exercise/ exp Cognitive Therapy/ therap*.ti,ab. 
non?pharmacol*.ti,ab. physiotherap*.ti,ab. rehabilitation.ti,ab. 
aromatherap*.ti,ab. art therap*.ti,ab. acoustic stimulation.ti,ab. (colo?r 
adj3 therap*).ti,ab. music.ti,ab. (play adj3 therap*).ti,ab. 
movement.ti,ab. role play.ti,ab. tai chi.ti,ab. 
*Full MEDLINE search strategy available in Appendix 1.
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After the search strategy was piloted in MEDLINE, a mapping exercise was conducted to 
determine the most appropriate MeSH headings for each database. In addition, wildcard (a 
symbol that is added towards the end of a word; e.g. therap* would search for therapy or 
therapies) and truncation symbols (a symbol that replaces or represents a single character; 
e.g. colo?r would search for colour and color) were adapted depending upon the interface. 
After adaptation of the search strategy, eight databases were searched; MEDLINE, 
EMBASE, AMED (Allied & Complementary Medicine Database), AgeLine, CINAHL, 
PsycINFO, Web of Science Core Collection, and The Cochrane Library.  
3.4.2 Additional searches 
In addition to database searches, I conducted further supplementary searches. The 
reference lists of the eligible papers, relevant commentaries, literature reviews, and 
systematic reviews were hand screened. Finally, a citation search of all included papers were 
tracked to ascertain subsequent potential publications, as well as searching the publications 
of researchers publishing in the area of dementia and pain. These additional searches 
reduced the chance of missing potentially relevant papers. 
3.4.3 Criteria for considering studies for this review 
3.4.3.1 Inclusion 
All full text peer-reviewed scientific journal articles were eligible for inclusion, irrespective of 
study design or publication date. Studies were eligible if they were published in English or 
other languages translatable via colleagues at the School of Primary, Community and Social 
Care.  
Study population 
 Study participants must have a diagnosis of dementia. The term ‘cognitive 
impairment’ or a cognitive assessment score (e.g. MMSE) was not deemed as a 
sufficient indication of dementia in isolation (see Section 1.5; Neumann-Podczaska et 
al., 2016). 
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 People with dementia must live in private residences or non-nursing home settings 
(Hunt et al., 2015). This includes living in their own home alone, with family members, 
in an assisted living facility, retirement community, or residential home (Prince et al., 
2014; Hunt et al., 2015; see Section 1.7).  
 If a study included people with dementia living in a variety of settings, the 
findings specific to people with dementia living in the community were 
extracted independently where possible. 
Issue of interest 
 Studies examining pain assessment; including self‐report, informant report, and 
behavioural observation pain tools and methods (Cohen-Mansfield & Lipson, 2008) 
 Studies examining pharmacological and non-pharmacological treatments for pain 
 Studies evaluating the effectiveness of pharmacological or non-pharmacological 
treatments for pain by using a pain-specific assessment tool 
Comparison group 
The presence, absence, or type of comparison group depends upon the study design. 
Examples of comparison groups may include: 
 Older adults without a diagnosis of dementia residing in the community 
 Older adults with dementia residing in an alternative setting (e.g. nursing homes). 
3.4.3.2 Exclusion 
 Studies solely focused on malignant pain. Cancer pain is distinctly different from 
persistent pain (Shega, Hougham, Stocking, Cox-Hayley & Sachs, 2006), and 
therefore beyond the realm of the present review. 
3.4.4 Screening of texts 
All identified texts were exported into RefWorks, where exact and close duplicates were 
checked for accuracy and removed. All remaining texts were exported into an excel 
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document to complete title and abstract screening, and to record whether the article was 
eligible or ineligible for the review, the reason for exclusion, and to provide comments.  
 I completed title screening to remove obviously irrelevant references 
 I completed abstract screening, with 20% of the abstracts blind screened 
independently by PC with good interrater agreement (>95%) 
After abstract screening, the references eligible for full text screening were retrieved where 
possible. I contacted the author to request access if full text articles could not be obtained. 
Full text articles were managed in Mendeley Reference Manager Software. This software 
had the ability to attach PDF documents, make in text notes, and write comments. To 
accompany the Mendeley Reference Manager Software, an excel document was used to 
record whether the article was eligible or ineligible for the review, reason for exclusion, and to 
provide comments. I completed full text screening, with 20% of the full text articles blind 
screened independently by PC with good interrater agreement (>95%).  
If at any point throughout the screening process discrepancies, disagreement, or uncertainty 
arose regarding the eligibility of references, a third independent reviewer (JB) was employed 
to aid consensus prior to a final decision. 
3.4.5 Data extraction 
I completed data extraction, which was checked for consistency and accuracy by two 
independent reviewers (PC and JB). Data were extracted onto a standardised data extraction 
form. The extracted data included bibliographic information (author, date, journal, country of 
origin), participant characteristics (sample size, the type and stage of dementia), and 
information regarding the pain assessment and pain treatments (e.g. the pain assessment 
tool used, the prevalence of analgesics). If further information or clarification was required, I 
contacted the author of the paper. 
3.4.6 Quality appraisal 
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Quality assessment is an integral element of the systematic review process to determine 
each paper’s susceptibility to bias. To assess the quality of papers in this review, the 
National Institute of Health (NIH) toolkit was used (National Heart, Lung, and Blood Institute, 
2014). The NIH tools were developed by researchers from the Agency for Healthcare 
Research and Quality Evidence-Based Practice Centres, the Cochrane Collaboration, and 
the National Health Service Centre for Reviews and Dissemination, as well as 
methodologists and experts in the field. Guidance documents were created to provide 
detailed descriptions, and applications of each assessment item to assist reviewers to focus 
on the concepts, questions, and domains that are integral for the critical appraisal and 
evaluation of internal validity. 
The NIH toolkit was chosen for numerous reasons. Firstly, despite the exploratory nature of 
this review, no eligible qualitative studies were identified that included participants with 
dementia living in the community. Therefore, all eligible studies were quantitative in nature, 
including case-control, observational cohort, cross-sectional, controlled intervention, pre-post 
studies with no control group, and ABAB within subject designs. At the time of conducting the 
review, there was no obvious ‘gold standard’ tool to assess the quality or risk of bias for 
ABAB within subjects study designs. However, in consultation with the systematic review 
team in the School of Primary, Community, and Social Care, the Before-After (Pre-Post) 
Studies with No Control Group tool by the NIH was determined as the most appropriate tool. 
Therefore, the NIH provided a suitable tool to quality appraise each of these study designs. 
Secondly, the NIH quality assessment tools have been used in other health related 
systematic reviews (Ofori-Asenso et al., 2017; Ismail et al., 2017; Hatzis, Dawe & Harnett, 
2017), and are highly regarded, and appropriate to quality assess observational and 
intervention designs (Sanderson, Tatt & Higgins, 2007). Finally, by using each tool within the 
NIH toolkit there was a degree of convergence and commonality across all tools. For 
example, each tool focused my attention to identify potential flaws in study method, 
implementation, confounding, study power, and other sources of bias (e.g. patient selection, 
performance, attrition, and detection). 
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Each tool in the NIH toolkit consists of 11 to 14 items (dependent on design type), each 
evaluated as ‘yes’, ‘no’, or ‘not applicable/cannot decide’ as guided by NIH guidance 
documents. Each item was used to guide the overall quality rating of ‘good,’ ‘fair,’ or 
‘poor’. The overall rating of the study was considered during the analysis process, with more 
confidence and weight being given to studies with a good and fair quality rating.  
I completed the quality assessment of included studies, with a 20% sample blind checked by 
PC, again, with good interrater agreement (>95%). Discrepancies were resolved in 
discussion with a third reviewer (JB).  
3.4.7 Analysis approach 
The results of a systematic review can be summarised statistically, in the form of a meta-
analysis, or descriptively, as a narrative synthesis. Due to heterogeneity; of the sample 
populations, settings, study designs, follow up periods, interventions, and reported outcomes, 
as well as a lack of statistical information to perform a meta-analysis, a narrative approach 
was adopted. Such an approach involves the ‘synthesis of findings from multiple studies that 
relies primarily on the use of words and text to summarise and explain the findings’ (Popay et 
al., 2006, p. 5). As Popay and colleagues continue to discuss, narrative synthesis 
approaches for systematic reviews are sometimes wrongly viewed as a ‘second best’ 
approach. The positives of conducting a narrative synthesis are often overlooked, with the 
ability to produce a convincing story based upon quality assessed evidence to bridge the 
gaps between research, policy, and practice. To conduct the narrative synthesis, the 
guidance document by Popay et al. (2006) was followed.  
Each study was assigned to the overarching theme or ‘cluster’ of ‘pain assessment’ and/or 
‘pain treatment’ (Popay et al., 2006). Studies were further clustered thematically to form sub-
domains. Sub-domains for pain assessment were self-report, informant report, and 
behavioural observation. Sub-domains for pain treatment were pharmacological (further 
clustered by analgesic potency; paracetamol, NSAID, and opioid) and non-pharmacological 
treatments. Studies were tabulated based on their domain and sub-domain. This allowed for 
Chapter Three: Systematic Review 
 
 
70 
 
the initial comparison within and across study findings. To deepen the analysis, idea webbing 
was used to identify the key relationships, connections, commonalities, groupings, and 
differences between the studies in each domain and sub-domain. Tabulation and idea 
webbing exercises allowed for the identification of patterns across the data to draw 
informative conclusions relevant to current research, policy, and practice, whilst taking into 
account the quality rating of each study (Popay et al., 2016).   
3.5 Results 
3.5.1 Identification of studies  
Searches were conducted from inception to October 2018. Searches identified 6741 unique 
records. One potentially eligible paper could not be obtained in full text despite contacting the 
authors (Park, Chun & Gang, 2015). Three additional papers were found through 
supplementary searching (Brummel-Smith et al., 2002; Schmader et al., 1998; Jensen-
Dahm, Gasse, Astrup, Mortensen & Waldemar, 2015). One hundred and twenty-nine papers 
were screened at full-text stage. A number of studies failed to provide clear definitions 
regarding the residency of the participants and therefore the authors were contacted. One 
author responded to confirm that participants lived in the community (Benedetti et al., 2006). 
This process resulted in 32 studies included within the review (see Figure 3.1). 
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Figure 3.1. PRISMA Flow diagram 
 
Upon full text screening it became apparent that a number of studies used the same sample 
but reported different outcomes. Three studies used the same sample identified from the 
Palliative Excellence in Alzheimer Care Efforts (PEACE) project (Shega, Hougham, Stocking, 
Cox-Hayley & Sachs, 2005; Shega et al., 2004; Shega et al., 2006). Two of these studies 
examined informant ratings using the VDS (Shega et al., 2005; Shega et al., 2004), while the 
other examined pharmacological pain treatment use (Shega et al., 2006). Additionally, three 
studies used the same Kuopio 75+ cohort to examine analgesic prescriptions for people with 
dementia (Hartikainen, Mäntyselkä, Louhivuori‐Laako, Enlund & Sulkava, 2005a; 
Hartikainen, Mäntyselkä, Louhivuori-Laako & Sulkava, 2005b; Mäntyselkä, Hartikainen, 
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Louhivuori-Laako, & Sulkava, 2004), however one study excluded two participants in their 
analysis (Mäntyselkä et al., 2004). 
Most of the studies in this review focused on dementia as a whole, without specifying the 
subtype diagnosis, with a minority of studies only recruiting participants with Alzheimer’s 
disease (AD), and Dementia with Lewy Bodies (DLB). No other subtypes of dementia were 
investigated independently, and no studies stratified their findings dependant on dementia 
subtype. Out of the 32 studies included in the review, 12 restricted recruitment to participants 
with mild-to-moderate, or ‘newly diagnosed’ dementia.  
Few studies included a matched control group of people without dementia (Hamina et al., 
2016; 2017; 2018; Hunt et al., 2015; Benedetti et al., 2006; Bell et al., 2011). Other studies 
used a non-matched comparator group of older adults without dementia living in the 
community (Brummell-Smith et al., 2002; Hartikainen et al., 2005a; 2005b; Mäntyselkä et al., 
2004; Haasum et al., 2011; Schmader et al., 1998; Jensen-Dahm et al., 2015; Haasum et al., 
2011). Two studies also included people with dementia living in nursing homes as 
comparator groups (Haasum et al., 2011; Jensen-Dahm et al., 2015). 
Of the included studies, 11 reported findings on pain assessment tools or methods, whereas 
27 reported findings that examined treatments for pain. Fifteen studies were conducted in 
North America, eight in Finland, two in Denmark, two in the United Kingdom, and one each in 
Canada, Sweden, France, Japan, and Italy.  
3.5.2 Quality assessment 
Using the NIH toolkit, four studies (12%) were assessed as good quality, 21 (66%) as fair 
quality, and seven (22%) as poor quality. 
Cross-sectional and cohort study designs were assessed using the NIH Quality Assessment 
Tool for Observational Cohort and Cross-Sectional Studies. Many questions in the tool 
received a high percentage of ‘no’ responses largely because of the cross-sectional design. 
For example, only seven (22%) studies investigated the exposure prior to the outcome. A ‘no’ 
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response did not necessarily lead to a poor quality rating, but rather indicated areas of 
potential biases that may influence the relationship between the exposure and outcome 
associated with cross-sectional designs. Intervention studies were quality assessed using the 
NIH Quality Assessment Tools for Controlled Intervention Studies, or Pre-Post Studies with 
No Control Group depending upon the presence of a comparator group. One study was a 
cohort design with a nested case-control study and was therefore quality assessed using 
both the Observational Cohort and Cross-Sectional tool, and the Case-Control tool (Gallini et 
al., 2013). The quality rating of each study is provided in the summary tables (see Table 3.2, 
Table 3.3, and Table 3.4). An in-depth investigation of quality assessment is provided in 
Appendix 2. 
3.5.3 Pain assessment tools and methods 
Eleven studies examined pain assessment tools and methods for community-dwelling people 
with dementia. Four studies examined self-report pain tools, seven studies examined 
informant ratings of pain, and one study examined a behavioural observation tool (see Table 
3.2). 
Only one study provided an overview of the frequency of pain assessment for community-
dwelling people with dementia in primary care (Li et al., 2015), with pain assessment 
documented in 98% of patients’ medical records. Of the pain assessments documented in 
this study, 94% used the Numerical Rating Scale (NRS), Visual Descriptor Scale (VDS), or 
Faces Pain Scale (FPS), whereas only 2% of medical records reported the use of modified or 
dementia-specific pain scales. However, people with dementia in this study had mild-to-
moderate dementia, and therefore modification may not be required. 
3.5.3.1 Self-report 
Four studies (one good quality; Snow et al., 2009, one fair quality; Breland et al., 2015, and 
two poor quality; Brummel-Smith et al., 2002; Krulewitch et al., 2000) examined self-report 
for people with dementia. Two poor quality studies examined the FPS, Visual Analogue 
Scale (VAS), and Pain Intensity Scale (PIS) (Brummel-Smith et al., 2002; Krulewitch et al., 
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2000), whereas two studies examined the Philadelphia Geriatric PIS (Snow et al., 2009; 
Breland et al., 2015). The completion rates of the FPS, VAS and PIS were between 53-67% 
for people with largely moderate-to-severe dementia (MMSE of 15.6, ± 5.9 SD; MMSE of 
15.7, ± 5.9 SD). Two studies found that the Philadelphia Geriatric PIS was sensitive to 
identify painful conditions and predictive of negative psychosocial events at 4 months follow 
up (Breland et al., 2015; Snow et al., 2009). 
3.5.3.2 Informant pain ratings  
In total, seven studies (four fair quality; Barry et al., 2016; Jensen‐Dahm et al., 2012; Orgeta, 
Orrell, Edwards, Hounsome & Woods, 2015; Shega et al., 2004, and 3 poor quality; 
Krulewitch et al., 2000; Hunt et al., 2015; Kunik et al., 2017) investigated informant ratings of 
pain compared to self-reported pain. Tools included the VDS, EQ5D, the Philadelphia 
Geriatric PIS, FPS, VAS, and PIS. Five of these studies compared the percentage of self-
reported and informant reported pain for community-dwelling people with dementia, finding 
that family caregivers reported pain presence in the person with dementia more than the 
person with dementia (see Figure 3.2). Three studies investigated the congruence between 
people with dementia and their family caregiver’s rating of pain, with interrater reliability 
ranging from 0.25 to 0.34 (Krulewitch et al., 2000; Jensen‐Dahm et al., 2012; Orgeta et al., 
2015), with two fair quality studies finding an average agreement of 58.6% (range 58.2% to 
59%; Orgeta et al., 2015; Shega et al., 2004). In accordance with these findings, Kunik et al. 
(2017) found that family caregivers reported a higher mean pain score than the person with 
dementia.  
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Figure 3.2. Bar chart to illustrate the percentage of pain self-reported by people with 
dementia compared to informant reported by a family caregiver 
 
3.5.3.3 Observation of pain behaviours   
One poor quality study investigated the Hospice Approach Discomfort Scale, a behavioural 
observation pain tool (Snow et al., 2009). Behavioural observation tools aim to identify pain 
using non-verbal cues (e.g. behaviour, facial expression, body language) (see Section 
2.3.3.1). Such tools are often psychometrically tested by comparing their score of pain to 
other means of pain assessment (e.g. self-reported pain; Zwakhalen et al., 2006). This study 
reported poor correlations between the Hospice Approach Discomfort Scale and self-
reported pain scales (FPS, VAS, and PIS); however, the authors of this study did not provide 
statistical evidence to support the findings and therefore estimations of concordance could 
not be reported.
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Table 3.2. Summary of pain assessment studies 
Author Orgeta et al (2015) Shega et al 
(2004; 2005) 
Jensen-Dahm et al(2012) Breland et al(2015) Snow et al(2009) 
Sub-theme Informant rating Informant rating Informant rating Self-report Self-report 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cohort 
Origin UK USA Denmark USA USA 
Diagnosis Dementia Dementia AD or DLB Dementia Dementia 
n (reference/control) 488¶| 115¶| 321¶ 136 171¶ 
Quality Fair Fair Fair Fair Good 
Pain assessment tool EQ5D VDS EQ5D PGC PIS PGC PIS 
Completion rate % - - - - - 
PWD (caregivers) % [p] 45 (59) [p<.001] 32 (52) 32.9 (52) - - 
Informant agreement 58.2% 
Kappa = 0.25 
59% congruent  
40% over report 
13% under report 
Kappa = 0.34 
(X2 = 71.7, df= 4; p<.001) 
- - 
Predictive validity - - - Pain diagnosis in 
previous year (β=.20, 
t132=2.17, p<.05) 
Increased depression (z=2.70) 
agitation (z= 2.33) decreased 
pleasant events (z=-2.38) 
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Table 3.2. cont. Summary of pain assessment studies 
Author Barry et al(2016) Li et al(2015) Brummel-Smith et 
al(2002) 
Krulewitch et al(2000) Hunt et al(2015) Kunik et al(2017) 
Sub-theme Informant rating Self-report Self-report Self-report 
Informant rating 
Behavioural observation 
Informant rating Informant rating 
Design Cross-sectional Cross-sectional Cohort Cross-sectional Cross-sectional Cross-sectional -
Intervention baseline 
Origin UK USA USA USA USA USA 
Diagnosis Dementia Dementia Dementia  Dementia Dementia Dementia 
n 
(reference/control) 
75 203 154 (255) 156¶ 802 (802) 203¶ 
Quality Fair Fair Poor Poor Poor Poor 
Pain assessment 
tool 
VDS PGC PIS FPS, VAS, PIS FPS, VAS, PIS, HADS VDS PGC PIS 
Use of tool % - 94% self-report 
2% modified tool 
- - - - 
Completion rate % - - 32.5 PIS, 62; FPS, 53; VAS, 53 
33 unable to complete 
FPS, VAS, or PIS  
- - 
PWD (caregivers) 
% [p] 
Pain now - 36 (53.3) 
[p=.033] 
- - - Activity limit 40.1 
(46.6) 
[p= .03] 
- 
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Table 3.2. cont. Summary of pain assessment studies 
Average day – 57.3 
(70.7) [p=.089] 
Bothersome 62.7 
(64.4) [p=.59] 
Informant 
agreement 
   kappa = .32 
HADS: NR 
 Mean Pain Score: 
Worst pain: 2.93 
(3.15) Overall pain: 
2.04 (2.24) 
Predictive validity - - - - -  
¶ dyadic paired participants (e.g. person with dementia and their family caregiver). 
Abbreviations: CI, confidence interval; FPS, Faces Pain Scale; HADS, Hospice Approach Discomfort Scale; IPT, Iowa Pain Thermometer; NR, not reported; NRS, 
numerical rating scale; OR, odds ratio; PGC, Philadelphia Geriatric Centre; PIS, Pain Intensity Scale; PWD, people with dementia; VAS, Visual Analogue Scale; VDS, 
Visual Descriptor Scale. 
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3.5.4 Treatments for pain  
Twenty-two papers (three good quality; Gilmartin et al., 2015; Hamina et al., 2017; Hamina et 
al., 2018, 16 fair quality; Haasum et al., 2011; Li et al., 2015; Barry et al., 2016; Jensen‐
Dahm et al.,, 2012; Hartikainen et al., 2005a; Mäntyselkä et al., 2004; Schmader et al., 1998; 
Jensen-Dahm et al., 2015; Hamina et al., 2016; Bell et al., 2011; Thakur et al., 2016; Breland 
et al., 2015; Shega et al., 2006; Regier & Gitlin, 2018; Grace, Allen, Ivey, Knapp & Burgio, 
2018; Gallini et al., 2013, and three poor quality; Brummel‐Smith et al., 2002; Hunt et al., 
2015; Nakanishi et al., 2018) provided an overview of the pain treatments used by people 
with dementia (see Table 3.3).  
3.5.4.1 An overview of analgesic use  
Two papers investigated the use of analgesics for community-dwelling people with dementia 
over time, irrespective of their analgesic potency (Gilmartin et al., 2015; Hamina et al., 2016). 
Hamina et al. examined analgesic use during the first 180 days after index date (dementia 
diagnosis, or equivalent for matched controls), stratified by the year of index date (from 2005 
to 2011). People with and without dementia in 2011 were 2.3 times more likely to be 
prescribed analgesic medication during the first 180 days after index date than in 2005. 
Alternatively, Gilmartin et al. found that analgesic use remained largely consistent from the 
first year following dementia diagnosis to five years after dementia diagnosis. These fair and 
good quality studies may suggest changes with prescribing practices over time (cohort 
effect), irrespective of dementia severity. 
Eleven papers reported that 24.7% to 63% of people with dementia used analgesic 
medication (Haasum et al., 2011; Li et al., 2015; Brummel‐Smith, 2002; Barry et al., 2016; 
Hartikainen et al., 2005a; Mäntyselkä et al., 2004; Hamina et al., 2016; Breland et al., 2015; 
Regier & Gitlin, 2018; Nakanishi et al., 2018; Gallini et al., 2013). Four papers found that the 
percentage of people with dementia reporting pain that did not use analgesic medication 
ranged from 30.3% to 68% (Jensen‐Dahm et al., 2012; Hunt et al., 2015; Thakur et al., 2016; 
Shega et al., 2006).  
Chapter Three: Systematic Review 
 
 
80 
 
When exploring the prevalence of analgesic use by community-dwelling people with 
dementia compared to a comparator group, four papers (all of which are fair quality) found a 
mixed trend. Research found that community-dwelling people with dementia had a lower 
(Mäntyselkä et al., 2004), similar (Hamina et al., 2016), or higher (Haasum et al., 2011) 
prevalence of analgesic medication compared to community-dwelling older adults without 
dementia. Furthermore, Schmader et al. (1998) found that community-dwelling people with 
dementia had a lower odds of analgesic prescription than community-dwelling older adults 
with mild cognitive impairment (adjusted OR 0.54, 95% CI 0.39 to 0.75). Although Haasum et 
al. found that community-dwelling people with dementia had a greater prevalence of 
analgesic prescription than community-dwelling people without dementia; they also found 
that people with dementia living in nursing homes had a higher prevalence of analgesic use 
than community-dwelling people with dementia, however this finding was non-significant 
(52.7% vs. 36%, respectively, adjusted OR 1.72, 95% CI 0.96 to 3.10). 
3.5.4.2 Categories of analgesics prescribed  
3.5.4.2.1 Paracetamol 
Good quality longitudinal research suggests that the use of paracetamol increased from the 
first year after dementia diagnosis to five-year follow up (Gilmartin et al., 2015). Despite 
being good quality, the sample size of this study became small throughout follow up due to 
attrition, potentially leading to imprecise estimates in the latter years of follow up.  
Paracetamol was used by 14% to 32% of people with dementia (Haasum et al., 2011; 
Brummel‐Smith et al., 2002; Barry et al., 2016; Hamina et al., 2016). The amount of 
paracetamol used by community-dwelling people with dementia (with the exception of 
Hamina et al., 2016) included over-the-counter and prescribed paracetamol. Evidence 
suggests that the prevalence of paracetamol use was higher for people with dementia 
compared to people without dementia (Haasum et al., 2011; Hamina et al., 2016). However, 
Haasum et al. found that people with dementia in nursing home settings used more 
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paracetamol than people with dementia in community settings (45.2% vs. 24.4%, 
respectively, adjusted OR 2.52, 95% CI 1.35 to 4.73). 
3.5.4.2.2 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
NSAID use decreased from the first year after dementia diagnosis to five years after 
diagnosis (Gilmartin et al., 2015). Additionally, the amount of NSAIDs prescribed during the 
first 180 days after index date (dementia diagnosis or equivalent for matched controls) also 
decreased each year from 2005 to 2011 (Hamina et al., 2016) suggesting a change in the 
practice of prescribing NSAID medication over time. 
Across all studies, the prevalence of NSAID use ranged from 5.9% to 21% (Haasum et al., 
2011; Brummel‐Smith et al., 2002; Barry et al., 2016; Hamina et al., 2016). Two studies 
found lower rates of NSAID use and prescription for people with dementia compared to 
people without dementia (Haasum et al., 2011; Hamina et al., 2016). Haasum et al. also 
found that people with dementia in nursing homes had a lower prevalence of NSAID 
prescription than community-dwelling people with dementia, however this was not significant 
(3.8% vs. 5.9%, respectively; OR 0.32, 95% CI 0.07 to 1.42) 
3.5.4.2.3 Opioids 
The use of opioids for community-dwelling people with dementia was relatively consistent 
from the first year after dementia diagnosis to five years after dementia diagnosis (Gilmartin 
et al., 2015). However, the amount of opioids prescribed during the first 180 days of index 
date (dementia diagnosis or equivalent for matched controls) increased each year from 2005 
to 2011, with participants in 2011 being 3.7 times more likely to be prescribed an opioid than 
in 2005 (Hamina et al., 2016). 
The prevalence of opioid use for community-dwelling people with dementia ranged from 
3.6% to 27.5% (Haasum et al., 2011; Brummel‐Smith et al., 2002; Barry et al., 2016; Hamina 
et al., 2016; 2017; 2018; Hartikainen et al., 2005a; Jensen-Dahm et al., 2015; Bell et al., 
2011). Three studies (two fair quality; Hamina et al., 2016; Bell et al., 2011, and one good 
quality; Hamina et al., 2017) show that the amount of community-dwelling people with 
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dementia prescribed opioids was less than age, sex, and region of residence matched 
controls without dementia. However, two studies (both of fair quality; Haasum et al., 2011; 
Jensen-Dahm et al., 2015) found that more people with dementia used (Haasum et al., 2011) 
or were prescribed (Jensen-Dahm et al., 2015) opioid medication compared to people without 
dementia (see Figure 3.3). 
 
Following statistical adjustment, mixed findings remained. People with dementia had higher 
odds (Jensen et al., 2015; adjusted OR 1.27, 95% CI 1.22 to 1.31), similar odds (Hamina et 
al., 2016; adjusted OR 1.02, 95% CI 1.00 to 1.02), and lower odds (Bell et al., 2011; adjusted 
OR 0.76, 95% CI 0.76 to 0.83) of opioid prescription than people without dementia. Haasum 
et al. (2011) found that people with dementia in nursing home settings had a higher odds of 
opioid use than people with dementia in community settings (adjusted OR 2.84, 95% CI 1.33 
to 6.07). 
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Figure 3.3. Prevalence of opioid use 
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When opioids were stratified based upon their strength (defined by the WHO analgesic pain 
stepladder), between 2.7% to 16.8% of people with dementia were prescribed weak opioids 
(Li et al., 2015; Jensen-Dahm et al., 2015; Hamina et al., 2016; Bell et al., 2011). The six 
month (Hamina et al., 2016) and annual crude prevalence (Bell et al., 2011) of weak opioid 
use was lower among community-dwelling people with dementia compared to older adults 
without dementia. This finding was also evident when annual prevalence estimates were 
adjusted (Jensen-Dahm et al., 2015). 
Strong opioids 
The proportion of people with dementia prescribed strong opioids ranged from 0.95% to 
17.4% (Li et al., 2015; Jensen-Dahm et al., 2015; Hamina et al., 2016; Bell et al., 2011). 
Hamina et al. (2016) found that the prevalence of strong opioid prescription was higher for 
community-dwelling people with dementia compared to matched older adults without 
dementia during the 180 days after index date (dementia diagnosis or equivalent for controls) 
(1.3% vs. 1.1%, respectively). In accordance with these findings, the annual prevalence of 
strong opioid prescription was higher among community-dwelling people with dementia 
compared to matched older adults without dementia (0.95% vs. 0.76%, respectively, 
adjusted OR 1.26, 95% CI 1.05 to 1.51; Bell et al., 2011), and a comparator group of older 
adults without dementia (17.4% vs. 7.1%, respectively, adjusted OR 1.79, 95% CI 1.72 to 
1.86; Jensen-Dahm et al., 2015).  
3.5.4.3 Non-pharmacological treatments used 
One fair quality study provided an overview of the non-pharmacological treatments used for 
community-dwelling people with dementia (Li et al., 2015). This study examined the quality of 
pain care for community-dwelling people with dementia using medical notes from primary 
care, geriatric, nursing, and mental health/psychiatric outpatient clinics. This study concluded 
that with the exception of exercise (45.8%), all other non-pharmacological treatments 
(physical therapy, pain education, and community resources) were underused (19.2%, 
29.6%, 17.2%, respectively). Although this paper concluded that non-pharmacological 
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treatments were underused for people with dementia, this may be implicated by poor 
recording of such treatments in medical records.
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Table 3.3. Summary of pain treatment studies 
Author Hartikainen et 
al(2005a;2005b) 
Mäntyselkä et 
al(2004) 
Schmader et 
al(1998) 
Jensen-Dahm et 
al(2012)  
Jensen-Dahm et 
al(2015) 
Haasum et al(2011) 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional 
Origin Finland Finland USA AD or DLB Denmark Sweden 
Diagnosis Dementia Dementia Dementia Dementia Dementia Dementia 
n (reference)† 77 (446) 75 (446) 100 (420) 321¶ 35,455 (870,645) 119 (2199†, 186‡) 
Quality Fair Fair Fair Fair Fair Fair 
Analgesic use % 
(control %) 
63  
 
33.3 (47.3) - 51.5†† 
8.3 received >1 
- 36 (24.3†, 52.7‡) 
Analgesic use, 
PWD vs. control 
[OR (95% CI)] 
- - 0.54 (0.39 to 0.75) 
(reference group 
cognitive 
impairment) 
- - Nursing home vs. 
community 1.72 (0.96 
to 3.10)§ 
Paracetamol 
use % (control 
%) 
58 (paracetamol 
and NSAID) 
- - - - 24.4 (15.4†, 45.2‡) 
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Table 3.3. Summary of pain treatment studies 
Paracetamol 
use vs. control 
[OR (95% CI)] 
- - - - - Nursing home vs. 
community 2.52 (1.35 
to 4.73)§ 
NSAID use % 
(control %) 
58 (paracetamol 
and NSAID) 
- - - - 5.9 (12†, 3.8‡) 
NSAID use vs. 
control [OR 
(95% CI)] 
 - - - - 0.32 (0.07 to 1.42)§ 
Opioid use % 
(control %) 
13 - - - 27.5 (16.9); Weak 14.9 
(12.4); Strong 17.4 
(7.1) 
 
14.3 (8†, 30.1‡) 
Opioid use vs. 
control [OR 
(95% CI)] 
- - - - All 1.27 (1.22 to 1.31); 
buprenorphine 2.57 
(2.41 to 2.74) 
Nursing home vs. 
community 2.84 (1.33 
to 6.07)§ 
Non-pharm (%) - - - - - - 
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Table 3.3 cont. Summary of pain treatment studies 
Author Brummel-Smith et 
al(2002) 
Gallini et al(2013) Gilmartin et 
al(2015) 
Hamina et al(2017) Hamina et al(2016) Barry et al(2016) 
Design Cohort Cohort, nested 
case-control 
Cohort Cohort Cohort Cross-sectional 
Origin USA France Finland Finland Finland Northern Ireland 
Diagnosis Dementia AD AD AD AD Dementia 
n (reference)† 154 (255) 595 236¶ 62,074 (62,074) 67,215 (67,215) 75¶ 
Quality Poor Fair Good Good Fair Fair 
Analgesic use % 
(control %) 
49 received >1 26 
13 persistent 
13.6, 10.6, 13.7, 
16.8, 15.3§§ 
- 34.9 (33.5) 40 
20 taking ≥2 
Analgesic use, 
PWD vs. control 
[OR (95% CI)] 
- - - - 2011 vs. 2005 [2.34 
(2.24 to 2.45)] 
AD vs. no AD [1.02 
(1.00 to 1.04)] 
- 
Paracetamol use % 
(control %) 
14 67.5¶¶ 5.5, 5.6, 5.4, 
13.0, 11.1§§ 
- 25 (19.1) 32 
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Table 3.3 cont. Summary of pain treatment studies 
Paracetamol use 
vs. control [OR] 
- - - - - - 
NSAID use % 
(control %) 
21 31.2¶¶ 8.1, 4.0, 7.7, 3.1, 
4.1§§ 
- 13.3 (17.4) 8 
NSAID use vs. 
control [OR (95% 
CI)] 
- - - - 2011 vs. 2005 [0.73 
(0.69 to 0.77)] 
AD vs. no AD [0.71 
(0.69 to 0.73)] 
- 
Opioid use % 
(control %) 
13 36.2¶¶ 1.3, 1.5, 3.0, 2.3, 
1.4§§ 
All 21.1 (26.8); 
Long term 7.2 (8.7) 
All 7.1 (8.3); Weak 5 
(6.9); Strong 1.3 (1.1) 
16 
Opioid use vs. 
control [OR (95% 
CI)] 
- - - - 2011 vs. 2005 [3.78 
(3.44 to 4.15)] AD vs. 
no AD [0.79 (0.75 to 
0.82)] 
- 
Non-pharm (%) - - - - - - 
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Table 3.3 cont. Summary of pain treatment studies 
Author Bell et al(2011) Hunt et al(2015) Thakur et 
al(2016) 
Breland et 
al(2015) 
Li et al(2015) Shega et al(2006) 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional 
Origin Finland USA USA USA USA USA  
Diagnosis 
(subtype) 
AD Dementia Dementia Dementia Dementia Dementia 
n (reference)† 28,089 (28,089) 802 (802) 202 136 203 115¶ 
Quality Fair Poor Fair Fair Fair Fair 
Proportion taking 
analgesic % 
(control %) 
- 69.7†† 56†† 49 59.7 32†† 
15‡‡ 
 
Analgesic - pwd 
vs. control [OR 
(95% CI)] 
- - - - - - 
Paracetamol % 
(control %) 
- - - 40 (non-
narcotics) 
32.5 (paracetamol/NSAID) 19†† 
8‡‡ 
Paracetamol use 
vs. control [OR 
(95% CI)] 
- - - - - - 
NSAID % (control 
%) 
- - - 40 (non-
narcotics) 
32.5 (paracetamol/NSAID) 8†† 
8‡‡ 
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Table 3.3 cont. Summary of pain treatment studies 
NSAID use vs. 
control [OR (95% 
CI)] 
- - - -  - 
Opioid % (control 
%) 
All 3.56 (4.62); 
Weak 2.68 (3.83); 
Strong 0.95 (0.76) 
- - 9 Weak 16.8   
Strong 1.5 
4†† 
0‡‡ 
Opioid vs. control 
[OR (95% CI)] 
All 0.77 (0.71 to 0.84); 
Weak 0.70 (0.64 to 
0.77); Strong 1.26 (1.05 
to 1.51) 
- - - - - 
Non-pharm (%) - - - - Exercise 45.8 - 
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Table 3.3 cont. Summary of pain treatment studies 
Author Regier & Gitlin(2018) Nakanishi et al(2018) Hamina et al(2018) Grace et al(2018) 
Design Cross-sectional Cross-sectional (baseline) Cohort Cross-sectional 
Origin USA Japan Finland USA 
Diagnosis (subtype) Dementia Dementia AD Dementia 
n (reference) 596¶ 219 24,747 total n 
3327 opioid initiators (3325 
non-opioid initiators) 
543¶ 
Quality Fair Poor Good Fair 
Proportion taking analgesic % 
(control %) 
40.1 24.7 - 22 Caucasian 
30 African American 
17 Latino 
Analgesic - pwd vs. control [OR 
(95% CI)] 
- - - - 
Paracetamol % (control %) - - 58.9 (21.5) (non-opioid 
initiators) 
- 
Paracetamol use vs. control 
[OR (95% CI)] 
- - - - 
NSAID % (control %) - - 16.4 (3.6) (non-opioid 
initiators) 
- 
NSAID use vs. control [OR 
(95% CI)] 
- - - - 
Opioid % (control %) - - 13.44 (total n) - 
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Table 3.3 cont. Summary of pain treatment studies 
Opioid vs. control [OR (95% 
CI)] 
- - - - 
Non-pharm (%) - - - - 
AD, Alzheimer’s disease; CI, confidence interval; NSAID, Non-Steroid Inflammatory Drugs; OR, Odds Ratio; PWD, people with dementia, USA, United States of America; DLB 
Dementia with Lewy Bodies 
The control/reference group is community-dwelling people without dementia unless noted otherwise. However, for Haasum et al. (2011) community-dwelling people without dementia 
(†) is labelled regardless for clarification between the multiple reference groups. 
† people without dementia living in the community; ‡ people with dementia living in a nursing home; § comparison of nursing home dwelling people with dementia to community-
dwelling people with dementia as the reference population.; ¶ dyadic paired participants (e.g. person with dementia and their caregiver); †† analgesic medication in a sample of people 
with dementia reporting pain; ‡‡ analgesic medication in a sample of people with dementia reporting no pain; §§ baseline, year 1, year 2, year 3, year 4, and year 5; ¶¶ percentage of 
each analgesic in a sample of people with dementia prescribed analgesic medication 
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3.5.5 The effectiveness of treatments for pain 
Five papers investigated the effectiveness of pain treatments for community-dwelling people 
with dementia (one fair quality; Benedetti et al., 2006 and four poor quality; Kunik et al., 
2017; Nakanishi et al., 2018; Elliott & Horgas, 2009; Park, 2010). Each study measured the 
effectiveness of the intervention using pain assessment scores. Two papers investigated 
pharmacological interventions (Benedetti et al., 2006; Elliott & Horgas, 2009), with three 
investigating a non-pharmacological intervention for pain (Kunik et al., 2017; Nakanishi et al., 
2018; Park, 2010). 
Concerning pharmacological treatments, Elliot and Horgas (2009) investigated the 
effectiveness of scheduled paracetamol in reducing pain behaviours (e.g. rubbing, grimacing, 
and sighing) for people with dementia with musculoskeletal pain. This study found that 
observed pain behaviours were lower in treatment phases than during baseline phases, 
indicating that scheduled paracetamol may be effective to relieve pain for people with 
dementia. Alternatively, Benedetti et al. (2006) conducted an experimental study to 
investigate the analgesic placebo mechanism for people with dementia. This study examined 
pain scores for people with and without dementia during the expected or unexpected 
application of a topical analgesic during the insertion of a needle. This study concluded that 
the placebo effect that is typically evident when an ‘expected’ analgesic is applied (openly 
discussed with the participant) was reduced for people with dementia, in line with their loss of 
frontal executive functions (as assessed using the Frontal Assessment Battery). This finding 
highlights the potential loss of placebo mechanism for people with dementia, which may 
make analgesic treatment less effective to relieve their pain. This study was fair quality; 
however further research is essential to validate these conclusions. 
In regard to the effectiveness of non-pharmacological treatments, one study investigated a 
music intervention (Park, 2010) by asking family caregivers to assess the person with 
dementia’s pain 30 minutes before, during, and after listening to their favourite music. Many 
comparisons indicated non-significant findings (see Table 3.4) however, pain was 
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significantly lower after listening to music than before listening to music. Two studies 
investigated the effectiveness of psychosocial interventions (Kunik et al., 2017; Nakanishi et 
al., 2018). Both interventions included an element of pain education and training targeted 
towards formal (Nakanishi et al., 2018) and informal family caregivers (Kunik et al., 2017) of 
community-dwelling people with dementia. Both interventions found that the person with 
dementia’s pain reduced from baseline to post-intervention. However, in regard to other 
outcomes the efficacy was mixed. All of the studies had a small sample size, and poor quality 
ratings (see Table 3.4), limiting reliable conclusions. 
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Table 3.4. Studies evaluating the utility and effectiveness of treatments for pain   
Author Elliott & Horgas(2009) Benedetti et al(2006) Park(2010) Nakanishi et al(2018) Kunik et al(2017) 
Design Before-after ABAB within 
subjects 
Non-RCT Before-after ABAB within 
subjects 
Before-after RCT 
Sub-theme Pharmacological Pharmacological Non-pharmacological Non-pharmacological Non-pharmacological 
Origin USA Italy USA Japan USA 
Quality Poor Fair Poor Poor Poor 
Diagnosis 
(subtype) 
Dementia AD Dementia Dementia Dementia 
n (reference/ 
control) 
3 38 (16) 15 219 101¶ (102¶) 
Pain 
assessment 
Coded pain behaviours NRS M-PADE Abbey Pain Scale PGC PIS 
Intervention Paracetamol 1.3g every 
8hrs during treatment 
phases 
Open-hidden application of 
1% lidocaine during 
insertion of needle 
Preferred music initiated 30 
minutes prior to peak agitation 
time 
2-day training course, a 
web-based tool for 
ongoing monitoring and 
assessment for 
challenging behaviour, 
and multi-agency 
discussion meetings for 
formal caregivers. 
6 to 8 weekly sessions of 
45-minute home visits 
targeted to informal 
caregivers. 
Improving: caregivers pain 
recognition, 
communication, making 
daily activities pleasant 
Follow up 24 day follow up.  1 year 8 week A = Baseline = 3, 4, 7, 8. 
B = Week 1, 2, 5, 6. 
6 months 3, 6, 12 months 
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Table 3.4. Studies evaluating the utility and effectiveness of treatments for pain   
Results  
(A = baseline,  
B = Intervention) 
Ppt 1: 32.1 (A1), 18.6 
(B1), 27.5 (A2), 17.5 
(B2) Ppt 2: 33 (A1), 22.5 
(B2), 31.1 (A2), 20.1 
(B2) Ppt 3: 57.8 (A1), 30 
(B1), 53.3 (A2), 29.8 
(B2). 
The effects of the open 
treatment lowered in AD 
after 1 year (t(27) = -5.151, 
p<.001). 
Pain during vs. before (p=.06) 
Pain during vs. after (p=.86). 
Intervention weeks vs. baseline 
(p=.22). Pain after vs. before 
(t=2.21; df=28; p<.05) 
Decreased pain after the 
intervention compared to 
before (t(218)=2.63, 
p=.009). No difference in 
analgesics after the 
intervention compared to 
before (X2(1)=2.00, 
p=0.5). 
Decreased pain over time 
for treatment group (PWD 
overall pain: F(3, 412) = 
4.59, p=.004). No 
difference between 
groups.  
¶ dyadic paired participants (e.g. person with dementia and their caregiver). 
USA United States of America, NRS numerical rating scale, AD Alzheimer’s Disease, PGC Philadelphia Geriatric Centre, PIS Pain Intensity Scale, PWD person with 
dementia, M-PADE Pain Assessment in Dementing Elderly, RCT randomised control trial, ppt participant 
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3.6 Discussion 
This review provides an overview of the current evidence on pain assessment and pain 
treatment for community-dwelling people with dementia. These two areas are discussed in 
turn, contextualised by contrasting with comparative population groups, and considering 
implications for practice, research and policy.  
3.6.1 Pain assessment 
The first aim of this review was to synthesise evidence that examined pain assessment tools 
and methods for community-dwelling people with dementia. A large proportion of people with 
dementia with moderate-to-severe cognitive impairment were unable to complete a self-
report pain instrument. This finding reflects research in formal care settings that show the 
majority of people with mild-to-moderate dementia were able to complete a self-report of their 
pain (Ware et al., 2006; Kaasalainen & Crook, 2004; Chibnall & Tait, 2001; Chen & Lin, 
2015), however, the ability to complete a self-report pain tool decreased as the severity of 
dementia increased (Closs et al., 2004; Kunz et al., 2007; 2009; Lukas et al., 2013a; see 
Section 2.3.1). Recommendations encourage the use of self-report measures for people with 
dementia (irrespective of their degree of cognitive ability); however, adaptation (e.g. 
simplified language and large fonts) may be required, especially for people with moderate-to-
severe cognitive impairment (Schofield, 2018). Despite recommendations highlighting the 
importance of attempting self-report for people with dementia irrespective of the severity of 
cognitive impairment, it is important to acknowledge that people with very severe cognitive 
impairment may be unable to self-report pain, even with adaptation and full assistance 
(Wynne, Ling, & Remsburg, 2000; Closs et al., 2004). Therefore, the findings from this 
review would reiterate previous recommendations that discourage a reliance on self-report 
methods in isolation, especially for people with moderate-to-severe dementia 
(Hadjistavropoulos et al., 2014).  
This review found a degree of congruence between the person with dementia’s self-report 
and their family caregiver’s informant rating of pain, however, family caregivers reported pain 
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more commonly. In nursing home settings, congruence between the informant and the 
person with dementia’s rating of pain has also been identified (Hemmingsson et al., 2017; 
Cohen-Mansfield, 2005; Ersek, Polissar & Neradilek, 2011; Scherder & van Manen, 2005; 
Chen, Lin, & Watson, 2010). However, in some cases, nurses and nursing assistants 
underestimated the pain experienced by the person with dementia (Chen et al., 2010) 
indicating potential differences dependant on the environment of care and the relationship of 
the informant. To illustrate, a recent systematic review and meta-analysis (not specific to 
dementia) found that healthcare professionals (e.g. nurses and physicians) underestimated 
pain, whereas informal caregivers over-estimated pain (Ruben et al., 2018). Informant ‘over 
and under’ estimations of pain are likely to have negative implications for pain treatment for 
people with dementia (Neumann-Podczaska et al., 2016; Rantala et al., 2014). Studies 
investigating informant ratings of pain included in this review used self-report instruments 
(such as the VDS and EQ5D) to compare informant and self-reports of pain. Tools created 
specifically informant use (e.g. Pain Assessment for the Dementing Elderly; PADE; 
Villanueva et al., 2003, and Pain Assessment in Noncommunicative Elderly Persons; PAIN; 
Cohen-Mansfield, 2006) are yet to be tested, or validated for community-dwelling people with 
dementia.  
This review identified only one, low quality study examining a behavioural observation pain 
assessment tool, suggesting a poor correlation with self-report methods. Previous reviews 
have evaluated behavioural observation pain tools for people with dementia residing in 
formal care settings (Herr et al., 2006a; Hadjistavropoulos et al., 2007; Van Herk et al., 
2007). These reviews suggest that behavioural observation pain tools hold promise to 
identify pain for people with dementia, with UK guidance recommending the PAINAD and 
Doloplus-2 (Schofield, 2018). However, a meta-review of systematic reviews found that there 
was no single behavioural observation tool that was deemed more reliable or valid than the 
others, with the need for further psychometric development and testing (Lichtner et al., 
2014). Behavioural observation tools may be suitable for community-dwelling people with 
dementia, with preliminary evidence suggesting that lay persons and care home nurses can 
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use behavioural observation tools to identify pain (Ammaturo, Hadjistavropoulos & Williams, 
2016). The current lack of testing and development in this setting, however, as illuminated by 
this review hinders the ability to provide definitive conclusions. 
3.6.2 Treatment of pain 
The second aim of this review was to synthesise the evidence examining pain treatments for 
community-dwelling people with dementia.  
This review found mixed evidence when comparing the analgesic medications used by 
community-dwelling people with and without dementia. This mixed evidence may be 
explained by the varying healthcare organisation and funding models across each region 
(USA, Finland, and Sweden). In nursing home settings, the abundance of research means 
that a clear picture is evident. A meta-analysis found that people with dementia had a 
significantly lower analgesic prevalence compared to people without dementia (Tan et al., 
2015).  
This review identified that 30.3% to 68.0% of people with dementia reporting pain did not use 
analgesic medication. This finding is comparable to nursing home settings, where 34.2% to 
38.4% of people with dementia did not receive an analgesic medication despite experiencing 
pain (Griffioen et al., 2017b; de Souto Barreto et al., 2013). 
When analgesic medications were stratified into therapeutic classifications, more community-
dwelling people with dementia used paracetamol compared to people without dementia. 
Similar findings are evident in nursing home settings (Tan et al., 2015; Haasum et al., 2011), 
and population settings (including nursing home and community-dwelling; Lövheim et al., 
2008). The higher use of paracetamol for people with dementia is consistent with 
recommendations suggesting paracetamol as a first-line analgesic treatment (Schofield, 
2018), and the notable preference towards paracetamol due to its good safety profile 
(Kovach et al., 2000). Additionally, the recent focus of pain in people with dementia may 
have contributed to increased paracetamol use, as an attempt to provide adequate treatment 
for this vulnerable population.  
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This review found that NSAID prescribing is lower for people with dementia compared to 
people without dementia, and that NSAID use decreased over time for people with dementia. 
In accordance with these findings, in nursing home settings fewer people with dementia use 
NSAIDs than people without dementia (de Souto Barreto et al., 2013; Tan et al., 2016; Bauer 
et al., 2016). These findings potentially reflect guidelines advising that NSAIDs should only 
be prescribed with caution for older adults, and only if alternative therapies have failed 
(NICE, 2015; Abdulla et al., 2013; McLachlan et al., 2011; Cavalieri, 2007; MHRA, 2015; 
Bedson et al., 2013). The reluctance to use NSAIDs for older adults are due to the numerous 
absolute and relative contraindications (AGS Panel, 2009; Cavalieri, 2007; MHRA, 2015; see 
Section 2.4.2.5). Cognitive impairment and certain vascular-based types of dementia may be 
perceived as an additional risk factor for NSAID treatment and may contribute to caution in 
prescription. The reduction of NSAID prescriptions may have contributed to the increased 
use of paracetamol as a compensatory treatment (Haasum et al., 2011).  
This review identified three studies (Hamina et al., 2016; 2017; Bell et al., 2011) that found 
less community-dwelling people with dementia were prescribed opioids, however, two 
studies (Haasum et al., 2011; Jensen-Dahm et al., 2015) found that more community-
dwelling people with dementia used opioid medication compared to people without dementia. 
Differences between the studies may contribute to the unclear findings; opioid prescriptions 
were identified at the time of the research interview (Haasum et al., 2011), during a six-
month period of dementia diagnosis (Hamina et al., 2016), or a one-year period (during 
2005) (Bell et al., 2011). A much larger percentage of opioid prescriptions were evident when 
the length of investigation increased to a five-year period (Hamina et al., 2017). A recent 
systematic review investigating opioid use for people with dementia (irrespective of 
residential status) found that people with dementia used less opioids than people without 
dementia (Griffioen et al., 2017a). High quality research to further explore opioid use for 
community-dwelling people with dementia is essential to determine if the findings align to 
those found in other residential settings. 
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Aside from pharmacological treatments for pain, this review also wished to synthesise the 
evidence investigating the use of non-pharmacological treatments of pain for community-
dwelling people with dementia. The findings of this review highlighted a dearth of evidence 
investigating non-pharmacological treatments in this population, with the limited research 
suggesting that they are underused. This is despite healthcare professionals perceiving non-
pharmacological treatments as useful to relieve pain (Barry et al., 2012; Barry et al., 2013). 
Finally, this review aimed to evaluate the effectiveness of pharmacological and non-
pharmacological treatments; however, evidence was limited and low quality. A pilot study 
found that scheduled paracetamol treatment reduced pain scores for people with dementia 
(Elliot & Horgas, 2009). Such findings are comparable to larger trials conducted in nursing 
home settings (Knopp-Sihota et al., 2016; see Section 2.3.5). Additionally, experimental 
evidence suggests people with dementia may require more analgesia to reach the 
appropriate level of pain relief, questioning the current efficacy of analgesic treatment for 
people with dementia (Benedetti et al., 2006), however more research is required to confirm 
this finding. This review identified only poor quality papers investigating the efficacy of non-
pharmacological treatments (including music and psychosocial interventions) for pain in 
community-dwelling people with dementia, with these studies highlighting mixed efficacy. 
Other systematic reviews report that non-pharmacological treatments (e.g. music therapy, 
Reiki, reflexology, person-centred showering or bathing) can be effective to reduce pain for 
people with dementia (Pu et al., 2018; Pieper et al., 2013). However alike to community 
settings, evidence from nursing home settings is also relatively limited, with small samples 
and low quality evidence (see Section 2.4.1). 
3.6.3 Strengths and limitations 
This review has notable strengths. It is the first to provide a broad overview of the evidence 
on pain assessment and treatment for pain for community-dwelling people with dementia. 
The search strategy developed in collaboration with experienced information specialists was 
comprehensive, and was conducted in a multitude of relevant databases to reflect the many 
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disciplines associated with both dementia and pain management (such as nursing, 
psychology, and physiotherapy). In addition to database searches, extensive supplementary 
searches were also completed. Despite extensive efforts, this review acknowledges the 
possibility that potentially eligible papers were not found, and thus not included in this review. 
For example, studies may have examined pain assessment and/or treatment for community-
dwelling older adults, however a proportion of the sample have dementia (despite dementia 
not being their primary focus). 
Despite best efforts to identify research conducted for people with dementia living in the 
community, many studies were not explicit regarding the residence of participants. In some 
cases, the necessary information was requested, but was not obtained (see Section 3.4.3.1) 
and therefore potentially eligible texts may have been excluded. Additionally, some studies 
provided information on pain assessment or pain treatment for people with cognitive 
impairment, using standardised instruments such as the MMSE. However, these studies did 
not provide sufficient information to confirm that participants had a diagnosis of dementia. 
Despite being ineligible for this review, the papers investigating pain assessment (Taylor & 
Herr, 2003; Taylor, Harris, Epps & Herr, 2005) and pain treatment (Maxwell et al., 2008; 
Hanlon et al., 1996; Pokela et al., 2010; Westerbotn, Hillerås, Fastbom & Agüero-Torres, 
2008) for community-dwelling people with cognitive impairment reflect the findings and 
conclusions of this review.  
As for all systematic reviews, there is the potential for publication bias or commonly coined 
‘file drawer problem’ (Rosenthal, 1979, p. 638); the idea that a much larger proportion of 
significant findings are published than non-significant findings. Publication bias may mean 
that published studies do not reflect reality, thus implicating the conclusions of a systematic 
review. For this review, a mix of findings are evident; it is therefore anticipated that the 
likelihood for publication bias is low.  
Finally, the conclusions of this review need to be contextualised within the limited research to 
date; 12 studies actively recruited participants with mild-to-moderate, or ‘newly diagnosed’ 
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dementia, with many more recruiting an insufficient number of participants with severe 
dementia. Therefore, the extent of evidence on people with advanced dementia is limited and 
further investigation is essential in this population. 
3.6.4 Clinical implications 
Due to the minimal high quality research to date, this review was unable to provide definitive 
recommendations regarding a pain assessment tool to use with community-dwelling people 
with dementia. Alternatively, healthcare professionals should adopt a multidimensional 
approach using ‘a hierarchy of pain assessment techniques’ including self-report 
assessments, pain history information, physical examinations, informant ratings, and 
observation of pain behaviours, in line with previous recommendations (Herr et al., 2011, p. 
231). Reliance on one method alone may lead to suboptimal assessment and treatment. 
In terms pain treatment, side effects, comorbidities, and polypharmacy are common in older 
adults, with the added complexity of cognitive impairment associated with dementia. Due to 
these complexities, care is particularly needed when new analgesics are initiated to balance 
the risks (e.g. side effects) against the need for pain relief. Additionally, regular and 
structured medication reviews are needed to assess the use, efficacy, and side effects of 
analgesic prescriptions in the community. In conjunction with pharmacological strategies, 
prescribing healthcare professionals should consider the use of non-pharmacological 
strategies to minimise pharmacological burden. Such measures are essential to improve pain 
treatment for people with dementia, which as identified in this review (and the literature 
review), remains suboptimal in many areas.  
3.6.5 Research Implications 
The explorative nature of this review wished to provide an overview of preliminary evidence 
into pain assessment and pain treatment for community-dwelling people with dementia. To 
complement the exploratory nature, no studies were excluded based on their study design. 
Despite many studies exploring pain assessment and pain treatment for people with 
dementia using qualitative designs, all of these studies failed to include community-dwelling 
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people with dementia (Geddis‐Regan et al., 2018). This highlights the need for qualitative 
research exploring pain assessment and pain treatment from the perspective of the 
community-dwelling person with dementia.  
In regard to pain assessment, research comparing multiple pain assessment instruments for 
a range of dementia severities using a clear, and pre-defined protocol within a community 
sample is required. High quality evidence is essential to assess the psychometric properties 
and clinical utility of pain assessment instruments (including self- and informant-based 
measures, and behavioural observation pain tools) for community-dwelling people with 
dementia. Additionally, only one study examined pain identification and assessment at a 
population level using primary care records for people with dementia (Li et al., 2015), calling 
for an epidemiological investigation of pain identification and assessment in UK primary care 
(Jennings et al., 2018b). 
Future research investigating treatments for pain should stratify analgesic medications by 
therapeutic classification, with a focus towards high quality longitudinal evidence. 
Longitudinal evidence would allow investigation into pain for people with dementia 
throughout the course of their condition. Such evidence is essential to provide a basis for 
future RCTs, alike to those conducted already in nursing home settings where patient benefit 
has been demonstrated (Husebo et al., 2011a; Husebo et al., 2014a).  
3.7 Conclusion 
This review identified a dearth of high quality studies exploring pain assessment and/or 
treatment for community-dwelling people with dementia. The following chapter provides an 
overview of the rationale, aims, and objectives of the mixed methods investigation employed 
in this thesis, and how such aims fill the knowledge gaps outlined in the literature review 
(Chapter Two), and this systematic review. 
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4 Chapter Four: Research Aim and Objectives 
This chapter provides a brief overview of the gaps identified throughout the literature review 
(Chapter Two) and the systematic review (Chapter Three), providing a rationale for this 
investigation. Finally, the objectives and research questions that steered this thesis are 
provided. 
4.1 Gaps in the literature and rationale 
The prevalence of pain is high for people with dementia (Jensen-Dahm et al., 2012; 
Krulewitch et al., 2000; Gilmartin et al., 2015; Barry et al., 2016; Shega et al., 2004; 
Mäntyselkä et al., 2004). Limited and inconsistent experimental evidence has been 
conducted to explore the physiological implications of dementia upon the experience of pain 
(Defrin et al., 2015). However, research to date suggests that brain atrophy and lesions 
associated with dementia do not lead to clinical reductions in the pain experience (Defrin et 
al., 2015; Hadjistavropoulos, Fitzgerald & Marchildon, 2010). In fact, recent research 
suggests that people with dementia may have a heightened perception of pain (De Tommaso 
et al., 2017). These findings cause great concern; especially considering that the majority of 
research evidence throughout the literature and systematic review indicate that pain for 
people with dementia remains inadequately assessed, and suboptimally treated (Chen & Lin, 
2016; Corbett et al., 2012). 
Pain identification, assessment, and treatment has gained a great deal of research attention 
in nursing home settings at present, however little research has focused on community-
dwelling people with dementia (Hunt et al., 2015). This point was illuminated in the 
systematic review which identified limited and low quality evidence for community-dwelling 
people with dementia (see Chapter Three). This is a significant omission within the present 
body of literature because the majority of people with dementia reside in community settings 
(Prince et al., 2014). Furthermore, pain identification, assessment, and treatment for 
community-dwelling people with dementia is likely to be distinct from nursing home 
populations. In nursing home populations, care and support is often provided by a team of 
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care professionals (e.g. care assistants and nursing home nurses). In contrast, many 
community-dwelling people with dementia do not have regular contact with qualified 
healthcare professionals (Cooper et al., 2016). Instead, the care and support for community-
dwelling people with dementia is often provided in the first instance by family and friends 
(Lakey et al., 2012). Unlike care professionals, it is likely that family and friends in the 
community will have limited professional experience when providing care for people with 
dementia. Additionally, the relationship between the person with dementia and their family 
caregivers in the community is likely to be distinct from relationships formed in nursing home 
settings, with unique motivations (a sense of love, spiritual fulfilment, sense of duty) and 
strains (balancing other demands, financial challenges, social isolation) when providing care 
(Brodaty & Donkin, 2009). The distinct motivations and strains are likely to influence the 
family caregiver’s approach to, and perspective towards pain identification, assessment, and 
management for people with dementia. If the family member or friend recognises the need 
for professional healthcare involvement, GPs are often the first point of contact for ongoing 
care and support in the community (Jennings et al., 2018b; Lakey et al., 2012). This clearly 
shows a series of interconnected mechanisms to access formal care and support for people 
with dementia in the community that differ to nursing home settings.  
When GPs consider the need for specialist input, the GP acts as a gatekeeper to secondary 
care services (Sripa, Hayhoe, Garg, Majeed & Greenfield, 2019). The pain experienced by 
people with dementia may be expressed as pain behaviours and interpreted as behavioural 
and psychological symptoms (Flo, Gulla & Husebo, 2014; Husebo et al., 2011a; Pieper et al., 
2013; Tampi et al., 2017). As a consequence, GPs may refer behavioural and psychological 
symptoms to specialist secondary care services (e.g. old age psychiatry) to determine the 
driver of the symptom (Bishara, Taylor, Howard & Abdel-Tawab, 2009; Banerjee, 2009), and 
anti-psychotic medication could be prescribed (Haw, Stubbs & Yorston, 2008). This may 
indicate the unique complexity of pain assessment and interpretation within community 
settings, with multiple levels of investigation and interpretation within and between informal 
caregivers, primary care, and secondary care.  
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Recent research has called for quantitative studies to examine pain assessment and 
analgesic prescribing for community-dwelling people with dementia (Jennings et al., 2018b), 
with many of the population-based prevalence studies to date being restricted to nursing 
home populations (Lövheim et al., 2008). The need for quantitative investigation was 
illuminated by the lack of high quality longitudinal research investigating pain assessment 
and pain treatment for community-dwelling people with dementia (see Chapter Three), with 
only two studies being conducted in the UK.  
A recent meta-review identified the lack of qualitative evidence exploring pain assessment 
and management for people with dementia (Geddis‐Regan et al., 2018). In particular, this 
review found that the perspectives of people with dementia towards pain identification, 
assessment, and treatment remain ignored in research, despite pain directly affecting their 
lives (Geddis‐Regan et al., 2018). Six studies have explored the perspective of informal 
(often family) caregivers (Geddis‐Regan et al., 2018; Kankkunen & Välimäki, 2014), however 
only one reflected upon pain in the community (Martin et al., 2005). Many studies have 
explored the perspective of healthcare professionals (including nurses, nursing assistants 
and care home managers) when identifying, assessing and managing pain in nursing home, 
hospice, and acute care settings (Geddis‐Regan et al., 2018). To date, only two studies have 
explored the perspective of GPs (albeit reflecting upon a residential aged care setting; Chang 
et al., 2009, or pain assessment at the end of life; De Witt Jansen et al., 2018), with research 
highlighting that ‘future qualitative research with GPs in this area would help gain a deeper 
understanding of the context and nuances that are involved in this complex area’ (Jennings 
et al., 2018b, p. 8). Studies are yet to explore the perspective of GPs and old age 
psychiatrists despite their important role to identify pain, and determine the driver of 
behavioural and psychological symptoms for people with dementia living in the community 
(Geddis‐Regan et al., 2018).  
These gaps in the literature suggest a mixed methods investigation (using quantitative and 
qualitative data) would be appropriate to provide an in-depth and encompassing 
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understanding of pain for community-dwelling people with dementia. A mixed methods 
investigation will inform the development of interventions to improve pain management for 
community-dwelling people with dementia in primary care (Jennings et al., 2018b). Such 
interventions are essential to improve pain identification, assessment, and treatment for 
people with dementia to directly reduce the occurrence of falls (Stubbs et al., 2014; Crowe et 
al., 2017a), emergency department visits (Hunt et al., 2018), delirium (Feast et al., 2018), 
cognitive decline (Cook et al., 1999; Buffum et al., 2004), and mortality (Rajkumar et al., 
2017). In addition to the direct benefits, improved pain management also has the potential to 
reduce behavioural and psychological symptoms for people with dementia, thus indirectly 
reducing the number of avoidable nursing home admissions, reducing anti-psychotic 
prescriptions, shortening hospital stays, and improving quality of life (Lichtner et al., 2014; 
Kales et al., 2015; Forester & Vahia, 2019; Ballard et al., 2009). Improved pain management 
therefore has the potential to contribute to UK recommendations and policy; to help reduce 
unnecessary anti-psychotic prescriptions for people with dementia (Department of Health, 
2015; Napp Pharmaceuticals, 2014), indirectly supporting people with dementia to continue 
living in the community (Lakey et al., 2012). 
4.2 Research aim and objectives  
The overarching aim of this thesis was to investigate pain identification, pain assessment, 
and pain management for community-dwelling people with dementia.  
This aim encapsulated a number of quantitative and qualitative focused research questions, 
in line with the convergent mixed methods design (Creswell & Plano Clark, 2018; see 
Section 5.4.2.1), which were conceptually captured by two research objectives:  
Chapter Four: Research Aim and Objectives 
 
 
109 
 
Research objective 1: To investigate pain identification and pain assessment for 
community-dwelling people with dementia 
Research questions: 
 What are the incidence and prevalence rates of musculoskeletal consultations for 
people with dementia compared to older adults without dementia? 
 What are the annual incidence and prevalence rates of musculoskeletal consultations 
over time for people with dementia? 
 How do family caregivers and healthcare professionals identify and assess pain for 
community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
perceive pain identification and assessment strategies for community-dwelling people 
with dementia? 
Research objective 2: To investigate the management of pain for community-dwelling 
people with dementia 
Research questions: 
 What is the prevalence of analgesic prescriptions for people with dementia compared 
to older adults without dementia? 
 What are the annual prevalence rates of analgesic prescription over time for people 
with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
manage the pain experienced by community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
perceive pain management strategies for community-dwelling people with dementia?  
4.3 Conclusion 
This chapter has provided an overview of the gaps in the literature, the rationale, and the 
research objectives of this study. The following chapters provide details of the mixed 
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methods approach adopted in this study (see Chapter Five), along with the quantitative and 
qualitative methods employed (see Chapter Six).    
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5 Chapter Five: Methodology 
5.1 Introduction 
This chapter provides an overview of ontology and epistemology, theoretical perspectives, 
and methodologies guiding social research. Throughout this chapter, the theoretical 
perspective, and mixed methodological approach of this thesis are discussed. 
5.2 The four elements of social research  
This thesis subscribes to Crotty’s (1998) ‘four elements’ of social research. These elements 
guide the justification of the methodology and methods employed in this thesis. Justification 
is provided by giving an overview of ontology, epistemology, and theoretical perspectives, 
along with their inherent assumptions1. An overview of these four elements are provided in 
Figure 5.1 
 
Figure 5.1. The four elements of social research (adapted from Crotty, 1998). 
 
The first three elements of Crotty’s (1998) framework are discussed sequentially throughout 
this Chapter. To aid explanation and to give a sense of the distinction and diversity between 
ontological, epistemological, and theoretical perspectives, I have chosen to use opposing 
perspectives that sit at either end of the continuum as guided by Moon and Blackman (2014; 
see Figure 5.2). I acknowledge that many additional philosophical and theoretical 
perspectives are also available to underpin research.
                                               
1 Crotty (1998) does not include ontology due to his perspective that ‘ontological issues and 
epistemological issues tend to emerge together’ (p. 10). However, this thesis provides a brief overview 
of ontology to provide context for the theoretical perspective of this thesis. 
Ontology and 
epistemology
Theoretical 
perspectives Methodology Methods
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Figure 5.2. Opposing epistemological, ontological, and theoretical perspectives 
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For research in the social sciences, two key areas of philosophical debate underpin each 
theoretical perspective. The first of which concerns the nature of reality, and the social world, 
known as ontology (see Section 5.2.1). The second is epistemology that relates to the nature 
of knowledge (see Section 5.2.2). To facilitate the discussion of ontology and epistemology, 
in each section outlined below, I have used opposing examples (e.g. realism vs. idealism, 
objectivism vs. constructionism) that sit at either side of the ontological and epistemological 
spectrum. The presentation of opposing perspectives provides the contextual information 
essential to understand the theoretical perspective of this thesis (see Section 5.3.2). 
5.2.1 What is ontology? 
Ontology relates to the nature of reality or what is real. Ritchie, Lewis, Nicholls, and Ormston, 
(2013) identify two distinct, yet broad ontological positions; realism and idealism (see Figure 
5.2). Realism suggests that an external reality exists independent of human interpretation, 
highlighting a distinction between ‘reality’ and our constructed beliefs and understanding of 
reality. In contrast, idealism (or similarly, relativism) believes that reality is dependant, and 
knowable only through the human mind and socially constructed meanings.  
5.2.2 What is epistemology? 
The second philosophical concept is epistemology, the theory of knowing, in other words, 
how we know what we know. Epistemology provides a philosophical grounding for what kind 
of knowledge is possible. Crotty (1998) identified objectivism and constructionism as 
opposing concepts within epistemological understanding (see Figure 5.2; Moon & Blackman, 
2014). The key tenants of objectivism and constructionism are provided in Table 5.1. 
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Table 5.1. Epistemological perspectives: Objectivism and constructionism 
Epistemological view Key tenants  
Objectivism  Objects exist as meaningful entities independently of 
consciousness and experience, that they have truth and 
meaning residing in them as objects 
Constructionism Truth or meaning comes into existence in and out of our 
engagement with the realities in our world. There is no meaning 
without mind. Meaning is not discovered, but rather constructed. 
Definitions adapted from Crotty (1998). 
5.3 Theoretical perspectives 
Theoretical perspectives describe the philosophical stance and the assumptions that lie 
behind the methodology, guiding the researcher (Crotty, 1998). This thesis uses the term 
‘theoretical perspective’ to illuminate the continuum of the philosophical spectrum. By doing 
so, I hope to move beyond the prescriptive connotations of the term ‘paradigm’ that has 
perpetuated the view that methods of enquiry are bounded or restricted (Shannon-Baker, 
2016). There are many theoretical perspectives to research described in the literature 
(Crotty, 1998). However, for the purpose of this thesis, I will again provide an overview of the 
perspectives that are perceived to sit at alternate ends of the philosophical spectrum; 
positivism and interpretivism (Creswell, 2009; see Figure 5.2). These theoretical perspectives 
were chosen to align with the previously discussed tenants of ontological realism and 
idealism, and epistemological objectivism and constructionism (Creswell, 2009). Additionally, 
positivism and interpretivism provide a sense of the ‘extremes’ at either end of the 
philosophical spectrum. 
5.3.1 Positivism and interpretivism  
Positivism is traditionally linked to empirical sciences, emphasising the importance of theory 
verification and an objective and measurable truth that reflects a universal reality. Positivists 
are optimistic and faithful in scientific progress, with scientific knowledge holding a high 
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degree of objectivity, precision and certitude. Positivism is objectivist in nature, meaning that 
objects have meaning prior to, and independently of our consciousness of them, allowing the 
world to be measurable and free from subjectivity. In more recent years, an attenuated 
version of positivism evolved to combat the ‘arrogance’ of positivism (Crotty, 1998), called 
post-positivism. Post-positivism recognised science to have a degree of objectivity, rather 
than absolute objectivity, and reflected upon the probability rather than certainty of scientific 
knowledge. At the alternate end of the theoretical perspective spectrum, interpretivism 
emerged in contradistinction to positivism as a theoretical perspective to explain human and 
social reality. In contrast to the single absolute truth associated with the positivist theoretical 
perspective, interpretivists acknowledge the need to understand how an individual engages 
with, and understands the social world based on their cultural, historical, and social 
perspectives. 
Each theoretical perspective is underpinned by an epistemological and ontological position, 
with restrictions as to which philosophical positions are appropriate for each theoretical 
perspective (Crotty, 1998). In the description of positivism (see above) it is clear to see the 
realist (ontology) and objectivist (epistemology) philosophical underpinnings (see Table 5.1). 
Similarly, in the description of interpretivism, the idealist (ontology) and constructionist 
(epistemology) philosophical underpinnings are clear. If positivism was not objectivist in 
nature, it would not be what we perceive it to be. Similarly, interpretivism could not have an 
objectivist epistemology, as this would go against the wish to explore subjective experiences 
of reality, shaped by culture and history.  
The contentions between the positivist and interpretivist theoretical perspectives have been 
coined as the ‘paradigm wars’, with purists suggesting that the two research cultures cannot, 
and should not coalesce (Howe, 1988; Guba, 1990). Depending on the theoretical 
perspective underpinning the research, differing methodologies, and methods of research 
enquiry are likely to be chosen. For example, positivists’ deterministic philosophy (meaning 
that the causes probably predict the outcome) often lead to quantitative based methodology 
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and methods (such as survey designs and experiments). Interpretivists seek to understand 
the world that we live in, by exploring individual’s subjective perspectives, views, and 
experiences often leading to qualitative based methodology and methods (e.g. ethnography 
and interviews). The contentions between the epistemological and ontological foundations of 
each theoretical perspective, and their chosen methodologies and methods means that some 
researchers believe that quantitative and qualitative methods are incompatible and cannot be 
consolidated in a single project (Reichardt & Rallis, 1994; as cited in Sale, Lohfeld & Brazil, 
2002).   
Other researchers argue, however, that the contentions between positivists and 
interpretivists are because of political diversions between social scientists, when in fact, both 
perspectives share many epistemological and ontological commonalities. Both positivism and 
interpretivism wish to uncover ‘truths’ that best represent or correspond to reality (whether 
that is a universal reality, or multiple-socially constructed realities). Therefore, although I 
acknowledge that philosophical and theoretical perspectives underpin the methodology (and 
ultimately the methods) of choice (Greene & Hall, 2010; Creswell, 2009), I do not agree that 
terms such as ‘quantitative’ and ‘qualitative’ are synonymous with a particular theoretical 
perspective. Instead, I believe that these terms should be purely used to describe the method 
of enquiry. 
5.3.2 Theoretical perspective for this thesis 
Positivism and interpretivism have been discussed as theoretical perspectives sitting at 
either side of the philosophical continuum (see Section 5.3.1). Each perspective is 
underpinned by opposing ontological and epistemological assumptions, determining what 
kind of knowledge is possible. Alternatively, critical realism was formed in response to the 
polarisation created by the paradigm wars between positivism and interpretivism (see Figure 
5.3), and is now the most prominent manifestation of realism in the social sciences (Maxwell, 
2012; Maxwell & Mittapalli, 2010).  
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Figure 5.3. Critical realism in the theoretical spectrum 
 
Critical realism is typically attributed to the work of Bhaskar (1978, 1989). The philosophical 
position of this thesis aligns with that described by Maxwell (2012) who draws upon various 
versions of ‘realism’, including critical realism, pragmatic realism, subtle realism, experiential 
realism, and emergent realism. This thesis uses the term ‘critical realism’ as a broad term to 
encompass the key common tenants of all of these versions of realism (Maxwell, 2012).  
The integral element of the critical realist stance is the constructionist epistemology, with a 
realist ontology (Maxwell, 2012; McEvoy & Richards, 2006; Pilgrim, 2019). In other words, 
critical realism denies an ‘objective’ or certain knowledge of the world, suggesting that all 
knowledge is grounded by each individual’s perspective. In line with this notion, a critical 
realist stance acknowledges that embedded structures, institutions, and bodily realities exist 
independent of our perception of them, however, each individual has their own subjective, 
real-world lived accounts shaped by culture, history, and experience (Williams, 1999; 
Williams, 2003). Therefore, knowledge is both constructed and based upon the reality of the 
world we experience and live in (Rogers & Pilgrim, 2014). This reflects my own ontological 
and epistemological perspective that bodily realities such as dementia and pain exist 
independent of our construction of them and therefore can be measured quantitatively. Each 
individual, however, has their own subjective perception dependent upon temporal and 
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contextual factors warranting qualitative exploration of perspective, views, and experience 
(Williams, 2003).  
The constructionist epistemology, along with a realist ontology makes critical realism a 
philosophical perspective that validates and supports the use of mixed methods (Maxwell, 
2012; Maxwell & Mattapalli, 2010; Creswell & Plano Clark, 2018).  
5.4 Mixed methodology 
Methodology is defined by Crotty (1998) as ‘the strategy, plan of action, process or design 
lying behind the choice and use of particular methods’ (p. 3). Based upon this definition, the 
methodology underpinning this thesis is a mixed methodology. Mixed methods research (or 
as otherwise referred to as multi-method, integrated, convergence and combined research; 
Creswell & Plano Clark, 2018) broadly relates to the combination of quantitative and 
qualitative methods. Mixed methods was first introduced by Campbell and Fiske (1959), and 
has grown in popularity since this time. However, there remains no consensus about how 
mixed methods research should be defined or conducted. To illustrate, Johnson, 
Onwuegbuzie and Turner (2007) obtained 19 definitions of ‘mixed methods’ by contacting 31 
methodologists. An analysis of these definitions was conducted, and on this basis, Johnson 
et al. (2007) provided their own broad definition of mixed methods research: 
Mixed methods research is the type of research in which a researcher or team of 
researchers combines elements of qualitative and quantitative research approaches 
(e.g., use of qualitative and quantitative viewpoints, data collection, analysis, inference 
techniques) for the broad purposes of breadth and depth of understanding and 
corroboration. 
Johnson, Onwuegbuzie and Turner, 2007, p. 123 
The convergence of both quantitative and qualitative data provides a comprehensive 
understanding of the research problem, allowing a ‘properly integrated methodology for the 
social sciences’ (Morgan, 2007, p. 73). The inherent dichotomous nature of quantitative and 
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quantitative methods suggests that the limitations of one method are likely to be the 
strengths of the other (Tashakkori & Teddlie, 2010). Johnson et al. (2007) noted (in 
agreement with many other researchers Creswell, 2009; Tashakkori & Teddlie, 2010) that 
mixed methods are utilised when either quantitative or qualitative methods independently do 
not answer the research objective in sufficient depth or breadth. A mix of quantitative and 
qualitative methods are not only acceptable, but in fact doing so is desirable in social 
research to meet the research objectives (Greene et al., 2005; Denscombe, 2008).  
Despite the strengths of mixed methods research, this methodology does pose limitations for 
the researcher, including the requirement for knowledge in both quantitative and qualitative 
methods, and the time-intensive nature of extensive data collection and analysis (Creswell, 
2009).  
5.4.1 Rationale for mixed methods 
While mixing methods may pose challenges, it was deemed the most appropriate approach 
to meet the objectives of this thesis. Given the limited research exploring pain identification, 
assessment, and management for community-dwelling people with dementia (as highlighted 
within the literature and systematic review), a mixed methods investigation is desirable to 
gain a wider and deeper understanding of the phenomena. Quantitative nor qualitative data 
in isolation could fulfil all of the research questions (see Section 4.2). For example, although 
quantitative data could investigate an aspect of pain management for people with dementia 
by examining the amount or frequency of analgesic prescriptions through the quantification of 
primary care consultations, this data is unable to explore the perspectives towards analgesic 
medications (see Section 4.2). 
5.4.2 Mixed method designs 
There are many strategies and design aspects to consider when formulating a mixed 
methods study. These design aspects include the timing, weighting, and mixing of 
quantitative and qualitative elements of a research project. This thesis follows the Creswell 
and Plano Clark (2018) mixed methods framework. This framework outlines three core mixed 
Chapter Five: Methodology 
 
 
120 
 
method designs, including the convergent, explanatory sequential, and exploratory 
sequential design (see Figure 5.4).  
 
Figure 5.4. Creswell and Plano Clark (2018) mixed methods designs 
 
5.4.2.1 Convergent mixed methods design 
The mixed methods design chosen for this thesis was the convergent mixed method design 
(or sometimes called parallel study, convergence model, or simultaneous triangulation). A 
convergent design means that the data collection and analysis for both the quantitative and 
qualitative streams were conducted in parallel (see Figure 5.4; Creswell & Plano Clark, 
2018). A convergent mixed methods design was chosen for this thesis to obtain ‘different but 
complementary data on the same topic’ (Morse, 1991. p. 122). This was important for this 
thesis, as the quantitative and qualitative research questions (thus different data) were 
mapped to an overarching, complementary research objective to develop a ‘complete’ 
understanding of the phenomena (see Section 4.2; Creswell & Plano Clark, 2018). The 
complete understanding is obtained as the strengths of quantitative data often reflect the 
weaknesses of qualitative data, and vice versa.  
In the nature of a convergent mixed methods design, the quantitative and qualitative data 
were collected, analysed, and integrated in parallel. Therefore, Creswell and Plano Clark 
(2018) recommend that the researcher does not employ multiple philosophical perspectives 
Convergent design
•Quantitative and 
qualitative data 
collection and analysis 
conducted concurrently
•Results are merged and 
compared
•Interpretation
Explanatory sequential 
design
•Quantitative data 
collection and analysis 
conducted first
•Followed by qualitative 
data collection and 
analysis
•Interpretation
Exploratory sequential 
design
•Qualitative data 
collection and analysis 
conducted first
•Followed by quantitative 
data collection and 
analysis
•Interpretation
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to approach a convergent mixed methods design. In line with this recommendation, this 
thesis approached the research with critical realism as the ‘umbrella’ theoretical perspective, 
acknowledging the existence of reality, and each individual’s subjective, real-world lived 
accounts shaped by culture, history, and experience (see Section 5.3.2), complementing the 
quantitative and qualitative methods (Creswell & Plano Clark, 2018). 
A convergent design to mixed methods research has many advantages. Unlike sequential 
designs, convergent designs are more efficient, allowing the data collection and analysis to 
run in parallel during a single phase of the study. Additionally, traditional approaches to 
quantitative and qualitative data analysis can be employed prior to integration, allowing team 
members with different methodological expertise to work together. The convergent design 
has notable challenges that the researcher must overcome (alongside the general 
challenges of mixed method designs; see Section 5.4). Firstly, as quantitative and qualitative 
data produce vastly different outputs (statistical vs. lexical) the integration of the findings can 
be challenging, especially if each do not directly address the same concept. Additionally, 
during integration the researcher must identify convergence and divergence between the 
quantitative and qualitative findings. However, as both quantitative and qualitative design, 
data collection, and analysis were conducted in parallel (see Figure 5.5); interpretations of 
the qualitative analysis may have been influenced by the ongoing quantitative analysis (and 
vice versa). This may influence and alter my perception of convergence or divergence. 
Finally, if findings diverge, Creswell and Plano Clark (2018) recommend additional data 
collection and/or analysis to explore the divergence. This process would add time and 
complexity to the study.  
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Figure 5.5. Procedural diagram to illustrate the convergent mixed methods design (adapted 
from Creswell & Plano Clark, 2018). 
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5.4.2.1.1 Data analysis 
Following quantitative and qualitative design and data collection, the findings are analysed 
separately, using the most appropriate method for the data in question (see Figure 5.5). The 
analytical approach employed for the quantitative and qualitative methods are outlined in the 
following Methods Chapter (see Chapter Six). Each findings chapter provides the separate 
quantitative and qualitative findings (prior to integration) relating to each research objective 
sequentially: 
 Chapter Eight: To investigate pain identification and pain assessment for 
community-dwelling people with dementia (research objective 1) 
 Chapter Nine: To investigate pain management for community-dwelling people with 
dementia (research objective 2) 
Following separate analysis, the quantitative and qualitative findings should be brought 
together to ‘combine’ or ‘compare’ the findings. This process in mixed methods is often called 
‘integration’ (Creswell & Plano Clark, 2018). One challenge of the convergent mixed method 
design involves the integration of two sets of very different data in a meaningful way. 
Therefore, to aid the integration process, Creswell and Plano Clark (2018) described several 
methods of quantitative and qualitative data integration: 
 Data transformation - typically transforming qualitative data into quantitative data to 
allow direct comparison  
 Joint display of data – the researcher merges the two forms of data into a table or 
graph; effectively merging the data into a single visual display 
 Side-by-side comparison – the researcher narratively reports the findings of one 
method (e.g. quantitative) and then discusses the findings from the alternate method 
(e.g. qualitative) that either confirm or disconfirm the findings 
For this thesis, neither quantitative nor qualitative data were deemed ‘dominant’ approaches, 
with each providing a valuable, detailed, and nuanced understanding of the phenomena that 
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would be lost if transformed or minimised into a visual display. Therefore, side-by-side 
comparison was chosen as the most appropriate method of integration. This approach allows 
convergence and divergence between the statistical trends and the voice of the participants 
to be explored and inferred (Creswell & Plano Clark, 2018).  
In this thesis, the quantitative and qualitative findings are integrated in the discussion chapter 
(see Chapter Ten); acting as a ‘vehicle for merging the results’ (Creswell & Plano Clark, 
2018, p. 226). Quantitative and qualitative findings are presented side-by-side in a narrative 
discussion organised by the research objectives (Creswell & Plano Clark, 2018). This 
method of integration allows for reflection as to how well the quantitative and qualitative 
findings agree (converge) or disagree (diverge), allowing for an in-depth and complete 
understanding of the phenomena. 
5.5 Conclusion 
This chapter provided an overview of the philosophical approaches to social research by 
exploring the opposing ontological, epistemological, and theoretical perspectives. Deviating 
from the prescriptive ‘paradigm wars’, this thesis positions itself within the broad spectrum of 
‘critical realism’. The constructionist epistemology, with a realist ontology reflects my 
personal worldview, and provides a philosophical underpinning for the mixed methodology of 
this thesis. This chapter continued to discuss the rationale for using a mixed methods design, 
and provided an overview of the convergent design chosen to investigate pain identification, 
assessment, and management for community-dwelling people with dementia. The following 
chapter describes the quantitative and qualitative methods that encapsulate the convergent 
mixed methods design, and the analytical approach. 
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6 Chapter Six: Methods 
6.1 Introduction 
In the previous Chapter, the theoretical perspective and mixed methods approach to this 
thesis were discussed. This Chapter provides an overview of the quantitative and qualitative 
methods used to investigate pain identification, assessment, and treatment for community-
dwelling people with dementia. Inherent with a convergent mixed methods design, the 
quantitative and qualitative data collection and analysis were conducted in parallel 
throughout the study; however, each are discussed sequentially for the purpose of this 
chapter. 
6.2 Quantitative methods 
Epidemiology is ‘the study of the distribution and determinants of health-related states or 
events in specified population and the application of this study to control health problems’ 
(Szklo & Nieto, 2014, p. 3). Three key inter-related characteristics encompass 
epidemiological principles – determinants, frequency, and distribution – all of which rely upon 
the availability of comprehensive data as a ‘prerequisite for any systematic investigation’ 
(Hennekens, Buring & Mayrent, 1987, p. 3). This study used epidemiological principles to 
determine numeric patterns and trends for a specific population, and specifically to answer 
the following research objectives and questions: 
Research objective 1: To investigate pain identification and pain assessment for 
community-dwelling people with dementia 
 What are the incidence and prevalence rates of musculoskeletal consultations for 
people with dementia compared to older adults without dementia? 
 What are the annual incidence and prevalence rates of musculoskeletal consultations 
over time for people with dementia? 
Research objective 2: To investigate the management of pain for community-dwelling 
people with dementia 
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 What is the prevalence of analgesic prescriptions for people with dementia compared 
to older adults without dementia? 
 What are the annual prevalence rates of analgesic prescription over time for people 
with dementia? 
6.2.1 Primary and secondary data 
Both primary, and secondary analysis of existing data would be suitable to investigate the 
epidemiology of pain identification, assessment, and treatment for people with dementia. 
Primary data is collected by the researcher (or research team) for the purpose of the 
research question and analysis. Contrarily, secondary analysis of existing data is the 
‘analysis of data collected by someone else’ (Boslaugh, 2007, p. ix), for example, national 
surveys, university records, government or census records, and electronic health records 
(EHR). Secondary analysis of existing data is primarily formulated in two ways: ‘driven by the 
research question’ or ‘driven by the data available’ (Cheng & Phillips, 2014). In most cases, 
the choice between these two drivers is an iterative process. In the first instance, the 
research may be driven by the research question, and datasets are found to suit such 
question, however specific variables may not be included, and therefore adaptations are 
driven by the available data.  
Due to time-restrictions imposed by the nature of this project, it was not possible to collect 
primary data. For example, the recruitment of sufficient numbers of participants for the 
quantitative analysis was not feasible in terms of time (i.e. a number of years of follow up 
data were required to reflect the course of dementia over time) as well as issues of cost and 
study management. Therefore, secondary analysis of existing and suitable data was used for 
this study.  
6.2.1.1 Electronic Health Records (EHR) 
EHR most often provide rich, longitudinal records for large populations (Casey, Schwartz, 
Stewart & Adler, 2016). In the UK, 98% of the population are registered with a general 
practice (NHS Digital, 2012), and as part of the NHS attending the general practice is free, 
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thereby making primary care EHR an ideal representative sample base. Primary care 
clinicians are the first contact health services (for non-emergency), acting as the gatekeeper 
to secondary care services in the UK (Sripa et al., 2019). Additionally, patient information is 
communicated from secondary care to the patient’s GP. Primary care EHR databases 
combine all of this information in one centralised record for patients and thereby contain 
extensive and varied routinely collected health-related information over a longitudinal period. 
Such factors have increased the use of primary care EHRs for research purposes generally 
(de Lusignan & van Weel, 2005; Weiskopf & Weng, 2013; Häyrinen, Saranto & Nykänen, 
2008), and for dementia specifically (Dunn, Mullee, Perry & Holmes, 2005; Rait et al., 2010; 
Walters et al., 2016; Dell'Agnello et al., 2018). However, primary care databases do not 
come without their challenges with the potential for incomplete and inaccurate data 
(Porcheret et al., 2004; Glasgow, Kaplan, Ockene, Fisher & Emmons, 2012). An overview of 
the general strengths and limitations of EHR data are provided in Table 6.1.  
Table 6.1. Strengths and limitations of secondary analysis of EHR 
Strengths Weaknesses 
1. Low cost* 1. Missing data 
2. Quick to gain longitudinal data 2. Incomplete, or incorrect data 
entries 
3. Reduced likelihood of bias e.g. 
retrospective recall 
3. Not inherently designed for the 
study in question 
4. Expensive to access 
4. High quality data  
5. Breadth of data available  
*In relative terms compared to collecting new data for a study (Boslaugh, 2007) 
Many UK primary care databases are available, and, the three largest in terms of potential 
sample are the Clinical Practice Research Datalink (CPRD; https://www.cprd.com/), The 
Health Improvement Network (THIN; https://www.ucl.ac.uk/iehc/research/primary-care-and-
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population-health/research/thin-database/database) and QResearch 
(https://www.qresearch.org/). 
6.2.1.2 Clinical Practice Research Datalink 
The CPRD (or as previously named, GPRD or VAMP) is a longitudinal primary care medical 
database. The CPRD GOLD contains data contributed by general practices using Vision 
software. As of June 2017, the GOLD dataset collected data from 693 contributing practices 
across England, Wales, Scotland, and Northern Ireland, and held information on 14.2 million 
research acceptable patients, of which 2.8 million were currently active (The Farr Institute, 
2017). Research conducted in 2013 found that when compared to the UK 2011 census, 
patients contributing to CPRD were representative of the UK population in relation to age, 
gender, and ethnicity (see Figure 6.1; Herrett et al., 2015). CPRD is representative as it is 
based on NHS data, in a healthcare system free at the point of use. CPRD data therefore 
tends to be more generalisable of the entire UK population than healthcare data in other 
healthcare systems based upon data from a portion of the population with medical insurance.  
CPRD GOLD includes all coding in general practice using practice and patient ‘pseudo-
identifiers’ to maintain anonymity; including data on demographics, diagnoses, symptoms, 
signs, prescriptions, and tests. Primary care staff contributing data to CPRD GOLD were 
historically requested to record a diagnostic code for any new problem (Lawson, Sherman & 
Hollowell, 1998). Additionally, diagnoses made in secondary care are included in the CPRD 
GOLD providing letters are communicated to the general practice and recorded appropriately 
(Appleyard, Ashworth, Bedson, Yu & Peat, 2019). All prescriptions issued by GPs are 
automatically recorded (Herrett et al., 2015). If a medication started in secondary care was 
continued as a repeat prescription by the GP (who is largely responsible for a patient’s 
ongoing prescription), this would appear in the CPRD GOLD data. Therefore, only one-off 
medication prescriptions initiated in secondary care may be missed. 
Anonymised primary care patient data in CPRD GOLD can be individually linked to 
secondary care data, and other health and area-based datasets, such as the Hospital 
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Episode Statistics (HES), Death registration data, and Index of Multiple Deprivation (IMD). 
For this study, CPRD GOLD data was linked to Practice Level IMD data. Practices with 
linked data have been shown to be similar to practices without linkage (Gallagher, Puri & van 
Staa, 2011).  
Despite the potential of CPRD for research purposes, there are limitations associated with 
CPRD (e.g. missing data and cost of access) that echo the limitations from EHR generally 
(see Table 6.1).   
 
Figure 6.1. Distribution of CPRD practices by region in England, Wales, Scotland, and 
Northern Ireland (Herrett et al., 2015)  
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6.2.2 Epidemiological study designs 
An important aspect of the investigation in this thesis was the longitudinal relationship 
between the exposure (dementia) and the outcome (consultations for potentially painful 
conditions and prescriptions of pain medication), rendering cross-sectional designs 
inappropriate. Cohort designs can be classified into retrospective or prospective depending 
upon the temporal relationship between the initiation of the study, and the outcome. An 
overview of retrospective and prospective cohort designs, as well as case-control designs 
are provided below. 
6.2.2.1 Cohort design 
Prospective designs recruit participants with the exposure, however the outcome has not yet 
occurred. A pictorial representation of a prospective cohort study design is provided in Figure 
6.2. 
 
Retrospective cohort design 
 
Retrospective designs are initiated after the exposure and outcomes have been recorded. 
See Figure 6.3 for a pictorial representation of a retrospective cohort study design. 
              PRESENT     FUTURE 
Figure 6.2. Pictorial representation of a prospective cohort design 
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6.2.2.2 Case-control designs 
Case-control designs are often confused with retrospective cohort designs. See Figure 6.4 
for a pictorial representation of a case-control study design. 
 
Figure 6.4. Pictorial representation of a case-control design 
The main difference between a retrospective cohort design and a case-control design is the 
identification of each group. Namely, retrospective cohort designs identify each cohort based 
on their exposure status (e.g. the exposure cohort, and the unexposed cohort), following the 
cohort over time until the occurrence of the outcome. Alternatively, case-control designs 
identify cases and controls based on their outcome status and work backwards to identify 
               PAST       PRESENT  
Figure 6.3. Pictorial representation of a retrospective cohort design 
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their exposure status. An overview of the strengths and limitations of each of these 
epidemiological study designs is provided in Table 6.2.
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Table 6.2. Advantages and disadvantages of epidemiological designs 
Study design Prospective cohort design Retrospective cohort design Case-control design 
Advantages  Can measure incidence 
 Data collected is suited to the project 
 Accurate assessment of exposure 
and outcome status 
 Rare exposures can be studied 
 Recall bias minimised 
 Can measure incidence  
 Rare exposures can be studied  
 Can utilise existing data (e.g. 
medical records) 
 Rare outcomes/diseases can be 
studied 
 No loss to follow up 
 Allows investigation into multiple risk 
factors 
 
Disadvantages 
 
 Expensive 
 Time consuming 
 Labour intensive  
 
 Can be limited to the available 
information  
 Missing data 
 Loss to follow up cannot be 
influenced 
 Poor for rare diseases 
 
 Those with the outcome of interest 
are more likely to recall the exposure 
 Not suitable to investigate the rates 
of disease in exposed and 
unexposed individuals  
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6.2.3 Choice of study design 
I selected a retrospective cohort study design as the most suitable to answer the above 
research questions (see Figure 6.3). In cohort studies, each cohort is identified and defined 
based on their exposure status. The exposed and unexposed cohorts are followed up over 
time until the occurrence of the outcome (or the end of the study period). Therefore, cohort 
studies (unlike case-control studies) allowed the incidence of musculoskeletal consultation 
for people with dementia to be examined.  
Cross-sectional studies are often viewed as the most appropriate design to establish point 
prevalence (‘the frequency of a disease or condition at a point in time’ Szklo & Nieto, 2014, p. 
71). However, cohort studies are able to estimate the period prevalence (‘the frequency of an 
existing disease or condition during a defined period’ Szklo & Nieto, 2014, p. 72) of an 
outcome for the cohort in question. For example, using a cohort study design, the period 
prevalence of musculoskeletal consultation and analgesic prescription can be established for 
a cohort of people with dementia. The period prevalence estimate has the potential to be 
generalised to the wider population of people with dementia, if the cohort is representative of 
the people with dementia in the UK. Additionally, cohort study designs have the ability to 
examine multiple outcomes, over a longitudinal time period. This is particularly important to 
examine musculoskeletal consultation and analgesic prescriptions from the time of diagnosis 
of dementia, and throughout the course of dementia progression.  
Finally, when choosing between a retrospective and prospective cohort design, a 
retrospective design was chosen as CPRD data has already been collected; rendering a 
prospective design inappropriate (see Figure 6.2).   
6.2.4 Data access and procedures 
Access to CPRD data was subject to internal and external peer review and approval. Firstly, 
the CPRD committee within the School of Primary, Community and Social Care approved the 
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project following internal peer review. To gain external approval, a comprehensive study 
protocol was submitted to the Independent Scientific Advisory Committee (ISAC) for peer 
review. This committee included statisticians, epidemiologists, and clinicians familiar with 
CPRD data. The study protocol included information pertaining to the research questions, 
study design, exposures, outcomes and covariates, and analysis plan. The ISAC committee 
granted approval of the study protocol and provided access to the data (17_240RA; see 
Appendix 3). 
6.2.5 Clinical codes 
EHR data is largely collected in UK primary care using Read codes entered by members of 
primary care staff. Read codes are a standard, hierarchical vocabulary of clinical terms used 
to document various clinical information, including but not limited to symptoms, signs, 
diagnoses, and prescriptions (NHS Digital, 2018). At the time of this thesis, two versions of 
Read codes are used: version 2 (v2) or version 3 (CTV3 or v3).  
The process of compiling clinical code lists to define, and identify the clinical entities of 
interest (i.e. the exposure, covariates, and outcome) is an important step when setting up a 
study utilising primary care EHR data (Springate et al., 2014). I used a four-step exercise to 
identify Read codes for the exposure, covariates, and outcomes used in this study:  
1 I obtained clinical code lists from within the School of Primary, Community and Social 
Care (https://www.keele.ac.uk/mrr/) where available. All clinical code lists were 
developed using consensus exercises, and validated using a localised Primary Care 
EHR databases (e.g. the Consultations in Primary Care Archive; CIPCA).  
2 Clinical Codes Repository was searched for suitable codes (www.clinicalcodes.org). This 
resource is a University of Manchester Institute of Population Health project funded by 
the NIHR School for Primary Care Research.  
3 Clinical code lists were obtained from previously published CPRD studies 
(https://cprd.com/bibliography).  
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4 I searched the Clinical Terminology Browser v1.04 to identify additional codes for each 
clinical entity. This browser contains the hierarchical vocabulary of clinical terms.  
Following the identification of codes, duplicates were removed and a consensus exercise 
with my supervisors JB (Academic General Practitioner with experience in EHR and code list 
development), and PC (Epidemiologist with experience in EHR and code list development) 
finalised each code list. This process resulted in a set of clinical code lists that represent the 
various variables used in this research project. Appendix 4 provides examples of each 
clinical code list. Full code lists are available upon request. 
6.2.6 Data Refinement 
The Research Data Manager within the School of Primary, Community and Social Care 
extracted CPRD data in March 2018. Data were retrieved from 1st January 1995 and 31st 
December 2017. Linked Practice Level Index of Multiple Deprivation (IMD) was also 
extracted (see Section 6.2.11.2). 
6.2.6.1 Cohort definitions 
6.2.6.1.1 Exposed: Dementia cohort 
A total of 104,488 patients were identified by the Research Data Manager with an incident 
dementia diagnostic Read code, or dementia medicinal product code between 1st January 
1997 and 31st December 2017 (see Section 6.2.7.2). Dementia was identified using 104 
dementia diagnostic Read codes, and 107 dementia medicinal product codes documented in 
the patient’s record. Table 6.3 provides examples of clinical codes used to define the patients 
included in the dementia cohort. Examples of each clinical code list are provided in Appendix 
4, with full code lists available upon request. 
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Table 6.3. Examples of dementia diagnostic Read codes and dementia medicinal product 
codes 
Read term Read code 
Senile dementia E00..11 
[X]Dementia in Alzheimer's disease, unspecified Eu00z00 
[X]Vascular dementia Eu01.00 
Product term  Product code 
Aricept 10mg tablets (Eisai Ltd) 5247 
Donepezil 10mg tablets 2931 
Memantine 10mg tablets 6225 
 
6.2.6.1.2 Unexposed: Older adult cohort 
The Research Data Manager identified 157,271 older adults on the basis of no evidence of a 
dementia diagnostic Read code, or dementia medicinal product code during the entire study 
period (1st January 1997 to 31st December 2017). This cohort was matched for age, gender, 
and practice to the dementia cohort (see Section 6.2.11.1). 
6.2.7 Date Setting 
The longitudinal nature of the study period (1st January 1997 to 31st December 2017) means 
that patients and general practices enter and exit the dataset at different time points. Three 
dates are particularly important when conducting longitudinal investigation in CPRD, 
including the patient’s entry date, index date, and exit date. 
6.2.7.1 Entry date 
The entry date for each patient was defined on two levels: i) a patient-level ‘current 
registration date’, and ii) a practice-level ‘up to standard date’.  
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i) The ‘current registration date’ for each patient was provided by CPRD, defined as 
the ‘date the patient’s current period of registration with the practice began’. This 
date reflects when the patient began contributing to CPRD. For example, this may 
be the date that the patient joined a general practice that was contributing to 
CPRD.  
ii) Each general practice had an ‘up to standard’ date. This date reflects a ‘date at 
which the practice data is deemed to be of research quality’.  
Therefore, each patient’s entry date was defined as their ‘current registration date’ or the ‘up 
to standard’ date, whichever occurred last. For example, if the patient’s current registration 
date was 6th January 2010, however the practice was not classified as ‘up to standard’ until 
10th July 2011, the patient’s entry date was defined as 10th July 2011.  
6.2.7.2 Index date 
 The index date for patients in the dementia cohort was defined as their incident 
dementia diagnostic Read code or dementia medicinal product code (whichever 
came first) from 1st January 1997 to 31st December 2017.  
 The index date for patients in the matched older adult cohort was defined as the 
index date for their matched-pair.  
6.2.7.3 Exit date  
The exit date was identified for all patients. The patient’s exit date considered both patient-
level and practice-level dates, defined based on whichever of the following dates occurred 
first: 
 Last collection date – ‘Date of the last collection for the practice’ 
 Transfer out date – ‘Date the patient transferred out of the practice, if relevant.’ 
 Death date – ‘Date of death of patient’ 
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 End of study period (31st December 2017)  
 Cancer pain is distinct from non-malignant pain, and therefore outside the scope of 
the present study (see Section 6.2.8). Therefore, people in the dementia cohort and 
older adult cohort no longer contributed to the study six months prior to their first 
morbidity cancer Read code during follow up (between their index and exit dates). It 
cannot be assumed that prescriptions within this 6-month pre-diagnosis period were 
not due to a cancer related illness that had not yet been diagnosed. This assumption 
was supported by work that has shown the majority of delayed cancer diagnoses 
occur within six months of its onset, and most being diagnosed within one to three 
months (National Patient Safety Agency, 2010).  
A pictorial representation of the ‘entry date’, ‘index date’, and ‘exit date’ is presented below 
for the incidence (see Figure 6.5) and prevalence investigation (see Figure 6.6).
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Figure 6.5. Pictorial representation of the study time points for dementia cohort and older adult cohort in the incidence investigation
 
 
Chapter Six: Methods 
 
 
141 
 
 
Figure 6.6. Pictorial representation of the study time points for dementia cohort and older adult cohort in the prevalence investigation
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6.2.8 Inclusion/exclusion criteria  
This section outlines the inclusion and exclusion criteria used to identify the dementia cohort 
and older adult cohort for both the prevalence and incidence investigations. 
 All patients in the dementia cohort and the older adult cohort were 50 years old or 
older at their index date to be eligible. In 2012, only 0.3% of people with dementia in 
England were under the age of 50 years old (Prince et al., 2014). Thereby excluding 
people under the age of 50 reduced the chance of misclassifying a patient to the 
dementia cohort based on an erroneous clinical code indicative of dementia, whilst 
also minimising the amount of true dementia cases being excluded.  
 This research wished to focus upon community-dwelling people with dementia (see 
Section 1.7). Therefore, all patients in the dementia cohort and the older adult cohort 
were excluded if they had evidence of a Read code indicative of formal care 
residence during the entire study period (1st January 1997 to 31st December 2017), as 
previous research identified formal care Read codes as a definitive marker of formal 
care residence (Shah et al., 2010). Read codes indicative of formal care residence 
were identified using the process outlined in Section 6.2.5 and are provided in 
Appendix 4.  
 Patients in the dementia cohort and older adult cohort must have had evidence of a 
face-to-face or telephone consultation with a GP or nurse within a 90-day pre-and-
post window of their (assigned) index date. This criterion minimised the chance that 
patients in the older adult cohort had dementia unknowingly to the healthcare 
professional. The 90-day period was chosen to reflect the general frequency of 
consultation for older adults. In 2008, females over the age of 65 consulted on 
average 7 times annually, with males over the age of 65 consulting on average 4-6 
times annually (Hippisley-Cox, Fenty & Heaps, 2007). Since 2008, the average 
annual consultation frequency has steadily increased (Baird, Charles, Honeyman, 
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Maguire & Das, 2016). Based on these conservative estimates, the general 
population of adults over the age of 65 consult on average once every 3 months.  
 All patients in the dementia cohort and the older adult cohort must have had at least a 
two-year time period between their entry date and their index date. This two-year time 
period was to: 
 Ensure that the index date reflected the incident dementia diagnosis Read 
code or dementia-related drug product code, and thus most accurately 
reflected the time of dementia diagnosis. A two-year period was chosen based 
upon the clinical justification that people with dementia should be reviewed at 
least once per year in general practice (Alzheimer’s Society, 2016). 
 Investigate the presence/absence of baseline covariates (see Section 
6.2.11.2)  
 Identify and exclude people with evidence of a Read code indicative of cancer 
diagnosis. People with evidence of a cancer Read code during follow up were 
also removed from the study six months prior to their first morbidity Read code 
(see Section 6.2.7.3). Examples of cancer Read codes are provided in 
Appendix 4.  
6.2.8.1 Incidence cohort 
In addition to those outlined above, an additional exclusion criteria were applied to the 
dementia cohort and older adult cohort to investigate the incidence of musculoskeletal 
consultation:  
 Patients in the dementia cohort and the older adult cohort were excluded if they had 
evidence of a musculoskeletal consultation during the 12-month period before their 
index date. Research suggests that between 27% and 33% of older adults consult for 
a musculoskeletal condition during an annual time period (Jordan et al., 2010). 
 
 
Chapter Six: Methods 
 
 
144 
 
Excluding this population allowed an investigation into the incidence of 
musculoskeletal consultation without prevalent cases causing bias, with similar 
approaches conducted in comparable incidence investigation (Yu et al., 2017). A 12-
month period was chosen, as a longer period may have resulted in healthy cohort 
bias (excluding unhealthier patients); thus leading to imprecise incidence estimates.  
The data refinement process for dementia cohort and older adult cohort for the incidence 
and prevalence investigation are provided in Figure 6.7 and Figure 6.8.
 
 
Chapter Six: Methods 
 
 
145 
 
 
Figure 6.7. Flow diagram to represent the data refinement process for the incidence cohort 
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Figure 6.8. Flow diagram to represent the data refinement process for the prevalence cohort 
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6.2.9 Outcomes 
6.2.9.1 Musculoskeletal consultation 
Musculoskeletal pain includes neck, back, shoulder, elbow, hand, hip, knee, and multiple 
joint pain (Urwin et al., 1998). The primary cause of persistent pain for older adults, including 
people with dementia are musculoskeletal conditions (Corbett et al., 2012; Corbett et al., 
2014), with research finding that 58% of people with dementia had pain that was 
musculoskeletal in nature (Husebo et al., 2010). Musculoskeletal consultations were used as 
a proxy for pain identification and assessment for a number of reasons:  
 A code indicative of a (likely painful) musculoskeletal condition would suggest that 
pain has been identified, assessed, and coded by a clinician in primary care. This 
approach has been undertaken in previous research in the absence of pain 
identification and assessment data for people with dementia (Balfour & O’Rourke, 
2003).  
 The prevalence of musculoskeletal conditions for older adults with and without 
dementia (see Section 1.12.2), and the high association between musculoskeletal 
conditions and pain (Dunn et al., 2010; Muller, Bedson & Mallen, 2012) renders 
musculoskeletal consultation as an appropriate marker to encapsulate pain (and thus 
identification and assessment) in CPRD.  
 Musculoskeletal conditions represent a more homogenous group of potentially painful 
conditions (in comparison to all-cause pain conditions), thereby minimising the 
various confounders requiring consideration, and ultimately the bias in the study 
(Richardson, Bedson, Chen, Lacey & Dunn, 2018).  
Musculoskeletal consultations were identified by Read codes documented in the patient’s 
record. Musculoskeletal Read codes have been developed and validated at the School of 
Primary, Community and Social Care (https://www.keele.ac.uk/mrr/morbiditydefinitions) and 
have since been used in numerous publications (Bedson et al., 2019; Bedson et al., 2016). 
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The table below provides a number of examples of clinical codes indicative of a 
musculoskeletal consultation (see Table 6.4). Appendix 4 provides an example list of the 
most commonly used musculoskeletal Read codes. Full clinical code lists are available on 
request. 
Table 6.4. Examples of musculoskeletal consultation clinical codes 
Read term Read code 
Osteoarthritis  N05.. 
Low back pain N142. 
Shoulder pain N2457 
Osteoarthritis NOS, of knee N05zL 
6.2.9.2 Analgesic prescription 
Analgesic prescriptions were identified by Product codes or CPRD ‘medcodes’ documented 
in the patient’s record. As there are over 300 analgesic preparations (Joint Formulary 
Committee, 2017) a hierarchical classification was used (Bedson et al., 2013). The analgesic 
hierarchical classification system was validated using a four-step consensus exercise and 
has previously been used in CPRD (Bedson et al., 2013). Analgesic prescriptions were 
categorised into six groups based on their analgesic potency, reflecting the World Health 
Organisation analgesic pain stepladder ([WHO], Ehrlich, 2003). A seventh group classified 
patients with evidence of any analgesic prescription, irrespective of potency. An overview of 
the analgesic hierarchical classification, along with an example of an analgesic product term 
and product code is provided in Table 6.5. An example list of the clinical codes is provided in 
Appendix 4, with full Read code lists available upon request.   
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Table 6.5. Analgesic hierarchical classification (Bedson et al., 2013) 
Classification of prescription Example product term Product code 
Any analgesic prescription Any of the below N/A 
Basic analgesics Paracetamol 500mg tablets 7 
Weak analgesics Co-codamol 8mg/500mg  625 
Moderate analgesics Nefopam 30mg tablets 4016 
Strong analgesics Tylex 30mg/500mg capsules  656 
Very strong analgesics  Oramorph 10mg/5ml oral solution 1503 
NSAIDs Acemetacin 60mg capsules 344 
NSAIDs non-steroidal anti-inflammatory drugs  
Low dose Aspirin (300mg or less) is typically prescribed for its cardiovascular protective 
properties, and was not classified as an analgesic prescription (Hartikainen et al., 2005a). 
Analgesic prescriptions were considered if they occurred within a period starting 14 days 
before a musculoskeletal consultation, and up to 90 days following it. This timeframe 
generated a temporal association between the musculoskeletal consultation and the 
analgesic prescription, to provide greater confidence that the medication was being 
prescribed for a painful condition (Bedson et al., 2016; Bedson et al., 2019; Richardson et al., 
2018).  
6.2.10 Bias in observational designs 
For observational studies, bias is important to identify and assess due to the ability to distort 
the association between the exposure and the outcome of interest. According to Hennekens 
et al. (1987) bias in observational studies can be classified into two overarching categories 
including selection bias and information bias. 
6.2.10.1 Selection bias 
Selection bias means that the sample selection does not reflect the target population, 
because of the recruitment or retention of participants (Szklo & Nieto, 2014). For example, 
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sampling bias may occur if participants self-select for the study, as they may be inherently 
the same as each other, but different than the rest of the population (that may not self-select 
for research). In regard to CPRD data, participants do not self-select to be included in the 
data, however there may be differences between those whom consult to primary care, and 
those who do not (and thus not included in CPRD data).  
Loss to follow up or attrition becomes a potential for bias if there is ‘systematic differences 
between groups in withdrawals from a study’ (Higgins & Green, 2011). If the patients lost to 
follow up are different from the patients that remain in the study concerning the exposure and 
the outcome, the observed association may contain bias (Hennekens et al., 1987). Research 
suggests that the mortality rate for people with dementia is three times higher than older 
adults without dementia (Rait et al., 2010). In addition, a systematic review suggests that the 
rate of nursing home admission increased up to 17-fold for people with dementia (Luppa et 
al., 2010). Mortality and nursing home admission rates may mean that people with dementia 
have a higher attrition rate than older adults without dementia. The potentially high attrition 
rate for people with dementia may lead to immortal time bias, which is the ‘period of follow-up 
during which, by design, death or the study outcome cannot occur’ (Lévesque, Hanley, 
Kezouh & Suissa, 2010). In other words, people with dementia may not have sufficient follow 
up time for the outcome to occur. Healthy cohort effects refer to the potential bias when 
‘unhealthy’ patients leave the study (i.e. due to mortality or nursing home admission), 
meaning that the cohort contains ‘healthier’ patients whom may be less likely to have the 
outcome.  
6.2.10.2 Information bias  
Information bias occurs when there is ‘systematic differences in the way data on the 
exposure or outcome are obtained from the various study groups’ (Hennekens et al., 1987, p 
274). Different types of information bias include: 
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 Misclassification bias – This can occur when participants are defined on the basis of 
their exposure, disease, or outcome, but are incorrectly classified to the wrong group. In 
this retrospective cohort study, this might involve the exposure or the outcome being 
misclassified (i.e. an incorrect code being entered, musculoskeletal pain being missed 
(particularly so for people with dementia), or an individual with a musculoskeletal 
condition not consulting to primary care). Misclassification bias may become a problem if 
these incorrect allocations are not conducted at random, and instead are performed 
unequally between each cohort. 
 Recall bias - This is a potential problem if the exposed cohort is likely to report their 
exposure experience as different, or with a different degree of completeness or accuracy 
than those that have not been exposed. In the context of CPRD, data is typically 
recorded at the time of consultation by the healthcare professional. Therefore, the 
exposure and the outcome are not dependent upon participants’ recall.  
 Interviewer bias – This can occur if there are systematic differences in the recording or 
the interpretation of information from participants. For instance, in retrospective studies, if 
the interviewer is aware of the exposure status of the participant, the interviewer may use 
different techniques to gain information. In the context of this study, healthcare 
professionals were likely aware of the exposure status (dementia diagnosis), and 
although this might alter their recording of the outcome (musculoskeletal consultation) 
this in itself is an important finding. 
6.2.10.3 Other bias 
Medical surveillance (or detection) bias is apparent when the exposure leads to a closer 
observation of the outcome. In other words, as a consequence of the exposure (dementia), 
the individual may have more regular healthcare contact (e.g. more visits to primary care) 
meaning that the outcome may be more likely recognised, discussed, investigated, or treated 
by GPs.  
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6.2.11 Confounding 
In addition to bias, confounding is also important to identify and assess in observational 
studies due to the ability to distort the association between the exposure and the outcome of 
interest. Confounding refers to when a ‘non-causal association between a given exposure 
and an outcome is observed as a result of the influence of a third variable’ (Szklo & Nieto, 
2014, p.153). Confounders are causally associated with the outcome, and either causally or 
non-causally associated with the exposure, however do not lie on the causal pathway 
between the exposure and outcome (see Figure 6.9). A confounder may distort the 
association between the exposure and the outcome.  
 
*The unidirectional arrow demonstrates a causal association, whereas the bidirectional arrow 
indicates a non-causal association. 
Figure 6.9. Pictorial representation of confounding (adapted from Szklo & Nieto, 2014). 
6.2.11.1 Methods to control of confounders 
There are many means of dealing with confounders in cohort studies, including restriction, 
matching, stratification, and multivariable adjustment (Kestenbaum, 2009). In this study, 
matching and multivariable methods were used. 
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Matching is the selection of participants with no evidence of the exposure, however similar 
concerning other important characteristics to the exposed cohort. Two types of matching are 
common in epidemiological research, individual and frequency matching (Szklo & Nieto, 
2014). 
 Individual matching ensures that for each exposed patient one or more unexposed 
patient is selected (1:n). Unexposed participants are identified on the basis of having 
the same specified criteria in the matched variable.  
 Frequency matching selects the unexposed cohort to balance the distribution of the 
matched variable(s).  
Matching is employed in cohort studies to create a balance of composition in the matched 
variable(s), allowing both cohorts to be comparable, and thus reducing the influence of 
confounders distorting the association between the exposure(s) and the outcome(s). 
However, matching may not always be suitable if there is not a sufficient pool of unexposed 
individuals to match to each exposed patient, especially depending on the rarity of matched 
variables. If a suitable unexposed patient is unavailable, the exposed participant may be lost. 
In relation to this project, a large pool of older adults without dementia were available for 
matching within the CPRD dataset, therefore matching on common factors was appropriate. 
Therefore, exposed and unexposed patients were matched one-to-one, based on their year 
of birth, gender, and practice. By doing so, the exposed and unexposed cohort were 
comparable with regards to age, gender, and general practice at baseline (Jordan et al., 
2010; Patel, Guralnik, Dansie & Turk, 2013). 
Multivariable analysis can handle a large number of covariates (including continuous and 
categorical variables) simultaneously. In epidemiology, linear regression, logistic regression, 
and proportional hazards (Cox) regression are multivariable analytical techniques that are 
frequently used (Szklo & Nieto, 2014). In this study, to examine time-to-event data, a 
proportional hazards (cox) regression was used. Additionally, to examine the association 
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between dementia and a categorical outcome, logistic regression was used. An in-depth 
overview of the analysis plan is provided in Section 6.2.13.  
6.2.11.2 Potential confounders 
Potential confounders were identified i) from the previous literature (in the literature and 
systematic review) and ii) guided by clinical knowledge of dementia as informed by clinicians 
involved in the research. All covariates were measured or observed during the two-year 
period before index date (with the exception of deprivation). Baseline covariates were used in 
this research (rather than time-varying covariates) as conditions were perceived as ‘fixed-
state’, and therefore unlikely to change during follow up. Each of the potential confounders 
included in this research are discussed below. 
Deprivation 
Deprivation is a multi-dimensional construct, focused on a variety of domains such as health, 
education, and crime (Payne & Abel, 2012). In the UK, IMD is the official measure of relative 
deprivation (Department for Communities and Local Government, 2015). This study used 
linked data from CPRD GOLD to the 2010 English IMD (Department for Communities and 
Local Government, 2011). The English IMD was calculated using 38 indicators, across seven 
distinct domains. The domains are:  
 Income   
 Employment 
 Health and disability 
 Education skills and training 
 Barriers to Housing and Other Services 
 Crime  
 Living Environment 
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Each domain was weighted to calculate an aggregate IMD score for each Lower layer Super 
Output Area (LSOA). In England, there is 32,844 LSOA, each of which represent a small 
homogenous area (Department for Communities and Local Government, 2015). The IMD 
ranks each LSOA in England on a continuum from ‘least deprived’ to ‘most deprived’ 
(Department for Communities and Local Government, 2011).  
In this study, patients in the dementia cohort and older adult cohort were linked to practice-
level IMD in accordance with other CPRD studies (Springate et al., 2017). Practice-level IMD 
was derived by mapping each general practice’s latest available postcode to a LSOA 
boundary. To protect patient’s area of residence, practice-level IMD was provided in 
quintiles, with 1 being the ‘least deprived’, to 5 being the ‘most deprived’. IMD has commonly 
been used as a proxy for socioeconomic status (Heald et al., 2017). Many studies have 
found an association between having dementia and having a lower socioeconomic status 
(Russ et al., 2013; Kukull et al., 2002), with older adults with low socioeconomic status being 
more likely to have pain than older adults with a high socioeconomic status (Patel et al., 
2013). Evidence also suggests that people with dementia classified as having the highest 
level of deprivation had an increased odds of analgesic prescription (compared to those with 
the lowest deprivation) than matched older adults without dementia (Hamina et al., 2017).  
Depression 
Depression was defined using Read codes indicative of depression or bipolar documented in 
the patient clinical record (see Appendix 4 for example codes). The Read codes were 
produced and validated in the School of Primary, Community and Social Care 
(https://www.keele.ac.uk/mrr/morbiditydefinitions) (Bedson et al., 2016; Burton, Campbell, 
Jordan, Strauss, & Mallen, 2012; Walker, Liddle, Jordan & Campbell, 2017) and in previous 
CPRD research (Windfuhr et al., 2016). Research suggests that people with dementia may 
be more likely to have depression (Bennett & Thomas, 2014). Research evidence also 
indicates that people with depression may experience pain differently (Li et al., 2015; Shega, 
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Paice, Rockwood & Dale, 2010b; Bhattacharjee, Oh, Reiman & Burke, 2017), and may be 
prescribed more analgesic medications than people without depression (Gilmartin et al., 
2015).  
Diabetes 
Diabetes was defined using Read codes indicative of diabetes documented in the patient 
clinical record (see Appendix 4 for example codes). Read codes to define a diabetes 
diagnosis have been used and validated in previous CPRD studies (Tate et al., 2017; 
Joseph, Movahedi, Dixon, & Symmons, 2017; Zhong et al., 2018; NHS Health and Social 
Care Information Centre, 2012). Diabetes was included as a covariate due to the specific 
vascular sequelae that may impact the diagnosis of dementia, in particular vascular dementia 
(BMJ Best Practice, 2018; Perkins et al., 2004). People with diabetes are more likely to 
experience neuropathic pain, potentially leading to increased pain-related consultation and 
prescription (Rosenfeld, 2014).  
Cardiovascular-related conditions 
Cardiovascular disease (CVD), and other cardiovascular-related conditions were defined 
using Read codes documented in the patient’s clinical record (see Appendix 4 for example 
codes). Cardiovascular-related conditions were included as a covariate due to their 
relationship with increased pain, and their specific vascular sequelae to vascular dementia, 
meaning that the dementia cohort may have a higher prevalence of cardiovascular-related 
conditions compared to the older adult cohort (BMJ, 2017; Perkins et al., 2004). Additionally, 
research suggests people with cardiovascular-related conditions are prescribed more and 
different types of analgesic medications (Pawlosky, 2013).  
Morbidity count 
A ‘morbidity count’ was calculated using the total number of unique British National 
Formulary (BNF) sections the patient was prescribed a medication from during the two years 
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before index date. For example, if a person with dementia had evidence of one Antimotility 
Drug (BNF section 1.4.2) prescription, three Respiratory Stimulant (BNF section 3.5.1) 
prescriptions, and two Selective Serotonin Re-Uptake Inhibitors (BNF section 4.3.3) 
prescriptions, their morbidity count would be three (due to having prescriptions from three 
unique BNF sections). The morbidity count acted as a proxy morbidity measure; indicating 
that patients with a higher frequency of prescriptions spanning a number of BNF sections 
have more morbid conditions. BNF prescription counts are equally effective as other complex 
morbidity measures in primary care databases (Perkins et al., 2004), and have been used as 
an indicator for morbidity in comparable studies (Bedson et al., 2019; Richardson et al., 
2018). Research suggests that people with dementia have more morbidity, with research 
finding that comorbidities increased the likelihood of musculoskeletal consultations and 
analgesic prescriptions for people with dementia (Hamina et al., 2017).   
Consultation frequency 
‘Consultation frequency’ or the amount of consultations by each patient during the two years 
before index date was defined as ‘any face-to-face or telephone consultation completed by a 
doctor or a nurse’ (Stevens et al., 2017). During the two-year period before index date, all 
face-to-face or telephone consultations completed by a doctor or nurse were identified and 
totalled for each patient. Dementia diagnosis may contribute to a higher frequency of 
consultation to primary care (Shah, Mcniece & Majeed, 2001). If the patient consulted 
frequently to primary care, their musculoskeletal pain may be more likely recognised, 
discussed, investigated, or treated (see Section 6.2.10.2).  
Length of follow up 
The length of follow up for patients in the dementia cohort and older adult cohort was 
calculated from index date to exit date, in days. People with dementia were expected to have 
a shorter follow up time than older adults, potentially limiting their opportunity for 
musculoskeletal consultation and/or analgesic prescription (see Section 6.2.10.1).   
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Year of index date 
The index date occurred at any time during the 20-year study period (1st January 1997 to 31st 
December 2017). The consultation and treatment of dementia and musculoskeletal 
conditions, including the prescribing of analgesic medications are likely to vary over this time 
period (Harkness, Macfarlane, Silman & McBeth, 2005; Bedson et al., 2013).  
6.2.12 Missing data 
Missing data is a known limitation of CPRD (Herrett et al., 2015; see Table 6.1). The 
variability of data completeness is likely to vary over time, and depend upon the clinical entity 
in question, with the morbidity coding of conditions with clear diagnostic features being more 
complete (Jordan, Porcheret & Croft, 2004). In line with this, lifestyle factors (such as 
smoking and obesity) are known to have a higher frequency of missing data (Herrett et al., 
2015; Bhaskaran, Forbes, Douglas, Leon & Smeeth, 2013), and potentially coded more 
commonly for people with health conditions. Therefore, although lifestyle factors were 
important to consider as a potential confounder they were not included as a covariate in this 
analysis. However, by controlling for factors such as IMD, the confounding effect of lifestyle 
factors was potentially negated (Szklo & Nieto, 2014). Additionally, Jordan et al. (2007) 
suggests that for chronic conditions, each consultation may not be coded, potentially under-
representing the prevalence of chronic conditions. Although missing data remained an 
important consideration, research continues to suggest reasonable correctness and 
completeness of morbidity coding in CPRD (Jordan et al., 2004). 
For the exposure (dementia), covariates, and outcome (musculoskeletal consultation and 
analgesic prescription) used in this research, the absence of a Read code indicative of the 
clinical entity in question was interpreted as absence of the condition for the patient (Herrett 
et al., 2015). This had the potential of high ‘positive predictive’ values however lower 
sensitivity. This is partially attributed to patients not consulting to primary care (and therefore 
not being coded) despite having the condition (as discussed in Section 6.2.10), and the 
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miscoding of conditions. However, research suggests that the clinical recording of a variety 
of conditions in CPRD are comparable to other medical record databases, and questionnaire 
data (Nissen et al., 2017; Jordan et al., 2007; Quint et al., 2014). A systematic review 
conducted by Herrett et al. (2010) investigated studies that validated clinical codes used in 
CPRD. This review suggested that in general, the validity of clinical coding was high. 
Additionally, when analgesic medications are prescribed in primary care, they are 
automatically coded in CPRD and therefore missing data for this outcome was not 
anticipated (Bedson et al., 2013; Herrett et al., 2015). 
6.2.13 Analysis 
This section describes the analysis plan and the statistical methods employed. The analysis 
plan was created in collaboration with a statistician (YC) at the School of Primary, 
Community, and Social Care. Data were analysed using IBM SPSS Statistics version 24.0 
(IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: 
IBM Corp).  
6.2.13.1 Descriptive statistics  
The distribution of each variable was examined for the dementia cohort and older adult 
cohort. Descriptive statistics were used to explore the similarities and differences between 
the dementia cohort and the older adult cohort in both the incidence and prevalence 
investigations. Demographic characteristics, covariates, and outcomes were explored using 
frequencies and percentages for categorical variables and distributions (means, standard 
deviations, medians, interquartile ranges) for continuous variables.  
Independent t-tests and Person’s chi-square tests examined the statistical differences 
between the dementia cohort and the older adult cohort. Independent t-tests were used when 
one variable was continuous, with Cohen’s d being used as the effect size estimate when 
sample sizes were the same, and Hedges’ g (g) when sample sizes were unequal. Cohen’s d 
and Hedges’ g were interpreted the same, with a small effect size 0.2, medium effect size 
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0.5, and large effect size of 0.8 (Cohen, 2013). Pearson’s chi-square test were used when 
both variables were binary/categorical (as no cell frequency was lower than 5), with Cramer’s 
V (V) used to determine the effect size (see Table 6.6; Kim 2017).  
Table 6.6. Effect size for a chi-square test: Cramer’s V 
Degree of freedom Small Medium  Large 
1 0.10 0.30 0.50 
2 0.07 0.21 0.35 
3 0.06 0.17 0.29 
4 0.05 0.15 0.25 
*Table adapted from Kim (2017) 
6.2.13.2 Follow up time periods 
Analysis described in the following sections were conducted for a number of time periods, 
including the i) five-year time period from index date, and ii) each annual time period from 
index date to five years after index date. 
i. A five-year follow up period is in line with the average survival period of 
people with dementia diagnosed in primary care, with Rait et al. (2010) 
suggesting that approximately 50% of 60-69 year olds, and 25% of 80-89 year 
olds live for five years from primary care recording of dementia diagnosis.  
ii. Stratification into annual time periods from index date allowed an insight into 
musculoskeletal consultation and analgesic prescription throughout the time 
living with a dementia condition. A similar approach was undertaken by 
Gilmartin et al. (2015) whom recruited people with dementia within one year of 
their dementia diagnosis and investigated their analgesic prescription 
prevalence during each annual period for five years.  
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Unlike all other analyses, cumulative incidence (Kaplan-Meier’s approach), and Cox 
Proportional Hazards models were examined for the five-year period from index date, but not 
for each annual time period as each of these methods calculated the incidence at the exact 
time that the outcome occurred.  
6.2.13.3 Testing Incidence 
Incidence is the ‘frequency of a new event’ in a defined population over specified period of 
time (Szklo & Nieto, 2014). The types of ‘incident’ events commonly investigated are newly 
developed disease, reoccurrence of disease, development of a drug side effect, or in the 
case of this study, an incident musculoskeletal consultation. The basic principle of an 
incidence indicator is the number of events in a defined population during a specified period 
of time divided by the population at risk of an event during the same time period. There are 
two main types of incidence measures depending on the denominator, including i) incidence 
based on person-time at risk, and ii) incidence based on person at risk. This section will 
describe the incidence calculations included in this thesis to investigate the incidence of 
musculoskeletal consultation; including person-time incidence rates, followed by cumulative 
incidence. 
For all incidence calculations, participants no longer contributed to the study following their 
exit date (see Section 6.2.7.3), or following their identified incident musculoskeletal 
consultation during follow up (see Figure 6.6). Participants were ‘censored’ if their exit date 
or the end of the study period (31st December 2017) occurred before evidence of identified 
incident musculoskeletal consultation. 
6.2.13.3.1 Person-time incidence rates 
Person-time incidence rates were calculated using the number of incident events within a 
specified time period divided by the amount of person-time contributed to follow up within the 
same specified time period for individuals at risk:   
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number of incident events 
the amount of person time contributed 
 
Person-time incidence rates are particularly useful when the amount of observation time is 
not constant for each person (i.e. people joining and leaving the study at different time points 
throughout follow up). 
6.2.13.3.1.1 Incidence Rate Ratio  
The incidence rate ratio (IRR) is the ratio of two incidence rates. The IRR used the person-
time incidence rates described above (sometimes referred to as an incidence density ratio). 
The IRR allowed comparison between the person-time incidence rate for the dementia cohort 
and the person-time incidence rate for the older adult cohort: 
𝐼𝑅𝑅 =
𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
 
6.2.13.3.1.2 Attributable Rate 
Attributable rate (or sometimes called ‘excess fraction’) is a measure of association based on 
the absolute difference between two person-time incidence rates (Szklo & Nieto, 2014). The 
calculation of incidence rate is analogous with attributable risk; however, incidence rates use 
person-time incidence rates (rather than the cumulative risk). The ‘excess’ rate can be 
attributed to the exposure, when assuming a cause-effect relationship between the exposure 
and outcome (no involvement of bias or confounding): 
ARexp (𝐸𝑥𝑝𝑜𝑠𝑒𝑑  𝑝𝑒𝑟𝑠𝑜𝑛 𝑡𝑖𝑚𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒
− 𝑈𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑐𝑜ℎ𝑜𝑟𝑡 𝑝𝑒𝑟𝑠𝑜𝑛 𝑡𝑖𝑚𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒)  
To express the attributable rate as a percentage, if the exposed (dementia) cohort has a 
higher incidence rate than the unexposed (older adult) cohort, the percentage attributable 
rate in the exposed (%ARexp) can be calculated: 
%𝐴𝑅𝑒𝑥𝑝 (
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 − 𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑
) × 100 
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If the exposed (dementia) cohort has a lower incidence rate than the unexposed (older adult) 
cohort, the ‘preventable fraction among the unexposed’ (%PRu) can be calculated: 
%𝑃𝐹𝑢 (
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 − 𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝑅𝑖𝑠𝑘 𝑖𝑛 𝑡ℎ𝑒 𝑛𝑜𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
) × 100 
This calculation determines the proportion (%) of incident musculoskeletal consultations in 
the older adult cohort that would be ‘prevented’ (or in the case of this study, unidentified, 
unassessed, or not coded) if they had evidence of the exposure (dementia). This percentage 
again assumes a causal-effect relationship between the exposure and outcome (no 
involvement of bias or confounding). 
6.2.13.3.2 Cumulative incidence 
Cumulative incidence investigated incidence based on persons at risk; the probability that a 
particular event will occur during a specific time period. Cumulative incidence forms the basis 
of survival analysis (Szklo & Nieto, 2014), including Kaplan-Meier approach, and Cox 
proportional hazards models. 
6.2.13.3.2.1 Kaplan-Meier approach 
The Kaplan-Meier approach calculates the probability of the outcome (musculoskeletal 
consultation) at the exact time that it occurred for patients in the dementia cohort and older 
adult cohort (as defined by an appropriate outcome coding within the dataset). The 
denominator for the Kaplan-Meier calculation was the amount of people at risk at the exact 
time of each events occurrence (Szklo & Nieto, 2014). The assumptions of the Kaplan-Meier 
approach are outlined in Table 6.7. Survival curves were plotted separately for the dementia 
cohort and the older adult cohort. The difference between the two cohorts was tested using 
the logrank test. The survival curves take into account patients whom were ‘censored’ (see 
Section 6.2.13.3). Both person-time based incidence rates and cumulative incidence have 
common assumptions that are important to consider (see Table 6.7).  
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Table 6.7. Assumptions of incidence calculations: person-time based incidence rates and 
cumulative incidence 
Incidence calculation Assumption 
Person-time based incidence  1. Those censored had the same probability of an 
incident event as those still under observation 
2. Lack of secular trends 
3. Risk of the event remains approximately consistent 
during the time period of interest 
Cumulative incidence 1. Those censored had the same probability of an 
incident event as those still under observation 
2. Lack of secular trends 
 
1. In this study, it was expected that there would be no difference in the risk of incident 
musculoskeletal consultation between censored patients in the dementia cohort and the 
older adult cohort compared to the difference between patients in the dementia cohort 
and older adult cohort that remain under observation.  
2. Secondly, the lack of secular trends (e.g. a fluctuating risk of musculoskeletal 
consultation over time) was an important assumption to acknowledge in this study as 
patient index dates fall within a 20-year study period (from 1st January 1997 to 31st 
December 2017). During this time, musculoskeletal consultation rates were likely to 
fluctuate. Additionally, incentives to improve earlier diagnosis of dementia during this 
period (e.g. Quality Outcome Framework incentives; NHS Employers, 2016) were likely 
to fluctuate the rates of dementia diagnosis (and coding) in primary care. To investigate 
secular trends, Kaplan-Meier curves were plotted for early and late entrants (see Table 
6.8).  
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3. Finally, the third assumption (not relevant for cumulative incidence) suggests that the risk 
of musculoskeletal consultation should remain consistent throughout the time period of 
interest. Szklo and Nieto (2014) described this as ‘n persons followed during t units of 
time’ being equivalent to ‘t persons followed during n units of time’ (p. 60). To minimise 
the risk of violating this assumption (especially for studies with a long follow up period), 
Szklo and Nieto (2014) suggest that the follow up period could be stratified into shorter 
time periods. In this study, the person-time incidence rates were stratified into annual 
time periods, with person-time incidence rates calculated for each time period (see 
Section 6.2.13.2).  
6.2.13.3.2.2 Cox Proportional Hazards Regression 
Cox Proportional Hazards regression is the most popular approach to model time-to-event 
data, modelling the data using the hazard scale (Szklo & Nieto, 2014). Unlike the Kaplan-
Meier approach, the Cox Proportional Hazards model can be multivariable (and therefore 
accounting of potential confounding), with the ability to model continuous covariates. In this 
study, the univariate and multivariable Cox Proportional Hazards regression examined the 
incidence of musculoskeletal consultation over time of follow up from index date for the 
dementia cohort compared to the older adult cohort.  
The coefficients in a Cox Proportional Hazards regression relate to hazard; a positive 
coefficient indicates an increased risk of the outcome and a negative coefficient indicates a 
decreased risk of the outcome for the variable in question. The hazard ratio (HR) is the 
exponent of its coefficient, and therefore a HR expresses the magnitude of difference 
between the dementia cohort and the older adult cohort. Specifically, a HR of >1 indicates 
that the dementia cohort had a higher rate of identified incident musculoskeletal consultation 
than the older adult cohort, with a HR of <1 denoting that the dementia cohort had a lower 
rate of identified incident musculoskeletal consultation than the older adult cohort.  
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To account for the matched cohort design of this study, the analysis was stratified by 
matched-pairs following previous methodology (Cummings, McKnight & Greenland, 2003). 
Assumptions of Cox Proportional Hazards Regression are described in Table 6.8. 
Table 6.8. Assumptions of Cox Proportional Hazards Regression 
Assumption How the assumption was tested 
 Continuous predictors: Categorical predictors: 
Assumption of proportional 
hazards: Predictors have a 
multiplicative effect on the 
hazard (in other words, the 
ratio was assumed constant 
over time). 
Scatter plot of Schoenfeld 
residuals vs. time until 
incident event.  
To meet the assumption, 
the scatter plot should look 
like a random scatter 
around zero  
Investigation of the log 
minus log plots of the 
covariates entered as strata, 
against the log scale of time. 
To meet the assumption, 
curves should be 
approximately parallel and 
should not cross.*  
Limited change in risk over 
time 
Patients were sorted in ascending order by their index 
date. Patients were median split into ‘early’ and ‘late’ 
entrants. Kaplan-Meier curves with early and late entrants 
entered as a binary independent variable. The assumption 
was met if the logrank test was non-significant (p>.05), 
indicating limited change in risk over time. 
*Some crossing at early time points during follow up may not constitute a violation of assumption, 
but rather be a product of noise in the survival estimates (George, Seals & Aban, 2014). 
6.2.13.4 Testing Prevalence  
Prevalence can be simply defined as the ‘frequency of an existing event’ (Szklo & Nieto, 
2014). Different types of prevalence are available depending on the length of time under 
investigation, including point prevalence (the prevalence at that point in time), period 
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prevalence (the prevalence over a defined period of time, for example annual prevalence), 
and cumulative or life-time prevalence (including all cases in the past, to the present day). In 
this study, the period prevalence of musculoskeletal consultation and analgesic prescription 
was investigated for each time period (see Section 6.2.13.2). Patients were included in the 
prevalence estimates if they had complete follow up for each time period. Patients 
contributed to the numerator of the equation if they had evidence of the outcome 
(musculoskeletal consultation or analgesic prescription) at least once during the time period, 
with further consultations or prescriptions ignored, in line with similar work in this area 
(Jordan et al., 2010). Period prevalence was calculated as a percentage, with confidence 
intervals calculated using the Wilson Score (Brown, Cai & DasGupta, 2001): 
(
total number of people with the outcome
total number of people with a complete follow up
) × 100 
6.2.13.4.1 Prevalence ratio 
For each time period the prevalence ratio (PR) was calculated to examine the prevalence of 
the outcome (musculoskeletal consultation and analgesic prescription) for the dementia 
cohort compared to the older adult cohort:  
𝑃𝑅 =
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎 𝑐𝑜ℎ𝑜𝑟𝑡
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑜𝑙𝑑𝑒𝑟 𝑎𝑑𝑢𝑙𝑡 𝑐𝑜ℎ𝑜𝑟𝑡
 
6.2.13.4.2 Conditional logistic regression 
Conditional logistic regression (CLR) is an extension of traditional logistic regression models. 
CLR is typically used when analysing matched data to examine the association between the 
exposure and the outcome (Szklo & Nieto, 2014; Hosmer & Lemeshow, 2000). When 
analysing data using CLR, matched-pairs are entered into the model as individual strata. 
CLR provides parameter estimates of regression coefficients for covariates that vary within 
the strata. Therefore, CLR does not provide parameter estimates when there is no variation 
within the strata (such as matched variables, including gender, year of birth, and practice), 
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meaning that the coefficients are considered to be adjusted based on the matching variables 
(Szklo & Nieto, 2014). CLR analyses produce odds ratios (OR). OR examine the ratio of 
probability; or in other words, the odds of the outcome in the dementia cohort compared to 
the odds of the outcome in the older adult cohort for each time period. An OR of >1 means 
that the dementia cohort has a higher odds of the outcome compared to the older adult 
cohort. If the OR is <1 the dementia cohort has a lower odds of the outcome compared to the 
older adult cohort. 
Univariate and multivariable CLR analyses also examine the ratio of the outcome, alike to the 
prevalence ratio, however, the CLR also accounts for potential covariates (in the 
multivariable analyses) and the matched-pair design, unlike the prevalence ratio. Despite the 
benefits of CLR models, it is important to acknowledge that the OR (produced by the CLR) 
may over exaggerate the magnitude of the association (especially for common outcomes) 
compared to the prevalence ratio (Szklo & Nieto, 2014).  
The assumptions of CLR models are provided in Table 6.9. The first and second assumption 
were met prior to modelling. The third and fourth assumption were checked post-hoc using 
the methods described in Table 6.9 and discussed in the following findings chapters.  
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Table 6.9. Assumptions of Conditional Logistic Regression (CLR) models 
Assumption How the assumption was tested 
1. A binary dependant variable  Dependant/outcome variable was: 
 Musculoskeletal consultation (yes/no) 
 Analgesic prescription (yes/no)  
2. Independence of 
observations 
All observations were independent, with no repeated 
measures in either cohort 
3. Little or no multicollinearity 
among the independent 
variables 
 Investigation of high correlations between variables 
 Investigation of VIF values greater than 10  
 Investigation of tolerance values less than 0.1  
4. Linearity of continuous 
covariates to the log of the 
outcome variable  
The interaction terms of each continuous covariate and 
their log were entered into the model post-hoc. The 
assumption is met if the interaction term is non-
significant (p>.05). 
Assumptions from Field (2016); VIF Variance inflation factor 
 
6.2.13.5 Sensitivity analysis 
6.2.13.5.1 Formal care residence  
Previous inclusion and exclusion criteria stipulated that any patient (in either cohort) with 
evidence of a Read code indicative of formal care residence was excluded (see Section 
6.2.8) as a Read code was deemed a definitive marker of formal care residence (Shah et al., 
2010). However, data checking revealed that only 11% of the dementia cohort had a Read 
code indicative of formal care residence, and this rate does not reflect UK statistics that 
suggest approximately 38.7% of people with dementia reside in formal care (Prince et al., 
2014). Therefore, sensitivity analyses were conducted using additional (albeit not definitive) 
criteria of formal care residence in line with previous research using primary care datasets 
(Shah et al., 2010). Two additional markers were used to identify patients for the community 
sensitivity analysis:  
i) A family number frequency indicating that equal to, or less than two older adults 
(≥50 years old) live in the same household 
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ii) No evidence of a consultation location in a formal care residence at any time 
during the study period (1st January 1997 to 31st December 2017). 
The additional exclusion criteria have been used in previous research to identify community-
dwelling populations (Cooper et al., 2016). The incidence cohorts lowered from n=21,093 to 
n=4850 and n=3477 for the dementia cohort and older adult cohort, respectively (see Figure 
6.10). The prevalence cohorts lowered from n=36,582 to n=8875 and n=8349, for the 
dementia cohort and older adult cohort, respectively (see Figure 6.11).
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Figure 6.10. Incidence cohort: Community sensitivity 
 
Figure 6.11. Prevalence cohort: Community sensitivity 
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This sensitivity analysis examined to what extent the main results reflect the restricted cohort 
of patients with a greater likelihood of living in the community. This sensitivity analysis from 
this point forward is referred to as a ‘community sensitivity analysis’. 
6.2.13.5.2 Healthy cohort  
Prevalence rates in the main analysis only included patients that remained in the study for 
the entire follow up period in question (e.g. full five-year prevalence) (see Section 6.2.13.4). 
This might induce a ‘healthy cohort’ bias, especially for the five-year period, where the 
prevalence estimates only included patients that remained in the study for the entire five-year 
period after index date. Sensitivity analysis therefore investigated the prevalence of 
musculoskeletal consultation and analgesic prescription for patients eligible at the mid-time 
point of the five-year period from index date (912 days after index date) (Szklo & Nieto, 
2014); see Sections 8.2.2.1.1.2 and Section 9.2.1.1.1.2. 
6.2.13.5.3 Analgesic prescriptions not matched to musculoskeletal consultation 
For the main analysis, analgesic prescriptions were considered if they occurred within a 
period starting 14 days before a musculoskeletal consultation, and up to 90 days following it 
(see Section 6.2.9.2). Sensitivity analysis examined all analgesic prescriptions irrespective of 
their temporal association with a musculoskeletal consultation. This analysis observed if the 
prevalence of analgesic prescriptions for potentially painful musculoskeletal conditions 
differed from analgesic prescriptions, irrespective of the pain driver. 
6.2.13.5.4 Analgesic prescription in the one year before index date 
Sensitivity analysis also investigated if the temporal trend of analgesic prescription 
prevalence changed over time if patients had received:  
1. Any analgesic prescription in the one year before index date 
2. No analgesic prescription in the one year before index date  
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This additional sensitivity analysis allowed investigation to see if previous analgesic 
prescription was related to analgesic prescription during follow up.  
6.2.13.5.5 Non-stratified and unconditional models 
Matched-pair stratified Cox Proportional Hazards models and CLR models account for the 
matching of the dementia cohort and the older adult cohort (see Section 6.2.13.4.2). 
Although one-to-one matching (of gender, year of birth, and practice) was completed at 
baseline, because of attrition, the amount of matched-pairs steadily reduced for each annual 
period of follow up (see Table 7.5). For example, in the first year (from index date to one year 
after index date), 73.5% of the matched-pairs remained, however by the final year of follow 
up (four years to five years after index date), only 15.9% of matched-pairs remained. The 
remaining 81.4% of patients were no longer matched. The reduction of matched-pairs over 
time means that the distribution of gender, year of birth, and practice did not remain equal 
(albeit they remained similar; see Table 7.5). Therefore, sensitivity analysis was conducted 
using non-stratified Cox Proportional Hazard models and univariate and multivariable logistic 
regression to account for the ‘imbalance’ of matched variables. These sensitivity analyses 
meant that the ‘matched’ covariates (year of birth, gender, and practice) could be included in 
the model as covariates to examine the impact of their ‘imbalance’.   
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6.3 Qualitative Methods 
This section of the chapter describes the qualitative methods used to investigate pain 
identification, assessment, and management for community-dwelling people with dementia. 
Qualitative research provides an in-depth and interpreted understanding of the social world 
through people’s perspectives, views, and history (Snape & Spencer in Richie & Lewis, 
2003), as reflected in the research questions below: 
Research objective 1: To investigate pain identification and pain assessment for 
community-dwelling people with dementia 
 How do family caregivers and healthcare professionals identify and assess pain for 
community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
perceive pain identification and assessment strategies for community-dwelling people 
with dementia? 
Research objective 2: To investigate the management of pain for community-dwelling 
people with dementia 
 How do people with dementia, family caregivers, and healthcare professionals 
manage the pain experienced by community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
perceive pain management strategies for community-dwelling people with dementia?  
To answer the above research questions, qualitative methods must capture the views and 
perspectives of the three key parties involved in the community-dwelling person with 
dementia’s pain; the person with dementia, the family caregiver of the person with dementia, 
and healthcare professionals. 
6.3.1 Research ethics 
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To provide ethical guidance, the British Psychological Society Code of Ethics and Conduct 
(2009) was followed. The code is underpinned by the four main principles of respect, 
competence, responsibility, and integrity. The Mental Capacity Act (Department of Health, 
2005) was also followed for the people with dementia participating in research. To 
complement this Act, the Mental Capacity Act 2005 Code of Practice (Department for 
Constitutional Affairs, 2007) was closely adhered to, shaping the way the Act was put into 
practice within a research context.  
One of the responsibilities of the researcher outlined by the Code of Practice is the approval 
of the research by a research ethics committee recognised by the Secretary of State 
(Department for Constitutional Affairs, 2007, p. 206). On this basis, Research Ethics Approval 
and Health Research Authority approval was obtained from London - Bromley Research 
Ethics Committee on 29th October 2017 (IRAS number: 230583) (see Appendix 5).  
6.3.2 Patient and Public Involvement and Engagement 
Patient and Public Involvement and Engagement (PPIE) allows members of the public to be 
actively involved in research projects. By involving the patients and public in research, it 
ensures that research is ‘carried out ‘with’ or ‘by’ members of the public rather than ‘to’, 
‘about’ or ‘for’ them.’ (INVOLVE, 2017). PPIE has a large impact on health and social care 
research to improve the quality, and the appropriateness of the research (Brett et al., 2012). 
This is especially true of dementia research, with Alzheimer Europe promoting the inclusion 
of people living with dementia, and recognising the importance of championing people with 
dementia’s unique perspective and contributions that have previously been ignored (Gove et 
al., 2018). Such recommendations have seen the inclusion of people with dementia as co-
researchers (Swarbrick et al., 2016). However, in a recent scoping review, inclusion and 
involvement continues to be inadequately reported in dementia research (Bethell et al., 
2018).  
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The PPIE team in the School of Primary, Community and Social Care operated a Dementia 
Research User Group (RUG) to facilitate research development. The RUG consists of lay 
people who meet regularly to give advice and feedback on grant applications and planned 
research studies. I initiated contact with the RUG, which included current and previous family 
caregivers of people with dementia. Unfortunately, although I attempted to involve people 
with dementia in the development of this research, there was no opportunities at the time of 
the initial project development. During the PPIE meeting, RUG members helped to co-
produce the research questions, study design, and recruitment procedures. PPIE members 
also provided comment on participant facing documents (e.g. invitation letters, information 
leaflets, consent forms, consultee advice forms, etc.), interview guides, and lay summaries. 
One way that the RUG group positively guided the development of this project was by 
emphasising the importance of ‘situational sensitivity’ when using the word dementia during 
interviews as the person with dementia may not be informed of, do not agree with, or may 
have forgotten their dementia diagnosis (Downs, Clibbens, Rae, Cook & Woods, 2002; 
Novek & Wilkinson, 2019). The RUG and I agreed that I would ask the family caregiver (prior 
to interview) about the insight of the person with dementia into their condition. If insight was 
uncertain, dementia was referred to as a ‘memory problem’ taking into account the ethical 
challenge of re-informing the individual with potentially distressing information (Heggestad, 
Nortvedt & Slettebø, 2013; Pesonen, Remes & Isola, 2011). This approach was deemed 
morally sensitive by the RUG group. Additional ways in which the RUG group aided the 
development of this study are discussed throughout this chapter. 
6.3.3 Interviews 
Reflecting on the research questions and theoretical perspective of this thesis, interviews 
were chosen as the method to explore the many dimensions of the participant’s subjective 
views, perspective, and experiences of pain identification, assessment, and management 
(Rubin & Rubin, 2012). Interviews allow researchers to see the world through an alternate 
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perspective by talking to people that have knowledge, or experience of a phenomena, in line 
with the critical realist perspective that each individual has their own subjective, real-world 
lived accounts shaped by culture, history, and experience (McEvoy & Richards, 2006). 
Interviews within a qualitative context are typically dichotomised into unstructured (otherwise 
referred to as non-standardised or in-depth), or semi-structured interviews. I chose to use 
semi-structured interviews to allow the narrative to focus on the research topic, yet remain 
flexible in response to the participant narrative.  
6.3.4 Interview guides 
Interview guides (also known as topic guides, or interview schedules) provide the key 
aspects to be explored during the interview, broken down into different areas for discussion 
(Arthur & Nazroo, in Richie and Lewis, 2003). In this research, the interview guide was used 
as an aide-memoire, ensuring that all of the relevant issues were covered during the 
interview, while again, maintaining a degree of flexibility to explore each participant’s 
personal perspective. For this study, I created two broad interview guides (see Appendix 6): 
1 The person with dementia and their family caregiver 
2 Healthcare professional 
Interview guides for people with dementia and family caregivers were developed in 
collaboration with the PPIE Dementia RUG, based upon previous literature that had 
conducted semi-structured interviews with healthcare professionals and family caregivers 
about pain in people with dementia (Lichtner et al., 2016; Brorson, Plymoth, Örmon & 
Bolmsjö, 2014). Following the collaborative development of the interview guides, each guide 
was checked to ensure that they reflected the research questions. After each interview, the 
interview guide was adapted to incorporate participant’s key ideas, notions, and experiences. 
The iterative and flexible adaptation and development of the interview guide facilitated the 
development of new insights not hitherto anticipated (Yeo et al. in Richie, Lewis, Nicholls & 
Ormston, 2013).  
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6.3.5 Person with dementia and family caregiver interviews 
Interviews are the most common qualitative data collection method for people with dementia 
(Steeman de Casterle, Godderis & Grypdonck, 2006). However, people with dementia are 
often excluded from interview studies due to the perception that they are ‘incapable’ of 
talking about their subjective experiences, thoughts, and feelings (Hubbard, Downs & Tester, 
2003; Quinn, 2017). In recent years, research has emphasised the inclusion of people with 
dementia in interview studies to promote social inclusion, and to challenge the stigmatised 
view of dementia (Pesonen et al., 2011; Hubbard, Downs & Tester, 2003; Quinn, 2017). 
Despite the importance of including people with dementia in qualitative research, it remains 
the researcher’s moral obligation to consider the unique ethical and methodological 
challenges.  
I chose to interview the person with dementia with their primary family caregiver, in a face-to-
face ‘dyadic’ or ‘joint’ interview. Dyadic interviews bring together two participants, and are 
particularly advantageous when the participants are in a natural coupling, for example 
partners, parents and their children, caregivers and the person they care for (Morgan, Ataie, 
Carder & Hoffman, 2013). Dyadic interviews allowed collaborative discussion to provide a 
shared narrative by both parties (Eisikovits & Koren, 2010); allowing both participants to 
reflect upon, and draw comparisons with the other person’s perspective. Previous research 
has highlighted the benefits of dyadic interviews for people with dementia and family 
caregivers to create a safe and comfortable environment to facilitate open and honest 
discussion (Morgan et al., 2013; Pesonen et al., 2011). Pragmatically, dyadic interviews also 
allow the family caregiver to be present for safeguarding purposes, and to act as a consultee 
if the person with dementia did not have capacity to provide informed consent (see Section 
6.3.5.4.1). 
When considering the ethical and methodological issues of dyadic interviews, the RUG group 
suggested that the person with dementia or family caregiver might wish to discuss something 
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that they would feel uncomfortable disclosing in the presence of the other person. However, 
no participants wished to complete a second interview on their own, suggesting that they had 
‘nothing to hide from each other’. Interviews were also offered to family caregivers on their 
own if the person with dementia was not eligible to participate (see Section 6.3.5.1). 
6.3.5.1 Eligibility 
This research aims to take an inclusive approach to dementia research and therefore did not 
include or exclude on the basis of cognitive test scores. Cognitive tests are criticised for their 
blanket approach to eligibility testing as they do not measure the amount an individual can 
discuss their experiences, perspective, and emotions (Pratt & Wilkinson, 2001; Heggestad et 
al., 2013). Excluding people with dementia in research goes against the principle of ‘equality’ 
and removes their right to a voice on their pain despite it directly affecting their life (Sherratt, 
Soteriou & Evans, 2007). 
In contrast, recent research has emphasised the positives of including people with dementia 
in research; with people with dementia describing research interviews as therapeutic, an 
opportunity to validate own perspectives and experiences, and allowing them to feel 
‘capable’ (Cahill et al., 2004). On these grounds, the present research adopted an inclusive 
approach to dementia research (Dewing, 2002; 2007; Hellström, Nolan, Nordenfelt & Lundh, 
2007). To achieve this, the recruitment approach ensured that all people with the ability to 
take part in a dyadic interview were provided the opportunity, even though the interview may 
require adaptation (e.g. increased flexibility for breaks, multiple visits, etc.) because of this. 
This is reflected below in the inclusion and exclusion criteria for people with dementia (see 
Table 6.10).  
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Table 6.10. People with dementia and family caregivers: Inclusion and exclusion criteria 
Person with dementia 
Inclusion criteria  
 Diagnosis of dementia as assumed by information provided in the Join Dementia 
Research records, or verbal confirmation from the person themselves or their caregiver 
 Live in the community (as defined in Section 1.7)  
 Have an informal caregiver willing to participate in a dyadic interview 
 Able to vocalise a willingness to take part in an interview 
 Verbally proficient in English 
Exclusion criteria 
 Cannot to contribute to an interview (e.g. no longer have the ability to verbally 
communicate) 
 Currently or recently experiencing any major psychological, physical distress, or 
emotive or stressful life event in which taking part in an interview may exacerbate (as 
asked to the caregiver) 
Family caregivers 
Inclusion criteria 
 Self-identify as the current or previous primary caregiver for an individual diagnosed 
with dementia. This may include a family member, relative, neighbour, or friend who is 
involved in care or spends the most time with the person with dementia (Orgeta et al., 
2015). 
 Willing to take part in an interview  
 Verbally proficient in English 
Exclusion criteria 
 Under the age of 16 years old 
 
6.3.5.2 Sampling and recruitment 
People with dementia and family caregivers were identified using a purposive sampling 
method using Join Dementia Research (JDR) 
(https://www.joindementiaresearch.nihr.ac.uk/). Briefly JDR is a platform to promote 
participation in dementia research by using a self-registration service that enables volunteers 
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with memory problems or dementia, caregivers of those with memory problems, or dementia 
and healthy volunteers to register their interest in taking part in research. In October 2018, 
JDR had 38,022 volunteers, 10,752 of which were enrolled onto research studies. JDR staff 
used the inclusion and exclusion criteria (see Section 6.3.5.1) to identify potentially eligible 
volunteers from their records. One hundred and thirty-two potential volunteers were identified 
within the West Midlands. I screened potential volunteers’ records, choosing participants that 
were eligible, yet diverse in regard to other characteristics (age, cognitive ability score) in line 
with the purposive sampling method (see Section 6.3.5.2). All volunteers consented to be 
contacted during the JDR registration process. Those deemed eligible during the initial 
screening process were contacted using their ‘preferred person to contact’ (often the family 
caregiver) using their ‘preferred method of contact’, including text, telephone, email, or post.  
During the first contact, I provided participants with more information about the study, and 
confirmed their eligibility. Following the initial contact, if the participant(s) was interested in 
the study, and was eligible to take part, I obtained permission to send the study pack in the 
post/via email (depending on the participant’s preference). A study pack (see Appendix 8) 
included: 
 An invitation letter  
 Two information leaflets, one each for the person with dementia and the caregiver  
After a minimum of 48 hours, I made follow up contact to the participant(s) to answer any 
questions, and to potentially arrange an interview. If the participant was happy to arrange an 
interview, the need for flexibility was required. I acknowledged that unfamiliar environments 
and the effects of sleep patterns might negatively affect the person with dementia’s ability to 
complete the interview (Beuscher & Grando, 2009). Interviews were therefore scheduled at a 
time suitable for the person with dementia, with the option to complete the interview at the 
participant’s own home. Conducting interviews with people with dementia in their own homes 
was perceived as protective, allowing them control over their own environment (Pesonen et 
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al., 2011). Choice and flexibility promotes inclusivity; providing participants with some control 
over the research process (Novek, & Wilkinson, 2019) 
After organising the interview, I confirmed with the participant that they were happy for me to 
send a form (either by post or email) detailing the confirmed arrangements of the scheduled 
interview. This form reminded participants of the scheduled interview date, location, and time. 
The form also reminded the participant that I would telephone call them approximately one 
hour before the interview. This pre-interview telephone call was suggested by the RUG 
group, not only to act as an additional reminder, but also to ensure that participants were in a 
good state of wellbeing, acting as an additional safeguarding technique and the opportunity to 
ask any outstanding questions. A flow diagram presenting the recruitment process of people 
with dementia and family caregivers is outlined in Figure 6.12. 
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Figure 6.12. Flow diagram to illustrate recruitment through Join Dementia Research 
6.3.5.3 The interview process 
The following sections discuss the interview process and ethical considerations immediately 
before (see Section 6.3.5.4), during (see Section 6.3.5.5), and at the end of the interview 
(see Section 6.3.5.6).  
 
 
Chapter Six: Methods 
 
 
184 
 
6.3.5.4 Before the interview 
Conducting interviews with people with dementia required thought and consideration to 
ensure that the most suitable environment was created. Building rapport with individuals prior 
to the actual interview is essential for all good research practice to allow the participant to 
feel comfortable sharing their thoughts and feelings. Building rapport based on trust, warmth, 
and empathy is even more important for people with dementia in the presence of potential 
power inequalities (Hellström et al., 2007). I began building rapport with the participant(s) by 
engaging in general conversation and providing information about myself. In addition, this 
allowed me to gain an initial insight into the person with dementia’s capacity. Before the 
interview began, I emphasised that there was no right or wrong answers, and the wish to 
hear the person with dementia’s thoughts before the family caregiver (see Section 6.3.5.5). 
Before the interview initiated, the information leaflets were discussed (see Appendix 8), 
during this process I highlighted the key information, including but not limited to a brief 
overview of the study, the contact details of the researcher, the researcher’s duty of care, 
and data management and storage. Following discussion of the information leaflet, I gave the 
participants time to consider any potential questions or thoughts.  
6.3.5.4.1 Capacity and informed consent 
The Mental Capacity Act (Department of Health, 2005) and many other papers (Dewing, 
2007; McKeown, Clarke, Ingleton & Repper, 2010; Welie & Welie, 2001; Heggestad et al., 
2013) highlight that a diagnosis of dementia does not automatically result in lacking capacity. 
A person-centred approach emphasises that people with dementia should have the 
opportunity to participate in research that directly concerns their illness (Moore & Hollett, 
2003).  
To assess the person’s capacity to participate in the research, I considered if the diagnosis of 
dementia means that the person is unable to make a decision if to, or if not to participate in 
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the interview at that time. To establish this, four key considerations as outlined by the Mental 
Capacity Act 2005 Code of Practice (Department for Constitutional Affairs, 2007) were:  
 The person with dementia’s general understanding of what decision they need to 
make and why they need to make it  
 The person with dementia’s general understanding of the likely consequences of 
taking part, or not taking part in the research  
 The person with dementia’s ability to understand, retain, use and weigh up their 
decision to participate in the interview  
 The person with dementia’s ability to communicate their decision 
If the person with dementia was deemed to have informed consent, the person with dementia 
and the family caregivers signed an informed consent form (see Appendix 8). If the person 
with dementia lacked capacity to provide informed consent, I consulted the family caregiver 
in accordance with section 32 of the Act to determine whether the person would wish to be 
included in the research.  
The consultee commented on two important aspects: 
 Whether the person who lacks capacity should take part in the project 
 What they think the person’s feelings and wishes would be, if they had capacity to 
decide whether to take part. 
If the family caregiver acted as a consultee, they were asked to read the consultee 
information sheet (see Appendix 8). This information sheet provided the information about 
the important aspects of the study, and the responsibilities of a consultee in research. 
Although the consultee was advising on the person with dementia’s feelings and wishes, the 
person with dementia had to express a willingness to participate. The family caregiver was 
asked to sign the consultee advice form on behalf of the person with dementia (see Appendix 
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8), and informed consent for their own participation (see Appendix 8). If a family caregiver 
participated alone, they were asked to sign informed consent for their own participation (see 
Appendix 8).  
To ensure an ethical and positive research experience for all parties, the process-consent 
method was utilised (Bartlett, 2012; Dewing, 2002; 2007). This framework reiterates the 
importance of gaining verbal confirmation at each stage of the research process that the 
participant is willing to continue and reminding participants that they can withdraw at any 
time, rather than consent being viewed as a priori research formality (Hubbard, Downs & 
Tester, 2003). This method is particularly beneficial when interviewing vulnerable 
populations, allowing each participant multiple occasions throughout the interview process to 
express their wish to continue participating. By monitoring ongoing consent, the research can 
be person-centred and inclusive, yet promote safety and personal well-being. 
6.3.5.5 During the interview 
6.3.5.5.1 Contextualising participants 
At the start of the interview, after initiating the audio recorder, I provided an overview of 
myself. This allowed participants time to settle into the interview environment. Additionally, 
this information assisted in building rapport by allowing the participant(s) an insight into my 
life. After I provided an overview of myself, the participant(s) was asked to give an overview 
of themselves. If the participant did not naturally include all relevant demographic information 
(e.g. age, pain condition), I prompted for this information when their narrative naturally came 
to a close.  
Assessment of pain  
To add further contextual information to participants’ accounts, it was important to gain an 
understanding of how people with dementia subjectively perceived their pain intensity. In the 
nature of this interview study, all people with dementia were able to verbally communicate, 
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and therefore self-reported pain was deemed appropriate (see Section 2.3.1). Throughout the 
literature review (see Chapter Two) and the systematic review (see Chapter Three) many 
self-report pain assessment tools were discussed. The Revised Iowa Pain Thermometer 
(IPT) demonstrated pain intensity with a thermometer graphic, accompanied with a Numerical 
Rating Scale (NRS) and verbal anchors (e.g. ‘mild pain’) to aid pain ratings (see Figure 6.13) 
The NRS and verbal pain descriptions in the IPT allowed the participant(s) multiple avenues 
to describe their pain. Investigation into the IPT for people with cognitive impairment 
suggested that the scale was ‘relatively easy to use and understand’ (Ware et al., 2006), and 
is preferred over other methods of assessing pain intensity (Ware et al., 2015). 
People with dementia were asked to ‘pick a number on the Pain Thermometer that best 
represents the intensity of your pain right now’ and ‘on average over the last four weeks’. 
Following this, family caregivers provided an informant report of pain, and were asked to ‘pick 
a number on the Pain Thermometer that best represents the intensity of [person with 
dementia’s name] pain right now’ and ‘on average over the last four weeks’. Both the person 
with dementia and family caregivers were encouraged to qualitatively discuss their 
perspective of this pain assessment method.  
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Used with permission Keela Herr, PhD, RN, AGSF, FAAN, College of Nursing, The University of Iowa, 
Iowa City, IA, USA 
Figure 6.13. Iowa Pain Thermometer (IPT) graphic 
6.3.5.5.2 Conducting the interview 
People with dementia may take longer to answer interview questions and may require a 
longer time to form their response (Pesonen et al., 2011). In many circumstances, this meant 
that I was comfortable with silence, allowing the person with dementia the time and space to 
form their response. In dyadic interviews, all interview questions were first directed towards 
the person with dementia. If the family caregiver initiated a response, I asked them to ‘hold 
that thought’ until the person with dementia had the opportunity to voice their perspective 
(Mastwyk, Ames, Ellis, Chiu & Bow, 2014). In addition, people with dementia may ‘go off 
topic’ or ‘get stuck’ on a particular topic. In this circumstance, I waited until the person with 
dementia reached a natural end to their narrative, before validating their response and 
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guiding the conversation topic back to the interview guide (Beuscher & Grando, 2009; 
Murphy, Jordan, Hunter, Cooney & Casey, 2014).  
Throughout the interview process, it was important to offer sufficient opportunities for breaks 
for people with dementia. In addition to breaks, participants were given the option to complete 
the interview during multiple visits to gain the depth and breadth of information required 
without causing irritability or fatigue due to a longer interview (Pesonen et al., 2011). Multiple 
interviews were, however, not required.  
6.3.5.6 Ending the interview 
Researchers have previously noted the importance of ending the interview ‘on a high’ by 
praising and thanking the participants for their contribution (Murphy et al., 2014). After the 
audio recorder was turned off, I ensured that the person with dementia felt positive about 
their contribution by spending time with the person with dementia and the family caregiver to 
reiterate my gratitude for their involvement and hospitality. Although this is important for all 
research, it is particularly so for people with dementia who may feel a sense of failure from 
‘giving the wrong answer’ or getting confused during the interview (Hellström et al., 2007; 
Murphy et al., 2014). Participants were offered a £10 voucher as a token of appreciation for 
their time.  
6.3.6 Healthcare professional interviews 
In addition to face-to-face interviews, alternative modes of interview are also frequently used, 
including telephone interviews. Research suggests that telephone interviews may require 
more frequent clarification of meaning, potentially lost nuances (due to the lack of facial 
expression and body language), and shorter interviews than face-to-face interview modes 
(Irvine, Drew & Sainsbury, 2012). Despite the potential limitations of telephone interviews, 
their inclusion was deemed necessary to overcome practical barriers of including healthcare 
professionals in research, such as time constraints and availability (Sturges & Hanrahan, 
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2004). Therefore, healthcare professionals were given the option to complete the interview 
face-to-face or via telephone, depending on their preference. 
6.3.6.1 Eligibility 
This study aimed to explore pain identification, assessment, and management from the 
perspective of healthcare professionals. The inclusion/exclusion criteria were left intentionally 
broad, however recruitment was targeted towards GPs and old age psychiatrists due to their 
involvement providing care for community-dwelling people with dementia (see Section 4.1). 
Inclusion and exclusion criteria are in Table 6.11. The restrictive nature of snowball sampling 
(see Section 6.3.6.2), along with the feasibility and scope of this study, meant that additional 
healthcare professionals (aside from GPs and old age psychiatrists) were not recruited.   
Table 6.11. Healthcare professionals: Inclusion and exclusion criteria 
Inclusion criteria  
 Healthcare professional (e.g. GP or Old Age Psychiatrist) with experience of working 
with people with dementia in a professional capacity 
 Willing to take part in an interview  
 Verbally proficient in English  
Exclusion criteria  
 Not directly involved in the provision of care for people with dementia 
6.3.6.2 Sampling and recruitment  
Healthcare professionals were recruited using a snowball sample. Healthcare professionals 
were approached through existing clinical networks within the School of Primary, Community 
and Social Care. My supervisors made contact with colleagues (using the study invitation 
letter) known to them to ask if they would like to participate. Healthcare professionals were 
also asked to pass the study invitation letter on to their clinical colleagues who fitted the 
eligibility criteria to ask if they may also wish to take part. My contact details were provided 
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within the study invitation letter, and therefore, only those that expressed an interest in the 
study (by telephone or email) were contacted and provided with further information. A flow 
diagram presenting the recruitment process of healthcare professionals is outlined in Figure 
6.14. 
 
Figure 6.14. Flow diagram to illustrate healthcare professional recruitment 
6.3.6.3 The interview process 
When a healthcare professional provided an explicit expression of interest, a study pack was 
sent by post or email depending on the potential participant’s preference, to allow the 
healthcare professional to read during their own time. A study pack (see Appendix 8) 
included:  
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 An invitation letter  
 An information sheet  
 Two copies of the consent form 
If the healthcare professional expressed a willingness to participate, a mutually suitable time 
and mode of interview (i.e. face-to-face or telephone) was arranged. 
Face-to-face interviews with healthcare professionals were completed within the School of 
Primary, Community and Social Care or within the healthcare professional’s place of work, 
depending on the participant’s preference. If the interview was arranged face-to-face within 
the School of Primary, Community and Social Care, I booked a room to complete the 
interview. If the interview was conducted on NHS premises, the healthcare professional was 
asked to choose a location suitable for a private interview. I discussed the information leaflet 
and consent form (see Appendix 8) with the healthcare professional before the interview to 
validate understanding, with time for participants to ask any questions. If the healthcare 
professional was happy to continue, written informed consent was obtained and 
countersigned before starting the interview. 
If the healthcare professional wished to complete a telephone interview, I booked a room 
within the School of Primary, Community and Social Care. By doing so, the interview 
environment was private and the audio recording of the interview did not exit the building. 
Before the interview, participants were asked to complete the informed consent form (as 
included in the study pack sent by email or post) and return it before the scheduled interview 
date. When the informed consent form was returned, I counter-signed the consent form and 
returned a copy of the form to the healthcare professional for information purposes. At the 
start of the telephone call, time was provided to allow the healthcare professional to ask any 
questions. Following this, I reiterated the key tenants of the consent form with verbal 
confirmation of understanding and willingness to continue from the participant. At the start 
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and throughout the interview, the participant was made aware when I started and stopped 
the audio recording.  
At the end of every interview, healthcare professionals were thanked for their time and 
offered reimbursement aligned to their hourly rate. 
6.3.7 Additional ethical considerations 
Throughout the previous sections, methodological and ethical considerations were 
discussed, most of which were appropriate for people with dementia and their family 
caregivers. The following sections discuss additional ethical considerations applicable to all 
interview studies, irrespective of the population. 
6.3.7.1 Duty of care and breaking confidentiality  
During the interview process, on rare occasions participants may divulge, incidentally, 
information that raises concern (for example, an expression of potential harm to themselves 
or to somebody else). I had a duty of care and responsibility to break confidentiality upon 
these grounds. This was explicitly outlined within the information leaflet and discussed prior 
to each interview. There were no instances in which such action was deemed necessary, 
however in such circumstances, I would have followed the Risk Protocol (see Appendix 9).  
6.3.7.2 Withdrawal 
All participants had the right to withdraw from the study at any time without implications to 
their care or legal rights. However, all participants were made aware that if they withdrew 
during or after the interview, their anonymous data would continue to be used, however no 
further information would be collected or contact made.  
If the family caregiver acted as a consultee to provide advice on behalf of the person with 
dementia, the family caregiver had the right to withdraw the person with dementia from the 
research at any time (Department for Constitutional Affairs, 2007). If the person with 
dementia expressed a wish to withdraw from the study (implicitly or explicitly) during or after 
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the interview, this was acted upon regardless of informed consent or consultee advice. As 
part of the process-consent method, the interviewer reiterated that all participation was 
voluntary and that participants were free to withdraw at any time at each stage of the study 
(outlined in Section 6.3.5.4.1). The researcher remained vigilant for changes in the 
participant’s presentation as upset or distress may be an implicit willing to withdraw from the 
research, especially for people with dementia.  
All participants were signposted to relevant organisations (including the National Dementia 
Helpline). Additionally, my contact details (as outlined in the information sheet; see Appendix 
8) were highlighted at the start, and upon closure of the interview.  
6.3.7.3 Interviewer Safety 
People with dementia and family caregivers could complete the interview in their own homes. 
Additionally, healthcare professionals could complete the interview on NHS premises. 
Although this approach was beneficial for the participants, safety was paramount. In these 
cases, I strictly abided by the Keele University Lone Working Policy. Before each visit, I 
completed the School of Primary, Community and Social Care visit proforma. This includes 
information such as the location and time of the interview, contact details for the researcher, 
or any notable risks. This information was shared with a nominated colleague. The visit 
proforma was destroyed after each visit to ensure confidentiality of personal information.  
6.3.8 Data management and storage 
All data management was in accordance with the Data Protection Act (1998) and General 
Data Protection Regulation (2018). All hard copies of consent forms were stored in a locked 
cabinet, within the lockable room at the School of Primary, Community and Social Care at 
Keele University (itself an electronically secure accessed building) and did not exit the 
School of Primary, Community and Social Care after the interview. Hard-copies of consent 
forms were stored for five years, as per Keele University policy at which point they were to be 
destroyed. All recordings and transcripts remained on a secure, password protected 
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computer at Keele University. Data were only accessible by myself or the supervisory team 
upon request. 
During transcription, each participant was allocated both a participant number and 
pseudonym to ensure that the participants’ personal details remain anonymous throughout 
the research process. When participants revealed personal information that may compromise 
their anonymity during the interview (i.e. address, place of work, name of relative, etc.), the 
identifiable information was deleted or replaced. The use of direct quotes was made explicit 
to all participants prior to interview. All anonymised transcripts were stored on a secure 
network drive with restricted access.  
6.3.9 Qualitative data analysis 
Thematic analysis is a method of identifying, analysing, and reporting patterns (or themes) 
across qualitative data in relation to the research question (Braun & Clarke, 2006). Braun 
and Clarke (2019) have recognised a ‘tripartite typology of thematic analysis’ (p. 593), 
including ‘coding reliability’, ‘codebook’ and ‘reflexive approaches’. This study uses the 
thematic analysis described by Braun and Clarke (2006; 2018; 2019), which they now refer 
to as reflexive thematic analysis (Braun & Clarke, 2019). Themes in reflexive thematic 
analysis are conceptualised as patterns of shared meaning underpinned by a central 
organising concept (Braun & Clarke, 2019) that capture something important in relation to the 
research question (Braun & Clarke, 2006; 2014). Unlike other versions of thematic analysis, 
reflexive thematic analysis is distinct in acknowledging the researcher’s role in knowledge 
production (Braun & Clarke, 2019).   
I chose to analyse the data using reflexive thematic analysis for a number of reasons. Firstly, 
reflexive thematic analysis is suitable to explore people’s behaviours or practices along with 
individual experiences, views and opinions (Braun & Clarke, 2013), thus aligning well with my 
research questions. Furthermore, thematic analysis identifies what is ‘common’ rather than 
unique or idiosyncratic perspectives (Braun & Clarke, 2014). This was important for my 
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research questions which wished to explore common themes across multiple participant 
populations. Additionally, reflexive thematic analysis offers a flexible approach compatible 
with many theoretical perspectives (Braun & Clarke, 2014). Therefore, researchers do not 
need to subscribe to a particular philosophical or theoretical approach to use thematic 
analysis (unlike many other qualitative data analysis methods). The theoretical flexibility of 
reflexive thematic analysis was particularly important for this study for two reasons. Firstly, 
the philosophical-free perspective complements the critical realist approach, and mixed 
methodology of this research, whereas alternative analytical approaches that are dependent 
on a particular philosophical position may cause tension with these approaches. Secondly, 
the flexibility may improve the accessibility of the findings when ‘stepping outside of 
academia’ (Braun & Clarke, 2014), with no need for the audience to be familiar with the 
deep-philosophical and theoretical commitments of some qualitative analytical methods. For 
this reason, thematic analysis is a useful approach for applied health research wishing to 
translate into practice (Braun & Clarke, 2014).  
Despite being theoretically flexible, researchers should articulate their assumptions that 
informed the analysis to promote reflexivity and transparency. The reflexive thematic analysis 
in this study was underpinned and informed by a critical realist theoretical perspective (see 
Chapter Five). The realist aspect of this theoretical perspective means that semantic codes 
and themes were identified within the explicit or surface meanings of the data. This method 
fits with the critical realist perspective by acknowledging participants’ individual perspectives 
that are based upon an assumed reality that is evident in the data. Regardless of the 
semantic approach to analysis, interpretation was essential to move beyond a ‘description’ of 
the data, to theorise the significance of the patterns and their broader meanings and 
implications (Braun & Clarke, 2013). 
Critical realism also guided the inductive or deductive (theoretically-driven) approach to the 
reflexive thematic analysis (Braun & Clarke, 2006). An inductive approach means that the 
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data drives the development of themes, and therefore the generated themes are strongly 
linked to the data. An inductive approach may mean that the generated themes have little 
resemblance to the questions asked of participants. Alternatively, themes can be identified in 
a deductive manner, driven primarily by the researcher’s theoretical or analytical interests to 
answer the pre-defined research questions. For this study, I primarily used an inductive 
approach to the analysis. The novelty of the research area and lack of previous qualitative 
exploration for community-dwelling people with dementia called for an inductive approach to 
ensure that the analysis was rich in detail and driven by the data. The inductive approach 
aligns with the constructionist epistemology associated with critical realism; allowing each 
individual’s subjective experience of reality to shape the generation of themes. Despite 
approaching the collected data in an inductive manner, I acknowledge that the pre-defined 
research questions means that the findings are in part theoretically-driven (rather than 
entirely driven by the participant data). 
6.3.9.1 The process of analysis 
For many years, thematic analysis was inconsistently used, with limited guidance regarding 
the application of the analytical approach (Braun & Clarke, 2014). Braun and Clarke (2006) 
therefore developed a six-step process of conducting thematic analysis. The six steps, along 
with the operationalisation of each step as provided by Braun and Clarke (2006) is provided 
in Table 6.12. Each step is presented sequentially, however the analytical process was 
recursive; moving backward and forward between stages. Many stages of analysis were 
facilitated by NVivo 11 (QSR International), a qualitative data management software. This 
software was used to add ‘memos’ (e.g. reflections, thoughts, ideas), to code extracts of 
transcripts, and to collate themes. 
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Table 6.12. Thematic analysis: Braun and Clarke (2006) 
Steps of thematic analysis Braun and Clarke description Operationalisation in this study 
Step 1: Familiarising yourself 
with the data 
 
Transcribing data (if necessary), 
reading and re-reading the data, 
noting down initial ideas 
I completed and transcribed all interviews to familiarise myself with the data.  
Following transcription, all transcripts were checked for accuracy while listening 
to the audio-recording.  
During this process, I noted down my initial thoughts and comments. 
Step 2: Generating initial 
codes 
Coding interesting features of the 
data in a systematic fashion across 
the entire data set, collating data 
relevant to each code 
Initial coding were generated for each participant group independently. After 
establishing initial codes, each participant group dataset were compared and 
contrasted to integrate the overall findings. All transcripts were systematically 
coded on paper, followed by coding using NVivo 11. Coding was conducted in 
an iterative, concurrent manner alongside data collection. 
Step 3: Generating* themes  
 
Collating codes into potential 
themes, fathering all data relevant to 
each potential theme 
Using NVivo 11, coded data extracts were collated into potential overarching 
themes. Each data extract was checked to ensure that it reflected the theme in 
question. Initial thematic maps were developed  
Step 4: Reviewing themes Checking if the themes work in 
relation to the coded extracts (level 
1) and the entire data set (level 2), 
generating a thematic map of the 
analysis 
I first re-read each coded extract to ensure that it reflected the theme in 
question. 
Secondly, I re-read each transcript to ensure that the themes adequately 
reflected the entire dataset.  
Thematic maps were produced to provide a visual conceptualisation of the data 
and to creatively interrogate the links between themes  
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Table 6.12. Thematic analysis: Braun and Clarke (2006) 
Steps of thematic analysis Braun and Clarke description Operationalisation in this study 
Step 5: Defining and naming 
themes 
Ongoing analysis to refine the 
specifics of each theme, and the 
overall story the analysis tells, 
generating clear definitions and 
names for each theme 
Themes were refined: collapsed into each other, or new themes were created if 
they were distinct. 
Thematic maps created in step 3 and 4 were developed further to reflect the 
overall story of the data (see Appendix 10 for a final thematic map). A document 
was created to outline the theme name, a descriptive overview of each theme (to 
outline the scope, depth, and diversity of each theme), followed by a number of 
illustrative (and contradictory) codes and data extracts from each population 
group (an adapted version is provided in Appendix 10).  
This method ensured that each theme contributed to the research questions, yet 
remained distinct from each other.  
The thematic maps, thematic document, and the provisional theme names were 
discussed, and finalised in collaboration with the supervisory team. 
Step 6: Producing the report 
 
Selection of vivid, compelling extract 
examples, relating back of the 
analysis to the research objectives 
and literature 
Each theme was reported using an in-depth description, and a number of 
supportive and contradictory data extracts from each population group. Themes 
are presented and split by their corresponding research objective, and discussed 
throughout Chapter Eight and Chapter Nine. 
* ‘Generating themes’ was updated from ‘searching for themes’ to highlight that themes are not are not ‘in’ the data awaiting retrieval by the researcher 
(Braun & Clarke, 2019) 
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6.3.10 Saturation 
Saturation is used in qualitative research as a ‘criterion for discontinuing data collection 
and/or analysis’ (Saunders et al., 2017, p. 1894), and although the concept originates from 
grounded theory, saturation is an accepted aspect of qualitative research generally. Inductive 
thematic saturation relates to the identification of new codes (Saunders et al., 2017), in other 
words, saturation was conceptualised as the ‘mounting instances of the same codes, but no 
new ones’ (Urquhart, 2013, p. 194). Therefore, when no ‘new codes’ were identified during 
the analysis, a degree of saturation was reached. This does not suggest that if data 
collection and analysis continued that no ‘new codes’ would be identified, however new 
codes would not add to the overall story of the data (Saunders et al., 2017).  
In this study, three participant groups were recruited. Data collection and data analysis was 
an iterative and concurrent process within and across each participant group. When new 
codes were no longer being identified for each participant group, I determined, along with my 
supervisors, that a sufficient degree of saturation was reached. 
6.3.11 Quality and trustworthiness considerations 
Trustworthiness is an important consideration for research; elements such as truth, 
applicability, consistency and neutrality are considered important for both quantitative and 
qualitative approaches (Lincoln & Guba, 1985). The assessment of these elements, 
however, differ between quantitative and qualitative research. Quantitative research often 
uses terms such as reliability, validity, generalisability, and objectivity. However, researchers 
suggest that an alternative language to assess the quality of qualitative research is essential 
to align with the principles of qualitative enquiry (Leininger, 1985; Agar, 1986), such as 
credibility, transferability, dependability and confirmability. This study used a variety of 
techniques to promote quality and trustworthiness of the qualitative findings, including: 
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 Data triangulation - Triangulation refers to the multiple methods or data sources in 
qualitative research to develop a comprehensive understanding of phenomena 
(Patton, 1999). By interviewing people with dementia, family caregivers, and 
healthcare professionals the findings reflected the accounts of multiple participant 
groups, increasing the credibility.  
 Analytical triangulation - Members of the research team coded the interviews 
separately, and discussed their interpretations (Nowell, Norris, White & Moules, 
2017). Triangulation of analysis allowed the opportunity to be reflexive on my 
assumptions. 
 Reflexivity - Reflexive questioning moved me beyond my own ‘taken for granted’ 
assumptions. Reflexive approaches allowed variability and decisions to be ‘audited’ 
and therefore trackable throughout the research process. Additionally, reflexive 
practices ensured that I remained self-critical of how I might influence the 
interpretation of the data. Throughout the research process I engaged with a number 
of reflexive practices:  
o A self-critical journal of my concerns, thoughts, assumptions, and questions.  
o A contact summary sheet immediately after each interview (Miles & 
Huberman, 1994), allowing immediate reflection on pertinent aspects of the 
interview (see Appendix 11). 
o Meetings with my supervisors and discussions with colleagues and peers 
promoted reflexive questioning.  
6.4 Conclusion 
This chapter provided an overview of the quantitative and qualitative methods used to 
explore the phenomenon of pain identification, assessment, and management for 
community-dwelling people with dementia as part of the mixed methods approach. Firstly, 
this chapter discussed the quantitative methods employed to examine pain identification, 
assessment, and treatment for community-dwelling people with dementia using primary care 
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EHRs. Following this, the qualitative methods used to explore the perspective and views of 
people with dementia, family caregivers, and healthcare professionals were discussed to 
illuminate the subjective perspective of the phenomenon. The following chapter provides a 
descriptive overview of the populations and the people included in the quantitative and 
qualitative findings, acting as a contextual foundation in preparation for the findings chapters.  
Chapter Seven: The Populations and the People 
 
203 
 
7 Chapter Seven: An Overview of the Populations and the People 
7.1 Introduction 
This chapter provides a description of the participants included in the quantitative and 
qualitative analysis. Firstly, the demographic characteristics of the incidence and prevalence 
cohorts are described. Secondly, an overview of the people with dementia, family caregivers, 
and healthcare professionals who took part in qualitative interviews are provided. This 
chapter therefore provides a descriptive overview of the participants included in the 
quantitative and qualitative methods in preparation for the subsequent findings chapters. 
7.2 Overview of the CPRD study population 
In the previous chapter, the identification and data refinement process of the dementia cohort 
and older adult cohort was discussed (see Section 6.2.6). Two sets of cohorts were identified 
to examine incidence and prevalence. This chapter provides a descriptive overview of the 
dementia cohort and older adult cohort used in the incidence and prevalence investigation.  
7.2.1 Incidence cohort 
To be included in the incidence cohort, all participants had no evidence of a musculoskeletal 
consultation in the 12 months before index date (see Section 6.2.8.1). Index date was 
defined as the incident dementia clinical code, or equivalent for the older adult cohort (see 
Section 6.2.7.2).  
7.1.1.1 Comparison to the wider pool of participants 
During the data refinement process, 65,112 patients with dementia were eligible (see Figure 
6.7), however, 44,019 patients with dementia did not have an eligible matched older adult. 
The loss of eligible participants with dementia during the matching process called for an 
investigation to examine if patients with dementia with evidence of a matched older adult 
(n=21,093) differed from patients with dementia without evidence of a matched older adult 
(n=44,019) (see Table 7.1).
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Table 7.1. Descriptive comparisons between people with dementia with (n=21,093) and without a matched older adult (n=44,019) 
n 21,093 
 
44,019 p  Effect Size 
Gender, female % (n) 59.1 (12,479) 63.2 (27,819) <.001** V = .03  
Age at index Mean (SD) 80.33 (8.20) 81.57 (8.52) <.001**  G = .15  
Year of index date Mean (SD) 2008.41 (4.97) 2009.07 (5.14) <.001** G = .13 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.9 (200) 
13.3 (2814) 
3.7 (0.6) 
0.6 (120) 
81.4 (14,166) 
0.1 (21) 
 
2.6 (1133) 
15.9 (7011) 
4.7 (2078) 
0.5 (212) 
76.1 (33,492) 
0.2 (93) 
<.001** V = .07 
Transfer out reason % (n) 
Death 
Data not entered 
Internal transfer  
New health authority 
Other 
 
34.9 (7360) 
29.0 (6107) 
24.9 (5252) 
7.7 (1617) 
3.6 (757) 
 
38.1 (16,780) 
28.7 (12,621) 
23.6 (10,411) 
6.5 (2845) 
3.1 (1362) 
<.001** V = .05  
Follow up (days) Median (IQR) 609 (241, 1182) 597 (237, 1170) .84  G = .00 
SD Standard Deviation; IQR interquartile range; **p<.001; *p<.05 
Cramer’s V (V) Effect size for chi-square  
Hedges’ g (G) Effect size for independent t-tests with unequal sample sizes 
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The descriptive data outlined in Table 7.1 highlighted significant differences between people 
with dementia with (n=21,093) and without a matched older adult (n=44,019) for all 
demographic characteristics (with the exception of follow up period). Despite significant 
differences brought about by the use of large sample size comparisons, the effect sizes 
indicate a small effect in differences. This would suggest that the dementia cohort identified 
for the incidence investigation (with a matched older adult) broadly reflects the original pool 
of eligible people with dementia. 
7.1.1.2 Comparison between the dementia cohort and older adult cohort 
After being matched one-to-one, a dementia cohort (n=21,093) and a matched older adult 
cohort (n=21,093) were identified to examine the incidence of musculoskeletal consultation. 
A descriptive overview of the dementia cohort and older adult cohort is provided in Table 7.2. 
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Table 7.2. Descriptive comparison between the dementia cohort (n=21,093) and older adult cohort (n=21,093)  
n Dementia cohort (n=21,093) Older adult cohort (n=21,093) p Effect size 
Gender, female % (n)# 59.1 (12,479) 59.1 (12,479) Matched Matched 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.9 (200) 
13.3 (2814) 
3.7 (772) 
0.6 (120) 
81.4 (17166) 
0.1 (21) 
 
0.9 (189) 
12.7 (2678) 
3.4 (717) 
0.4 (92) 
82.4 (17381) 
0.2 (36) 
.01 V = .02 
Transfer out reason  
Death 
Data not entered 
Internal transfer  
New health authority 
Other 
 
34.9 (7360) 
29.0 (6107) 
8.1 (1716) 
7.7 (1617) 
20.4 (4293) 
 
26.6 (5617) 
59.7 (12591) 
3.0 (632) 
3.9 (824) 
6.8 (1429) 
<.001** V = .33 
Age at index date Mean (SD) 80.3 (8.2) 80.3 (8.2) Matched Matched 
Year of index date Mean (SD) 2008.41 (4.97) 2008.41 (4.97) Matched Matched 
Follow up (days) Median (IQR) 609 (241, 1182.5) 1246 (557, 2307) <.001** d = .58 
Practice IMD# 
1 – Least deprived 
2 
3 
4 
5 – Most deprived  
 
15.9 (3358) 
19.0 (4013) 
20.5 (4324) 
21.1 (4460) 
23.4 (4938) 
 
15.9 (3358) 
19.0 (4013) 
20.5 (4324) 
21.1 (4460) 
23.4 (4938) 
Matched Matched 
Morbidity (BNF) Median (IQR)£ 9 (5, 15) 9 (5, 14) <.001** d = .11 
Consultation freq£ Median (IQR) 30 (16, 49) 25 (13, 42) <.001  d = .18 
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CVD yes % (n) £ 7.0 (1482) 5.6 (1184) <.001** V = .03 
Depression/bipolar yes % (n) £ 7.2 (1526) 2.2 (456) <.001** V = .12 
Diabetes yes % (n) £ 15.7 (3322) 14.2 (2997) <.001** V = .02 
*p=<.05, **p=<.001; #Matched on year of birth, gender, general practice; £Measured during the 2-year period before index date 
SD Standard Deviation; CVD cardiovascular-related conditions; IMD practice-level Indices of Multiple Deprivation; BNF British National Formulary, IQR interquartile 
range; Cramer’s V (V) Effect size for chi-square; Cohen’s d (d) Effect size for independent t-test 
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The dementia cohort and older adult cohort were 59.1% female, with a mean age of 80.3 
(SD, 8.2) at index date. 15.9% of the dementia cohort and older adult cohort were classified 
as ‘least deprived’, with an incremental increase in the percentage for each level of 
deprivation, with 23.4% of the dementia cohort and older adult cohort classified as ‘most 
deprived’ based on their practice-level IMD. Matching on gender, year of birth, and general 
practice resulted in no statistical difference between the dementia cohort and the older adult 
cohort in these characteristics.     
The dementia cohort had significantly shorter median follow up (in days) than the older adult 
cohort (609 vs. 1246, respectively), with a medium effect (d = 0.58). 
Various characteristics were examined during the two-year period before index date, 
including morbidity count (BNF frequency), evidence of cardiovascular-related conditions, 
evidence of depression, and evidence of diabetes. As expected the dementia cohort had 
increased evidence of cardiovascular-related conditions, evidence of depression, and 
evidence of diabetes than the older adult cohort. Despite significant differences between the 
dementia cohort and the older adult cohort, effect sizes, again indicate a small effect in the 
differences reported. 
7.2.2 Prevalence cohort 
To examine the prevalence of musculoskeletal consultation and analgesic prescription, a 
prevalence cohort was developed. Unlike the incidence cohort described earlier, there was 
no need for the prevalence cohort to have a musculoskeletal consultation-free period before 
index date. The index date was defined as the incident dementia clinical code, or equivalent 
for the older adult cohort (see Section 6.2.7.2).  
7.1.1.3 Comparison to the wider pool of participants 
The previous chapter provided an overview of the data refinement process for the dementia 
cohort and older adult cohort established for the prevalence investigation. During the 
establishment of the dementia cohort, although 87,809 people with dementia were eligible, 
51,227 with dementia did not have an eligible older adult match (see Figure 6.8). People with 
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dementia that did not have an eligible older adult match (n=51,227) were not included in the 
final dementia cohort. The loss of eligible people with dementia during the matching process 
called for an investigation to determine if people with dementia with a matched older adult 
(n=36,582) differed from people with dementia without an eligible match (n=51,227) (see 
Table 7.3). 
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Table 7.3. Descriptive comparisons between people with dementia with (n=36,582) and without a matched older adult (n=51,227) 
n 36,582 51,227 p  Effect size 
Gender, female % (n) 59.8 (21,860) 64.4 (32,992) <.001** V = .05 
Year of index date Mean (SD) 2008.67 (4.9) 2009.17 (5.16) <.001** G = .10 
Age at index Mean (SD) 79.94 (8.26) 81.83 (8.35) <.001**  G = .23 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.9 (330) 
14.0 (5111) 
3.5 (1297) 
0.6 (224) 
80.8 (29,576) 
0.1 (44) 
 
2.7 (1394) 
17.0 (8700) 
5.0 (2583) 
0.5 (270) 
74.5 (38,163) 
0.2 (117) 
<.001** V = .09  
Transfer out reason % (n) 
Death 
Data not entered 
Internal transfer 
Removal to new health authority 
Other 
 
33.1 (12,175) 
31.6 (11,621) 
24.4 (8969) 
7.5 (2740) 
3.4 (1267) 
 
28.3 (19,645) 
28.8 (14,760) 
10.4 (5288) 
6.4 (3272) 
16.1 (8262) 
<.001** V = .08 
Follow up (days) Median (IQR) 621 (250, 1192) 605 (239, 1185) .98  V = .00  
*p=<.05, **p=<.001 
SD standard deviation, IQR interquartile range 
Cramer’s V (V) Effect size for chi-square  
Hedges’ g (G) Effect size for independent t-tests for different sample sizes 
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The descriptive data outlined in Table 7.3 highlighted many significant differences between 
people with dementia with and without an eligible match (again, with the exception of follow 
up period). Although significant differences between the two cohorts were found, they often 
had small effect sizes indicating marginal differences. Such findings would suggest that the 
dementia cohort identified to examine prevalence (n=36,582) were broadly comparable to 
people with dementia without a matched older adult (n=51,227). 
7.1.1.4 Comparison between the dementia cohort and older adult cohort 
After being matched one-to-one, a dementia cohort (n=36,582) and a matched older adult 
cohort (n=36,582) were identified to examine the prevalence of musculoskeletal consultation 
and analgesic prescription. A descriptive overview of the dementia cohort and older adult 
cohort is provided in Table 7.4. 
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Table 7.4. Descriptive comparison between the dementia cohort (n=36,582) and older adult cohort (n=36,582) 
 Dementia cohort (n=36,582) Older adult cohort  (n=36,582) p  Effect size 
Gender, female % (n)# 59.8 (21,860) 59.8 (21,860) Matched Matched 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.9 (330) 
14.0 (5111) 
3.5 (1297) 
0.6 (224) 
80.8 (29576) 
0.1 (44) 
 
0.9 (326) 
13.4 (4912) 
3.4 (13.4) 
0.5 (174) 
81.6 (29851) 
0.2 (71) 
.002 V = .02 
Transfer out reason % (n) 
Death 
Data not entered 
Internal transfer 
Removal to new health authority 
Other 
 
33.1 (12110) 
31.6 (11571) 
24.4 (8969) 
7.5 (2740) 
3.4 (1267) 
 
24.8 (9090) 
67.9 (22644) 
7.9 (2889) 
3.9 (1413) 
1.5 (546) 
<.001** V = .33 
Year of index date Mean (SD) # 2008.67 (4.91) 2008.67 (4.91) Matched Matched 
Age at index date Mean (SD) # 79.9 (8.3) 79.9 (8.3) Matched Matched 
Follow up (days) Median (IQR) 621 (250, 1192) 1225 (551, 2246) <.001**  d = .67 
Practice IMD# 
1 – Least deprived 
2 
3 
4 
5 – Most deprived  
 
16.3 (5958) 
19.2 (7010) 
19.8 (7259) 
21.2 (7743) 
23.5 (8612) 
 
16.3 (5958) 
19.2 (7010) 
19.8 (7259) 
21.2 (7743) 
23.5 (8612) 
Matched Matched 
Chapter Seven: The Populations and the People 
 
213 
 
Table 7.4. Descriptive comparison between the dementia cohort (n=36,582) and older adult cohort (n=36,582) 
Morbidity (BNF) Median (IQR) £ 11 (6, 16) 10 (6, 15) <.001**  d = .11 
Consultation freq Median (IQR)£ 34 (19, 55) 28 (15, 47) <.001**  d = .20 
CVD yes % (n) £ 7.4 (2705)  6.0 (2194)  <.001** V = .03 
Depression yes % (n) £ 8.1 (2962)  2.6 (965)  <.001** V = .12 
Diabetes yes % (n) £ 16.7 (6115) 14.9 (5459) <.001** V = .03 
*p=<.05, **p=<.001; SD Standard Deviation; CVD cardiovascular-related conditions disease; IMD practice-level Indices of Multiple Deprivation; BNF British National 
Formulary, IQR Interquartile Range 
#Matched on year of birth, gender, practice; £Evidence during the 2 years before index date 
Cramer’s V (V) Effect size for chi-square  
Cohen’s d (d) Effect size for independent t-tests for equal sample sizes 
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The dementia cohort and older adult cohort were 59.8% female, with a mean year of birth of 
1928.7 (SD, 9.8). 16.3% of the dementia cohort and older adult cohort were classified as 
‘least deprived’, with an incremental increase in the percentage for each level of deprivation, 
with 23.5% classified as ‘most deprived’.  
Similarly to the incidence cohort examined previously (see Section 7.1.1.2), the dementia 
cohort had a significantly shorter median follow up (in days) than the older adult cohort (621 
vs. 1225, respectively), with a medium to large effect (d = 0.67). 
Various characteristics were examined during the two-year period before index date, 
including morbidity (BNF frequency), consultation frequency, evidence of cardiovascular-
related conditions, evidence of depression, and evidence of diabetes were significantly 
higher for the dementia cohort than the older adult cohort. Despite significant differences 
between the dementia cohort and the older adult cohort, effect sizes indicate a small effect. 
These findings would again suggest marginal differences between the dementia cohort 
(n=36,582) and older adult cohort (n=36,582). 
7.1.1.5 Annual stratification 
Period prevalence was calculated for a five-year period from index date. In addition, annual 
period prevalence was calculated from index date to five years after index date (see Section 
6.2.13.2). People in the dementia cohort and older adult cohort were included in each annual 
prevalence calculation if they remained in the study for each annual time period (see Section 
6.2.13.4). Earlier comparison indicated that the dementia cohort had a significantly shorter 
median follow up than the older adult cohort (see Table 7.4). The difference in follow up 
between the dementia cohort and older adult cohort may cause concern if unhealthy 
members of the dementia cohort leave the study, meaning that the cohort becomes healthier 
with each annual time period (see Section 6.2.10.1). A descriptive overview of the dementia 
cohort and older adult cohort at each annual period is provided in Table 7.5.
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Table 7.5. Descriptive characteristics of the dementia cohort and older adult cohort during each annual period 
Annual Time period 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 
Matched-pairs % 73.5 53.4 36.6 24.7 15.9 
Dementia cohort 
n 24,247 16,110 10,314 6471 3893 
Gender, female % (n) 59.7 (14473) 60.0 (9671) 60.7 (6259) 61.1 (3953) 61.7 (2403) 
Age at index Mean (SD) 79.0 (8.2) 82.07 (6.6) 82.5 (6.0) 83.3 (5.6) 84.1 (5.4) 
Year of index date Mean (SD) 2008.1 (4.7) 2007.5 (4.5) 2007.3 (4.2) 2006.6 (3.9) 2005.9 (3.6) 
Morbidity (BNF) Median (IQR)£ 10 (6, 15) 10 (6, 15) 9 (5, 14) 9 (5, 13) 9 (5, 14) 
Consultation freq Median (IQR)£ 30 (16, 51) 31 (16, 51) 31 (16, 51) 32 (17, 51) 31 (16, 51) 
Follow up (days) Median (IQR) 966 (626, 1503) 1289 (968, 1801) 1614 (1322, 2142.3) 2463 (1889, 3319) 2346 (2046, 2833) 
Practice IMD (%)      
1 – Least deprived 16.0 (3869) 15.8 (4083) 15.8 (1632) 15.9 (1030) 16.0 (624) 
2 19.4 (4713) 19.2 (4737) 19.3 (1988) 19.5 (1259) 18.7 (729) 
3 19.9 (4814) 19.6 (4793) 19.4 (2006) 19.3 (2146) 19.6 (764) 
4 20.8 (5052) 20.9 (5184) 20.9 (2155) 21.1 (1366) 21.3 (828) 
5 – Most deprived  23.9 (5799) 24.4 (5935) 24.6 (2533) 24.3 (1571) 24.4 (948) 
CVD yes % (n) £  7 (1698) 6.9 (1106) 6.8 (705) 6.6 (430) 6.4 (784) 
Depression yes % (n) £ 8.4 (2035) 8.8 (1423) 9.3 (961) 9.8 (637) 10.6 (411) 
Diabetes yes % (n) £ 
15.9 (3844) 15.0 (2421) 14.2 (1466) 13.4 (869) 12.4 (484) 
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Table 7.5. Descriptive characteristics of the dementia cohort and older adult cohort during each annual period 
Annual Time period 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 
Matched-pairs % 73.5 53.4 36.6 24.7 15.9 
Older adult cohort 
n 30,316 24,732 19,849 15,663 12,276 
Gender, female % (n) 60.1 (18,230) 60.4 (14946) 60.7 (12056) 61.2 (9582) 61.2 (7515) 
Age at index Mean (SD) 79.6 (8.1) 81.68 (6.5) 83.0 (6.0) 83.8 (5.7) 84.5 (5.4) 
Year of index date Mean (SD) 2008.4 (4.6) 2007.9 (4.4) 2006.8 (4.3) 2006.2 (4.0) 2005.5 (3.8) 
Morbidity (BNF) Median (IQR)£ 10 (6, 15) 9 (5, 14) 9 (5, 14) 9 (5, 13) 8 (5, 13) 
Consultation freq Median (IQR)£ 31 (17, 51) 31 (17, 51) 31 (17, 51) 32 (17, 51) 32 (17, 52) 
Follow up (days) Median (IQR) 1507 (872, 2506) 1813 (1202, 2764) 2132 (1533, 3039) 2463 (1889, 3319) 2774 (2236.3, 3572) 
Practice IMD % (n)      
1 – Least deprived  16.5 (4989) 16.5 (2551) 16.6 (3298) 16.9 (2641) 16.9 (2080) 
2 19.2 (5811) 19.2 (3091) 19.2 (3816) 19.1 (2989) 19.2 (2353) 
3 19.6 (5949) 19.4 (3165) 19.0 (3778) 18.8 (2946) 18.8 (2304) 
4 20.9 (6328) 21.0 (3370) 21.0 (4176) 21.4 (3346) 21.2 (2597) 
5 – Most deprived  23.9 (7239) 24.0 (3933) 24.1 (4781) 23.9 (3741) 24.0 (2942) 
CVD yes % (n) £ 6 (1825) 6.1 (1506) 5.1 (1214) 6.1 (951) 6.7 (262) 
Depression yes % (n) £ 2.6 (796) 2.7 (657) 2.7 (545) 2.8 (437) 2.7 (335) 
Diabetes yes % (n) £ 14.3 (4332) 13.8 (3402) 13.0 (2571) 12.1 (1889) 11.5 (1407) 
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CVD cardiovascular disease, SD Standard Deviation, IQR interquartile range, BNF British National Formulary, IMD Indices of Multiple Deprivation  
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The number of people that remained in the dementia cohort was lower than the older adult 
cohort (see Table 7.5), as expected by the shorter follow up period identified previously (see 
Table 7.4). Attrition throughout follow up means that the amount of matched-pairs lowered 
from 100% at baseline, to 15.9% at five years after index date.  
For the dementia cohort and the older adult cohort, people in the final years of follow up (i.e. 
four to five years after index date) had an earlier year of index date and a longer follow up 
period than people in the first year of follow up. This is synonymous with their eligibility in the 
latter years of follow up.  
It was important to investigate if the high attrition (especially for the dementia cohort) meant 
that ‘unhealthy patients’ were leaving the study (i.e. dying, being diagnosed with cancer, 
moving out of practice), meaning that as time from index date increased, the ‘healthier’ the 
cohorts became (see 6.2.10.1).  
Firstly, the median consultation frequency remained relatively constant in each annual period 
throughout follow up for the dementia cohort and older adult cohort. The percentage of 
people with dementia with evidence of cardiovascular-related conditions during the two years 
before index date decreased from the first year to the final year of follow up (7% to 6.4%, 
respectively), with a similar trend for diabetes (15.9% to 12.4%, respectively). However, the 
percentage of people in the older adult cohort with evidence of cardiovascular-related 
conditions increased slightly from the first year to the final year of follow up (6% to 6.7%, 
respectively), whilst evidence of diabetes decreased from the first year to the final year of 
follow up (14.3% to 11.5%, respectively). However, the percentage of people with dementia 
with evidence of depression during the two years before index date increased from the first 
year to the final year of follow up (8.4% to 10.6%, respectively), whereas the percentage of 
older adults with evidence of depression during the two years before index date remained 
relatively stable throughout follow up. For the dementia cohort and the older adult cohort, the 
median morbidity count (BNF frequency) slightly decreased throughout follow up.  
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Overall, there was a slight decrease in factors such as morbidity, evidence of cardiovascular-
related conditions, and evidence of diabetes for each annual period throughout follow up for 
the dementia cohort. Such decreases were, however minimal. This means that the dementia 
cohort and older adult cohort do not seem to diverge toward ‘healthier’ or ‘unhealthier’ in the 
latter years of follow up. 
7.1.1.6 Community sensitivity  
In the previous Chapter, the identification of people in the dementia cohort and older adult 
cohort living in the community was discussed (see Section 6.2.13.5.1). Sensitivity analysis 
was conducted using additional, strict criteria to identify a restricted cohort of people with a 
greater likelihood of living in the community:  
 Incidence cohort: A total of n=4850 people with dementia, and n=3477 older adults 
without dementia were identified using the strict criteria (see Figure 6.10). 
 Prevalence cohort: A total of n=8875 people with dementia, and n=8349 older adults 
without dementia were identified using the strict criteria (See Figure 6.11). 
People with dementia identified using the strict criteria were compared to people with 
dementia not identified as eligible for the community sensitivity analysis. Additionally, older 
adults identified using the strict criteria were compared to older adults that were not identified 
as eligible for the community sensitivity analysis. These comparisons (see Appendix 12) 
suggest marginal differences between the characteristics of people with dementia and older 
adults identified for the community sensitivity analyses, and those not.   
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7.3 Participants in the qualitative study 
This section of the Chapter shifts the focus from the populations identified for the quantitative 
sample, to the people who participated in the qualitative element of this thesis. Firstly, 
demographic characteristics of the people with dementia and family caregivers who 
participated within the interviews are presented. To provide contextual information, the self 
and informant reported pain scores are also given. Secondly, a description of the healthcare 
professionals who were interviewed are also presented. 
7.3.1 People with dementia and family caregiver interviews 
Nine interviews explored pain identification, assessment, and treatment from the perspective 
of the person with dementia and family caregivers of people with dementia. The sampling 
and recruitment methods are described in 6.3.5.2. Interviews included eight people with 
dementia and nine family caregivers of people with dementia (see Table 7.6). 
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Table 7.6. Demographic details of people with dementia and family caregivers of people with dementia participating in an interview 
Pseudonym name Relationship Age Previous occupation Diagnosis (date) Cognitive test score (test, date)%$ 
1 Patricia*  
Robert  
Wife 
Husband 
82 
82 
Occupational Therapist 
Aviation  
AD (2014) 
Caregiver 
18/30 (MMSE, 2016) 
- 
2 James* 
Mary 
Husband 
Wife 
74 
74 
Purchaser  
Personal Assistant 
AD (2016) 
Caregiver 
87/100 (ACE-R, 2016) 
- 
3 Barbara** 
John 
Wife 
Husband 
67 
67 
Teacher 
Electrician 
PCA 
Caregiver 
- 
- 
4 William*  
Carol 
Husband 
Wife 
78 
74 
Lecturer 
Probation officer 
AD (2012) 
Caregiver 
24/30 (MMSE, 2014) 
- 
5 Richard*  
David 
Father 
Son 
83 
52 
Tile making 
Catering# 
Mixed (2015) 
Caregiver 
Unknown 
- 
6 Mark* 
Brenda 
Husband 
Wife 
73 
68 
Probation officer 
Nurse 
AD (2014) 
Caregiver 
81/100 (ACE-R, 2014) 
- 
7 Steven* 
Michelle 
Husband 
Wife 
57 
53 
Postman 
- 
Mixed/FTD (2017) 
Caregiver 
Mild (MMSE, 2017) 
- 
8 Linda* 
Charles 
Wife 
Husband 
77 
77 
Administrative  
Optometrist  
FTD (2017) 
Caregiver 
25/30 (MMSE, 2017) 
- 
9 Greg* 
Denise 
Husband 
Wife 
64 
66 
Royal Air Force 
Shop assistant 
Mixed/FTD (2017) 
Caregiver 
48/100 (ACE-R) 
- 
AD Alzheimer’s Disease; FTD frontotemporal dementia; MMSE Mini Mental State Examination Score; ACE-R The Addenbrooke's Cognitive Examination Revised; PCA 
Posterior Cortical Atrophy. *Person with dementia participated in an interview; **Person with dementia did not participate in an interview %Self- or informant-reported 
during the interview; $Information obtained from Join Dementia Research records; #Currently employed 
Chapter Seven: The Populations and the People 
 
222 
 
Eight people with dementia and their respective family caregiver completed interviews 
together in a joint, or dyadic style. Seven of the eight interviews were husband and wife 
dyads, with one father and son dyad. One family caregiver, John, completed the interview 
alone, with his wife, Barbara, present in a nearby room. All interviews were completed in the 
participants’ home, located in the West Midlands. Interviews typically lasted for one and a 
half hours, ranging from 37 minutes to two hours in length. The length of interview was 
reflective of the dyadic nature, but also the time needed to remain flexible for the person with 
dementia to talk about their perspective without feeling pressured. The considerations 
needed when conducting interviews with people with dementia are discussed in Section 
6.3.5.  
Interviews included two female and six male people with dementia, with a mean age of 73.5 
(range 57 to 83). All people with dementia were White British and retired. Half of the people 
with dementia had AD, three reported mixed dementias (two of which were mixed with AD 
and frontotemporal dementia (FTD), and one mixed with AD and vascular dementia), and 
one reported their diagnosis as FTD. Although Barbara did not participate in an interview, her 
husband reported her diagnosis as Posterior Cortical Atrophy. Steven and Greg were 
diagnosed with early-onset dementia, being diagnosed before 65 years old. The MMSE and 
The Addenbrooke's Cognitive Examination Revised (ACE-R) scores provide an insight into 
the person with dementia’s cognitive ability; albeit the tests were often completed many 
years ago (e.g. Mark’s last recorded test was in 2014). 
Interviews were conducted with five female and four male family caregivers, with a mean age 
of 68 years (range 52 to 82). All family caregivers were White British. All family caregivers 
reported being retired, aside from David who continued to work in catering. Spousal 
caregivers cohabited with the person with dementia. Both Mark and Brenda, and Steve and 
Michelle lived with additional dependant family members. David (son) resided next door to 
his father with dementia, Richard, sharing caregiving responsibility with his Mother (Richard’s 
wife). In each dyad, the family caregiver recognised themselves as (one of) the primary 
caregiver for the person with dementia. Mark (person with dementia) and Brenda (wife, 
Chapter Seven: The Populations and the People 
 
223 
 
family caregiver) completed their interview as a dyad, however Brenda also reflected upon 
her Mother who also had a diagnosis of dementia. Brenda’s mum lived alone (receiving care 
from her children), and was perceived by Brenda to have more advanced dementia than her 
husband, Mark. John’s wife did not wish to participate in the interview, however she was 
happy for John to discuss his experiences as her family caregiver. 
At the start of the interview, the person with dementia completed the IPT, rating their pain 
now and in the past four weeks. Following completion by the person with dementia, the 
family caregiver provided an informant rating of pain for the person with dementia. Pain 
ratings using the IPT are presented in Table 7.7, with pain conditions experienced by the 
person with dementia reported throughout the interview also presented. 
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Table 7.7. Overview of the types of pain, and severity of pain reported by people with 
dementia (self-report) and their family caregiver (informant report) 
Pseudonym  Current pain conditions* Pain now 
Self-report 
Informant report 
Pain 4 weeks  
Self-report 
Informant report 
Patricia*  
Robert  
Spinal injury Moderate 
 
Unable to judge 
Moderate 
Unable to judge 
James* 
Mary 
Arthritis (neck) None 
None 
None 
None 
Barbara** 
John 
Neuralgia, osteoporosis - 
Severe 
- 
Moderate 
William*  
Carol 
Arthritis (knees) Mild 
None 
Mild 
Mild 
Richard*  
David 
Arthritis (back) Moderate 
None 
Moderate 
Mild 
Mark* 
Brenda 
Tooth pain None 
None 
None 
Mild 
Steven* 
 
Michelle 
Back pain None 
 
None 
Mild 
 
Mild 
Linda* 
 
Charles 
Arthritis, gout   Mild 
 
Moderate 
Unanswered 
 
Moderate 
Greg* 
 
Denise 
Frozen shoulder, tennis 
elbow, spondylitis, arthritic 
hips 
Moderate 
 
Moderate 
Moderate 
 
Moderate 
*Current pain conditions experienced by the person with dementia as reported at any point 
throughout the interview 
**Person with dementia did not take part in the interview. Pain experienced by the person with 
dementia is reported by the family caregiver only. 
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Many of the pain conditions experienced by the person with dementia were musculoskeletal 
in nature. Most people with dementia and family caregivers perceived the pain experienced 
by the person with dementia to be mild to moderate pain, with John perceiving his wife’s 
current pain caused by neuralgia as severe.  
A number of people with dementia and family caregivers perceived the person with dementia 
to be experiencing ‘no pain’, despite painful conditions being noted and discussed throughout 
the interview. For Steven and Michelle, Carol and William, and Richard and David the rating 
of ‘no pain’ was attributed to the pain being exacerbated during activity, which was not the 
case when sitting to complete the interview. However, the rating of pain may have also been 
implicated by alternative factors, such as stoicism (see Section 8.4.1.1). Additionally, some 
family caregivers had difficulty providing an informant report of pain and were therefore 
classed as ‘unable to judge’ (see Section 8.4.3).  
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7.3.2 Healthcare professional interviews 
Semi-structured interviews explored healthcare professionals’ perspective on pain 
identification, assessment, and treatment for people with dementia. An overview of the 
healthcare professional characteristics are outlined in Table 7.8. 
Table 7.8. Details of healthcare professionals participating in an interview 
Pseudonym Current profession(s) Years of experience in 
current role 
Tom General Practitioner  12 years 
Alan General Practitioner 33 years 
Jenny General Practitioner 30 years 
Jessica General Practitioner 1 year 
Muhammad General Practitioner 3 years 
Lisa General Practitioner  11 years 
Ishann General Practitioner 1 year 
Amy General Practitioner 5 years 
Chris General Practitioner 7 years 
Prisha Consultant - Old Age Psychiatry 10 years 
Hayma Consultant - Old Age Psychiatry 8 years 
Aska Associate specialist - Old Age Psychiatry  11 years 
Rina Consultant - Old Age Psychiatry 3 years 
Mel Associate specialist - Old Age Psychiatry 18 years 
 
All healthcare professionals were recruited from within the West Midlands. Each interview 
lasted for approximately 45 minutes, with a range from 31 minutes to 59 minutes.  
Out of the 14 interviews, nine were General Practitioners (GPs), five males and four females. 
Face-to-face interviews were completed in the GP’s practice, or in the School of Primary, 
Community and Social Care. Interviews with Tom and Amy were completed by telephone. 
Some GPs noted having an additional role or professional commitment, with Tom working as 
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a Consultant Geriatrician in a local hospital, and Lisa working in out-of-hours urgent care 
alongside being a GP. A snowball sampling technique through the contacts within the School 
of Primary, Community and Social Care meant that Muhammed, Jessica, Chris, and Ishann 
had additional research commitments. Aside from additional commitments, Jenny also 
discussed her specialist interest in end of life care, working closely with her local hospice. 
The years of experience working as a GP ranged from 1 year to 33 years, with a mean 
experience of 11.4 years.  
Interviews were also conducted with five female old age psychiatrists, three of which were 
consultants, and two associate specialists. Three interviews were completed face-to-face 
within the School of Primary, Community and Social Care. Interviews with Rina and Mel were 
completed by telephone. Mean length of time working as an old age psychiatrist was 10 
years (range 3 to 18 years). Before becoming an old age psychiatrist, Mel worked as a GP.  
7.4 Summary of participants in the qualitative study 
Twenty-three interviews were completed: eight people with dementia, nine family caregivers 
of people with dementia, nine GPs, and five old age psychiatrists explored their perspective 
of pain identification, assessment, and treatment for people with dementia.  
7.5 Chapter Summary  
This chapter provided an overview of the participants included in the quantitative and 
qualitative investigation. This chapter provides a contextual foundation for the subsequent 
findings chapters. In line with the mixed methods approach, each of the following findings 
chapters focus upon a research objective, rather than being separated by the method of 
enquiry (e.g. a quantitative chapter and a qualitative chapter). Chapter Eight therefore 
includes quantitative and qualitative findings to investigate pain identification and pain 
assessment for community-dwelling people with dementia (research objective 1). Chapter 
Nine also includes quantitative and qualitative findings to investigate pain management for 
community-dwelling people with dementia (research objective 2). This approach allows 
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complementary findings to sit sequentially, in preparation for integration in the Discussion 
Chapter (see Chapter Ten). 
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8 Chapter Eight: Pain Identification and Assessment  
8.1 Introduction 
This chapter meets the first research objective: to investigate pain identification and 
assessment for community-dwelling people with dementia (see Section 4.2) using 
quantitative and qualitative data. Quantitative data was drawn from analysis of two cohorts 
used to i) examine and report on incidence, and ii) to examine and report on prevalence, of 
musculoskeletal consultations for people with dementia (dementia cohort) compared with 
older adults without dementia (older adult cohort). Qualitative data was drawn from 
interviews with people with dementia, family caregivers, and healthcare professionals. The 
quantitative and qualitative findings are presented separately in line with the convergent 
mixed methods design described in Section 5.4.2.1. The quantitative and qualitative findings 
are narratively integrated in the discussion chapter to highlight inferences, interpretations, 
convergent, and divergent findings (Creswell & Plano Clark, 2018).  
8.2 Pain identification and pain assessment: Quantitative findings 
This section of the chapter examined musculoskeletal consultations for people with dementia 
(dementia cohort) compared to older adults without dementia (older adult cohort). 
Musculoskeletal consultations were used in this thesis as a marker for the identification and 
assessment of pain (as justified in Section 6.2.9.1). This section of the chapter answers the 
following research questions:  
 What are the incidence and prevalence rates of musculoskeletal consultations for people 
with dementia compared to older adults without dementia? 
 What are the annual incidence and prevalence rates of musculoskeletal consultations 
over time for people with dementia? 
8.2.1 Incidence of musculoskeletal consultation 
This section explores the incidence of musculoskeletal consultation for the dementia cohort 
compared with the older adult cohort. To calculate incidence for both cohorts, inclusion 
criteria stipulated that participants had no evidence of musculoskeletal consultation during 
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the 12 months before index date (see Section 6.2.8.1). Firstly, person-time incidence rates, 
and the incidence rate ratios determine the rate of identified incident musculoskeletal 
consultation occurring in the dementia cohort compared to the older adult cohort. Following 
this, the five-year cumulative incidence of musculoskeletal consultation for the dementia 
cohort and older adult cohort is presented, using the Kaplan-Meier approach and Cox 
Proportional Hazard models.  
8.2.1.1 Incidence Rate and Rate Ratio 
Person-time incidence rates were calculated to determine the number of incident 
musculoskeletal consultations for the dementia cohort and older adult cohort. The number of 
incident musculoskeletal consultations per time period was divided by the amount of person-
time contributed during that time period (see Section 6.2.13.3.1). Following this, the 
incidence rate ratio (IRR) was calculated to examine the rate of musculoskeletal consultation 
for the dementia cohort compared to the older adult cohort during the specified time period 
(see Section 6.2.13.3.1.1). Calculations were completed for the five-year period from index 
date, and stratified into annual periods from index date to five years after index date. Annual 
time periods allowed investigation into the trends of incident musculoskeletal consulting from 
dementia diagnosis (index date) for the dementia cohort, and how this compares to the older 
adult cohort (see Table 8.1).  
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Table 8.1. Person-time incidence rate and incidence rate ratio of musculoskeletal 
consultation for the dementia cohort and older adult cohort stratified into annual time 
blocks 
Time period 
(years) 
Incidence Rate (95% CI) 
(per 100 person years) 
IRR (95% CI) 
 Dementia cohort  Older adult cohort   
0 to 5 16.28 (15.85 to 16.71) 22.22 (21.78 to 22.67) .73 (.71 to .75) 
0 to 1 19.53 (18.85 to 20.24) 26.98 (26.21 to 27.77) .72 (.70 to .75) 
1 to 2  15.37 (14.56 to 16.21) 21.72 (20.86 to 22.61) .71 (.67 to .75) 
2 to 3  12.73 (11.75 to 13.77) 18.17 (17.21 to 19.18) .70 (.64 to .77) 
3 to 4  10.69 (9.52 to 11.98) 17.64 (16.49 to 18.85) .61 (.54 to .69) 
4 to 5  9.35 (7.87 to 11.00) 14.91 (13.62 to 16.29) .63 (.52 to .75) 
IRR Incidence Rate Ratio; CI Confidence Interval 
 
During the five-year period from index date, the incidence rate of musculoskeletal 
consultation was 16.3 per 100 person-years for the dementia cohort, compared to 22.2 per 
100 person-years for the older adult cohort. The dementia cohort had 0.73 (95% CI 0.71 to 
0.75) times the rate of incident musculoskeletal consultation compared to the older adult 
cohort. 
The rate of incident musculoskeletal consultation in each annual period was consistently 
lower for the dementia cohort than older adult cohort per 100 person-years (see Figure 8.1). 
This was reflected in the incidence rate ratio, in which the dementia cohort had 0.72 (95% CI 
0.70 to 0.75) times the rate of incident musculoskeletal consultation compared to the older 
adult cohort in the first annual time period. In the final annual period (four to five years after 
index date), the dementia cohort had 0.63 (95% CI 0.52 to 0.75) times the rate of incident 
musculoskeletal consultation compared to the older adult cohort.  
Chapter Eight: Pain Identification and Assessment 
 
 
232 
 
 
Figure 8.1. Person-time incidence rates of musculoskeletal consultation for the dementia 
cohort and older adult cohort stratified by annual periods from index date to five years after 
index date 
 
8.2.1.2 Attributable rate 
Attributable rate determines the amount of incident musculoskeletal consultation attributable 
to the exposure, in this case having dementia (see Section 6.2.13.3.1.2). In addition, the 
‘preventable fraction’ among the older adult cohort was calculated to give a sense of the 
effect difference between cohorts overall and year by year (see Table 8.2). 
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Table 8.2. Attributable rate (ARexp) and percentage preventable fraction (%PFu)  
Time (years) Incidence rates (95% CI) Attributable rate (AR) 
 Dementia cohort Older adult cohort ARexp %PFu 
0 to 5  16.28 (15.85 to 16.71) 22.22 (21.78 to 22.67) -5.94 26.73% 
0 to 1 19.53 (18.85 to 20.24) 26.98 (26.21 to 27.77) -7.45 27.61% 
1 to 2  15.37 (14.56 to 16.21) 21.72 (20.86 to 22.61) -6.35 29.24% 
2 to 3  12.73 (11.75 to 13.77) 18.17 (17.21 to 19.18) -5.44 29.94% 
3 to 4  10.69 (9.52 to 11.98) 17.64 (16.49 to 18.85) -6.95 39.40% 
4 to 5  9.35 (7.87 to 11.00) 14.91 (13.62 to 16.29) -5.56 37.29% 
Attributable rate (AR), Attributable rate (ARexp), percentage attributable fraction (%PFu), CI 
Confidence Interval 
 
During the five-year period from index date, 26.7% of the incident musculoskeletal 
consultations in the older adult cohort would have been unidentified, unassessed, or not 
coded (‘prevented’) if they had dementia. Additionally, the percentage of incident 
musculoskeletal consultations in the older adult cohort that would be unidentified, 
unassessed, or not coded if they had dementia increased from 27.6% in the first year of 
follow up to 37.3% in the final year of follow up. If assuming a causal association between 
the exposure (dementia) and identified incident musculoskeletal consultation (and therefore 
no evidence of bias or confounding), the reduction in incident musculoskeletal consultation 
can be ‘attributed’ to dementia. 
8.2.1.3 Kaplan-Meier approach (five-year period) 
When investigating cumulative incidence over the five-year period from index date, 15,015 
incident musculoskeletal consultations were identified. During the five-year period, 74.3% of 
the dementia cohort and 54.6% of the older adult cohort were censored. The dementia 
cohort had a greater mean time until the occurrence of incident musculoskeletal consultation 
than the older adult cohort (1262.9 days vs. 1093.7, respectively). Figure 8.2 shows the 
Kaplan-Meier curves for the dementia cohort and older adult cohort from index date (day 0) 
to 5 years after index date (day 1825 of follow up).  
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Figure 8.2. Kaplan-Meier curve to show cumulative incidence of musculoskeletal 
consultation from index date to five years (1825 days) after index date for the dementia 
cohort and older adult cohort 
 
 
The logrank test identified a significant difference between the dementia cohort and older 
adult cohorts’ time to musculoskeletal consultation during the five-year period (χ2=430.7, 
p=<.001). The Kaplan-Meier curve demonstrates that the dementia cohort had a higher 
probability of not being coded for a musculoskeletal consultation than the older adult cohort 
during the five-year period from index date (see Figure 8.2).   
Chapter Eight: Pain Identification and Assessment 
 
 
235 
 
8.2.1.4 Cox Proportional Hazards Regression Model 
To build upon the Kaplan-Meier approach, The Cox Proportional Hazards Regression model 
examined the association between the cohort status (dementia cohort and older adult cohort) 
and identified incident musculoskeletal consultation (see Section 6.2.13.3.2.2). 
Assumptions of Cox Proportional Hazards Regression models are outlined in detail in Table 
6.8. Two important assumptions were tested post-hoc, including i) the assumption of 
proportional hazards, and ii) limited change in risk over time (i.e. that those at the start of 
data collection have the same risk of incident musculoskeletal consultation as those towards 
the end of data collection). To assess the assumption of proportional hazards, Schoenfeld 
residuals were plotted vs. time for continuous covariates, and log-log transformations of the 
Kaplan-Meier survival curves were investigated for categorical covariates. These tests 
indicated that each covariate fulfilled the assumption of proportional hazards. The second 
assumption was met as there was no significant difference in the risk of incident 
musculoskeletal consultation between patients with an index date between 1997 to 2009 and 
patients with an index date between 2009 to 2017 (χ2=.90, p=.34, HR 0.98, 95% CI 0.95 to 
1.02). Univariate and multivariable Cox Proportional Hazards Regression models, stratified 
by matched-pairs are provided in Table 8.3.  
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Table 8.3. Univariate and multivariable Cox Proportional Hazard Regression models to 
examine the association between cohort status and incident musculoskeletal consultation 
Univariate Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.33 (.02)** .69 .72 .75 
Model χ 2(1) = 248.20, p=<.001.  
Multivariable Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Adjusted Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.34 (.03)** .68 .71 .75 
CVD (yes=1) -.08 (.07) .81 .93 1.05 
Depression (yes=1) -.01 (.07) .87 .99 1.14 
Diabetes (yes=1) .20 (.05)** 1.12 1.22 1.34 
Morbidity (BNF)£  03 (.00)** 1.03 1.03 1.04 
Follow up (days)£ .00 (.00)* 1.00 1.00 1.01 
Consultation frequency£ .00 (.00)** 1.00 1.00 1.00 
Model χ2(7) = 571.64, p=<.001. *p<.05, **p<.001 
£Continuous covariates; Categorical reference categories = 0 
SE Standard Error; BNF British National Formulary; CI Confidence Interval; CVD Cardiovascular 
related-conditions 
 
The univariate Cox Proportional Hazards model found that during the five-year period from 
index date, incident musculoskeletal consultation was significantly lower for the dementia 
cohort than the older adult cohort (b = -.33, Wald χ2(1) = 245.95, p=<.001). The dementia 
cohort had a lower rate of incident musculoskeletal consultation than the older adult cohort 
(HR 0.72, 95% CI 0.69 to 0.75). 
The multivariable Cox Proportional Hazards model used to adjust for potential confounders 
also found that during the five-year period from index date, incident musculoskeletal 
consultation was significantly lower for the dementia cohort than the older adult cohort (b = -
.34, Wald χ2(1) = 184.02, p=<.001). The dementia cohort had a lower rate of identified 
incident musculoskeletal consultation than the older adult cohort during the five-year period 
(adjusted HR 0.71, 95% CI 0.68 to 0.75). The comparable findings in the univariate and 
multivariable models indicate minimal confounding. Similar findings were also evident in the 
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models that did not stratify by matched-pairs, but rather included ‘matched’ variables as 
covariates in the analysis (see Appendix 13a). 
8.2.1.4.1 Sensitivity analysis  
8.2.1.4.1.1 Community sensitivity  
Sensitivity analysis was planned with a restricted sample of people with dementia and older 
adults without dementia with a greater likelihood of living in the community (see Section 
6.2.13.5.1). Person-time incidence rates were therefore calculated with a reduced sample of 
the dementia cohort (n=4850) and older adult cohort (n=3477) with no evidence of a formal 
care consultation location, and a family number of ≤2 as a sensitivity analysis (see Table 
8.4).  
Table 8.4. Community sensitivity analysis: Person-time incidence rate and incidence rate 
ratio of musculoskeletal consultation for the dementia cohort and older adult cohort (per 
100 person-years) 
Time (years) Incidence Rate (95% CI)  
(per 100 person years) 
Rate Ratio (95% CI) 
 Dementia cohort Older adult cohort  
0 to 5  17.59 (16.64 to 18.59) 21.92 (20.83 to 23.04) .80 (.76 to .85) 
0 to 1 20.87 (19.39 to 22.44) 25.79 (23.93 to 27.76) .81 (.75 to .88) 
1 to 2  16.09 (14.33 to 18.01) 23.31 (21.12 to 25.67) .69 (.61 to .78) 
2 to 3  14.16 (11.92 to 16.70) 17.03 (14.76 to 19.57) .83 (.70 to .99) 
3 to 4  11.66 (8.94 to 14.95) 17.67 (14.85 to 20.86) .66 (.53 to .89) 
4 to 5  10.07 (6.69 to 14.56) 13.85 (10.81 to 17.47) .73 (.49 to 1.07) 
CI Confidence Interval 
The sensitivity analysis found comparable person-time incidence rates as the main analysis 
(see Table 8.1). Person-time incidence rates were consistently lower for the dementia cohort 
than the older adult cohort irrespective of time period. The sensitivity analysis found that the 
dementia cohort had 0.80 (95% CI 0.76 to 0.85) times the rate of incident musculoskeletal 
consultation than the older adult cohort during the five-year period from index date. This 
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incidence rate ratio was smaller (attenuated to 1) than that found in the main analysis. During 
the final year of follow up (four to five years after index date) the dementia cohort had 0.73 
(95% CI 0.49 to 1.07) times the rate of identified incident musculoskeletal consultation 
compared to the older adult cohort. Unlike the main analysis, this finding was not significant 
as the upper confidence interval crossed 1. Importantly, the cohort sample size and the 
amount of person-time contributed by the dementia cohort and older adult cohort reduced for 
each annual period after index date. For example, only 383 (out of n=4850) of the dementia 
cohort contributed person-time to the final year of follow up, potentially implicating the 
accuracy of this estimate.  
Sensitivity analysis using the Kaplan-Meier’s approach found that 73.9% of the dementia 
cohort and 55.8% of the older adult cohort were censored during follow up, with censoring 
reflecting the main analysis. The dementia cohort had a greater mean time until the 
occurrence of identified incident musculoskeletal consultation than the older adult cohort 
(1231.7 days vs. 1100.7, respectively). The logrank test found a significant difference 
between the cumulative incidence of musculoskeletal consultation for the dementia cohort 
compared to the older adult cohort, albeit with a smaller effect than found in the main 
analysis (χ2=50.58, p=<.001). The findings of the sensitivity analysis were comparable to the 
main analysis (see Section 8.2.1.3). 
Sensitivity analysis also investigated the incidence of musculoskeletal consultation using 
univariate and multivariable Cox Proportional Hazards models stratified by matched-pairs 
(see Table 8.5).  
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Table 8.5. Univariate and multivariable Cox Regression: Community sensitivity analysis 
Univariate Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.48 (.08)** .52 .62 .75 
Model X2(1) = 25.94, p=<.001.  
 
Multivariable Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Adjusted Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.48 (.112)** 0.50 0.62 0.77 
CVD (yes=1) -.04 (.31) 0.53 0.97 1.76 
Depression (yes=1) .33 (.30) 0.78 1.40 2.51 
Diabetes (yes=1) .42 (.21)* 1.01 1.52 2.29 
Morbidity (BNF)£ .06 (.01)** 1.03 1.06 1.09 
Consultation frequency£ -.00 (.00) 0.99 1.00 1.01 
Follow up (days) £ .00 (.00) 1.00 1.00 1.000 
Model X2(7) = 48.41, p=<.001. *p<.05, **p<.001 
£Continuous covariates; Categorical reference category = 0 
SE Standard Error; BNF British National Formulary; CI Confidence Interval; CVD Cardiovascular 
related-conditions 
Sensitivity analysis found an increased rate (away from 1) of identified incident 
musculoskeletal consultation for the dementia cohort compared to the older adult cohort 
using the univariate model (sensitivity analysis: HR 0.62, 95% CI 0.52 to 0.75; main analysis: 
HR 0.72, 95% CI 0.69 to 0.75). Similar findings were also evident for the multivariable 
analysis (sensitivity analysis: adjusted HR 0.62, 95% CI 0.50 to 0.77; main analysis: adjusted 
HR 0.71, 95% CI 0.68 to 0.75). Therefore, the sensitivity and main analysis agree that the 
dementia cohort continued to have a lower rate of identified incident musculoskeletal 
consultation than the older adult cohort. 
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8.2.2 Prevalence of musculoskeletal consultation  
8.2.2.1 Period prevalence of musculoskeletal consultation 
Period prevalence examines the frequency of people consulting for musculoskeletal 
consultation during a given period of time for the dementia cohort and older adult cohort (see 
Section 6.2.13.4). The number of patients in the dementia cohort and older adult cohort 
consulting for musculoskeletal conditions during the five-year period from index date was 
examined. Period prevalence calculations were also stratified into annual time blocks, 
starting from index date to five years after index date. For each annual period, the number of 
people consulting for musculoskeletal conditions (with a complete follow up for that year) was 
divided by the number of people with complete follow up for that year (see Section 6.2.13.4). 
An overview of the demographic characteristics of each annual cohort are provided in Table 
7.5, showing that the demographic characteristics of the dementia cohort and the older adult 
cohort remained relatively stable throughout each follow up. The stratified annual prevalence 
estimates allowed investigation into trends in musculoskeletal consulting over time for the 
dementia cohort compared to the older adult cohort (see Table 8.6). 
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Table 8.6. Period prevalence of musculoskeletal consultations for the dementia cohort and the older adult cohort stratified by years from index date 
 Dementia cohort Older adult cohort Prevalence Ratio (PR) 
Time (years) Total n Prevalence % (95% CI) Total n Prevalence % (95% CI) PR (95% CI) 
0 to 5 3,893 58.54 (56.99 to 60.08) 12,276 70.76 (69.95 to 71.56) 0.83 (0.80 to 0.85) 
0 to 1 24,247 24.46 (23.92 to 25.00) 30,316 30.79 (30.27 to 31.31) 0.79 (0.77 to 0.82) 
1 to 2 16,110 22.26 (21.62 to 22.90) 24,732 30.55 (29.98 to 31.12) 0.73 (0.70 to 0.75) 
2 to 3 10,314 19.94 (19.18 to 20.73) 19,849 30.56 (29.92 to 31.21) 0.65 (0.62 to 0.68) 
3 to 4 6,472 19.27 (18.33 to 20.25) 15,663 31.71 (30.99 to 32.44) 0.61 (0.58 to 0.64) 
4 to 5 3,893 19.52 (18.29 to 20.80) 12,276 31.04 (30.23 to 31.87) 0.63 (0.59 to 0.67) 
PR Prevalence Ratio; CI Confidence Interval  
0 is index date; dementia diagnosis or equivalent for the older adult cohort 
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During the five-year period following index date, the dementia cohort had a 12.2% lower 
prevalence of musculoskeletal consultation than the older adult cohort (58.5% vs. 70.8%, 
respectively), with the dementia cohort having a 0.83 times lower prevalence ratio than the 
older adult cohort. The prevalence of musculoskeletal consultation for the dementia cohort 
gradually decreased in each annual time period from index date to five years after index date 
(24.5% to 19.5%, respectively). In contrast, the prevalence of musculoskeletal consultation 
for older adults remained relatively stable throughout follow up, with a slight increase in 
consultation prevalence during the latter time periods (see Table 8.6). The growing 
discrepancy in the prevalence of musculoskeletal consultation between the dementia cohort 
and older adult cohort from index date throughout follow up can be clearly seen in Figure 8.3.  
 
Figure 8.3. Period prevalence of musculoskeletal consultation for the dementia cohort and 
older adult cohort in each annual period 
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8.2.2.1.1 Sensitivity analysis 
8.2.2.1.1.1 Community sensitivity 
Sensitivity analysis examined the period prevalence estimates for the dementia cohort 
(n=8875) and older adult cohort (n=8349) with a family number frequency of ≤2, and no 
evidence of formal care consultation location (see Table 8.7). 
Table 8.7. Period prevalence of musculoskeletal consultations for dementia cohort and 
older adult cohort stratified by years from index date: community sensitivity 
 Dementia cohort Older adult cohort 
Time (years) Total n Prevalence % (95% CI) Total n Prevalence % (95% CI) 
0 to 5 808 60.40 (56.98 to 63.71) 2494 70.09 (68.26 to 71.85) 
0 to 1 5700 25.47 (24.36 to 26.62) 6788 29.71 (28.64 to 30.81) 
1 to 2 3648 22.67 (21.34 to 24.06) 5377 30.13 (28.92 to 31.37) 
2 to 3 2243 20.86  (19.23 to 22.60) 4203 29.84 (28.47 to 31.24) 
3 to 4 1370 20.00 (17.97 to 22.20) 3268 31.40 (29.83 to 33.01) 
4 to 5 808 20.30 (17.67 to 23.21) 2494 31.11 (29.31 to 32.98) 
CI Confidence Interval 
Similar to the main analysis, the sensitivity analysis found that the dementia cohort had a 
lower prevalence of musculoskeletal consultation than the older adult cohort, irrespective of 
the time period. Additionally, the sensitivity analysis continued to demonstrate the lowering 
prevalence of musculoskeletal consultation during follow up for the dementia cohort, whilst 
the prevalence remained stable for the older adult cohort. 
8.2.2.1.1.2 Healthy cohort effects 
A sensitivity analysis was planned to account for potential ‘healthy cohort’ bias. The previous 
period prevalence investigation only included members of each cohort if they remained in the 
study throughout the five-year period from index date (see Section 6.2.13.4). Sensitivity 
analysis therefore examined the period prevalence of musculoskeletal consultation for the 
dementia cohort and older adult cohort that remained in the study at the mid-point of the five-
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year period. This analysis therefore included people with and without dementia that remained 
in the study 912 days after their index date (as outlined in Section 6.2.13.5.2; see Table 8.8).  
Table 8.8. Period prevalence of musculoskeletal consultations for the dementia cohort 
and older adult cohort stratified by years from index date: Healthy cohort effects 
sensitivity analysis 
 Dementia cohort Older adult cohort 
Time (years) Total n Prevalence % (95% CI) Total n Prevalence % (95% CI) 
0 to 5 12967 51.92 (51.06 to 52.78) 22237 66.32 (65.69 to 66.94) 
CI Confidence Interval 
This sensitivity analysis indicated a lower prevalence of musculoskeletal consultation during 
the five-year period from index date for the dementia cohort (sensitivity analysis: 51.9% vs. 
main analysis: 58.5%) and the older adult cohort (sensitivity analysis: 66.3% vs. main 
analysis: 70.8%) than in the main analysis. This finding suggests that the sensitivity analysis 
using the mid-point cohort identified a lower period prevalence of musculoskeletal 
consultation for both cohorts. In line with the main analysis, the sensitivity analysis continued 
to find that the dementia cohort had a lower prevalence of musculoskeletal consultation than 
the older adult cohort (see Section 8.2.2).  
8.2.2.2 Conditional Logistic Regression  
The crude period prevalence investigation identified that the dementia cohort had a lower 
period prevalence than the older adult cohort (see Section 8.2.2.1). To build upon these 
findings, the association between dementia and musculoskeletal consultation was examined 
using univariate and multivariable conditional logistic regression models (see Section 
6.2.13.4.2). Multivariable methods were used to discern and control for confounding 
variables (Szklo & Nieto, 2004).  
The assumptions of conditional logistic regression models are provided in Table 6.9. Many of 
the assumptions were confirmed prior to modelling. The assumption of little or no 
multicollinearity was investigated and met for each multivariable model. When investigating 
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linearity of independent variables and log odds, however, various continuous covariates 
violated the assumption (with the exception of consultation frequency). Log and square root 
data transformations were performed with all continuous variables violating the assumption, 
however neither transformation was successful. To overcome this violation, morbidity (BNF) 
and follow up were categorised into quintiles with homogeneity within each strata implicitly 
assumed (see Table 8.9).  
Table 8.9. Categorisation of continuous variables for the multivariable conditional logistic 
regression analyses 
Covariate Nº categories Categorisation  
Morbidity (BNF) 5 0-20%, 20%-40%, 40%-60%, 60-80%, 80-100% 
Follow up 5 0-20%, 20%-40%, 40%-60%, 60-80%, 80-100% 
BNF British National Formulary  
Consultation frequency was entered into the model as a continuous covariate 
Univariate and multivariable conditional logistic regression models were completed for the 
five-year period from index date, and each annual period from index date to five years after 
index date. The final univariate models included cohort status (dementia cohort vs. older 
adult cohort) as the predictor, with evidence of musculoskeletal consultation (yes/no) as the 
outcome. Multivariable models also included cohort status (dementia cohort vs. older adult 
cohort) as the predictor, and evidence of musculoskeletal consultation (yes/no) as the 
outcome. Additional covariates were also included in the multivariable models: evidence of 
cardiovascular-related conditions (CVD), evidence of diabetes, evidence of depression, 
morbidity count (BNF), follow up (days), and consultation frequency (see Table 8.9). Matched 
variables were accounted for in the analysis inherent with a conditional logistic regression 
model (see Section 6.2.13.4.2). Details of the univariate and multivariable conditional logistic 
regression models are provided in Table 8.10.  
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Table 8.10. Conditional logistic regression reporting odds ratio (OR) and adjusted OR for 
the dementia cohort compared to the older adult cohort: Musculoskeletal consultation 
Time (years) OR (95% CI) Adjusted OR (95% CI) 
0 to 5 .84 (.79 to .90) .83 (.78 to .89) 
0 to 1 .80 (.77 to .83) .82 (.78 to .85) 
1 to 2 .73 (.70 to .77) .73 (.70 to .77) 
2 to 3 .65 (.61 to .69) .66 (.62 to .71) 
3 to 4 .60 (.56 to .65) .62 (.56 to .67) 
4 to 5 .63 (.57 to .70) .61 (.54 to .68) 
OR Odds Ratio, CI Confidence Interval  
 
Univariate and multivariable conditional logistic regression models indicate that the dementia 
cohort had a lower odds of musculoskeletal consultation than the older adult cohort, 
irrespective of time period. Negligible differences between the OR and adjusted OR indicated 
minimal confounding (see Table 8.10). 
Multivariable conditional logistic regression models found that during the five-year period 
from index date, the dementia cohort had a 0.83 lower odds of musculoskeletal consultation 
than the older adult cohort (adjusted OR 0.83, 95% CI 0.78 to 0.89).  
Stratification into annual time periods highlighted the trends of musculoskeletal consultation 
over time; that as the amount of time from index date increased, the lower the odds of 
musculoskeletal consultation for the dementia cohort (compared to the older adult cohort). To 
exemplify, during the first year of follow up (index date to one year after index date), the 
dementia cohort had a 0.82 lower odds of musculoskeletal consultation than the older adult 
cohort (adjusted OR 0.82, 95% CI 0.78 to 0.85). However, during the final year of follow up 
(four years to five years after index date), the dementia cohort had a 0.61 lower odds of 
musculoskeletal consultation than the older adult cohort (adjusted OR 0.61, 95% CI 0.54 to 
0.68). 
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8.2.2.2.1 Sensitivity analysis 
Univariate and multivariable models examined the association between cohort status 
(dementia cohort vs. older adult cohort) and musculoskeletal consultation using a variety of 
sensitivity analyses (see Section 6.2.13.5), including a community sensitivity, healthy cohort 
sensitivity, and unconditional (rather than conditional) logistic regression sensitivity analyses 
(see Appendix 13b). In line with the sensitivity analyses examined previously (see Section 
8.2.2.1.1), findings of these sensitivity analysis reflected the findings of the main analysis.    
8.3 Summary of the quantitative findings 
 The incidence rate of musculoskeletal consultations was lower for the dementia 
cohort than the older adult cohort during the five-year period from index date, and 
consistently shown for each annual period from index date.  
 During the five-year follow up period, a high percentage (26.7%) of incident 
musculoskeletal consultations for the older adult cohort would be unidentified, 
unassessed, or not coded if they had dementia. This percentage steadily increased 
from the first year of follow up (27.6%) to the final year of follow up (37.3%).   
 When controlling for potential confounders, the dementia cohort had a significantly 
lower rate of identified incident musculoskeletal consultation than the older adult 
cohort (adjusted HR 0.71, 95% CI 0.68 to 0.75). All sensitivity analyses performed 
confirmed these findings.  
 The period prevalence of musculoskeletal consultation was lower for the dementia 
cohort than the older adult cohort during the five-year period from index date (58.5% 
vs. 70.8, respectively).  
 The annual period prevalence of musculoskeletal consultation lowered from index 
date for the dementia cohort (from 24.5% to 19.5% over a five-year period from index 
date), whilst remaining relatively stable for the older adult cohort (from 30.8% to 
31.0% over a five-year period from index date). 
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 The dementia cohort had a consistently lower odds of musculoskeletal consultation 
than the older adult cohort, irrespective of the time period, even following 
multivariable adjustment. All sensitivity analyses bolstered these findings. 
8.4 The identification and assessment of pain: Qualitative findings  
To complement the quantitative findings presented above, qualitative data explored pain 
identification and assessment strategies for people with dementia, to answer the first 
research objective, as outlined at the start of this chapter (see Section 8.1). This section of 
the chapter answered the following qualitative research questions: 
 How do family caregivers and healthcare professionals identify and assess pain for 
community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals perceive 
pain identification and assessment strategies for community-dwelling people with 
dementia? 
To answer these questions, the perspectives of people with dementia (n=8), family 
caregivers (n=9), GPs (n=9), and old age psychiatrists (n=5) were integrated, and three key 
themes were identified: 
 Gathering information to identify pain 
 Disentangling the self-report of pain 
 Observing changes  
 The importance of familiarity  
 The use of pain assessment tools 
Although the person with dementia’s perspective is included throughout the following 
themes, due to the nature of pain identification and assessment, the views, perspectives, and 
experiences of the family caregiver and healthcare professional feature more heavily.  
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8.4.1 Gathering information to identify pain 
To identify and assess the experience of the person with dementia, healthcare professionals 
gathered information and used their intuition in an attempt to build a comprehensive picture: 
we shouldn't use the word gut feeling, because it's not a gut feeling, it's using all of 
the subtle signs 
Chris, GP 
This is where in dementia we really need to be like detectives… It's gathering as 
much information as possible 
Amy, GP 
So... it's about picking up the clues, and putting pieces together really... 
Hayma, psychiatrist 
Healthcare professionals often gathered information from various sources and investigations 
to exclude explanations for the presentation, as a ‘process of elimination’:  
you just rule out things, you- you- it's a diagnosis by exclusion, so it's not a UTI, you 
do a blood test to make sure there's no inflammatory processes going on, you do a 
blood test to make sure there's no increase in development, poor sampling, that the 
liver function test, that their amylase is alright, and- and- and again you resort to 
objective veterinary techniques, because there's nowhere else you can go. 
Alan, GP 
so my experiences of seeing people with dementia are usually that, I'm eliminating 
other things, like... um.... like infections, urine retention, or constipation 
Jessica, GP 
Each piece of information gathered by the healthcare professional guided or ‘narrowed’ their 
understanding of the presentation: 
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one little sign can send you down a different pathway... It's the same with any patient, 
but particularly, with patients with dementia... 
Lisa, GP 
if I don't find information from the carers, and from the patient, then we do look into 
their records if you like, if- if- if I’m in doubt... I think it all depends on my findings from 
the first exercise, and then I would decide the second step, depending on my first. 
Prisha, psychiatrist 
The process of gathering information to identify and assess pain for people with dementia 
was, however, perceived as a complex task associated with uncertainty for many healthcare 
professionals:  
I think it's- it's difficult, because it's trying to untangle a ball of wool.  
Alan, GP 
Ooh, sometimes it's just the facial expressions, or the sounds they produce, you can 
see that they're in pain, that they're not comfortable, they are restless, turning from 
one side to another... we just make guesses. 
Rani, psychiatrist 
Not all felt that this was the case, Jenny (GP) reported that she felt confident that the 
information gathered as part of a multidimensional assessment provided an accurate picture 
of the pain experienced by people with dementia: 
You look at their records and see if they've suffered with things in the past (…) then 
you've got the history, now you might not be able to get that from the patient, but you 
might be able to get that from the carer (…) and then there's the basic assessment, 
so they- they- are they sweaty hot and clutching something? are they sort of, not 
peeing? or are they peeing too much? (…) and then, sort of, y'know physically looking 
at the patient, by the time you get to the examination, you've got an awful lot of 
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information that actually is probably going to be channelling you, narrowing down 
your decision making. So by the time you’ve done all of that you should have a pretty 
accurate assessment and then you have to make a decision. Y’know... and... 
common sense, and experience play into that as well... 
Jenny, GP 
Jenny described extensive experience working as a GP, with part of her post being in a local 
hospice. The broad exploration of pain identification and assessment described by Jenny, by 
virtue of her experience and knowledge of this area, aided her confidence when identifying 
and assessing pain for people with dementia (‘I’m very confident actually, but that's partly 
because of my palliative care experience’ Jenny, GP).  
The following subthemes explore the strategies used by family caregivers and healthcare 
professionals to gather information about pain; including self-report and observation of 
changes in presentation (behavioural, psychological, and physical). Each of these strategies 
were perceived to have their own unique challenges which are highlighted in the following 
subthemes. 
8.4.1.1 Disentangling the self-report of pain 
This subtheme captures the importance of self-report to gather information, yet sometimes 
difficulty of disentangling and interpreting the self-reported pain provided by the person with 
dementia. Factors that impeded the interpretation of self-reported pain, as included in this 
subtheme were communication difficulties, the ‘reliability’ of the self-report, and stoical 
attitudes towards pain. Each of these factors made it difficult for family caregivers and GPs to 
determine if the self-report reflected the pain experienced by the person with dementia.  
Family caregivers acknowledged the importance of self-reported pain to gather information, 
and to understand the pain experienced by the person with dementia:  
I think because you're verbally- you're still very verbally articulate to actually explain 
that you've actually got a problem, I think that's- from Mark's view, but I think- and 
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even my mum to a certain degree has articulation, so that she can explain (…). So 
articulation is important, even if it's not quite right, it's good that she can still do that, 
really. 
Brenda, wife, daughter, caregiver 
Communication was an integral element of pain identification and assessment for family 
caregivers, even when the self-report of pain was perceived as not being ‘quite right’. 
However, throughout the progression of dementia, self-reported pain became more 
challenging: 
I would start by taking pain out of the question... How is our communication? Urm... 
Not good... Urm, because of Linda's cognitive ability it's difficult to have a 
conversation... then if you put into that equation her memory difficulty, having 
forgotten what she said in the previous sentence then... then conversation is, urm... 
very difficult 
Charles, husband, caregiver 
GPs also reflected upon the importance, yet sometimes challenge of self-report as a method 
of gathering information about the person with dementia’s pain experience: 
I would say that most people with mild to moderate dementia, you just treat them in 
the same way (…) but it's- it's more the severe end that I’m talking about here, where 
it's difficult having a conversation with someone, and sort of answering those [self-
report and history] questions can sometimes be a tricky area... 
Chris, GP  
Um, I suppose... you- you can't rely on so much verbally on how they can- well, I try 
and see how much I can get verbally from them and I ask the relatives how much 
they're able to communicate as well, but sometimes it can fluctuate over time, so they 
may be able to express more at a different time in the day, how they were feeling 
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Jessica, GP 
The ability to provide a self-report was perceived to diminish in line with the progression of 
dementia. Additionally, self-report becomes increasingly challenging due to fluctuations in 
cognitive ability throughout the day.  
Despite the potential difficulty for people with dementia to self-report their pain (depending 
upon the severity of cognitive impairment), when a person with dementia provided a self-
report of their pain, most family caregivers and healthcare professionals did not doubt or 
question their self-reported experience:  
You can tell me when you're uncomfortable like you did... when you had your bladder 
cancer (...) I can understand that, and I believe that was real and that was right. 
Brenda, wife, caregiver 
It's a basic- it's a basic primary modality, pain, so if people are- if people are able to 
say, then you can usually get an inkling, ‘I've got a painful ankle’ or ‘I've hurt my wrist’ 
or something, yea you can. I- I- I wouldn't ignore it. If somebody came in and said 
‘I've got a painful wrist’, what you would do is exclude any pathology there, and if you 
didn't then you'd be a fool, because they're probably right. 
Alan, GP 
If somebody uses the word pain, I think it's a strong word, I think it's one that you learn 
early in our lives, and I suspect it's one we lose late. So if someone responds to that 
word, and seems to react to it, then I would take that quite seriously... if somebody 
says they're in pain, you've got to believe it. 
Lisa, GP 
Most family caregivers and GPs trusted that the self-report reflected the pain experienced by 
the person with dementia. The explicit use or response (verbal or non-verbal) to the word 
‘pain’ was viewed as a strong indicator that required further investigation by the GP. 
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However, contrary to this, some family caregivers seemed to question to what extent the self-
report reflected the pain experienced by the person with dementia:  
Well sometimes you feel it [discomfort] in your back, don't you? But it only seems to 
be a problem when I want you to go and do something…  
David, son, caregiver 
What do I look for? I look for consistency. If it's consistent then I um... I accept that, 
that's the case. If it's- if it's looking more like an excuse, then I’m probably less 
sympathetic. She's- she's quite capable of using it in a manipulative way (…) when 
I'm trying to get her to get up in the morning, and- and she's using pain as a reason 
why she shouldn't... 
Charles, husband, caregiver 
Some family caregivers questioned the intentions of the person with dementia’s self-report of 
pain. The disclosure of pain was viewed as a means for the person with dementia to avoid 
activities that they did not want to do. Consistent reports of pain increased family caregivers’ 
confidence that the self-report of pain reflected the pain experienced by the person with 
dementia. However, the consistency of self-reported pain for people with dementia may be 
implicated by memory difficulties. The person with dementia may have difficulty remembering 
or reflecting upon their past pain experience, potentially contributing to discordant or 
inconsistent reports of pain over time: 
Someone says, ‘what were you like last week?’ I haven't a clue. (…) The only one 
that you just have to go on is how it is now, there's no good saying is it any better 
than it was earlier on, because I can't remember what it was like earlier on... 
Greg, husband, person with dementia 
The inconsistent self-report of pain by the person with dementia may lead to discordance 
between the self-report and the family caregiver report of pain: 
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You will hear her overnight, because I sleep- stay over, and you'll hear her ‘Oh! Ah!’ 
[pain noises] and you have to go in, and you have to say ‘Wh-what is it?’ that kind of 
thing, and she- she ‘it's my foot, it's my foot’ (...) The interesting thing is that when she 
wakes up in the morning, if you actually say to her (…) ‘do you remember waking up 
because you'd got pain in your foot?’ ... ‘I didn't!’ No recollection of that experience 
y'see? So if you then were to get to the GP (…) she'd make you look a fool, that's- 
that's- that's quite difficult really (…) [from] the time you've had your issue, and the 
time you get somebody to look there's a complete mismatch in terms of... cause and 
effect if you like.  
Brenda, daughter, caregiver 
The inconsistency and tension between the self-report of the person with dementia and the 
family caregiver may create additional complexity for healthcare professionals attempting to 
disentangle the pain experience. This challenge was also echoed by GPs:  
Lots of patients that will be brought in by family members and they're saying the 
patient is really struggling with knee pain, and then you talk to the patient and they're 
saying ‘oh no I’m fine, everything is okay...’ and it's that inconsistent history that 
makes y'know the diagnosis... the assessment challenging, and potentially inaccurate 
and therefore the management plan not always appropriate   
Amy, GP 
Disentangling the pain experienced by the person with dementia amid the inconsistent 
reports and history may lead to inaccurate assessment and inappropriate management of 
pain. In addition to the inconsistent history, GPs also reflected on the challenge of unravelling 
the experience of pain when there is tension between self-reported pain and the GP’s clinical 
judgement: 
I've seen a- a patients with dementia who if you ask them if they- if it hurts anywhere 
or whatever, they'll say no, and they're in significant pain, and conversely, I have 
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seen patients with dementia if you ask them y'know ‘are you in pain?’ ‘Oh yea, 
incredible pain’ ‘where's it hurt?’ ‘oh, everywhere’ and actually in my perspective, in 
my clinical perspective, y'know they've not got any issues causing them pain, and it 
can be really challenging  
Ishann, GP 
Last year I had a lady come in urr, she'd snapped two bones here [holding wrist] in 
her hand, and it was really, really deformed, and she came in, and... Carer came in 
with her, this lady was really old, 96? I said ‘is this painful?’ ‘No.’ ‘Is this painful?’ ‘No.’ 
‘Is anything painful?’ ‘No.’ I don't believe you can fracture two bones, and they weren’t 
just fractured, they were comminuted, they were smashed- I don't- she slipped on the 
ice- I don't believe that wasn't painful.  
Alan, GP 
GPs sometimes perceived the observed painful condition to warrant self-reported pain, or a 
pain response from the person with dementia; however, the person with dementia denied 
experiencing pain. The opposite was also true, where the person with dementia self-reported 
pain, however, in the GP’s clinical perspective, there was no obvious indication or cause of 
pain. The person with dementia may have the ability to respond to self-report questions, 
however the GP’s clinical judgement may mean that the self-reported pain is perceived as an 
unreliable indication of the pain experience. When self-report was not deemed to reflect the 
pain experience, alternative strategies and indicators were used to disentangle the self-
report, and to corroborate their clinical judgement: 
…And even if the patient will nod and say ‘no’, you're not entirely confident that 
maybe that's accurate, in terms of what's going on, and I think sometimes you have to 
rely on other parameters and indicators, to actually help you in that assessment  
Jenny, GP 
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We can't just rely on them just saying that they're in pain, it's all other things that 
indicate that they are in pain 
Rani, psychiatrist 
In addition to the factors mentioned above, a stoical attitude towards pain was an additional 
consideration when determining if the self-report of pain was a ‘reliable indication’ of the pain 
experienced by the person with dementia. Many people with dementia expressed a stoical 
attitude towards their pain:  
I've lived with it for so long, it's, y'know it's something you live with, isn't it? You just 
get used to it, and live with it. 
Greg, husband, person with dementia 
Well there is nothing I can do about it. I’ve just got it. I’ve got to live with it.  
Patricia, wife, person with dementia 
I think you've got to realise that, y'know I'm going to be in some discomfort for the rest 
of my life (…) I think there will always be some discomfort around. Don't think I will 
ever be able to get rid of that.  
Richard, father, person with dementia 
People with dementia frequently used stoical phrases such as ‘living with it’. Pain was often 
viewed as an inevitable part of their life that they had no choice but to ‘live with’. The 
experience of pain in the past seemed to lower the expectation for pain to be alleviated in the 
future. When pain was viewed as a part of life that was not going away, people with dementia 
chose to get ‘used to it’. Therefore, the length of time living with pain in the past, and the 
perceived inevitability of pain in the future were contributing factors influencing the person 
with dementia’s acceptance, and ultimately, their stoical attitude towards their pain.  
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In addition to these factors, family caregivers reflected upon the perceived importance of pain 
as a priority amidst competing health conditions. In other words, people with dementia may 
accept their pain due to the perception that pain is a ‘lower priority’ problem: 
The thing is Barbara wouldn't regard pain as a big factor in her life, it's the 
helplessness that's the big factor in her life, and all the things she can't do are far 
more important to her, than mere pain. I mean Barbara just accepts it 
John, husband, caregiver 
People with dementia and family caregivers also perceived that healthcare professionals 
viewed pain as a lower priority problem. In particular, the pressures of primary care 
negatively affected GPs’ time to consider pain, with other conditions taking priority, 
potentially illustrating a hierarchy of consultation, in which pain is perceived to come second 
to many other conditions: 
Denise: They probably haven't got time to be honest, they probably haven't got time. 
Greg: Right down the bottom of their to-do list. 
Greg (person with dementia), and Denise (wife, caregiver) 
I think most professionals are too busy to be- to be worried about pain, so I don't think 
that's on their spectrum, and it's strange when you think about it...  
Charles, husband, caregiver 
In addition to the reasons described above, pain was sometimes accepted as a ‘normal’ part 
of ageing, leading to a stoical attitude towards pain: 
It's just arthritis, y'know. It's just old age, y'know. Your bones are aching […] But it's 
not like he's in agony, you know what I mean? When you get to our age you just 
expect to get a few, y'know, knees go, an' neck goes an’ shoulders go. I dunno 
whether it's our age group, but we just get on with it. Y'know, we're not always at the 
doctors, are we? Saying I've got this, that, and the other. 
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Mary, wife, caregiver 
Some family caregivers normalised the pain experienced by the person with dementia as an 
expected part of ageing that they should ‘just get on with’. This is particularly important as the 
family caregiver often managed the person with dementia’s physical health, including the 
organisation of GP appointments. The acceptance towards pain as a normal part of ageing 
seems to act as a barrier to accessing primary care.  
 
Figure 8.4. Factors contributing to a stoical attitude towards pain 
 
The acceptance of pain, for the many reasons described above (see Figure 8.4), seemed to 
contribute to the person with dementia’s stoical attitude towards pain. Consequently, a stoical  
attitude seemed to influence the self-report by the person with dementia: 
I'm not the sort of person to sort of be- I tend to shrug off pain… So I never really talk 
about pain...  
Steven, husband, person with dementia 
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Similarly, family caregivers linked the person with dementia’s stoical attitude (or ‘high pain 
threshold’) to a reduced self-report of pain:  
I- It's interesting, if think if you asked Barbara, 'cause she's got an incredibly high pain 
threshold (…) I think she's such a stoic person that she's got... an ability to handle 
pain that a lot of people perhaps, won’t have... she's not indulgent in any way. (…) 
she very rarely admits to anything (…) y'know I’m distracted by other things I don't 
notice anyway, so she could go... two or three hours in pain, and neither of us would 
know it... well... I wouldn't know it, and she wouldn't admit it. 
John, husband, caregiver 
He's not a moaner at all... I think he's got quite a high pain threshold, when his knee 
starts, then it does hurt him, but you- but you can tell that 'cause he can't walk... 
Carol, wife, caregiver 
The stoical attitude towards pain made it difficult for family caregivers to disentangle if the 
self-report of pain reflected the pain experienced by the person with dementia:  
But the fact that she- she tolerates pain probably better than the average person... 
makes it hard to be certain 
Charles, husband, caregiver 
What concerns me, is if she had a really bad pain, or something was going on with- 
with- with her (…) she wouldn't be able to tell you very sensibly because her need is 
to be alright for everybody... Y'know her whole persona is ‘I'm okay’ she's always 
okay, the doctor comes and she's absolutely fine, even though she's deaf as a post, 
so actually there's no- there- there isn't a truth there. 
Brenda, daughter, caregiver 
Although family caregivers attributed the reduced self-report of pain to the person with 
dementia’s stoical attitude or ‘high pain tolerance’ or ‘threshold’, it remains unclear if stoicism 
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is the reason for the lack of self-reported pain, or if the person with dementia had difficulty 
verbally articulating their pain experience (which may be incorrectly attributed by family 
caregivers as stoicism).  
To support the findings from people with dementia and family caregivers, GPs also 
recognised that the stoical attitude held by older adults (including people with dementia) may 
influence the self-report of pain: 
I still hear it quite a lot, still there's a hesitation from older adults to not trouble their 
GP, so they may actually- may actually result in them not telling you that they've got a 
new pain, or it's not getting any better, just hobble along, kind of, on walking sticks, 
and things. 
Muhammed, GP 
the pre-1948 attitude, that's the attitude that people have... because the NHS, of 
getting on with it, dealing with it yourself, not calling the doctor, not troubling the 
doctor  
Alan, GP 
GPs acknowledged older adults’ (including people with dementia) reluctance to discuss pain 
with their GP, with older adults employing their own methods to ‘live with’ their pain, rather 
than troubling the doctor. The GP perspective illuminated previous reflections that stoicism 
may impede the self-report of pain and also impact on access to care. This demonstrates 
that people with dementia may hold stoical attitudes towards pain that may cause difficulty 
when attempting to disentangle if the self-report of pain reflects their pain experience. 
However, stoical attitudes seemed relevant for older adults generally (as evidenced by the 
family caregivers and GPs in this study), and therefore although relevant for people with 
dementia, they do not seem specific to people with dementia.  
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8.4.1.2 Observing changes 
In addition to self-report, this subtheme presents an alternative strategy to gather information 
about the pain experienced by people with dementia; the observation of behavioural, 
psychological and physical changes. This subtheme illuminated the challenge of observing 
changes to identify and assess pain. 
Many family caregivers described their observations that may indicate that the person with 
dementia was experiencing pain: 
Lots of sighing and holding and... and [deep heavy breathing outwards], lots of that. 
And he will sort of- say if he's been in the garden, and he'll go a bit quiet, so I do 
notice 
Michelle, wife, caregiver 
she starts to get a little bit [pause] either ratty, or withdrawn. And just the look on her 
face and I know that y'know she- she's suffering. 
John, husband, caregiver 
Family caregivers reported changes in behaviour (lack of appetite, changes in sleep patterns, 
inactivity), facial expressions (grimacing, frowning), mood (ratty, withdrawn), body language 
(guarding), and non-verbal expressions (sighing, wincing) as indications of pain. Family 
caregivers vigilantly observed the person with dementia to identify and monitor changes that 
may be indicative of pain: 
I think I'm not too worried about it [pain], simply because you observe... she can get 
up in the morning, she can walk, she can go to the loo, she doesn't complain about it 
most of the time, I think it's just an overnight thing, so it's just teasing out whether it's 
cramp, do you- that kind of thing. It's quite difficult to gauge if you're not observing... 
really... 
Brenda, daughter, caregiver 
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GPs and old age psychiatrists echoed the observations of family caregivers, with behavioural 
changes, facial expressions, mood, and body language being associated with pain for people 
with dementia:  
If it's more, say for example abdominal pain, it's being able to see them kind of y'know 
rubbing the area, or bending over, or leaning over, so it's an objective assessment. If 
they're becoming more aggressive, if they're more withdrawn, if they're- any of these 
more subtle changes that actually highlight that there's something else going on...  
Amy, GP 
I guess sometimes, there's body language cues, so they're rubbing their leg or 
whatever, ur... But I think a lot of it, and certainly as dementia progresses more I think 
a lot is much more non-verbal, urm... and just changes in pres- presentation and 
behaviour, urm... changes in appetite and sleep patterns, um... yea... agitation, things 
like that 
Mel, psychiatrist 
Many GPs and old age psychiatrists perceived observation as an objective method to gather 
information, especially for people with dementia who had difficulty providing a verbal self-
report. Observation meant that changes in presentation could be identified; indicating that 
‘something else might be going on’. However, determining what that ‘something else’ might 
be was often difficult for GPs:  
the chronic pain presentation can be so varying, from physical symptoms, to 
behavioural changes, to mental health symptoms, it can actually be very, very 
challenging. 
Amy, GP 
if I've got that distressed patient with dementia, and I think they might be in pain or 
they might not... that I think is- is I find that situation far more challenging... 
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Ishann, GP 
The presentation of the person with dementia when experiencing pain may be varied. If the 
observed change was not pain specific (such as a loss of appetite, a change in sleep 
patterns, or distress), it was challenging for the GP to determine the driver of the 
presentation. The challenge of determining the cause of the changed presentation may mean 
that pain is overlooked: 
More troublesome, more demanding, more disruptive (…) People don't consider the 
pain as being a cause, they just don't consider it (…). You've got to think of the 
diagnosis before you can make the diagnosis, if they don't think of the diagnosis then 
you can't make the diagnosis, it just gets missed. 
Alan, GP 
I think part of the job that's quite important, but difficult for us, is to assess whether 
changes in behaviour are due to changes in pain experience (…) it's very easy to 
overlook the pain issues, and I think you have to actively be enquiring and looking for 
signs of that, but again that can be really tricky to identify. Often people will say 
‘maybe it's a UTI’, and there might be some other explanation for the change in 
behaviour which, y'know is easier to perhaps find evidence of a- a- of something like 
that, and try and treat that, because y'know it's quicker as well, and easier, um but 
actually, I think we're probably missing a lot of discomfort.  
Lisa, GP 
GPs perceived pain to be overlooked as a potential driver of the changed presentation for 
people with dementia; especially when the GP was not actively investigating the presence of 
pain. This may be perpetuated by the pressures in primary care and the difficulty of 
determining the driver of behavioural and psychological changes. GPs might wish to identify 
a ‘quick’ and ‘easy’ fix, or resort to the identification of the ‘usual suspects’ that are 
associated with behavioural changes for people with dementia (e.g. a urinary tract infection). 
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The challenge of determining the underlying cause of behavioural changes may mean that 
they are attributed to dementia itself, rather than being perceived as an expression of an 
unmet need: 
it's [pain] clearly an under recognised, and under diagnosed, urm... issue... urm... 
y'know I think dementia with psycho-behavioural disturbance, BPSD, and it's often 
just put down to the dementia itself 
Tom, GP 
The difficulty of determining the underlying cause of the behavioural changes in primary care, 
and the attribution of behavioural changes as a direct ‘symptom of dementia’ may lead to 
inappropriate referrals to secondary care:  
I think a lot of people look at this situation and think, oh gosh... I haven't got a clue 
what to do here, and therefore don't do anything... ‘I don't have the expertise’ 
yea...  ‘I'll refer- I'll tell the memory team that I'm not happy with this patient and then 
we'll see what they say’, and then the memory team don't necessarily have the skills 
to address that, and then it just gets delayed and delayed and delayed, at the end of 
the day nothing has happened in 6 months or something... So... I think... I think it's- it 
is difficult for a lot of people... 
Jenny, GP 
When asked about behavioural and psychological changes, old age psychiatrists 
emphasised the importance of investigating if they are driven by physical problems (such as 
pain), rather than automatically attributing symptoms to dementia itself: 
I think that would be- the physical side of things, whether that's constipation, UTIs, or 
pain, or whatever, that's always something that we try to go through first before- 
before y'know coming to sort of psychiatric reasons, or psychiatric management of- of 
um... of the behavioural or psychological symptoms...  
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Mel, psychiatrist 
You always think, first think about physical discomfort, physical problems (...) I think 
that people who have dementia, they are, more so sort of pushed towards the mental 
side of things, rather than having a good service for their physical... Some people 
think it's all mental, it's all confusion... No... It’s not that, the person is elderly, and 
they have physical problems... 
Aska, psychiatrist 
Psychiatrists discussed that ‘physical things’ (including pain) should be given priority when 
investigating the driver of behavioural and psychological symptoms for a person with 
dementia. However, psychiatrists continued to highlight that the label of ‘dementia’ may 
overshadow examination into physical conditions, and lead to (potentially inappropriate) 
referrals to secondary care. Despite acknowledging the association between ‘physical things’ 
and behavioural and psychological symptoms, psychiatrists did not view physical health as 
part of their job role, but rather the responsibility of the GP (‘we rely on our GP colleagues to 
do that’ Aska, psychiatrist). This sits in tension with GPs who previously discussed that pain 
is overlooked in primary care as a driver of behavioural and psychological changes. 
Therefore, psychiatrists reflected upon the need for GPs to recognise and investigate pain 
when behavioural changes are observed. By doing so, psychiatrists believed that avoidable 
referrals to secondary care could be reduced: 
I think a more robust... intervention from GPs would be very helpful... I personally 
think that it shouldn't come to a psychiatric nurse, or a psychiatrist for someone with a 
physical problem, this should have been looked into by their own doctor. 
Aska, psychiatrist 
Family caregivers, GPs, and old age psychiatrists each reflected upon behavioural changes 
that may suggest that the person with dementia was experiencing pain. However, it may be 
difficult for GPs to determine if pain or ‘something else’ was causing the observed change in 
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presentation, potentially leading to the under identification of pain and inappropriate referrals 
to secondary care. 
In addition to observing behavioural and psychological changes as potential indications of 
pain, family caregivers also remained vigilant to observe physical changes that may be 
indicative of pain for people with dementia:  
I had no idea that people got problems like this... none at all... We've managed to get 
to our age without these things... I think sometimes people forget that we haven't got 
a degree in Medicine (…) there's no manual, is there? Telling you what to do... Just I 
suppose a life time’s experience dealing with your children, and a cat, and me mum, 
and me dad I suppose... that you think ‘right let's have a look’ and I saw, well it's all 
swollen, but you have to use your own common sense... there's no guide... 
Carol, wife, caregiver 
My mother had a little bit of a discharge, and I know she'd got a vaginal pessary, now 
she'd gone for the few years before regularly, to have that changed, all sorted in her 
own head, she hasn't picked up...I can't believe that she wasn’t uncomfortable, 
because if she was, she wasn't telling us she was. (…) when she'd broke her foot she 
needed help and assistance. It gave us the way forward to begin to monitor... her 
body, her changes 
Brenda, daughter, caregiver 
The close care provided by family caregivers may aid the observation and monitoring of 
physical changes indicative of pain. Despite remaining vigilant, some family caregivers at 
times questioned their ability to identify pain-related changes (partly due to the lack of 
knowledge and guidance provided), drawing upon ‘common sense’ to guide their judgement. 
The importance of the close relationship between the person with dementia and the family 
caregiver was reiterated by GPs:  
Chapter Eight: Pain Identification and Assessment 
 
 
268 
 
I think what's important is these carers provide close care to the patient, they urm... 
they provide the personal care, they toilet the patient, they assist with feeding, etc... 
So they're in close contact, and observation of the patient, and they can give a lot of 
information. 
Tom, GP 
The close care provided by the family caregiver may aid the observation and identification of 
physical changes indicative of pain that may otherwise go unnoticed. The close contact and 
familiarity of family caregivers was often relied upon by GPs (see section 8.4.2). Alike to 
family caregivers, many GPs also recognised the importance of observing and examining 
physical changes that may be indicative of pain for people with dementia: 
Examination can be helpful too, depending on where you feel the pain is, I mean 
certainly if it's- if it's a joint, you can examine that joint, and if you elicit pain y'know it's 
all then, well they can move 90 degrees and it's causing them extreme pain it seems, 
you can kind of- urm... you- you can kind of identify the severity of things that way... 
Chris, GP 
If I’m pressing on an area, or examining an area to say that it is painful, y'know 
looking at their- looking at their body to see y'know if they urm clutching, or pulling 
away, looking at their face to see if they’re grimacing  
Ishann, GP 
Many GPs discussed that physical examination may be a useful method to gather 
information regarding the potential pain experience, especially when the person with 
dementia can no longer self-report their pain. In particular, some GPs observed the reaction 
of the person with dementia (e.g. clutching, pulling away, and grimacing) during the 
examination to identify behaviours associated with the presence of pain. Behavioural 
changes during the examination may indicate to the GP that the examination had elicited 
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pain for the person with dementia. Despite the insights gained from physical examination as 
a pain identification strategy, it did not come without its own challenges:  
You have to go through a fairly detailed... examination (…) the trouble with that, quite 
bluntly, takes a long time... we're meant to have 10 minutes, there's just no way in 
God's earth you can even get them on the couch in 10 minutes very often, you know, 
there's lot of coercion 
Alan, GP 
People with dementia may require more time and explanation during a physical examination. 
Some GPs, however, viewed the potential adaptations and flexibility required to examine a 
person with dementia to be difficult during the time-limited context of a GP consultation.  
8.4.2 The importance of familiarity  
Family caregivers and healthcare professionals recognised the importance of familiarity with 
the person with dementia to identify and assess pain. Family caregivers reflected upon how 
familiarity aided the identification of pain due to their in-depth knowledge of their pain history, 
and their ability to observe and recognise changes in their presentation: 
I could see he wasn't well... because he wouldn't- he didn't want to eat, and he 
wanted to lie down, he wasn't well, he was sleeping a lot, and that's the kind of cue 
that I s'pose you only get because you know somebody very well, and you live with 
them 
Carol, wife, caregiver 
If you live with somebody long enough, you're normally tuned with them, and you 
know if something is wrong or out of place... So if he goes quiet for a length of time, 
I’m always asking if you're alright, aren't I? 
Denise, wife, caregiver 
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Family caregivers reflected that knowing the person for a long time and knowing the person 
well (with extended exposure to their subtle behaviours) were key factors when identifying 
changes in the person with dementia’s presentation that deviated from their ‘normal’. 
Familiarity with the person with dementia aided pain identification, and thus prompting further 
questioning and investigation of the potential pain.   
GPs echoed the perspective of family caregivers, recognising the importance of familiarity 
when identifying the pain experienced by people with dementia. Earlier in this chapter, GPs 
recognised the importance of identifying subtle changes in presentation that were ‘out of 
character’ (see Section 8.4.1.2). However, to aid the identification of subtle changes, the GP 
must be familiar with the person with dementia:  
you can just observe, and I guess sometimes, urm, y'know you have patients you see 
quite regularly (…) if you know the patient before, and they seem pretty good, and 
suddenly they're not 
Chris, GP 
GPs acknowledged the benefits of knowing and being familiar with the person with dementia. 
Knowledge of the person with dementia could be used as a baseline comparison to their 
current presentation. Despite the benefits of familiarity to identify pain, many GPs continued 
to reflect upon the lack of continuity of care implicating their familiarity with the person with 
dementia. Their lack of familiarity may mean that subtle changes in the person with 
dementia’s presentation are missed, and thus pain remains unidentified: 
There is a huge problem in terms of continuity, and I think what, y'know the old GP 
would have been able to pick up as a change in Mrs Blogs, maybe now won’t get 
noticed, so yea... so lost  
Lisa, GP 
In accordance with GPs, people with dementia also reflected upon the importance of 
relationship continuity with their GP: 
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I'd rather have a doctor that I see every time because they- they know your history 
then, you build up a, y'know they build up a knowledge of how you're like. You never 
get that. They don't even look back through the notes. I could go with this [painful 
shoulder], and they'll say ‘well when did you have this done?’ and I don't know when it 
was done, look in your notes!  
Greg, husband, person with dementia 
In particular, some people with dementia reflected that the lack of relationship continuity 
implicated GP’s knowledge of their pain history. To buffer healthcare professionals’ potential 
lack of familiarity with the person with dementia, GPs and old age psychiatrists relied upon 
family caregivers as a substitute familiarity, which the healthcare professional may no longer 
be able to provide: 
Well I mean, urm... First of all, I mean... If I’m honest, I do rely a lot on relatives, or 
carers... because they're the people that know them, and I'm talking about an 
extreme, y'know at the more severe end here. But I rely on relatives, and carers, 
because they're the people that will see the change, and we often kind of, y'know sort 
of... you- they will be the ones who will be able to direct you sort of saying ‘well she 
can normally put a jumper on but now they can't’ y'know or... ‘He doesn't seem to be 
using his right arm’ 
Chris, GP 
As a doctor or a nurse you will see the snapshots in the middle, I go and see 
someone in one hour, I will have a good idea, but how the behaviour is in the evening 
I would not know... So it's very important the information I get... and I try my best to 
get detailed information from people who are closest to the person. 
Aska, psychiatrist 
Relatives are better at picking up the changes- the subtle changes in their loved ones 
behaviour, because they're there 24/7 
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Hayma, psychiatrist  
Many healthcare professionals reflected upon the time-limited nature of their consultations, 
only gaining a short ‘snapshot’ perspective of the person with dementia. In antithesis, family 
caregivers were highly familiar, often spending many hours each day with the person with 
dementia. Therefore, many GPs and old age psychiatrists viewed family caregivers as a 
valuable asset. People with dementia may be unable to provide a history of their pain 
condition, or to provide a self-report of their pain. In these circumstances, family caregivers’ 
familiarity means that they may be able to provide context and history as the person who 
knows them best. Additionally, family caregivers’ familiarity and knowledge of the person with 
dementia’s ‘normal’ provides greater opportunity to identify changes in presentation that may 
be indicative of pain. The family caregiver’s ability to provide a surrogate history and to 
observe and report changes in presentation may provide direction to the healthcare 
professionals’ investigation.  
The family caregiver’s familiarity and in depth knowledge was perceived as beneficial by all 
GPs, especially when the person with dementia was no longer able to communicate. 
However, some GPs also acknowledged the alternate perspective towards family caregiver’s 
familiarity and involvement in the consultation:    
I think they're probably essential [laugh] ur depending again on the level of cognitive 
impairment you've got... They can be actually... it's sometimes, an annoyance, if the 
person is actually perfectly capable of expressing themselves, the patient I mean, the 
caregiver sometimes y'know, you sometimes get the odd spouse, often... who will not 
keep quiet, and allow the person to talk 
Lisa, GP 
Family members are proactive in looking after, y'know the relative’s health, which is 
really positive, but it can over step the limit, and I have found that as well, where I'm 
trying to have a conversation with the patient (…). y'know ‘my dad's in a lot of pain’ so 
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they're going to be quite emotive as well, which makes it more challenging for me, in 
that step to really have ur... a good connection with the patient. 
Ishann, GP 
GPs perceived that the in depth involvement of family caregivers might overshadow the 
perspective of the person with dementia. This may have a negative impact upon the 
relationship between the GP and the person with dementia.  
8.4.3 The use of pain assessment tools 
At the start of the interview, people with dementia were asked to rate their own pain using the 
IPT. Following the self-reported pain rating, family caregivers were also asked to rate the 
person with dementia’s pain using the same tool (see 6.3.5.5.1). Some family caregivers 
reflected upon the difficulty of using a pain assessment tool to rate the person with 
dementia’s pain. 
[sigh] yea, I mean, it- numbers don't really tell the story anyway do they? 
John, husband, caregiver 
I have no way of judging [long pause] I know she has pain… But I wouldn't be able to 
describe the intensity [pause] since I am not feeling it. 
Robert, husband, caregiver  
John rated his wife’s pain as 7 out of 10, classifying her pain as ‘severe’ (see Table 7.7). 
However, John did not believe that numbers adequately reflected his wife’s experience of 
pain, suggesting that numbers fail to ‘tell the story’. Similarly, Robert had difficulty describing 
the intensity of Patricia’s (wife, person with dementia) pain. The abstract nature of pain may 
make informant pain assessment difficult for family caregivers, considering that they are not 
feeling the pain themselves. 
GPs were asked to reflect on pain assessment tools that they used to assess the pain 
experienced by people with dementia: 
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No specific pain tools that I use, in practice generally actually, just kind of... urm a few 
pain questions. Sometimes I use the 1-10 scale, 10 being the most painful, I would 
ask a few questions around where the pain moves, and if it's there- the key things in 
older adults with dementia would be if you can get out of the, urm- the severity of the 
pain... I wouldn't rely on too much with a person with dementia, because that might 
not be accurate... 
Muhammed, GP 
so we ask for the symptoms, and 1-10, y'know severity scores, and those sorts of 
things don't compute at all  
Lisa, GP 
I’m not sure how effective our standard- on a scale of 1-10 are, in that sort of 
situation, because it's always a bit tricky to sort of discuss  
Chris, GP 
Many GPs were aware of rating pain using a numerical 1 to 10 scale. However, GPs 
perceived numerical pain assessment scales as potentially inappropriate for people with 
dementia; providing potentially inaccurate pain reports. This links to the previous finding, that 
some GPs questioned the extent self-reported pain reflected the pain experienced by the 
person with dementia (see Section 8.4.1.1). Unlike the majority of GPs, some were aware of 
other self-report tools, aside from the numerical rating of pain on a 1 to 10 scale: 
I know there's the- the sort of smiley face charts, aren't there? With the- the different 
faces on... But to be honest, in routine practice, I don't use these... Um... perhaps 
something that I should consider [laughing] there's no specific tool that I use really... 
Jessica, GP 
obviously we need to ask the patient, and- and y'know use what we can, and I should 
probably use pain scores, and smiley face, and that kind of stuff more often... 
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Ishann, GP 
Jessica and Ishann reflected upon alternative self-report pain assessment tools such as 
‘smiley face charts’. Despite their awareness of alternative pain assessment tools (albeit 
limited), Jessica and Ishann did not use a validated tool when assessing the person with 
dementia’s pain, despite both reflecting that the incorporation of a tool into their practice may 
be worth considering. 
The majority of GPs were unaware of pain assessment tools developed specifically for 
people with dementia, such as behavioural observation methods of pain assessment (‘you're 
going to tell me that there's a dementia pain scale...’ Chris, GP). Tom was the only GP that 
reflected upon a behavioural observation tool developed for people with dementia: 
The Abbey Pain Scale, that's one scale... that we sometimes use... urm... but in my 
practice, and y'know there are some, ur... visual scales, of y'know facial expression 
for example, there are some other scales available that we sometimes use, urm... so 
yea... But you tend to really go by, urm... the observations of carers that formed a 
relationship with the patient, know the patient well, y'know over a period of time. 
Urm... they often provide the best source- the best and most reliable source of 
information, Ur and that- I value that the most in my own practice.  
Tom, GP 
Despite Tom’s awareness of the Abbey Pain Scale for people with dementia, he reflected 
upon his preference for the information and observations of family caregivers. Tom’s 
preference for information provided by family caregivers echoes the earlier finding of the 
importance of familiarity when identifying and assessing pain for people with dementia, 
especially as their condition progresses, and verbal articulation of pain diminishes (see 
Section 8.4.2).   
Psychiatrists did not perceive themselves to be ‘the primary assessor’ of pain (Prisha, 
psychiatrist). Additionally, earlier in this chapter, psychiatrists suggested that ‘physical health’ 
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should be investigated by GPs before referring the person with dementia to secondary care 
(see Section 8.4.1.2). Therefore, rather than assessing pain for people with dementia 
directly, psychiatrists adopted a holistic approach by monitoring behavioural and 
psychological symptoms as an indication of the presence/absence of pain: 
Our indicator of pain control, or good pain control, or rather the lack of it, is the 
behaviour, so the unsettled patient (…) we rely quite heavily on the GPs to look after 
the other side of the health, physical side of the health, and pain- pain control itself is 
under the GP's care, although we communicate in terms of assessing pain as such, 
we don't... We don't use it separately, we don't do it separately 
Hayma, psychiatrist 
Although psychiatrists did not view themselves as experts in pain (‘GPs have the expertise in 
physical health problems’ Mel, psychiatrist), and did not assess pain themselves, a number 
of psychiatrists were aware of dementia-specific behavioural observation pain tools: 
Urm... I think I probably do- I don't know if it's a general doctor thing, I think my 
perception would be, maybe just anecdotal that doctors go much more on history 
urm, and nurses- and nursing staff are often very good at doing the more formalised 
assessments. I know our nurses use the Abbey Pain Scale, I know that's used in 
some of the nursing homes that we go to. Although there's the PAINAD scale, which I 
don't think we use as much, I think it's more the Abbey Pain Scale, but I guess that's 
for more advanced dementia, so may not be as relevant for people who are in their 
own home.  
Mel, psychiatrist 
There is something called the Abbey Pain Scale... Um... Some of the staff are using 
that as well... To be honest I don't personally rely on a particular scale or- or score, I 
just look at the whole picture, at the whole medication, and the whole physical history, 
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and just try to give provisional diagnosis of provisional reasoning, and try to tackle 
them one by one.  
Rani, psychiatrist 
Despite being aware of behavioural observation pain assessment tools, psychiatrists relied 
upon alternative markers (e.g. history, caregiver reports; see section 8.4.2) and their clinical 
judgement to determine if the current presentation was driven by pain. Although the majority 
of healthcare professionals did not use validated pain assessment tools for people with 
dementia, some continued to reflect upon the benefits of incorporating a dementia-specific 
pain assessment tool into their practice: 
If you could introduce a certain amount of objectivity in it, so that- so that there was 
some sort of decision making tool in terms of pain, and then- and then giving 
medication then that would be helpful...  
Chris, GP 
Because you have to depend a lot on the subjective information, so how do you make 
it more objective? (…) We use memory scales, we use other scales, like we call it 
activities of daily living scale, for example... why can't we use a pain scale? Obviously 
that's extra work, ur, but it's worth it because often that's what probably would give 
you a lot more information than anything else... 
Prisha, psychiatrist 
Some healthcare professionals perceived pain assessment tools as a way to add objectivity 
to an inherently subjective phenomenon. Despite the perceived benefits, adding a pain 
assessment scale into their practice was recognised as a potential source of burden for 
healthcare professionals (albeit the positives outweighing the negatives), potentially acting as 
a barrier to their incorporation. 
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8.5 Summary of qualitative findings 
 A range of strategies were considered important to gather information about the pain 
experienced by people with dementia. These strategies included; self-report, family 
caregiver report, and observation of the presentation (including the observation of 
behavioural, psychological, and physical changes).  
 Family caregivers and GPs reflected upon the importance, yet challenge of self-
reported pain for people with dementia, especially as communication ability 
diminished in line with the progression of dementia.  
 Most family caregivers and GPs did not question the self-reported pain provided by 
the person with dementia. In some circumstances, however, family caregivers and 
GPs questioned the extent that the self-report reflected the pain experienced by the 
person with dementia; especially if there were inconsistencies i) over time, ii) between 
the self-report of pain and family caregiver report of pain, and iii) between the self-
reported pain and the GP’s clinical judgement. 
 A stoical attitude towards pain may also negatively influence the extent that the self-
report of pain reflected the pain experience, and thus the identification and 
assessment of pain for people with dementia. 
 Family caregivers and healthcare professionals observed many changes in 
presentation that may be indicative of pain for people with dementia. However, pain 
was perceived to be inadequately recognised as a differential diagnosis of 
behavioural and psychological symptoms.  
 Observation of physical changes and physical examinations were an important 
means to gather information about the potential pain experience for people with 
dementia, especially if they could no longer provide a self-report of their pain. 
 Family caregiver’s familiarity with the person with dementia aided the ability to 
provide history and context, and to identify changes in presentation. Healthcare 
professionals were often unfamiliar with the person with dementia, relying upon the 
family caregiver as a surrogate familiarity.  
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 Healthcare professionals often did not use dementia-specific pain assessment tools 
(rather relying upon alternative markers), however acknowledged that incorporation of 
a tool may be a useful addition to their practice.  
8.6 Conclusions 
This chapter investigated pain identification and pain assessment for people with dementia 
using quantitative and qualitative methods. Findings from the quantitative and qualitative 
data were provided and summarised separately in line with the convergent mixed methods 
design. The quantitative and qualitative findings from this chapter are narratively integrated in 
Chapter Ten to highlight inferences, interpretations, convergent, and divergent findings. By 
doing so, the quantitative and qualitative findings provide an investigation of pain 
identification and pain assessment for people with dementia (Creswell & Plano Clark, 2018). 
The following chapter provides the quantitative and qualitative findings relating to the 
management of pain for people with dementia. 
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9 Chapter Nine: Management of pain  
9.1 Introduction 
This chapter meets the second research objective: to investigate the management of pain for 
community-dwelling people with dementia (see Section 4.2) using quantitative and qualitative 
data. Firstly, using the Clinical Practice Research Datalink (CPRD), quantitative data was 
used to examine the analgesic prescriptions for people with dementia compared to older 
adults without dementia as a key pain management strategy. Secondly, people with 
dementia, family caregivers, and healthcare professionals’ views and perspectives of pain 
management strategies were explored using qualitative methods. These findings build upon 
the previous chapter investigating pain identification and pain assessment for people with 
dementia. The quantitative and qualitative findings are presented separately in line with the 
convergent mixed methods design described in Section 5.4.2.1. The quantitative and 
qualitative findings are narratively integrated in the discussion chapter (see Chapter Ten) to 
highlight inferences, interpretations, convergent, and divergent findings (Creswell & Plano 
Clark, 2018). 
9.2 Management of pain: Quantitative findings 
This section of the chapter examined analgesic medications prescribed to people with 
dementia (dementia cohort), compared to older adults without dementia (older adult cohort), 
as a key pain management strategy. All analysis was conducted using the dementia cohort 
(n=36,582) and older adult cohort (n=36,582) (see Figure 6.8). Firstly, the prevalence of 
analgesic prescriptions was calculated for both cohorts (see Section 6.2.13.4). Following this, 
conditional logistic regression models were used to examine the association between 
dementia and analgesic prescription. This section of the chapter answers the following 
research questions: 
 What is the prevalence of analgesic prescriptions for people with dementia compared 
to older adults without dementia? 
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 What are the annual prevalence rates of analgesic prescription over time for people 
with dementia? 
9.2.1 The prevalence of analgesic prescription 
The prevalence of analgesic prescription, and prevalence ratio was calculated during the 
five-year period from index date (dementia diagnostic Read code, or dementia medicinal 
product code, or equivalent matched date for the older adult cohort) for the five years 
following index date. The annual period prevalence of analgesic prescription was also 
calculated starting from the index date to five years after index date (see Section 6.2.13.2). 
Stratification into annual time periods allowed the prevalence of analgesic prescription over 
time (trends) to be examined for both cohorts. Analgesic prescriptions were categorised into 
basic analgesic, weak analgesic, moderate analgesic, strong analgesic, very strong 
analgesic, or non-steroidal anti-inflammatory drugs (NSAIDs) based on their analgesic 
potency (further details regarding the classification of analgesic prescriptions is provided in 
Section 6.2.9.2). The prevalence of prescriptions for these six analgesic categories was also 
calculated and presented. For the analyses discussed in this chapter, analgesic prescriptions 
were matched within a 14-day pre, and 90-day post window of a musculoskeletal 
consultation to increase the likelihood of identifying analgesic prescriptions associated with 
the musculoskeletal consultation following previous methodology (Bedson et al., 2016; 
Bedson et al., 2019; Richardson et al., 2018). However, sensitivity analysis including all 
analgesic prescriptions (irrespective of matching to a musculoskeletal consultation) was also 
conducted (see Section 6.2.13.5.3). 
Table 9.1 provides the period prevalence, and prevalence ratio estimates of analgesic 
prescription (matched to a musculoskeletal consultation) for the dementia cohort and the 
older adult cohort.  
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Table 9.1. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Any Analgesic Classification 
Dementia cohort (n) 24,247 16,110 10,314 6471 3893 3893 
Older adult cohort (n) 30,316 24,732 19,849 15,663 12,276 12,276 
Dementia prevalence %  
(95% CI) 
21.08 
(20.57 to 21.60) 
18.81 
(18.21 to 19.42) 
16.82 
(16.11 to 17.56) 
15.65 
(14.79 to 16.56) 
16.72 
(15.58 to 17.93) 
49.04 
(47.47 to 50.61) 
Older adult prevalence % 
(95% CI) 
25.47 
(24.99 to 25.97) 
25.21 
(24.68 to 25.76) 
25.42 
(24.82 to 26.03) 
26.25 
(25.56 to 26.94) 
26.16 
(25.39 to 26.94) 
60.07 
(59.20 to 60.93) 
PR (95% CI) .83  
(.80 to .85) 
.75  
(.72 to .78) 
.66  
(.63 to .70) 
.60  
(.56 to .63) 
.64  
(.59 to .69) 
.82  
(.79 to .85) 
Basic Analgesic 
Dementia prevalence %  
(95% CI) 
14.74 
(14.30 to 15.20) 
13.38 
(12.87 to 13.92) 
11.99 
(11.38 to 12.63) 
11.14 
(10.40 to 11.93) 
11.56 
(10.59 to 12.60) 
36.89 
(35.38 to 38.41) 
Older adult prevalence %  
(95% CI) 
16.44 
(16.03 to 16.86) 
16.40 
(15.94 to 16.86) 
16.73 
(16.21 to 17.25) 
17.57 
(16.98 to 18.17) 
18.03 
(17.36 to 18.72) 
44.61 
(43.73 to 45.49) 
PR (95% CI) .90  
(.86 to .93) 
.82  
(.78 to .86) 
.72  
(.67 to .76) 
.63  
.59 to .68) 
.64  
(.58 to .70) 
.83  
(.79 to .87) 
Weak Analgesic 
Dementia prevalence % 
(95% CI) 
5.82 
(5.54 to 6.13) 
5.00 
(4.67 to 5.34) 
4.61 
(4.22 to 5.03) 
4.31 
(3.84 to 4.83) 
4.55 
(3.94 to 5.25) 
18.39 
(17.21 to 19.64) 
Older adult prevalence % 
(95% CI) 
7.38 
(7.09 to 7.68) 
7.47 
(7.15 to 7.80) 
7.56 
(7.20 to 7.94) 
8.00 
(7.59 to 8.44) 
7.90 
(7.44 to 8.39) 
25.11 
(24.35 to 25.88) 
PR (95% CI) .79  
(.74 to .84) 
.67  
(.62 to .73) 
.61  
(.64 to .75) 
.54  
(.47 to .61) 
.58  
(.49 to .67) 
.94  
(.68 to .79) 
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Table 9.1. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Moderate Analgesic 
Dementia prevalence % 
(95% CI) 
2.95 
(2.74 to 3.17) 
2.65 
(2.41 to 2.91) 
2.27 
(2.00 to 2.57) 
2.15 
(1.82 to 2.53) 
2.62 
(2.16 to 3.17) 
9.40 
(8.52 to 10.36) 
Older adult prevalence % 
(95% CI) 
4.12 
(3.90 to 4.35) 
3.94 
(3.70 to 4.19) 
3.87 
(3.62 to 4.15) 
4.00 
(3.70 to 4.32) 
3.72 
(3.40 to 4.07) 
13.37 
(12.78 to 13.98) 
PR (95% CI) .72  
(.65 to .78) 
.67  
(.60 to .75) 
.59  
(.51 to .68) 
.54  
(.45 to .64) 
.70  
(.57 to .87) 
.70  
(.63 to .78) 
Strong Analgesic 
Dementia prevalence % 
(95% CI) 
5.00 
(4.84 to 5.28) 
4.57 
(4.26 to 4.90) 
3.85 
(3.50 to 4.24) 
4.31 
(3.84 to 4.83) 
3.96 
(3.39 to 4.62) 
14.23 
(13.17 to 15.36) 
Older adult prevalence % 
(95% CI) 
6.85 
(6.57 to 7.14) 
6.97 
(6.66 to 7.30) 
6.76 
(6.42 to 7.12) 
7.05 
(6.66 to 7.46) 
7.28 
(6.84 to 7.76) 
19.93 
(19.23 to 20.64) 
PR (95% CI) .72  
(.67 to .77) 
.64  
(.58 to .70) 
.55  
(.49 to .62) 
.59  
(.52 to .68) 
.52  
(.44 to .63) 
.67  
(.60 to .74) 
Very Strong Analgesic 
Dementia prevalence % 
(95% CI) 
.62 
(.53 to .73) 
.55 
(.45 to .68) 
.60 
(.47 to .77) 
.53 
(.38 to .73) 
.54 
(.35 to .82) 
1.62 
(1.27 to 2.07) 
Older adult prevalence % 
(95% CI) 
.65 
(.56 to .74) 
.78 
(.68 to .90) 
.68 
(.57 to .80) 
.67 
(.55 to .81) 
.71 
(.58 to .87) 
1.94 
(1.71 to 2.20) 
PR (95% CI) .96  
(.78 to 1.19) 
.71  
(.55 to .91) 
.89  
(.66 to 1.20)  
.78  
(.53 to 1.15) 
.76  
(.47 to 1.22) 
.83  
(.63 to 1.10) 
NSAIDs 
Dementia prevalence % 
(95% CI) 
3.72 
(3.49 to 3.97) 
3.09 
(2.83 to 3.36) 
2.65 
(2.35 to 2.98) 
2.63 
(2.26 to 3.05) 
3.06 
(2.56 to 3.65) 
13.43 
(12.40 to 14.54) 
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Table 9.1. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
 
Older adult prevalence 
% (95% CI) 
6.23 
(5.97 to 6.51) 
5.99 
(5.70 to 6.30) 
5.57 
(5.26 to 5.90) 
5.59 
(5.24 to 5.96) 
5.31 
(4.93 to 5.72) 
20.72 
(20.02 to 21.45) 
PR (95% CI) .60  
(.55 to .64) 
.51  
(.47 to .57) 
.48  
(.42 to .54) 
.47  
(.40 to .55) 
.58  
(.48 to .70) 
.65  
(.59 to .71) 
CI confidence intervals; NSAID Non-Steroidal Anti-Inflammatory Drugs, PR prevalence ratio  
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The five-year prevalence from index date of analgesic prescription (irrespective of potency) 
was 11% lower for the dementia cohort compared to the older adult cohort (49% vs. 60%, 
respectively), with the prevalence ratio indicating a 0.82 lower prevalence for the dementia 
cohort than the older adult cohort (PR = 0.82, 95% CI 0.79 to 0.85).  
Consideration over time, from index date, shows the annual prevalence of analgesic 
prescription steadily decreased from the first year of follow up (index date to one year after 
index date) until the final year of follow up (four years to five years after index date) for the 
dementia cohort (21.1% vs. 16.7%, respectively). Whereas the annual prevalence of 
analgesic prescription remained relatively stable (with indications of a slight increase) 
throughout follow up for the older adult cohort (25.5 vs. 26.2%, respectively) (see Figure 9.1). 
Consideration of the prevalence ratio in Table 9.1 shows that during the first year of follow 
up, the prevalence of analgesic prescription for the dementia cohort was 0.83 times lower 
than the older adult cohort (PR = 0.83, 95% CI 0.80 to 0.85). However, by the final year of 
follow up the prevalence of analgesic prescription for the dementia cohort was 0.64 times 
lower than the older adult cohort (PR = 0.64, 95% CI 0.59 to 0.69). 
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Figure 9.1. Period prevalence of being prescribed any analgesic  
 
To investigate the prevalence of analgesic prescription further, period prevalence estimates 
were stratified by analgesic classification (see Table 9.1). The five-year prevalence estimates 
indicate that the prevalence of basic analgesics was highest for the dementia cohort and 
older adult cohort (36.9%, 44.1%, respectively), followed by weak analgesics, strong 
analgesics, moderate analgesics, NSAIDs, and lastly, very strong opioids (1.6%, 1.9%, 
respectively) (see Table 9.1). The dementia cohort had a lower prevalence of being 
prescribed any of the analgesic classifications, irrespective of potency, compared to the older 
adult cohort. The exception to this statement is for very strong analgesics where the 
percentage is lower for the dementia cohort compared to the older adult cohort (as with other 
categories) but the difference is statistically non-significant (PR = 0.83, 95% CI 0.63 to 1.10). 
The annual prevalence of analgesic prescription was again, stratified into analgesic 
classifications. The dementia cohort had a lower annual prevalence of basic analgesic, weak 
analgesic, moderate analgesic, strong analgesic, and NSAID prescription compared to the 
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older adult cohort (see Table 9.1). For basic analgesics, weak analgesics, and strong 
analgesics, the discrepancy between the dementia cohort and the older adult cohort 
increased throughout follow up (see Figure 9.2). For moderate analgesics, the discrepancy 
between the dementia cohort and older adult cohort increased throughout follow up however 
decreased in the latter years of follow up (see Figure 9.2). The annual prevalence of very 
strong analgesic prescription was similar for the dementia cohort and older adult cohort 
throughout follow up, with prevalence ratios indicating no difference between the dementia 
cohort and older adult cohort (e.g. year 0-1 PR = 0.96, 95% CI 0.78 to 1.19; year 4-5 PR 
0.76, 95% CI 0.47 to 1.22) (see Table 9.1). 
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Figure 9.2. Period prevalence of analgesic prescriptions stratified by classification 
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9.2.1.1.1 Sensitivity analysis 
9.2.1.1.1.1 Community sensitivity 
As outlined in Section 6.2.13.5.1 a sensitivity analysis was planned to account for potential 
bias by the inclusion of persons who may reside within a formal care residence. This 
sensitivity analysis examined the period prevalence of analgesic prescription for the 
subgroup of the dementia cohort (n=8875) and older adult cohort (n=8349) with no evidence 
of a consultation location in a formal care residence, and a family number of ≤2. Similar to 
the analysis presented above, calculations were stratified into annual periods, and analgesic 
categories. The sensitivity analysis highlights minimal differences from the main analysis, 
with the dementia cohort having a lower prevalence of being prescribed any classification of 
analgesic medication compared with the older adult cohort (see Table 9.2).
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Table 9.2. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period: Community sensitivity analysis 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Any Analgesic Classification 
Dementia cohort (n) 5700 3648 2243 1370 808 808 
Older adult cohort (n) 6788 5377 4203 3268 2494 2494 
Dementia prevalence %  
(95% CI) 
22.04  
(20.98 to 23.13) 
19.76 
(18.50 to 21.09) 
17.61 
(16.09 to 19.24) 
16.57 
(14.69 to 18.63) 
17.45 
(14.99 to 20.22) 
50.74 
(47.30 to 54.18) 
Older adult prevalence % 
(95% CI) 
24.72 
(23.71 to 25.76) 
24.94 
(23.80 to 26.11) 
25.41 
(24.12 to 26.75) 
25.18 
(23.73 to 26.70) 
25.30 
(23.63 to 27.04) 
59.10 
(57.16 to 61.02) 
PR (95% CI) 0.89 
(0.84 to 0.95) 
0.79 
(0.73 to 0.86) 
0.69 
(0.62 to  0.77) 
0.66 
(0.58 to 0.75) 
0.69 
(0.59 to 0.81) 
0.86 
(0.80 to 0.93) 
Basic Analgesic 
Dementia prevalence %  
(95% CI) 
15.56 
(14.64 to 16.53) 
14.01 
(12.92 to 15.17) 
12.35 
(11.05 to 13.78) 
11.39 
(9.81 to 13.18) 
12.13 
(10.06 to 14.56) 
38.74 
(35.44 to 42.14) 
Older adult prevalence %  
(95% CI) 
15.57 
(14.73 to 16.45) 
16.25 
(15.29 to 17.26) 
16.63 
(15.54 to 17.79) 
16.77 
(15.53 to 18.09) 
17.04 
(15.62 to 18.57) 
43.22 
(41.29 to 45.18) 
PR (95% CI) 1.00 
(0.92 to 1.09) 
0.86 
(0.78 to 0.95) 
0.74 
(0.65 to 0.85) 
0.68 
(0.58 to 0.80) 
0.71 
(0.58 to 0.87) 
0.90 
(0.81 to 0.99) 
Weak Analgesic 
Dementia prevalence % 
(95% CI) 
6.09 
(5.50 to 6.74) 
5.56 
(4.87 to 6.36) 
4.64 
(3.84 to 5.59) 
4.89 
(3.87 to 6.16) 
5.07 
(3.76 to 6.81) 
20.79 
(18.14 to 23.73) 
Older adult prevalence % 
(95% CI) 
6.88 
(6.30 to 7.51) 
7.44 
(6.77 to 8.17) 
7.35 
(6.60 to 8.18) 
6.95 
(6.12 to 7.87) 
7.46 
(6.49 to 8.56) 
24.62 
(22.97 to 26.35) 
PR (95% CI) 0.88 
(0.77 to 1.01) 
0.75 
(0.64 to 0.88) 
0.63 
(0.51 to 0.78) 
0.70 
(0.54 to 0.92) 
0.68 
(0.49 to 0.95) 
0.84 
(0.73 to 0.98) 
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Table 9.2. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period: Community sensitivity analysis 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Moderate Analgesic 
Dementia prevalence % 
(95% CI) 
2.89 
(2.49 to 3.36) 
2.91 
(2.41 to 3.50) 
2.10 
(1.58 to 2.78) 
2.12 
(1.48 to 3.02) 
2.60 
(1.71 to 3.94) 
9.65 
(7.80 to 11.88) 
Older adult prevalence % 
(95% CI) 
3.99 
(3.55 to 4.49) 
3.92 
(3.44 to 4.48) 
3.83 
(3.29 to 4.45) 
3.79 
(3.19 to 4.51) 
3.49 
(2.84 to 4.28) 
12.95 
(11.69 to 14.33) 
PR (95% CI) 0.72 
0.60 to 0.88) 
0.73 
(0.59 to 0.93) 
0.54 
(0.40 to 0.75) 
0.55 
(0.37 to 0.83) 
0.74 
(0.47 to 1.19) 
0.72 
(0.59 to 0.94) 
Strong Analgesic 
Dementia prevalence % 
(95% CI) 
5.37 
(4.81 to 5.98) 
4.74 
(4.10 to 5.48) 
4.64 
(3.84 to 5.59) 
5.26 
(4.19 to 6.57) 
5.32 
(3.98 to 7.09) 
16.21 
(13.83 to 18.91) 
Older adult prevalence % 
(95% CI) 
7.07 
(6.49 to 7.71) 
7.05 
(6.40 to 7.76) 
6.71 
(5.99 to 7.51) 
7.37 
(6.53 to 8.32) 
7.18 
(6.23 to 8.26) 
19.85 
(18.33 to 21.46) 
PR (95% CI) 0.76 
(0.66 to 0.87) 
0.67 
(0.56 to 0.80) 
0.69 
(0.56 to 0.86) 
0.71 
(0.55 to 0.92) 
0.74 
(0.54 to 1.02) 
0.82 
(0.69 to 0.97) 
Very Strong Analgesic 
Dementia prevalence % 
(95% CI) 
0.88  
(0.67 to 1.15) 
0.63 
(0.42 to 0.94) 
0.76 
(0.47 to 1.21) 
0.58 
(0.30 to 1.15) 
0.37 
(0.13 to 1.09) 
2.23 
(1.41 to 3.49) 
Older adult prevalence % 
(95% CI) 
0.72 
(0.55 to 0.95) 
0.84 
(0.63 to 1.12) 
0.74 
(0.52 to 1.05) 
0.70 
(0.47 to 1.05) 
1.04 
(0.71 to 1.52) 
2.45 
(1.91 to 3.13) 
PR (95% CI) 1.22 
(0.82 to 1.80) 
0.75 
(0.46 to 1.24) 
1.03 
(0.57 to 1.85) 
0.83 
(0.37 to 1.85) 
0.36 
(0.11 to 1.17) 
0.91 
(0.54 to 1.53) 
NSAIDs 
Dementia prevalence % 
(95% CI) 
3.84 
(3.37 to 4.37) 
3.10 
(2.58 to 3.71) 
2.63 
(2.05 to 3.38) 
2.85 
(2.09 to 3.87) 
2.85 
(1.90 to 4.24) 
14.23 
(11.99 to 16.81) 
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Table 9.2. Period prevalence of analgesic prescriptions for the dementia cohort and older adult cohort stratified by analgesic classification and annual 
time period: Community sensitivity analysis 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Older adult prevalence 
% (95% CI) 
6.32 
(5.77 to 6.92) 
5.49 
(4.91 to 6.13) 
5.97 
(5.30 to 6.73) 
5.66 
(4.92 to 6.51) 
5.41 
(4.59 to 6.37) 
20.93 
(19.38 to 22.57) 
PR (95% CI) 0.61 
(0.52 to 0.71) 
0.56 
(0.46 to 0.70) 
0.44 
(0.33 to 0.58) 
0.50 
(0.36 to 0.71) 
0.53 
(0.34 to 0.81) 
0.68 
(0.56 to 0.82) 
CI confidence intervals; NSAID Non-Steroidal Anti-Inflammatory Drugs, PR prevalence ratio  
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9.2.1.1.1.2 Healthy cohort effects  
A sensitivity analysis was planned to account for potential ‘healthy cohort’ bias. The previous 
period prevalence investigation only included members of each cohort if they remained in the 
study throughout each time period. This sensitivity analysis considered the prevalence of 
analgesic prescription using members of the dementia cohort (n=12,967) and older adult 
cohort (n=22,237) that remained in the study at the mid-point of the five-year follow up period 
(912 days after index date; see Section 6.2.13.5.2). Sensitivity analysis indicated minimal 
differences in the prevalence of analgesic prescription compared to the main analysis, with 
the dementia cohort having a lower prevalence of analgesic prescription than the older adult 
cohort (see Table 9.3). 
Table 9.3. Period prevalence of analgesic prescription for dementia cohort and older adult 
cohort: Healthy cohort effects sensitivity analysis 
 0 to 5 years 
Dementia cohort (n) 12,967 
Older adult cohort (n) 22,237 
Any analgesic 
Dementia prevalence % (95% CI) 42.80 (41.95 to 43.65) 
Older adult prevalence % (95% CI) 55.79 (55.14 to 56.44) 
PR (95% CI) 0.77 (0.75 to 0.79) 
Basic analgesic 
Dementia prevalence % (95% CI) 33.03 (32.23 to 33.84) 
Older adult prevalence % (95% CI) 41.41 (40.77 to 42.06) 
PR (95% CI) 0.80 (0.77 to 0.82) 
Weak analgesic 
Dementia prevalence % (95% CI) 14.62 (14.02 to 15.24) 
Older adult prevalence % (95% CI) 22.04 (21.50 to 22.59) 
PR (95% CI) 0.66 (0.63 to 0.70) 
Moderate analgesic 
Dementia prevalence % (95% CI) 7.88 (7.43 to 8.36) 
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Table 9.3. Period prevalence of analgesic prescription for dementia cohort and older adult 
cohort: Healthy cohort effects sensitivity analysis 
Older adult prevalence % (95% CI) 12.27 (11.85 to 12.71) 
PR (95% CI) 0.64 (0.60 to 0.69) 
Strong analgesic  
Dementia prevalence % (95% CI) 11.71 (11.16 to 12.27) 
Older adult prevalence % (95% CI) 18.63 (18.12 to 19.14) 
PR (95% CI) 0.63 (0.60 to 0.66) 
Very strong analgesic 
Dementia prevalence % (95% CI) 1.64 (1.44 to 1.88) 
Older adult prevalence % (95% CI) 2.22 (2.04 to 2.42) 
PR (95% CI) 0.74 (0.63 to 0.87) 
NSAID 
Dementia prevalence % (95% CI) 9.33 (8.84 to 9.84) 
Older adult prevalence % (95% CI) 17.17 (16.68 to 17.67) 
PR (95% CI) 0.54 (0.51 to 0.58) 
CI confidence intervals; NSAID Non-Steroidal Anti-Inflammatory Drugs, PR prevalence ratio  
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9.2.1.1.1.3 Analgesic prescriptions not matched to musculoskeletal consultation 
This sensitivity analysis investigated the period prevalence of all analgesic prescriptions (not 
only prescriptions matched to a musculoskeletal consultation as shown in the main analysis 
above; see Section 9.2.1) the rationale for this sensitivity analysis is outlined in Section 
6.2.13.5.3. As expected, this sensitivity analysis found that the prevalence of analgesic 
prescription increased for both cohorts, indicating additional analgesic prescriptions not 
connected to musculoskeletal pain consultations. For example, during the five-year period 
following index date, the prevalence of any analgesic prescription (matched to a 
musculoskeletal consultation) in the main analysis was 49% for the dementia cohort (see 
Table 9.1). This prevalence increased to 76.7% in the sensitivity analysis (see Table 9.4), 
meaning that 27.7% of analgesic prescriptions were not matched to a musculoskeletal 
consultation within the specified time window (14 days previous and 90 days after 
prescription). 
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Table 9.4. Period prevalence of analgesic prescription, not matched to a musculoskeletal consultation, for the dementia cohort and older adult cohort  
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Any Analgesic Classification 
Dementia cohort (n) 24247 16110 10314 6472 3893 3893 
Older adult cohort (n) 30316 24732 19849 15663.00 12276.00 12276.00 
Dementia prevalence %  
(95% CI) 
51.73 
(51.10 to 52.36) 
50.55 
(49.78 to 51.32) 
49.20 
(48.23 to 50.16) 
48.64 
(47.42 to 49.86) 
49.58 
(48.01 to 51.15) 
76.73 
(75.37 to 78.03) 
Older adult prevalence % 
(95% CI) 
54.18  
(53.62 to 54.74) 
54.41 
(53.79 to 55.03) 
54.55 
(53.85 to 55.24) 
55.14 
(54.36 to 55.91) 
55.73 
(54.85 to 56.61) 
78.99 
(78.26 to 79.70) 
PR (95% CI) 0.95 
(0.94 to 0.97) 
0.93 
(0.91 to 0.95) 
0.90 
(0.88 to 0.92) 
0.88 
(0.86 to 0.91) 
0.89 
(0.86 to 0.92) 
0.97 
(0.95 to 0.99) 
Basic Analgesic 
Dementia prevalence %  
(95% CI) 
37.30 
(36.69 to 37.91) 
36.86 
(36.12 to 37.61) 
36.64 
(35.71 to 37.57) 
36.22 
(35.06 to 37.40) 
36.58 
(35.08 to 38.10) 
63.45 
(61.92 to 64.95) 
Older adult prevalence %  
(95% CI) 
35.78 
(35.24 to 36.32) 
36.19 
(35.60 to 36.79) 
36.82 
(36.15 to 37.50) 
37.57 
(36.81 to 38.33) 
38.91 
(38.05 to 39.78) 
62.13 
(61.27 to 62.98) 
PR (95% CI) 1.04 
(1.02 to 1.07) 
1.02 
(0.99 to 1.05) 
1.00 
(0.96 to 1.03) 
0.96 
(0.93 to 1.00) 
0.94 
(0.90 to 0.99) 
1.02 
(0.99 to 1.05) 
Weak Analgesic 
Dementia prevalence % 
(95% CI) 
13.61 
(13.18 to 14.05) 
12.68 
(12.17 to 13.20) 
12.19 
(11.57 to 12.83) 
11.28 
(10.53 to 12.07) 
10.97 
(10.03 to 11.99) 
31.34 
(29.90 to 32.81) 
Older adult prevalence % 
(95% CI) 
15.49 
(15.09 to 15.90) 
15.58 
(15.13 to 16.04) 
15.46 
(14.96 to 15.97) 
16.18 
(15.61 to 16.76) 
16.49 
(15.84 to 17.15) 
36.49 
(35.64 to 37.34) 
PR (95% CI) 0.88 
(0.84 to 0.92) 
0.81 
(0.77 to 0.86) 
0.79 
(0.74 to 0.84) 
0.70 
(0.65 to 0.75) 
0.67 
(0.60 to 0.73) 
0.86 
(0.82 to 0.90) 
Moderate Analgesic 
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Table 9.4. Period prevalence of analgesic prescription, not matched to a musculoskeletal consultation, for the dementia cohort and older adult cohort  
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
Dementia prevalence % 
(95% CI) 
7.04 
(6.73 to 7.37) 
6.32 
(5.95 to 6.71) 
6.22 
(5.77 to 6.71) 
6.38 
(5.81 to 7.00 
6.40 
(5.67 to 7.21) 
17.98 
(16.81 to 19.22) 
Older adult prevalence % 
(95% CI) 
8.52 
(8.21 to 8.84) 
8.48 
(8.14 to 8.83) 
8.29 
(7.91 to 8.68) 
8.03 
(7.61 to 8.46) 
7.83 
(7.37 to 8.32) 
22.15 
(21.42 to 22.89) 
PR (95% CI) 0.83 
(0.78 to 0.88) 
0.75 
(0.69 to 0.80) 
0.75 
(0.69 to 0.82) 
0.80 
(0.71 to 0.89) 
0.82 
(0.71 to 0.93) 
0.81 
(0.75 to 0.87) 
Strong Analgesic 
Dementia prevalence % 
(95% CI) 
11.12 
(10.73 to 11.52) 
10.42 
(9.95 to 10.90) 
9.71 
(9.16 to 10.30) 
9.86 
(9.16 to 10.61) 
9.84 
(8.94 to 10.81) 
22.86 
(21.57 to 24.21) 
Older adult prevalence % 
(95% CI) 
13.06 
(12.68 to 13.44) 
13.31 
(12.90 to 13.74) 
13.28 
(12.81 to 13.75) 
13.55 
(13.02 to 14.09) 
13.69 
(13.09 to 14.30) 
28.36 
(27.57 to 29.17) 
PR (95% CI) 0.85 
(0.81 to 0.89) 
0.78 
(0.74 to 0.83) 
0.73 
(0.68 to 0.78) 
0.73 
(0.67 to 0.79) 
0.72 
(0.65 to 0.80) 
0.81 
(0.76 to 0.86) 
Very Strong Analgesic 
Dementia prevalence % 
(95% CI) 
1.35 
(1.21 to 1.50) 
1.40 
(1.23 to 1.59) 
1.41 
(1.20 to 1.65) 
1.17 
(0.94 to 1.47) 
1.54 
(1.20 to 1.98) 
2.90 
(2.42 to 3.48) 
Older adult prevalence % 
(95% CI) 
1.30 
(1.18 to 1.43) 
1.42 
(1.28 to 1.57) 
1.39 
(1.23 to 1.56) 
1.33 
(1.17 to 1.53) 
1.40 
(1.21 to 1.63) 
3.01 
(2.72 to 3.32) 
PR (95% CI) 1.04 
(0.89 to 1.20) 
0.99 
(0.84 to 1.17) 
1.01 
(0.83 to 1.24) 
0.88 
(0.68 to 1.14) 
1.10 
(0.82 to 1.47) 
0.96 
(0.78 to 1.19) 
NSAIDs 
Dementia prevalence % 
(95% CI) 
6.97 
(6.66 to 7.30) 
6.29 
(5.92 to 6.67) 
5.51 
(5.08 to 5.96) 
5.08 
(4.57 to 5.65) 
5.68 
(4.99 to 6.45) 
19.21 
(18.01 to 20.48) 
Older adult prevalence 
% (95% CI) 
11.09 
(10.74 to 11.44) 
10.62 
(10.24 to 11.01) 
10.17 
(9.76 to 10.60) 
9.75 
(9.29 to 10.22) 
9.53 
(9.02 to 10.06) 
28.26 
(27.47 to 29.06) 
PR (95% CI) 0.63 0.59 0.54 0.52 0.60 0.68 
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Table 9.4. Period prevalence of analgesic prescription, not matched to a musculoskeletal consultation, for the dementia cohort and older adult cohort  
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
 
(0.59 to 0.66) (0.55 to 0.64) (0.49 to 0.59) (0.46 to 0.59) (0.52 to 0.68) (0.63 to 0.73) 
CI confidence intervals; NSAID Non-Steroidal Anti-Inflammatory Drugs, PR prevalence ratio  
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The sensitivity analysis found that the prevalence of analgesic prescription in the five-year 
period from index date was similar for the dementia cohort and older adult cohort (76.7% vs. 
79.0%, respectively, PR = 0.97, 95% CI 0.95 to 0.99). This finding is discordant to the main 
analysis that found that the dementia cohort had a lower prevalence of analgesic prescription 
(when matched to a musculoskeletal consultation) than the older adult cohort (49% vs. 
60.1%, respectively, PR = 0.82, 95% CI 0.79 to 0.85). However, the sensitivity analysis 
continued to find a growing discrepancy between the dementia cohort and the older adult 
cohort in each annual period after index date (see Table 9.4), this trend reflects the findings 
of the main analysis (see Table 9.1).  
The sensitivity analysis also found that the prevalence of basic analgesic prescription in the 
five-year period from index date was similar for the dementia cohort and older adult cohort 
(63.5% vs. 62.1%, respectively, PR = 1.02, 95% CI 0.99 to 1.05). The prevalence of basic 
analgesic prescription also remained relatively stable in each annual period from index date 
for the dementia cohort and older adult cohort. This contrasts the main analysis that found 
that the dementia cohort had a lower prevalence of basic analgesic prescription (when 
matched to a musculoskeletal consultation) than the older adult cohort (36.9% vs. 44.6%, 
respectively, PR = 0.83, 95% CI 0.79 to 0.87), with the prevalence of basic analgesic 
prescription incrementally lowering for the dementia cohort in each annual period (Table 9.1).  
Inspection of the prevalence of weak analgesics, moderate analgesics, strong analgesics, 
and NSAIDs showed comparable trends to the main analysis. In both the main and sensitivity 
analyses, the dementia cohort had a lower prevalence of prescription during the five-year 
period from index date compared to the older adult cohort. Additionally, the dementia cohort 
had a generally lowering prevalence of weak analgesic, moderate analgesic, strong 
analgesic, and NSAID prescription in each annual period from index date in both the 
sensitivity and main analyses. 
Additionally, the sensitivity analysis found that the prevalence of very strong analgesic 
prescription was similar for the dementia cohort and older adult cohort, in the five-year period 
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from index date (2.9% vs. 3.0%, respectively, PR = 0.96, 95% CI 0.78 to 1.19). Finally, the 
sensitivity analysis found a similar prevalence of very strong analgesics in each annual time 
period from index date to five years after index date (see Table 9.4). This finding is 
comparable to the main analysis (see Table 9.1). 
9.2.1.1.1.4 Analgesic prescription in the one year before index date 
The main analysis investigated analgesic prescription prevalence for the dementia cohort 
and older adult cohort, irrespective of their analgesic prescription before index date. In this 
sensitivity analysis further stratification examined if previous analgesic prescription was 
related to analgesic prescription during follow up (see Section 6.2.13.5.4). The dementia 
cohort and older adult cohort were stratified into two subgroups:  
 People with no evidence of analgesic prescription during the one year before index 
date  
 People with evidence of any analgesic prescription during the one year before index 
date 
No evidence of analgesic prescription 
The prevalence of analgesic prescription for members of the dementia cohort and older adult 
cohort with no evidence of analgesic prescription during the one year before index date 
steadily increased throughout follow up. However, similar to the non-stratified prevalence 
trends described earlier (see Table 9.1), the prevalence of analgesic prescription was lower 
for the dementia cohort than the older adult cohort (see Figure 9.3). When the analysis was 
stratified by analgesic category, the dementia cohort had a lower prevalence of all analgesic 
category prescriptions than the older adult cohort (with the exception of very strong analgesic 
prescriptions; see Appendix 13c). 
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Figure 9.3. The prevalence of analgesic prescription for the dementia cohort and older adult 
cohort with no evidence of analgesic prescription during the one year before index date 
 
Evidence of any analgesic prescription 
The prevalence of analgesic prescription for members of the dementia cohort and older adult 
cohort with evidence of any analgesic prescription (irrespective of potency) during the one 
year before index date steadily decreased throughout follow up (see Figure 9.4). Again, the 
prevalence of analgesic prescription was lower for the dementia cohort than the older adult 
cohort, with the discrepancy between the cohorts growing over time.  
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Figure 9.4. The prevalence of analgesic prescription for the dementia cohort and older adult 
cohort with evidence of any analgesic prescription during the one year before index date 
When the analysis was stratified by analgesic category, the dementia cohort had a lower 
prevalence (again decreasing over time) of all analgesic category prescriptions than the older 
adult cohort, with the exception of very strong analgesic prescriptions (see Appendix 13c). 
9.2.1.1.2 Conditional Logistic Regression  
The previous section investigated the period prevalence of analgesic prescriptions for the 
dementia cohort and the older adult cohort. This section builds upon the period prevalence 
estimates by investigating the association between dementia and analgesic prescription, 
whilst controlling for potential confounders.  
Associations were examined using univariate and multivariable conditional logistic regression 
analysis. An overview of conditional logistic regression is provided in Section 6.2.13.4.2. 
Univariate and multivariable conditional logistic regression analyses were conducted for the 
five-year time period from index date, and for each annual time period from index date to five 
years after index date.  
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Various assumptions of conditional logistic regression analyses were confirmed prior to 
modelling (see Table 6.9). The assumptions of little or no multicollinearity and linearity of 
independent variables and log odds were investigated for each multivariable model using the 
methods outlined in Table 6.9. Continuous covariates (with the exception of consultation 
frequency) violated the assumption of linearity of independent variables and log odds. Log 
and square root data transformations were performed with all continuous variables violating 
the assumption, however neither transformation was successful. All continuous covariates 
(other than consultation frequency) were categorised in which homogeneity within stratum 
was implicitly assumed (see Table 8.9) to overcome the violation. All reported models met 
the assumption of little to no evidence of multicollinearity (see Table 6.9). 
Univariate conditional logistic regression models included cohort status as the predictor and 
evidence of analgesic prescription (yes/no) for each analgesic category as the outcome. 
Multivariable conditional logistic regression models included cohort status as the predictor. 
Baseline covariates also included; evidence of cardiovascular-related conditions (CVD), 
evidence of diabetes, evidence of depression, morbidity (BNF frequency), follow up (days), 
and consultation frequency. Evidence (yes/no) of analgesic prescription for each analgesic 
category was the outcome (see Table 9.5).  
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Table 9.5. Conditional logistic regression reporting odds ratio (OR) and adjusted OR for the dementia cohort compared to the older adult cohort: 
Analgesic prescription 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
Any Analgesic Classification 
OR (95% CI) .84 (.80 to .87) .76 (.72 to .80) .67 (.63 to .71) .60 (.55 to .65) .66 (.59 to .74) .84 (.78 to .90) 
Adj OR (95% CI) .85 (.81 to .89) .76 (.71 to .80) .68 (.63 to .74) .61 (.55 to .67) .63 (.56 to .72) .82 (.76 to .88) 
Basic Analgesic 
OR (95% CI) .91 (.87 to .95) .83 (.78 to .88) .73 (.67 to .79) .65 (.59 to .72) .65 (.57 to .75) .86 (.79 to .93) 
Adj OR (95% CI) .93 (.88 to .98) .82 (.76 to .88) .75 (.68 to .82) .67 (.59 to .75) .62 (.53 to .72) .84 (.77 to .91) 
Weak Analgesic 
OR (95% CI) .79 (.74 to .85) .70 (.63 to .77) .60 (.53 to .69) .52 (.44 to .62) .62 (.50 to .76) .75 (.67 to .84) 
Adj OR (95% CI) .79 (.72 to .86) .72 (.64 to .81) .62 (.53 to .71) .55 (.45 to .67) .65 (.51 to .83) .75 (.66 to .84) 
Moderate Analgesic 
OR (95% CI) .74 (.67 to .81) .79 (.69 to .90) .67 (.56 to .80) .47 (.37 to .59) .77 (.56 to 1.03) .74 (.63 to .87) 
Adj OR (95% CI) .78 (.69 to .88) .76 (.65 to .90) .67 (.54 to .83) .46 (.35 to .62) .68 (.48 to .96) .72 (.60 to .87) 
Strong Analgesic 
OR (95% CI) .72 (.67 to .78) .66 (.60 to .73) .59 (.51 to .67) .61 (.51 to .72) .59 (.78 to .74) .71 (.62 to .80) 
Adj OR (95% CI) .65 (.59 to .71) .61 (.54 to .69) .52 (.44 to .61) .55 (.45 to .68) .48 (.36 to .63) .63 (.54 to .72) 
Very Strong Analgesic 
OR (95% CI) .96 (.76 to 1.21) .75 (.56 to 1.00) 1.03 (.72 to 1.48) .79 (.49 to 1.27)  .68 (.34 to 1.39) .73 (.50 to 1.07) 
Chapter Nine: Management of Pain 
 
 
305 
 
Adj OR (95% CI) .78 (.57 to 1.06) .77 (.52 to 1.14) 1.01 (.59 to 1.73) .47 (.21 to 1.05) .36 (.09 to 1.53) .57 (.33 to .98) 
NSAIDs 
OR (95% CI) .62 (.57 to .67) .51 (.45 to .57) .47 (.41 to .56) .48 (.39 to .58) .69 (.53 to .89) .66 (.58 to .74) 
Adj OR (95% CI) .65 (.59 to .72) .52 (.46 to .60) .48 (.40 to .57) .52 (.41 to .65) .62 (.46 to .83) .65 (.57 to .75) 
OR Odds Ratio; Adj OR Adjusted Odds Ratio; NSAID Non-Steroidal Anti-Inflammatory Drugs; CI confidence interval 
Adjusted for: evidence of cardiovascular-related conditions, evidence of diabetes, evidence of depression, morbidities (BNF), follow up (days), and consultation 
frequency. All analgesic prescriptions matched to musculoskeletal consultation. 
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During the five-year period from index date, the dementia cohort had 0.84 times lower odds 
of being prescribed analgesic medication than the older adult cohort during the five-year 
period (OR 0.84, 95% CI 0.78 to 0.90). The multivariable conditional logistic regression 
model identified minimal negative confounding (adjusted OR 0.82, 95% CI 0.76 to 0.88). 
When stratified by analgesic classification, the dementia cohort continued to have 
significantly lower odds of analgesic prescription compared to the older adult cohort, 
irrespective of classification, with the exception of very strong analgesics (see Table 9.5). 
Analysis was also stratified into annual periods from index date to five years after index date. 
The odds of the analgesic prescription for the dementia cohort was significantly lower than 
the older adult cohort during the first year following the index date (adjusted OR 0.85, 95% CI 
0.81 to 0.89). By the final year of follow up the odds of analgesic prescription for the 
dementia cohort was 0.63 times lower than the older adult cohort (adjusted OR 0.63, 95% CI 
0.56 to 0.72). Adjusted OR were similar to crude OR, indicating minimal confounding. A 
similar trend was evident when the annual analysis was further stratified by analgesic 
classification. The odds, and adjusted odds of basic, weak, moderate, strong analgesic, or 
NSAID prescription were significantly lower for the dementia cohort compared to the older 
adult cohort during all annual periods (see Table 9.5), with the odds lowering (in general) as 
time from index date increased. The odds and adjusted odds of very strong analgesic 
prescription was lower for the dementia cohort than the older adult cohort during each annual 
period, however, the association was often non-significant.  
9.2.1.1.2.1 Sensitivity analysis 
A number of sensitivity analyses were conducted using conditional logistic regression to 
reflect previous sensitivity analyses (see Section 9.2.1.1.1). All sensitivity analyses reflected 
the key findings presented in the main analysis, and the sensitivity analysis presented 
previously (see Section 9.2.1.1.1) (see Appendix 13d). 
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9.3 Summary of quantitative findings 
 The five-year prevalence of analgesic prescription was 11% lower for people with 
dementia compared to older adults without dementia (49% vs. 60%, respectively), 
 The prevalence of basic analgesics was highest for the people with dementia and 
older adults without dementia (36.9%, 44.1%, respectively), followed by weak 
analgesics, strong analgesics, moderate analgesics, NSAIDs, and lastly, very strong 
opioids (1.6%, 1.9%, respectively). People with dementia had a consistent lower 
prevalence, and a consistent lower odds of analgesic prescription than older adults 
without dementia, with the exception of very strong analgesic prescriptions, which 
was shown to be more comparable between the people with and without dementia.  
 Findings highlight a pattern of prevalence and odds over time from index date to five 
years after index date. The overall trend of analgesic prescription lowered with each 
additional year of follow up for people with dementia. Conversely, the overall trend 
remained relatively stable with each additional year of follow up for older adults 
without dementia.   
 Sensitivity analysis including analgesic prescriptions not matched to a 
musculoskeletal consultation found a similar prevalence of any analgesic prescription, 
and basic analgesic prescription for the dementia cohort and older adult cohort. This 
finding was divergent from the main analysis. However, the dementia cohort 
continued to have a lower prevalence of weak analgesic, moderate analgesic, strong 
analgesic, and NSAID prescription than the older adult cohort, reflecting the main 
analysis.  
 Additional sensitivity analyses were also conducted (including community, healthy 
cohort, and analgesic prescriptions during the one year prior to index date). The 
findings from the sensitivity analyses reflected those found in the main analysis, 
offering greater confidence in the findings.  
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9.4 Management of pain: Qualitative findings 
To complement the quantitative findings presented above, qualitative data explored pain 
management strategies for people with dementia, to answer the second research objective, 
as outlined at the start of this chapter (see Section 9.1). This section of the chapter answered 
the following qualitative research questions: 
 How do people with dementia, family caregivers, and healthcare professionals 
manage the pain experienced by community-dwelling people with dementia? 
 How do people with dementia, family caregivers, and healthcare professionals 
perceive pain management strategies for community-dwelling people with dementia?  
To answer these questions, interviews were conducted with people with dementia (n=8), 
family caregivers (n=9), GPs (n=9), and old age psychiatrists (n=5), and their perspectives 
integrated. Three key themes were identified:  
 Non-drug management of pain 
 Concerns related to analgesic medication 
 Side effects 
 Illness and treatment burden 
 Weighing up the concerns 
 Responsibility of the caregiver to manage pain 
9.4.1 Non-drug management of pain 
This theme explores the non-drug strategies used to manage the pain experienced by people 
with dementia, and the perspectives of people with dementia, family caregivers, and 
healthcare professionals towards such strategies.  
Many people with dementia and family caregivers used a variety of non-drug strategies in an 
attempt to alleviate pain. Some engaged with exercises recommended by a physiotherapist, 
or had regular physiotherapy sessions:  
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I mean I was already doing quite a few exercises (…) I know a fair few things to do 
myself without them [physiotherapists] telling me... A lot of the exercise I'm doing 
already… I'm doing them every morning… Even with the exercise they're [shoulders] 
slowly getting worse... 
Greg, husband, person with dementia 
Someone [physiotherapist] who we've very luckily found who comes 5 days a week 
(…) because of that, I personally feel, and I think mum does as well, that y’know 
dad's mobility- well we were amazed at the physio that he can y'know walk with one 
stick (…) but then there's a lot of ‘oh me back hurts’ and ‘oh this hurts’ 
David, son, caregiver 
People with dementia and family caregivers reflected upon the benefits of exercise for their 
pain, with David highlighting the improvement in his dad’s (Richard, person with dementia) 
mobility, which he attributed to the regular physiotherapy sessions. Despite the perceived 
benefits of physiotherapy, exercises alone did not completely alleviate the pain experienced 
by the person with dementia, with some perceiving exercise to have short-term benefits. In 
accordance with people with dementia and family caregivers, GPs also considered the 
benefits of physiotherapy to improve the pain experienced by people with dementia: 
Putting medicine aside for a minute y'know any exercises they can do, things they 
can do at home, elevating the joint, keeping active, physio referrals, making sure that 
we don't automatically just go to prescribing medication, because yes that's useful, 
but in the long term y'know keeping the joint active is much more beneficial than 
putting someone on co-codamol. 
Amy, GP 
the physio, and occupational therapy, they're definite things that I would consider, that 
I think they're useful alternatives, particularly if you think it's someone who's at high 
risk if you're going to give them opiates, or neuropathic pain killers... 
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Jessica, GP 
Healthcare professionals commented upon the potential long-term benefits of exercise, 
especially for people with dementia. This contrasts the perspective of people with dementia 
whom reflected upon the limited long-term benefits for their pain. For healthcare 
professionals, the perceived long-term benefits of physiotherapy juxtaposed the short-term 
relief of analgesic medication. In addition to the long-term benefits of physiotherapy, non-
drug strategies were perceived by GPs as useful alternatives to manage pain when reflecting 
upon their concerns related to analgesic medication for people with dementia (see Section 
9.4.2). Although physiotherapy was regarded as important, healthcare professionals 
continued to reflect upon the lack of services in the community:  
A lot of the pain is from more sedentary and less active lives that people with 
dementia in the community have, they would probably respond really well to physio, 
and- and y'know more movement and guided support with that. (…) but it's just not 
available (…) the services in the community just aren't there 
Mel, psychiatrist 
Despite the support for physiotherapy to manage pain, some acknowledged the barriers to 
non-drug strategies, especially exercise, that required an element of self-management: 
They [physiotherapist] gave me, urrr, urrr, [long pause] a card, or a- two or three- two 
page card with ‘do these exercises’. Which I wasn't very good at following was I? I 
don't use them now, I should do. I should do. But I don't bother. 
James, husband, person with dementia 
It can be difficult, and you do wonder if they're actually going to do it, I’ll be honest... It 
can be difficult to convince people, um, and I think in the elderly particularly, that if 
I've got arthritis I shouldn't be using the joint, for example, that's still out there as a, 
sort a myth, it can be quite hard to overcome 
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Lisa, GP 
Some people with dementia did not persist with the exercises recommended by the 
physiotherapist. In accordance, GPs questioned ‘adherence’ to exercise, and the 
misconceptions held by older adults, including people with dementia, that may act as barriers 
to non-drug approaches. Persistence with non-drug strategies that required an element of 
self-management may rely upon input from family caregivers in the community (see Section 
9.4.3). 
Aside from exercise, many participants supported the use and reflected upon the benefits of 
regular massage to manage pain: 
David: Definitely massage, and no matter what it [the problem] is, that always helps 
Richard: I don't think it does any harm, I think it helped... 
Richard (person with dementia) and David (son, caregiver) 
I massage his feet with, um... sort of- body lotion every morning, um... and I check if 
there's any ulc- any open wounds, which is what you've got to be careful of... 
because there's some neuropathy in his feet, which I didn't realise before 
Carol, wife, caregiver 
Other things that can be really helpful that I suggest often is massage. If it's sort of 
neck pain, shoulder pain, if it's very tense and tight (…) some gentle massage 
techniques... 
Lisa, GP 
Massage involved minimal risk or harm for the person with dementia (in antithesis to 
perceptions of analgesic treatment; see Section 9.4.2) and could be easily completed by the 
family caregiver. Although massage was primarily perceived as a pain management strategy, 
Carol also used massage as an opportunity to proactively examine her husband’s feet for 
potential indications of pain (see Section 8.4.1.2). In addition to massage, many family 
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caregivers reflected upon other at-home non-drug strategies to provide comfort and warmth 
when the person with dementia was experiencing pain: 
She always has a hot water bottle at night, so she's always warm and comfortable, 
and all of that helps, y'see. From my point of view, that's what we do... common 
sense really, isn't it? 
Brenda, daughter, caregiver 
Denise: There's the old wheaty bag 
Greg: Those are good (…) I use it for my neck, my shoulder, I've even put it on my 
elbow before now (…) Helps my neck, definitely... 
Greg (husband, person with dementia) and Denise (wife, family caregiver) 
Non-drug treatments that provided comfort and warmth, and could be completed easily at-
home were perceived as beneficial by people with dementia and family caregivers. In many 
circumstances, family caregivers prompted the person with dementia to engage with non-
drug approaches when experiencing pain (see Section 9.4.3), with family caregivers 
perceiving warmth, comfort, and relaxation as ‘common sense’ strategies to manage pain for 
the person with dementia.  
In addition to the strategies outlined above, people with dementia, family caregivers, and a 
small number of GPs discussed the importance of distraction techniques to cope with pain:  
Well, you can forget it sometimes if you're chatting, or doing something, ya know? 
You’re not worrying all of the time [pause] it's just there. I just put up with it. 
Sometimes if I am walking about doing something else, I forget that the pain is there. 
Patricia, wife, person with dementia 
We do- do we do word games together and we do cross words together, we do... 
urm... All sorts of, mainly word puzzles, urm... things together (…) I have found 
actually that by distracting her with a cross word... urm... y'know, just something other 
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than just sitting in the chair suffering. (…) If she can concentrate on cross word clues 
being shouted at her (...) that will distract her from the pain. Doesn't necessarily mean 
that the pain has gone... just means that we're both coping better with it 
John, husband, caregiver 
Or distraction techniques, y'know? Rather than focusing on the pain, trying to go off 
and do something like listen to the radio, watch the television, have something else 
going on, or get out into the garden and potter about, and do a few odd jobs, and 
things like that. 
Lisa, GP 
Although distraction did not directly alleviate the pain, people with dementia seemed to cope 
better when their attention was re-directed away from their painful experience. For example, 
Patricia suggested that distraction helped her to forget about her pain, despite experiencing 
persistent moderate pain due to her spinal injury (five out of 10 on the IPT; see Table 7.7). 
This perspective was reiterated by family caregivers and Lisa (GP) who also acknowledged 
distraction as a method to avoid ‘focusing on the pain’, helping people with dementia to cope 
with their pain.  
In addition to the many non-drug strategies already discussed (including exercise, massage, 
warmth and comfort strategies, and distraction), a minority of family caregivers voiced their 
perspective towards pain management strategies often classified as ‘alternative’ and 
‘complementary’:   
we've tended to go down the alternative medicine route (…) mum's a great one with 
the turmeric thing, and she’s convinced that's working but urm I don't know whether it 
is or not 
David, son, caregiver 
I mean, we've thrown money at it… An acupuncturist was recommended to us… Well 
I mean people have mentioned mindfulness (...) some of it just sounds rather mad 
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new age stuff to me (…) you might regard them as quackery. What’s the other one? 
Oh yes, we've got a pot of (…) aloe vera cream which she quite likes, I mean I don't 
know how effective it is, but she quite likes that, so I'll- I'll put that on her temples. 
John, husband, caregiver 
In an attempt to alleviate pain, a minority of family caregivers reflected upon a variety of 
complementary and alternative treatments, such as acupuncture, Indian head massages, 
facial massages, mindfulness, aromatherapy, and turmeric. Although some were completed 
at-home (e.g. facial massage and turmeric) most were completed by specialised services 
(such as acupuncture and Indian head massages). Despite trying many strategies, family 
caregivers seemed uncertain and sceptical of their usefulness for pain; with John describing 
alternative treatments as ‘mad new age stuff’. Many of the alternative treatments tried by 
John and Barbara (John’s wife with dementia) were unavailable on the NHS, therefore 
having financial implications. John’s willingness to ‘throw money’ at alternative treatments 
that he was sceptical towards may illuminate John’s desperation to identify an effective way 
to alleviate Barbara’s severe pain (see Table 7.7), which she was reluctant to manage using 
analgesic medication (see Section 9.4.2).  
Aside from family caregivers, GPs also reflected upon alternative and complementary 
treatments for pain experienced by people with dementia: 
The reality is, unless- and there are- there are a few people who do have ur... Reiki, 
is it called? (…) Some will try acupuncture, and that works for some and not for 
others, some try hand massage, what the hell is a hand massage? (…) y'know I think 
these things are very nice, but I think they're an added extra by enlarge. I don't have 
access to them, they don't normally come into my- my cognisance when I'm thinking 
about these things. (…) If you're backed into a corner, and you're desperate, and 
you're in pain 24/7, you'll- you'll- you'll try anything (…) so I get why they're doing it, 
but in terms of part of the repertoire of- of treatment of the management pain- it 
wouldn't come into my mind... 
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Alan, GP 
In terms of other things like- there's a whole host of other complementary 
medicines… I generally don't offer them... Generally, I don't suggest them... I guess 
on occasion I have, but I generally don't suggest them (…) but my personal 
perspective I support it, I say yea, you can try it... 
Ishann, GP 
suppose it's- it's not going to do them any harm, is it? So if it was something that they 
independently wanted to explore, um... it's not something that I have actively 
suggested 
Jessica, GP  
Despite GPs’ positive regard towards other non-drug strategies for pain (as discussed earlier 
in this theme), GPs did not regularly recommend complementary or alternative treatments for 
pain. In accordance with family caregivers, GPs were sceptical of alternative and 
complementary strategies, with many being perceived as an added extra, rather than a 
treatment option in isolation. Although many GPs were sceptical, they often seemed 
empathetic to their patient’s desperation to identify an effective strategy to alleviate their 
pain. Therefore, although GPs often did not recommend alternative and complementary 
strategies, they continued to support their patient’s wish to try a variety of treatment options 
as they were ‘unlikely to cause harm’.  
A number of GPs continued to discuss reasons why they felt unable to recommend 
alternative and complementary treatments to people with dementia for their pain:  
We never... as doctors we can't prescribe those things, because they're not 
necessarily accessible on the NHS (…) It's just difficult to access them sometimes. 
The other thing is the cost implications, so people do go for alternative therapies, 
whatever that might be, there is a cost implication so... it’s often deemed a bit 
unethical to tell patients ‘you must have this’ knowing that it's going to cost them £30 
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a go. (…) I think as practitioners you have to practice evidence based medicine, so if 
there's not robust support for these things, then it's difficult. 
Jenny, GP 
There's lots of things about lavender, for example, or like aromatherapy, music, so 
there's loads of other things, that the whole- I mean none of them are conclusive as 
such (…) there's enough evidence to say that if not fully helping with the full symptom 
aetiology, they definitely help with the wellbeing, and overall wellness if you like... 
Prisha, psychiatrist 
Many non-drug treatments were not available on the NHS, and therefore GPs’ were wary to 
recommend treatments with limited accessibility. Recommending non-drug treatments that 
were not available on the NHS had the potential for negative financial burden, as reflected 
earlier by family caregivers. Additionally, healthcare professionals reiterated the importance 
of practicing evidence-based medicine. Therefore, treatments without a large scientific 
evidence base may not be recommended for people with dementia, despite their potential to 
improve ‘overall wellness’. These findings may provide explanation as to why exercise was 
viewed in higher regard by GPs than alternative and complementary treatments. 
In addition to the type of non-drug strategy, healthcare professionals considered the timing 
and ‘place’ (i.e. appropriateness) of non-drug strategies to manage pain. Many GPs reflected 
upon the importance of recommending non-drug strategies for pain before initiating analgesic 
medication: 
In terms of non-pharmacological management, I think that's really important (…) and 
that's something (…) I like to think before prescribing anything for this patient with 
dementia (…) if there is any non-pharmacological things that we can do that means 
that they potentially save them from being prescribed something (…) that's really, 
really important 
Ishann, GP 
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I would always try non-pharmacological as much as I could... urm... urm... because, 
because once you get into the prescribing habits, urm... it just- the habit of prescribing 
things, it just does become a bit complicated... 
Chris, GP 
Many GPs viewed non-drug strategies as the first-line treatment for pain in people with 
dementia. By employing non-drug strategies, pharmacological burden may be minimised. If 
non-drug approaches are not sufficient in isolation, GPs seemed to consider a dual approach 
to pain treatment using both non-drug and drug approaches: 
you always, before- before you go to pharmacology you must always do your non-
pharmacological things first, y'know it's very, very important. You must, y'know prior, 
but y’know if that doesn't work, you may have to use a combination of that- with um 
pharmacology. 
Tom, GP 
Alternatively, psychiatrists often supported the use of non-drug approaches for people with 
dementia, however unlike GPs, non-drug strategies were viewed as a holistic approach to 
manage behavioural and psychological symptoms, rather than specific for pain:  
the management plan would be quite... kind of urm... could be multi-targeted, and 
pain would be one of them (…) I don't y'know... think about pain management as 
such... for my patients with dementia, I don't think about it separately...  
Hayma, psychiatrist 
We often don't, urm, y'know delve that much into it... it's more of a holistic type of 
thing... (…) We don't specifically suggest any non-pharmacological for the pain, I 
think it would be non-pharmacological for BPS [behavioural and psychological 
symptoms] really. (…) What we tend to do is offer this non-pharmacological for a 
range of thing, not specifically for the pain if you like... 
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Prisha, psychiatrist 
Pain was perceived as a potential driver contributing to behavioural and psychological 
symptoms (see Section 8.4.1.2) that may be managed using non-drug strategies. However, 
psychiatrists did not use non-drug strategies to manage pain directly. In line with this 
perspective, some healthcare professionals questioned the appropriateness of non-drug 
treatments depending upon the severity of the pain experienced by the person with 
dementia: 
But if somebody is in a lot of pain, then that's [non-drug treatments] not really going to 
relate to them at all... they're not gonna, not gonna hear that, I think 
Lisa, GP 
If there is a pain, non-pharmacological... there's no place for that. If they're genuinely 
in pain, if they're in pain you can't really just ask them to do things while they're 
suffering. Control the pain first and then do whatever- or give any advice about non-
pharmacological (…) otherwise they won’t enjoy, or they won’t participate 
Rani, psychiatrist 
Healthcare professionals again reflected upon the idea of ‘genuine’ pain, highlighting the 
subjectivity and the challenge of disentangling the pain experienced by people with dementia 
(see Section 8.4.1.1). If a person with dementia was perceived to be experiencing a lot of 
pain, some healthcare professionals viewed non-drug strategies as potentially inappropriate 
as a first-line treatment.  
9.4.2 Concerns related to analgesic medication 
This theme explores the concerns of people with dementia, family caregivers, and healthcare 
professionals relating to analgesic medication for people with dementia. Old age psychiatrists 
did not perceive their role to involve analgesic medication (‘If it is pain killer, if it is analgesic, 
it's the GP’ Hayma, psychiatrist) and therefore their perspective often did not contribute to 
this theme. 
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Some people with dementia and family caregivers voiced no explicit concerns towards 
analgesic medications, with some even being open to their use and benefits for the pain 
experienced by people with dementia: 
So [she] now wears a morphine patch and that has helped a lot. It is quite strong and 
all of that sort of thing and oh, that was it, urm, and she continued with that ever 
since. So it has helped. (…) I can see that there was a change once she had started 
and had– had- been on it for a little while, that she was a bit more comfortable with 
the pain, if that makes sense? 
Robert, husband, family caregiver  
I just take the pills... I've got no problem with anything to do with the pills, if the pills 
are going to help I take the pills, same for Mark really 
 Brenda, wife, caregiver 
The benefits of analgesic medication for the person with dementia was determined by the 
family caregiver observing changes in their behaviour (see Section 8.4.1.2). Family 
caregiver’s perspectives towards analgesic medication was particularly important as they 
were often in control of prompting the use of analgesic medication for their relative with 
dementia (see Section 9.4.3). Brenda’s positive perspective towards analgesic medication 
may reflect her previous employment as a palliative care nurse. She perceived the 
knowledge, training, and experience of pain management gained during her career as ‘a 
transfer of skills’ when caring for her husband (Mark, person with dementia) and mother with 
dementia.  
The positive perspective towards analgesic medication was, however, over shadowed by the 
many people with dementia that were explicitly reluctant to use analgesic medications for 
their pain due to their concerns:  
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I hate taking tablets at the best of times, so I've got to be getting pretty bad before I'll 
take them… I've got an aversion to taking poisons... Every tablet is a poison of some 
kind 
Greg, husband, person with dementia 
I'll get a sudden lock, but it is painful... Urm...Sometimes I will get that in my legs as 
well they will lock, and that's painful, but like... as far as taking pain killers to sort of 
deal with things like that, I tend to shrug that off... 
Steven, husband, person with dementia 
Many people with dementia voiced their concerns towards analgesic medications, with the 
perception that analgesic medication was a last resort treatment for pain. Steven’s reluctance 
to use analgesic medication appears to stem from his stoical attitude towards pain, especially 
when he perceived pain to be short lived or transient. In the previous chapter, the impact of 
stoicism upon pain assessment was discussed (see Section 8.4.1.1), with this further 
indicating that a stoical attitude may increase reluctance to take analgesics.  
9.4.2.1 Side effects 
In accordance with people with dementia, a number of family caregivers also seemed 
reluctant for the person with dementia to take analgesic medication. This reluctance was 
often linked to their concerns related to potential side effects: 
I'm not a tablet person, I don't want people to give us medication, y'know? You'd 
probably get worse from the side effects of it! 
Mary, wife, caregiver 
We manage without it [analgesic medication]. I'm not very keen on him taking a lot of 
pain killers, I think sometimes you're just adding on another problem, urm, I dare say 
the stuff the doctor could give him, but I dunno… [Sigh] You've got to be careful of 
some of this stuff. 
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Carol, wife, caregiver 
Many family caregivers reflected upon the side effects associated with analgesic 
medications. Carol’s concerns were illuminated as she only prompted William (husband, 
person with dementia) to take analgesic medication if she ‘really can't avoid him walking’. 
William has arthritis in his knees, which triggers pain during impact. Therefore, to minimise 
the pain experience (and ultimately William’s use of analgesic medications) William regularly 
used a wheelchair to avoid pain. This highlighted the extent that herself and William were 
willing to stretch to alleviate pain, without using analgesic medication.  
In line with family caregivers, GPs were also concerned about the side effects associated 
with analgesic medication for people with dementia. Therefore, when deciding what 
analgesic to prescribe to the person with dementia, all GPs noted a preference for simple 
analgesic medications: 
This is KISS, you know KISS? Keep It Simple, Stupid. Keep it simple, and go for the 
what- y'know there's an old adage in medicine, if you can't do any good, don't do any 
harm. The potential to do harm... particularly for this group...  you've this group of 
patients that are particularly susceptible to side effects of certain drugs so you have 
to be careful, so you go with a drug which is the simplest... with the lowest side effect 
profile, and the staple one is paracetamol... 
Alan, GP 
GPs considered the importance of avoiding analgesic medications that would cause side 
effects for the person with dementia. For this reason, paracetamol was preferred due to the 
good safety profile, thereby minimising the risk of side effects. Despite the preference 
towards simple analgesics (such as paracetamol) for this reason, some participants reflected 
upon the limited efficacy of paracetamol: 
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she takes paracetamol, she probably has one or two doses a day, which um... I think 
given the amount of pain, doesn't help a lot... She would need to be taking more than 
that, I think to- to cope with the pain... 
Charles, husband, family caregiver 
That's almost like going through the motions, 'cause she doesn't believe they [pain 
killers] work. I mean we both regard ordinary paracetamol as- as sweets to be 
honest… that that- doesn't cut the mustard. 
John, husband, caregiver 
If the simple measures deal with the problem, y'know like rubbing gels and things like 
that, absolutely fine, but I think it depends on the- on the type of pain, if there's- if 
there's significant pain from a significant problem... y'know it depends what the pain 
is, doesn't it? 
Jenny, GP 
Some family caregivers and GPs suggested that paracetamol was insufficient to provide pain 
relief, depending upon the severity of the pain experienced by the person with dementia. The 
perceived inefficacy of paracetamol was illuminated by John using a metaphor to compare 
the effectiveness of paracetamol to that of sweets (i.e. useless). Additionally, unlike all other 
GPs interviewed, that largely viewed paracetamol as a risk-free analgesic choice, Jessica 
also reflected upon her concerns related to the side effects associated with paracetamol: 
I'd start with paracetamol, as... as long as I checked their weight because there is the 
risk if they're low weight of overdosing them if you give them the wrong dose 
Jessica, GP 
When reflecting upon alternative analgesics (other than paracetamol), such as NSAIDs and 
opioid medications, all interviewed GPs discussed their concerns of side effects: 
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Would you go for... non-steroidal anti-inflammatories? (…) They cause your stomach 
to bleed, they impair your renal function, they probably cause some electrolyte urm... 
disturbance, you need other medication to take with them so that you don't get a 
gastric ulceration. Urm... And particularly in the elderly, y'know you- y'know you're not 
asking for trouble, but it's a well-recognised fact that these people get into trouble 
with nonsteroidal anti-inflammatories.  
Alan, GP 
side effects in patients with dementia (…) they’re more susceptible to any potential 
problems such as psychosis, with the opioids, urm... and y'know things like, 
constipation which might sound like a mild symptom, can actually end up progressing 
and causing significant problems 
Amy, GP 
Many GPs discussed the side effects associated with NSAIDs and opioid medications that 
are common for older adults, with the presence of dementia being perceived as an additional 
risk factor when considering the risk of side effects (e.g. opioid medications may exacerbate 
confusion for people with dementia). The concerns related to analgesic side effects may 
contribute to pain being undertreated for people with dementia: 
opiate medication (…) can cause constipation and confusion and that can exacerbate 
dementia (…) it does worry me sometimes that y'know that maybe as a result of that, 
that we do under treat people's pain, but having said that, we're often told that we're 
over treating people's pain anyway, with all these opiates, and use of NSAIDs, so... 
y'know so you end up between a rock and a hard place really... 
Chris, GP 
The under treatment of pain for people with dementia was, however, in contention with the 
need to reduce NSAID and opioid prescribing in primary care.  
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9.4.2.2 Illness and treatment burden 
In addition to the concerns of side effects, an additional expressed concern was the illness 
and treatment burden experienced by people with dementia:  
He can only take paracetamol 'cause he's on warfarin he's very limited as to what 
other drugs he can take... He can't take things like ibuprofen... um... or aspirin...  
Carol, wife, caregiver 
if you're taking medication for urm... y’know for memory problems, taking them- it for 
gout, and thing and another, suddenly have another load of pills thrust at you, plus 
y'know paracetamol (…) Goodness knows what all of these other things will have an 
effe- y'know sort of an effect, y'know on... 
David, son, caregiver 
Comorbid conditions and their associated treatments may mean that certain analgesic 
medications were not appropriate, with Carol illuminating that her husband’s heart condition 
limited the number of appropriate analgesic medications for his pain. Family caregivers were 
concerned about the effects of taking numerous medications for different health conditions. 
In addition to potential contraindications, the sheer number of medications already being 
taken by the person with dementia may increase concerns and reluctance to take analgesic 
medication: 
she's got... quite a lot of drugs to take so she doesn't really want extra...  
John, husband, caregiver 
He’s on 10 tablets a day anyway, for his various conditions, so pain killers are over 
and above... 
Denise, wife, caregiver 
Brenda: You don't like taking extra pills, as you've got enough to take as you say... 
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Mark: That's right... 
Brenda: He's got four boxes. So taking extra pills is a pain, isn't it really? (…) You got 
so frustrated with your pills, throw them all, threw the boxes, ‘I don't want any more 
bloody medication’ [imitating Mark] (…) so in terms of actually adding any more in... I 
don't know how much suffering you'd have to do for that to happen! We'd might have 
to look and see is there something we could lose? 
Mark (husband, person with dementia) and Brenda (wife, caregiver) 
Many people with dementia had numerous conditions, including but not limited to their 
dementia diagnosis and their painful conditions. The treatment burden of taking numerous 
daily medications increased reluctance to add additional analgesics into their already 
extensive medication regimen. The number of medications being taken by many people with 
dementia had reached maximum capacity, meaning that a medication must be removed 
before an analgesic could be added. For many people with dementia, their pain was not 
perceived sufficient to warrant an analgesic medication replacing a different medication. This 
again may highlight that pain is perceived as a lower priority compared to other health 
conditions requiring medication (see Section 8.4.1.1).  
In line with people with dementia and family caregivers, some GPs were also concerned 
about the number of comorbidities, and thus the amount of medications being taken by the 
person with dementia: 
Often these people in the community with dementia are older adults, with other 
comorbidities, and then it may be vascular dementia as well, so if- if they have a 
history of heart problems, or a history of stomach ulcers, or bleeds in the gut, or if 
they have vascular dementia, we want to avoid anti-inflammatories, because they're 
not safe for those groups...  
Jessica, GP 
Before prescribing analgesic medication, GPs considered the potential contraindications with 
comorbidities and other medications. This was especially important for older adults who may 
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have many morbidities, and thus taking many different medications. The concerns when 
prescribing analgesic medications was further intensified for people with dementia, who were 
perceived to have additional risk factors (i.e. people with vascular dementia) above and 
beyond ageing alone.  
9.4.2.3 Weighing up the concerns 
People with dementia, family caregivers, and GPs had many concerns related to analgesic 
medications, including side effects, illness burden, and treatment burden, each of which 
contributed to a reluctance for people with dementia to take analgesics. To minimise and 
assess concerns, many GPs titrated up the strength of the analgesic medication: 
What we want to do, is use the- is the minimum dose and minimum frequency that 
controls their pain, and it doesn't have to be completely gone, but sufficiently, that 
they're happy with that level of pain 
Chris, GP 
when it comes to prescribing it will be starting off at a very, very low dose, and then 
titrating, but slowly (…) because we know that there's more chance of side effects in 
patients with dementia 
Amy, GP 
First of all, paracetamol. Then you could consider moving up the analgesic ladder 
with caution really, because many of these patients... don't y'know don't tolerate, or 
they don't do well with opiates 
Tom, GP 
Upwards titration allowed GPs to identify the minimum possible analgesic medication that 
provided sufficient comfort for the person with dementia, while assessing for potential side 
effects. This process often meant that analgesic treatment started with paracetamol. Earlier 
in this theme, paracetamol was the preferred treatment option (due to its good safety profile). 
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However, many also noted that paracetamol was not always sufficient to provide adequate 
pain relief depending upon the severity of pain. In these circumstances, it was important for 
GPs to consider ‘moving up the analgesic ladder with caution’ even amid the many concerns. 
Therefore, when prescribing NSAIDs or opioids, GPs often weighed up their concerns 
associated with each medication: 
I think most things have an element of ‘well I've got to do something, and I hope it's 
going to be okay’ and it's really a risk benefit analysis that you make at that point 
really... and... the reality is, y'know if you're 88 and you're in pain, you have to do- you 
have to do something about that pain for the person, because even if it limits their life 
expectancy, or reduce- or reduces the life expectancy, you've still got to manage the 
pain. Sometimes you have to try these things… and say look, this is probably the best 
thing you can offer them, and there's still a risk associated with it, but shall we go for 
this, because we can't leave them like that... 
Lisa, GP 
you keep going until you feel you've got the best situation... y'know, because you 
don't want people- you've got to balance things up, a lot of medication we use for pain 
is quite... bad for the elderly in lots of ways, so... it's risk, benefit, harm, and all the 
rest of it 
Jenny, GP 
To identify the most suitable analgesic treatment, GPs weighed up and evaluated the pros 
and cons of each analgesic medication, in a ‘risk benefit analysis’. GPs often viewed it as 
their professional responsibility to identify a suitable medication to provide pain relief to the 
person with dementia. To fully evaluate the effect of the analgesic medication, GPs often 
attempted a trial: 
We would talk about the risks and benefits, and there's- it's not an absolute 
contraindication to give it to them, urm... so it's- it could be worth a small trial, but you 
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have to make clear that it does come with some possible side effects, and then just 
keep observing how they go, it can get difficult sometimes 
Muhammed, GP 
But again, the pharmacology is very, very challenging because you know compliance, 
side effects, tolerance, and drug interactions, and opiate sensitivity, and allergies etc. 
So the whole pharmacological management it's extremely challenging, it's often trial 
and error 
Tom, GP 
GPs avoided medications with an absolute contraindication, yet acknowledged that many 
analgesics have their own specific concerns that require consideration. A trial of analgesic 
medication allowed investigation to see if the advantages (potential pain relief) out-weighed 
the potential disadvantages (concerns such as side effects and interactions with other 
medications). This method allowed GPs to try to identify the ‘most appropriate’ analgesic 
medication which the patient found tolerable, whilst monitoring for side effects and other 
related concerns. Despite efforts to identify the ‘most appropriate’ analgesic, the many 
concerns associated with analgesics contributed to GPs’ sense of having ‘limited’ treatment 
options: 
So you really are... trying to tailor analgesia for somebody who's y'know... maybe got 
a million and one things that you can't give, and that can be really, you can be quite 
boxed in quite quickly 
Lisa, GP 
you go round and round and round (…) you're really, really limited y'know [what you] 
can you go on to... 
Alan, GP 
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The challenge of weighing up and determining the most suitable analgesic medication, 
among the ‘limited’ treatment options, may impede GPs’ confidence when prescribing 
analgesics to people with dementia: 
I think it's- it's [analgesic treatment] definitely much more challenging than in patients 
without dementia... urm... I think (…) so I’d say I’m less confident in- in managing 
patients with, ur... with pain and dementia then managing patients with pain in 
general... 
Ishann, GP 
Pain management is complex, in whatever field, but when you add complications like 
dementia into it, I think it becomes quite specialised, actually (…) I think their pain is 
often under treated because people are scared of making the situation worse 
Jenny, GP 
The multifactorial concerns inherent in analgesic medication were intensified by the presence 
of dementia. GPs suspected that concerns associated with analgesic medications 
contributed to the under treatment of pain for people with dementia, due to the fear of ‘doing 
more harm than good’. 
9.4.3 Responsibility of the caregiver to manage pain 
This theme captured the responsibility for family caregivers to manage analgesic medications 
and non-drug strategies for the pain experienced by the person with dementia in the 
community. Firstly, the role of family caregivers to prompt analgesic medication use was 
highlighted: 
I mean occasionally she'll ask for a pain killer, but, ur I'm offering her pain killers 
before she asks for them… I don't think she'd ever ask. Honestly don't think she'd 
ever ask. 
John, husband, caregiver 
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My mother wouldn't automatically reach for medication (…) she doesn't instinctively, 
like she used to, actually think how do I solve the problem? She can't solve the 
problem... She- she wouldn't know what to do, she wouldn't reach for the 
paracetamol, she wouldn't instinctively get the gel to put- put on her foot, five years 
ago that would have been a logical thing to do 
Brenda, daughter, caregiver 
If it's just a one off ‘oh’ [wince, pain noise] I tend to ignore that, but if he does it again, 
then I say have some paracetamol and then- sometimes I have to get up and get the 
paracetamol or the ibuprofen for him ‘cause he won’t, I have to make him take them... 
Michelle, wife, caregiver 
The person with dementia may have difficulty recognising or fulfilling their need for pain 
relief. Therefore, family caregivers were responsible to observe and determine if the person 
with dementia required pain relief, and if so, prompt the person with dementia to take 
analgesic medication. This was particularly highlighted by Michelle who vigilantly observed 
Steven to identify behaviours that may be indicative of pain (see 8.4.1.2).   
In accordance, GPs considered the benefits of family caregivers to prompt analgesic use for 
people with dementia in the community: 
they're not going to remember when they last took it (…) If they have someone to 
prompt to give them the medications, you would be a bit more reassured 
Amy, GP 
there's always that nagging feeling that (…) the medications that you've prescribed 
despite telling- discussing y'know it's still not done right, you can never be 100% sure, 
unless of course they've got a relative who's going to do whatever you've prescribed 
for them... in which case you're sort of onto a bit more of a winner. 
Chris, GP 
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So you have to sort of, give permission for the caregiver to take on that role almost, to 
initiate those things, and maybe say ‘do you want some paracetamol?’ ‘are you in 
pain?’ and sort of ask, rather than... ‘hasn't asked for any therefore doesn't need any’ 
Jenny, GP 
Most GPs reflected that analgesic medications may not be used as recommended. The 
memory of the person with dementia may impede their ability to remember to take regular 
analgesic medications. GPs identified the presence of a family caregiver as reassuring; 
relying upon family caregivers to proactively identify pain and prompt analgesic use in the 
community. In accordance with this, many GPs considered the care and support provided to 
the person with dementia when deciding upon the analgesic regimen:  
you'd have to think about delivery, because it's okay me saying you have two of these 
four times a day, but if there isn't going to be somebody there four times a day, 
there's no point, so you would see if you could give long acting drugs or... or skin 
y'know or... y'know... patches. you'd have to... tailor it, so if it was somebody who for 
example lived with their daughter, who responded well to two paracetamol twice a 
day or three times a day, you'd leave it to that, because if they live with them then 
they- they- they- they- can do it. 
Alan, GP 
The analgesic regimen was tailored depending upon the extent and regularity of support and 
care provided to the person with dementia in the community. Longer lasting analgesic 
preparations may be considered if the person with dementia had less input from caregivers. 
When tailoring an analgesic regimen based upon the extent and regularity of support from 
family caregivers, the responsibility of analgesic management shifts from the GP to the family 
caregiver in the community. GP’s reliance upon family caregivers was heightened when 
reflecting upon strong analgesic medication for people with dementia: 
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So it depends who they're with, who's going to be able to help them (…) say there's 
Oramorph [opioid analgesic medication] in the house, you've got to make damn sure 
there's someone there can administer it appropriately, who understands how much, 
how regularly, what to do if there's a problem, what to do if it's not working, etc, etc. 
So that can be difficult. 
Lisa, GP 
GPs reflected upon their role to ensure safe prescribing. GPs’ concerns relating to the 
prescription of strong analgesic medication (as discussed in Section 9.4.2) seemed to be 
amplified if a family caregiver (or other support) was not present to prompt correct analgesic 
use. To aid the administration and prompting of analgesic medication in the community, a 
number of family caregivers and GPs reflected positively upon compliance aids: 
It's a god send, it really is a god send [referring to the automatic pill dispenser]. 
Brenda, wife, caregiver 
People really like blister packs for that reason, because they almost feel that the 
responsibility is taken from them then, they're not the person who's going to have to 
dole it out, and get it wrong, potentially, and cause problems. So, for that reason 
really, I try to stick to stuff that can be blister packed, or managed in an acceptable 
way. 
Lisa, GP 
Family caregivers and GPs viewed compliance aids as beneficial to minimise the 
responsibility for family caregivers to manage analgesic medications for the person with 
dementia. In particular, compliance aids ensured that the correct medication was easily 
prompted by family caregivers. Although a structured analgesic regimen reduces the 
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responsibility for family caregivers to initiate treatment, this strategy minimises the flexibility 
of ‘as-required’ analgesic treatment: 
They may have these dosette boxes, they may be given medication by their carers, 
and then it becomes tricky, because you have to prescribe a given amount. It has to 
be x so many times a day (…) you can't say, well if you don't need them, then don't 
take them... (…) because then you sort of say, ‘oh well, you're the carer, you can tell 
when they're in pain’, and they say ‘well I'm not clinical, it's not my job’ 
Chris, GP 
Chris highlighted the shift of responsibility to the family caregiver to assess pain and 
determine when the person with dementia needed more or less analgesic medication. 
However, he continued to reflect upon family caregiver’s resistance to be responsible for 
analgesic administration. Responsibility for analgesic treatment may be burdensome for 
family caregivers, especially when they have no previous knowledge or experience in pain 
management. Despite the potential burden, some family caregivers also discussed their wish 
to be in control of analgesic medications:  
She's almost completely dependent upon me now... um... which- which is actually a bit 
of a relief to me, because she- she wouldn't let me do that, until relatively recently (...) 
we've had to be much more, what's the word? Over seeing... how she's dealing with 
her medications now... she generally allows me to do that now, which she resisted for a 
long, long time...  
Charles, husband, caregiver 
Despite resistance, Charles manages Linda’s (wife, person with dementia) medications. The 
potential risk of overdose was a pressing concern for Charles, as Linda had recently 
accidently overdosed on ‘some particularly nasty tablets’. The risks associated with analgesic 
medications in conjunction with the symptoms of dementia (i.e. memory problems leading to 
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incorrectly taking medications) means that despite the potential burden of pain management, 
family caregivers may be relieved to take responsibility of analgesic use.  
In addition to prompting analgesic medication in the community, GPs also relied upon family 
caregivers to monitor and feedback to the GP: 
So I would say that would be the- the biggest- the biggest problem, there's nobody to 
monitor it, and there's nobody to feedback to us, whether the patient is improving, if 
they're taking their medication, if they're not taking their medication, it's sort of, cast to 
the individual patient, which is a bit unfair, or y'know, falls to the relatives. 
Alan, GP 
Give safety netting advice to the carers so they can... contact us if they're concerned, 
if they're getting bad side effects from the treatment... 
 Jessica, GP 
GPs often relied upon family caregivers to monitor the effectiveness and potential side 
effects of analgesic treatment for the person with dementia. The responsibility placed upon 
family caregivers to manage analgesic medications for people with dementia was, again, 
perceived as burdensome or ‘unfair’, however, many GPs felt unable to adequately monitor 
analgesic medications themselves: 
it would be nice to follow up a lot more patients really, but we just don't have the 
capacity really (…) I suppose in an ideal world, we would follow up everyone and 
have the time to do that, but sometimes we don't... 
Chris, GP 
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the other big, big challenge is actually, the time to keep an eye on it... to monitor it... 
because other stuff will roll in, other acute things that take your eye off- you might 
want to go back and see Joe Blogs 10 days later, but you may not be able to... 
Lisa, GP 
The time-limited nature of primary care meant that GPs felt unable to follow up, or monitor 
analgesic medications prescribed to people with dementia. Therefore, the responsibility of 
pain management, including monitoring and feedback was shifted to the family caregivers in 
the community.  
In addition to managing analgesic use for the person with dementia, the family caregiver was 
often responsible to manage non-drug pain management strategies as often seen in Section 
9.4.1. 
Brenda: I got one of those heat- wheat bags… put it in the microwave, popped you 
back into bed and you put that on your cheek, and you found that was quite helpful 
Mark: Yea... That’s right. 
Brenda (wife, caregiver) and Mark (person with dementia) 
Michelle: it's really good... a bowl of water, put your feet in 
Steven: That again is something that would be offered, rather than I'd do myself  
Michelle: Yes, I'd suggest it, and I would say do it! It will help!  
Michelle (wife, caregiver), and Steven (person with dementia) 
Family caregivers were often proactive, prompting and encouraging the person with 
dementia to engage with various non-drug comfort strategies for their pain. Although many 
family caregivers did not express any burden when prompting non-drug strategies, some 
continued to highlight the impact of this responsibility: 
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But y'know, this is another example of her helplessness, it- she can't do it herself, 
therefore I have to do it for her (…) that's the nature of- of living with someone with 
dementia, they can't do anything... so your time is their time. 
John, husband, caregiver 
Earlier in this chapter, John discussed the importance of distraction to help his wife, Barbara 
(person with dementia) to cope with her pain (see Section 9.4.1). John perceived Barbara as 
unable to distract herself from her own pain (largely because of her limited mobility and 
impaired vision). The need to distract Barbara from her pain was perceived as an additional 
care burden. 
GPs relied upon family caregivers to take upon the responsibility of managing the pain 
experienced by the person with dementia using non-drug strategies (in addition to analgesic 
medication): 
Some of the sort of self-management problems can be a bit tricky, because they do 
need to be self-management, and if they've- you've got someone who's got sort of 
severe dementia then- then they don't remember to do that self-management. When 
you're- unless you've got a relative who's a carer, it makes it a bit more straight 
forward, because they can help to exercise, and they can prompt and all that sort of 
thing. 
Chris, GP 
The symptoms associated with dementia may act as a barrier to the self-management of 
pain using non-drug strategies (as discussed previously in Section 9.4.1). In the 
circumstance that the person with dementia was unable to manage their own pain, GPs 
viewed family caregivers as integral to prompt and encourage engagement with non-drug 
strategies. In addition, GPs perceived family caregivers to be reasonably accepting of such 
simple ‘at-home’ non-drug strategies: 
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heat packs, cold packs, if it's the right thing, y'know that sort of thing... and those are 
nice and safe aren't they, and easier? Easier to manage, and people are surprisingly 
willing to, caregivers I mean, really quite keen to try those things, maybe because it is 
less threatening than tablets, more easy to comprehend, and understand. 
Lisa, GP  
Non-drug strategies were viewed as a ‘safe’ and ‘easy’ alternative to analgesic medication. In 
fact, some GPs, alike to Lisa, gave the indication that family caregivers were keen to try non-
drug strategies, potentially highlighting the family caregiver’s proactive approach towards 
pain management for the person with dementia. This positive perspective towards non-drug 
strategies does however, somewhat contrast to the perspective of John, who reflected upon 
the burden of non-drug strategies to managing his wife’s pain, as discussed earlier in this 
theme. 
9.5 Summary of qualitative findings 
 A variety of pain management strategies were used by people with dementia, 
including analgesic and non-drug strategies.  
 Non-drug strategies commonly used by people with dementia included exercise and 
other simple at-home strategies (such as massage, comfort, relaxation, and 
distraction techniques). People with dementia, family caregivers, and GPs seemed to 
have a positive regard for these treatments.  
 A minority of people with dementia and family caregivers used or had tried other non-
drug treatments for pain, which were largely classified as ‘alternative or 
complementary therapies’ (e.g. acupuncture). Such treatments were supported by 
GPs, but often not recommended. Family caregivers and GPs were sceptical of their 
efficacy. GPs also had concerns surrounding the accessibility and the evidence-base 
supporting these treatments. 
 People with dementia, family caregivers, and GPs reflected upon their numerous 
concerns related to analgesic treatment for people with dementia, including potential 
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side effects, illness burden, and treatment burden. Each of these multifactorial 
concerns intensified the reluctance for people with dementia to use analgesic 
treatments. GPs often had the complex task of weighing up the need for pain relief 
against their numerous concerns to identify the ‘most suitable’ treatment option. 
 Family caregivers were often responsible to manage analgesic medication for 
community-dwelling people with dementia, with GPs relying upon the presence of a 
family caregiver to manage the analgesic medication regimen in the community. 
9.6 Conclusions 
This chapter investigated pain management strategies for people with dementia using 
qualitative and quantitative methods. Findings from the qualitative and quantitative data 
relating to pain management were provided separately in line with the convergent mixed 
methods design (see Section 5.4.2.1). The quantitative and qualitative findings from this 
chapter are narratively integrated in the following chapter (along with the quantitative and 
qualitative findings related to pain identification and assessment) to highlight inference, 
interpretation, convergence and divergence between the findings (Creswell & Plano Clark, 
2018). 
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10 Chapter Ten: Discussion 
10.1 Introduction  
This chapter begins by recapping the objectives of this thesis. A narrative discussion then 
follows, organised by the research objectives to provide an integrated summary of the 
quantitative and qualitative findings highlighting areas of convergence and divergence, all 
within the backdrop of the current published literature. The strengths and weaknesses of the 
mixed methods approach are also outlined. Finally, implications for practice, policy and future 
research are discussed.  
This research was guided by the overarching aim to understand pain identification, pain 
assessment, and pain management for community-dwelling people with dementia. 
Research objective 1: To investigate pain identification and pain assessment for 
community-dwelling people with dementia 
Research objective 2: To investigate the management of pain for community-dwelling 
people with dementia 
10.2 Summary of findings and comparison to previous literature 
In a convergent mixed methods research design, following initial separate analysis the 
quantitative and qualitative findings should be summarised independently (see Chapter Eight 
and Chapter Nine). Following the separate analysis, the quantitative and qualitative findings 
should be narratively discussed to highlight inferences, interpretations, convergent, and 
divergent findings (Creswell & Plano Clark, 2018). The following section provides an 
integrated summary of the key quantitative and qualitative findings organised by each 
research objective, with reflection upon published literature from the literature review (see 
Chapter Two), and the systematic review (see Chapter Three).  
10.2.1 Pain identification and assessment 
This section provides an integrated summary of the key quantitative and qualitative findings 
to meet the following research objective: 
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Research objective 1: To investigate pain identification and pain assessment for 
community-dwelling people with dementia 
Incidence of musculoskeletal consultation 
Quantitative analysis found that the person-time incidence rate (i.e. the first recorded record) 
of musculoskeletal consultation was consistently lower (i.e. less incidence) for people with 
dementia compared to older adults, in the five-year period from index date, and at each 
annual time period following index date. Furthermore, people with dementia had a greater 
mean time until the occurrence of incident musculoskeletal consultation, with a significantly 
lower rate of incident musculoskeletal consultation than older adults without dementia 
(adjusted HR 0.71, 95% CI 0.68 to 0.75). Considering attributable rate during the five-year 
period from index date, a high percentage (26.7%) of incident musculoskeletal consultations 
for the older adult cohort would not have been coded if they had dementia. Each of these 
findings suggest the rate of identified incident musculoskeletal consultation was significantly 
lower for people with dementia compared to older adults without dementia. Such findings 
indicate a reduced recording of musculoskeletal consultation for people with dementia 
compared to older adults without dementia. This may suggest that fewer incident 
musculoskeletal conditions were identified or assessed for people with dementia compared 
to older adults without dementia, especially as the time from index date increased.  
Research examining the incidence of pain for older adults is yet to be widely investigated 
(Shi et al., 2010), with a notable gap in the evidence examining the incidence of pain for 
people with dementia. Of the limited research to date, research found that the incidence of 
pain was 4.7 per 100-person years for older adults (Shi et al., 2010), with other studies 
indicating that the incidence ranged from 3.3% to 16% for older adults (Elliott et al., 2002; 
Thomas et al., 2007; Jordan et al., 2008; Magni et al., 1993). The incidence of pain found in 
this thesis sits at the higher end of this range (22.2 per 100-person years for older adults, 
and 16.3 per 100 person-years for people with dementia). The difference between previous 
findings, and the findings of this thesis may be due to the data collection method. To 
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exemplify, Shi et al. (2010) identified pain by asking survey participants: ‘are you frequently 
troubled by pain?’, this method may produce lower pain responses than direct primary care 
consultation records as used in this thesis as the question used by Shi et al considers not 
only presence of pain but also that it is frequent, and troubling to the person.    
Prevalence of musculoskeletal consultation 
The five-year prevalence of musculoskeletal consultation was 58.5% for people with 
dementia. Additionally, the annual prevalence of musculoskeletal consultation ranged from 
19.3% to 24.5% (depending upon the annual period after index date) for people with 
dementia. Previous cross-sectional research shows highly variable estimates in the point 
prevalence of pain for community-dwelling people with dementia (16.7% to 87.5%) (Jensen-
Dahm et al., 2012; Krulewitch et al., 2000; Barry et al., 2016; Shega et al., 2004; Mäntyselkä 
et al., 2004). The five-year prevalence of musculoskeletal consultation identified in this thesis 
is understandably towards the higher end of this range of point prevalence estimates due to 
the longer period of investigation. In nursing home settings, a systematic review found that 
the cross-sectional point prevalence of self-reported pain for people with dementia ranged 
from 15.0% to 42.6%, and staff ratings (observation or documentation in medical records) of 
pain ranged from 19.1% to 43.2% (Tan et al., 2015). Variation in the point prevalence 
estimates of pain reflect the different methods of identifying pain for people with dementia; 
using self-report, informant report, medical records, and behavioural observation tools. 
Additionally, the heterogeneous settings and sample characteristics are likely to contribute to 
the wide prevalence estimates (van Kooten, Smalbrugge, van der Wouden, Stek, & Hertogh, 
2017; Takai, Yamamoto-Mitani, Okamoto, Koyama, & Honda, 2010; Björkman, Sorva & 
Tilvis, 2008; Chen et al., 2010). Despite the variations within the literature on prevalence 
there is comparable support that this cohort is in accordance and reflective of the wider 
dementia population. In a more comparable study, Jørgensen et al. (2018) investigated 
medical records and determined the point prevalence of musculoskeletal conditions for 
people with dementia in nursing home settings as 22.4%. This is comparable to the annual 
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prevalence of musculoskeletal consultation found for people with dementia in this study 
(19.3% to 24.5%), again, providing support that the findings of this thesis reflect the wider 
literature.  
Although the five-year prevalence of musculoskeletal consultation was high for people with 
dementia, it was significantly lower than older adults without dementia (58.5% vs. 70.8%, 
respectively, adjusted OR 0.82, 95% CI 0.76 to 0.88). Additionally, the annual prevalence of 
musculoskeletal consultation was also significantly lower for people with dementia (19.3% to 
24.5%) than older adults without dementia (30.6% to 31.7%). To support these findings, 
previous meta-analysis by Tan et al. (2015) found that people with dementia had a 
significantly lower prevalence of self-reported and staff ratings of pain (observation or 
documentation in medical records) than people without dementia (OR 0.36, 95% CI 0.28 to 
0.45). Additionally, a number of studies have found that people with dementia may receive 
fewer pain and physical health assessments than older adults without dementia in nursing 
home settings (Nakashim et al., 2019; Jørgensen et al., 2018). Particularly, in line with the 
findings of this thesis, Jørgensen et al. (2018) found that the point prevalence of potentially 
painful musculoskeletal conditions was lower for people with dementia than older adults 
without dementia (22.4% vs. 29.8%, respectively). The findings from this thesis, along with 
evidence from the previous literature suggests a lower recording of musculoskeletal 
consultations, potentially indicating a lower identification and assessment of (potentially 
painful) musculoskeletal conditions for people with dementia.  
Contradictory evidence has also been identified. In a similar study design, Hoffman et al. 
(2014) using health insurance claims data, found people with and without dementia had a 
similar prevalence of pain diagnosis during the first year after their incident dementia 
diagnosis (74.4% vs. 72.5%, respectively; p=0.11). This study included a number of painful 
conditions (in addition to musculoskeletal consultations) potentially explaining the heightened 
prevalence estimates compared to this thesis. This study by Hoffman et al. only examined 
Chapter Ten: Discussion 
 
 
343 
 
pain during the first year following dementia diagnosis and therefore cannot conclude if 
dementia progression reduced identification and assessment of pain.  
When examining musculoskeletal consultation trends over time, the results of this thesis also 
show that the annual prevalence and odds incrementally lowered from the first year to the 
final year of follow up for people with dementia (24.5% to 19.5%, respectively). In contrast 
the annual prevalence of musculoskeletal consultation remained consistent over time for 
older adults without dementia. These findings suggest that the rate of potential identification 
and assessment of musculoskeletal conditions lowered as the time from dementia diagnosis 
(index date) increased for people with dementia. Similar findings were also highlighted in 
previous literature, with both Reynolds et al. (2008) and Jørgensen et al. (2018) finding that 
the identification of pain and potentially painful conditions lowered in line with increasing 
cognitive impairment.  
10.2.1.1 Gathering information to identify pain 
The qualitative findings provide a greater understanding and interpretation to the quantitative 
findings outlined above. Family caregivers and GPs used multiple pain identification and 
assessment strategies, including self-report, family caregiver report, and observation of 
changes in presentation (behavioural, psychological, and physical), in line with 
recommendations (Herr et al., 2011; Horgas & Miller, 2008; Schofield; 2018).  
Many GPs, however, continued to perceive the presence of dementia as intensifying the 
challenge of pain identification and assessment. With many perceiving pain identification as 
a ‘process of elimination’. This finding is reflected in previous qualitative literature, in which 
nurses perceived pain assessment as a ‘complex process’ (Monroe et al., 2015; Kovach et 
al., 2000) that may lead to pain being inadequately identified, assessed, and treated 
(Kaasalainen et al., 2007). In accordance with these findings, the vast majority of nursing 
home managers (Barry et al., 2012), nurses (Burns & McIlfatrick, 2015b), and GPs (Jennings 
et al., 2018b) agreed that the presence of dementia can make pain assessment difficult 
(91.7%, 91%, 98%, respectively). The perceived complexity of pain identification and 
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assessment for people with dementia, as found in the qualitative findings, may provide 
potential explanation as to why people with dementia had a lower incidence and prevalence 
of musculoskeletal consultation (especially as time from index date increased) compared to 
older adults without dementia, as found in the quantitative findings. 
It is also important to acknowledge divergent findings. Although the majority of GPs 
perceived pain identification and assessment as complex and inadequate for people with 
dementia, a minority of GPs were confident that by employing multiple pain identification and 
assessment strategies (along with common sense and experience) an accurate assessment 
of pain could be determined. This finding diverges from the quantitative findings, as if an 
accurate assessment was achieved, it would be expected the incidence and prevalence of 
musculoskeletal consultation was similar for older adults with and without dementia. Such 
discordance cannot be explained by healthy cohort bias, as the dementia cohort and older 
adult cohort remained stable over follow up concerning their baseline characteristics.  
10.2.1.1.1 Disentangling the self-report of pain 
Communication difficulties 
This study found that family caregivers and healthcare professionals perceived self-reported 
pain as an important method of pain identification for people with dementia. However, as 
communication ability decreased, self-report became increasingly difficult. In previous 
literature using focus groups, nursing home staff and family caregivers perceived self-report 
as the ‘most meaningful assessment route’ for people with dementia (Corbett et al., 2016). 
The challenge of communication has, however, been well documented in the literature. A 
meta-ethnography of qualitative evidence exploring pain assessment for people with 
dementia found that reduced or altered verbal communication was a barrier to pain 
assessment and treatment for people with dementia (Geddis-Regan et al., 2018). 
Additionally, research has found that the percentage of people with dementia able to self-
report pain or use a self-report measure reduces as the severity of dementia increases 
(Closs et al., 2004; Kunz et al., 2007; 2009; Lukas et al., 2013a). These findings were 
Chapter Ten: Discussion 
 
 
345 
 
concordant with the systematic review (see Chapter Three) suggesting that a large 
proportion of those who have moderate-to-severe dementia were unable to complete a self‐
report pain instrument. The challenge of self-report throughout the progression of dementia 
was reiterated as many healthcare professionals believed that ‘a person with dementia is not 
able to accurately provide a self-report of their pain’ (Jenning et al., 2018; Barry et al., 2012; 
Burns & McIlfatrick, 2015b). The challenge of self-report with increased cognitive impairment, 
provided further explanation to the lower musculoskeletal consultation for people with 
dementia compared to older adults, especially as time from index date increased, as 
reported in this thesis. 
Self-report reflecting the pain experience 
In the qualitative findings, most family caregivers and GPs did not doubt or question the self-
report of the person with dementia. This finding is concordant with pain assessment 
guidelines emphasising that self-report remains the most reliable and accurate pain 
assessment method for people with dementia (Herr et al., 2011; Schofield, 2018). In previous 
qualitative research, nurses illuminated the importance of trusting the person with dementia’s 
self-report of pain (Karlsson et al., 2014).  
Discordant to these findings, this thesis found that some family caregivers questioned the 
intentions of their relative with dementia’s self-reported pain. The disclosure of pain was 
viewed as a means for the person with dementia to avoid activities that they did not want to 
do; and therefore the motives behind self-reported pain were questioned. Additionally, a 
number of GPs questioned the extent that self-reported pain reflected the pain experienced 
by the person with dementia, further highlighting the complexity of interpretation of self-
report. Previous qualitative research found that some family caregivers perceived the person 
with dementia’s pain report as ‘dramatic’ as a means of gaining attention (Mentes et al., 
2004), with family caregivers and nurses concerned that a person with severe dementia 
would be unable to provide an ‘accurate and reliable’ response to self-report questions 
(Martin et al., 2005). The challenge of disentangling the potentially ‘unreliable’ self-report of 
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pain was demonstrated by family caregivers of people with dementia in hospice settings, as 
they reflected upon the difficulty of differentiating between ‘real’ and ‘imagined’ pain due to 
communication barriers (Tarter et al., 2016).  
When determining the extent that the self-report of pain reflected the pain experience, the 
findings of this thesis found consistency to be an important factor. Three main sources of 
inconsistency were identified; inconsistency between self-report ratings over time, 
inconsistency between the self-report and the family caregiver report; and inconsistency 
between the self-report and the GP’s clinical judgement. The importance of consistency has 
not been explicitly identified in previous qualitative research. However, qualitative interviews 
with healthcare professionals in a hospital setting suggest that multiple pain assessments 
should be used to support or refute the self-reported pain (Dowding et al., 2016). These 
findings highlight the need to gather consistent information to support the self-report provided 
by the person with dementia, without a reliance upon self-report in isolation (McAuliffe et al., 
2009).  
The challenge of disentangling a self-report from the person with dementia provides clear 
interpretation to the quantitative findings that indicate people with dementia have a 
consistently lower incidence and prevalence of musculoskeletal consultation than older 
adults without dementia. Additionally, obtaining and disentangling a self-report was found 
increasingly challenging with the progression of dementia (due to various inconsistencies) 
and this does link as a potential explanation for the lowering prevalence of musculoskeletal 
consultation as the time from dementia diagnosis increases (and thus it is assumed as 
dementia progresses). Although it is acknowledged that with medical record data alone there 
is no way of knowing what was actually discussed in the consultation, or the severity of 
dementia at the time of the consultation, or indeed if a family caregiver was present. 
Stoical attitude towards pain 
An additional consideration when disentangling the self-reported pain of people with 
dementia is their often reported acceptance of pain, and consequently their stoical attitude 
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towards their pain experience. This meant that the person with dementia often ignored or 
‘shrugged off’ their pain. Family caregivers and healthcare professionals perceived the 
stoical attitude held by people with dementia as impeding self-reported pain, and acting as a 
barrier to accurate pain identification. A stoical attitude towards pain may make it difficult to 
interpret if the self-report of pain reflects the pain experience. Previous qualitative research 
reflecting upon people with dementia living in nursing home settings found that family 
members of people with dementia (Mentes et al., 2004; Martin et al., 2005), older adults, and 
healthcare professionals (Martin et al., 2005) perceived stoicism as a barrier to pain 
identification and assessment, with people with dementia denying or minimising their pain 
experience. Whilst the qualitative findings have highlighted acceptance of pain as an 
important concept, the broader literature suggests this would be a uniform concept for older 
adults and not necessarily specific to dementia. Certainly, research suggests that older 
adults may hold attitudes, beliefs and expectations about pain, with stoicism reducing pain 
reporting for older adults, which may in turn delay identification, diagnosis, and treatment 
(AGS Panel, 2002; Blomqvist & Hallberg, 2001; McDonald, 2009; Cornally & McCarthy, 
2011; Schofield & Abdulla, 2018; Gammons & Caswell, 2014). This broader literature 
suggests that the acceptance of pain is not specific to dementia and therefore not a likely 
explanation for the differences reported in the quantitative findings. Regardless, the attitudes 
held by older adults are important for people with dementia whom often receive care from 
their older adult relative in the community. The attitudes held by an older adult caregiver may 
reduce the identification, assessment, and treatment of pain for the person with dementia. 
When exploring the acceptance of pain for people with dementia, the qualitative findings 
suggested that the many competing conditions taking priority might be one influential factor. 
In other words, pain may be relegated as ‘a lower priority problem’. In line with this finding, 
this thesis also found that people with dementia and family caregivers also perceived pain 
experienced by the person with dementia to be a lower priority concern for healthcare 
professionals. Previous qualitative research by Sale et al. (2006) found that older adults’ 
perceived non-pain related conditions as being more serious than pain. Therefore, Sale et al. 
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found that painful conditions were accepted because they were tolerable, and not life 
threatening. Research conducted by Bedson, Kadam, Muller and Peat (2011) found that 
consultations for musculoskeletal knee problems by older adults (50+ years) were preceded 
by a three-month period of fewer consultations for other persistent comorbid conditions. 
These findings suggest that older adults consulted for their knee problem when other 
comorbid conditions were no longer a priority. This literature suggests that older adults may 
view pain as a lower priority condition, thus the findings may not be specific to people with 
dementia. That said, clearly the defined cohort with dementia used within the quantitative 
analysis do have what may be interpreted as a ‘priority’ condition and this may give further 
explanation for the differences reported. These findings continue to raise an important issue 
about healthcare professionals being mindful of considering the wider health of the person 
with dementia when consulting. 
In the context of this thesis, the acceptance of pain and ultimately the stoical attitude towards 
pain has been framed as a negative attitude (or barrier) due to entanglement with self-
reported pain. Alternative research has however reflected upon the positives of accepting 
pain (Molton & Terrill, 2014). Older adults with stoical attitudes had lower levels of affective 
distress relative to their pain levels (Cook & Chastain, 2001), with stoicism being perceived 
as a means for older adults to exert control over their pain, which is considered a positive 
coping mechanism (Gammons & Caswell, 2014).  
10.2.1.1.2 Observing changes  
Family caregivers and healthcare professionals relied upon observation as a key strategy to 
identify and assess pain, especially when the person with dementia did not, or could not 
provide a self-report of their pain. These findings were reflected in a recent meta-
ethnography of the qualitative evidence into pain assessment for people with dementia, in 
which non-verbal approaches were used to ‘build a picture’ of the potential pain experience 
(Geddis‐Regan et al., 2018). The importance of non-verbal pain assessment was reiterated 
in questionnaire research, where the majority of GPs (Jenning et al., 2018) and community 
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pharmacists (Barry et al., 2013) agreed that observing behavioural and physiological 
indicators of pain are important when assessing pain in a person with dementia. These 
findings reflect UK national pain assessment guidelines for older adults (with a focus on 
cognitive impairment) that recognise behaviour, facial expressions, and changes in normal 
functioning as useful indicators that the person with dementia may be experiencing pain 
(Schofield, 2018). 
When observing behavioural and psychological changes in a person with dementia, GPs 
discussed difficulty determining what was causing the presentation, especially if the 
behaviour was non-specific (e.g. a loss of appetite). GPs and old age psychiatrists were 
therefore concerned that pain was inadequately recognised as a driver of behavioural and 
psychological symptoms of dementia (BPSD). The difficulty of determining the cause of 
behavioural and psychological changes, along with the label of ‘dementia’ may mean that 
healthcare professionals do not look beyond the condition to explore why the person with 
dementia may be behaving differently. Such findings may suggest that behavioural and 
psychological changes continue to be attributed as a direct symptom of dementia. GPs and 
psychiatrists were concerned that changes in presentation may be inappropriately referred to 
secondary care rather than pain treatment being initiated in primary care. In accordance with 
the findings of this thesis, a literature review (McAuliffe et al., 2008), and previous qualitative 
findings (Martin et al., 2005; Gilmore-Bykovskyi & Bowers, 2013; Jennings et al., 2017) 
highlighted the difficulty of determining the reason for behavioural and psychological changes 
for people with dementia. Again, alike to this thesis, previous literature suspected that the 
difficulty may arise as behavioural and psychological changes are not a specific indication of 
pain (Zwakhalen et al., 2018), and may indicate many other pathologies (e.g. urinary tract 
infection or constipation), or a symptom of dementia itself (i.e. linked to neurobiological 
pathways due to neurodegeneration from disease; Proitsi et al., 2011; Liperoti, Pedone & 
Corsonello, 2008). The challenge of determining the driver of the observed presentation may 
lead to inadequate pain identification and assessment (Jennings et al., 2017). These 
qualitative findings, therefore, may provide further explanation to the lowering incidence and 
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prevalence of musculoskeletal consultation for people with dementia, especially as the time 
from dementia diagnosis increased, as the misattribution of behavioural and psychological 
changes are more likely in the advanced stages of dementia. Alternatively, BPSD may take 
‘clinical dominance’ in a consultation, meaning that the behavioural and psychological 
symptoms are coded by the GP, with musculoskeletal codes, again relegated as a ‘lower 
priority condition’ (Jørgensen et al., 2018). 
In addition to the observation of behavioural and psychological changes, family caregivers 
and GPs also observed physical changes and used physical examination to identify and 
assess pain for people with dementia. In particular, family caregivers and GPs reflected upon 
the importance of family caregivers providing close care (e.g. dressing, bathing, going to the 
toilet) to identify physical changes for the person with dementia. In accordance with these 
findings, in recent questionnaire studies, the majority of GPs (Jennings et al., 2018b) and 
nurses (Burns & McIlfatrick, 2015b) agreed that physiological indicators of pain (e.g. heart 
rate, blood pressure, temperature) were an important aspect of pain assessment for people 
with dementia. The importance of personal care by the family caregiver has not been 
explored in previous literature, however interviews with nursing assistants reflect upon the 
usefulness of physical examination during daily care tasks to identify physical changes that 
may be indicative of pain (Karlsson et al., 2012; De Witt Jansen et al., 2017a).  
Although physical examination was beneficial to gather information about the potential pain 
experienced by a person with dementia, some GPs in this thesis reflected upon the difficulty 
of examination. The time-limited nature of primary care consultations intensified the 
challenge of persuading and encouraging the person with dementia to be comfortable and 
happy to be physically examined, in line with previous qualitative findings (Chang et al., 
2009) which reflected upon the ‘lack of co-operation’ with the examination. This thesis is the 
first to qualitatively focus upon GPs’ perspective of pain identification and assessment for 
people with dementia in primary care, which gives a uniqueness to this context (e.g. 
pressures of primary care with time-limited consultations) that are not explored in previous 
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literature. The challenge of observing physical changes for people with dementia, especially 
in the absence of a family caregiver providing close care, and the difficulty of physical 
examination (especially in the absence of self-report) may further explain the lower incidence 
and prevalence rates of musculoskeletal consultation for people with dementia compared to 
older adults; especially as the time from dementia diagnosis (or index date) increased based 
on the assumption of dementia progression over time.  
10.2.1.2 The importance of familiarity  
Familiarity with the person with dementia was an important factor when identifying and 
assessing pain. Family caregivers were close family members (spouse or child) of the person 
with dementia. The family caregiver often lived with the person with dementia, and had 
known them for many years before the onset of dementia. The in-depth knowledge of the 
person with dementia, along with the available time to observe the person with dementia 
(compared to the time-restricted observation period of the GP) allowed the family caregiver 
to have a greater insight into their pain history, and the ability to identify subtle changes in 
presentation. The benefits of familiarity or ‘knowing the person’ for pain identification and 
assessment for people with dementia has been identified in previous studies, especially 
when the person with dementia is no longer able to verbally articulate their pain (Corbett et 
al., 2016; Geddis-Regan et al., 2018). Familiarity with the person with dementia allows for the 
identification of unusual or ‘out of character’ behaviour that may go unnoticed if the person’s 
usual behaviour is unknown (Kovach et al., 2000; Liu, 2014; Mentes et al., 2004).  
In contrast, healthcare professionals (both GPs and psychiatrists) often felt unfamiliar with 
the person with dementia, hindering their ability to have an in-depth knowledge of the 
patient’s history or to identify subtle changes in presentation. In an attempt to overcome the 
lack of knowledge resulting from poor continuity, healthcare professionals relied upon family 
caregivers as a surrogate familiarity (and other markers of pain identification; including 
medical records, examination); to provide history, report their observations, and to guide 
examinations. This thesis provided the first qualitative exploration of pain identification and 
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assessment for people with dementia from the perspective of GPs in primary care and from 
psychiatrists involved in dementia services. However, previous literature has explored the 
importance of family caregivers to aid the identification and assessment of pain using 
quantitative methods, and alternative healthcare professionals. The majority of GPs 
(Jennings et al., 2018), community pharmacists (Barry et al., 2013), and nurses (Burns & 
McIlfatrick, 2015b) agreed that when assessing pain for people with dementia it was 
important to consider the family perspective. These studies were questionnaire-based, and 
therefore did not provide further exploration into the importance of family caregivers. 
However, Monroe et al. (2015) found that nurses were concerned that people with dementia 
who were not well known by staff would have their pain inadequately identified, assessed, 
and consequently treated. To clarify the presence of pain, nurses communicated with family 
members to gain a greater insight into the pain history or changed behaviour of the person 
with dementia (Monroe et al., 2015). Similarly, in hospital settings, family caregivers acted as 
‘messengers on behalf of the patient’; aiding interpretation of pain cues due to their 
knowledge of the person with dementia (Lichtner et al., 2016, p. 7). The findings of this thesis 
supported by previous research reiterate the importance of familiarity and the potential under 
identification of pain if the healthcare professional does not have relationship continuity with 
the person with dementia. The under identification may be further intensified if the family 
caregiver was not present to act as a surrogate familiarity; potentially explaining the lower 
incidence and prevalence rates of musculoskeletal consultation for people with dementia 
compared to older adults without dementia, as found in the quantitative findings.  
10.2.1.3 The use of pain assessment tools  
Some family caregivers reflected upon the challenge of providing an informant pain report on 
behalf of the person with dementia; with the IPT scores often highlighting a discrepancy 
between people with dementia and their family caregiver report of pain (see Table 7.7). 
These findings are concordant with the findings of the systematic review (see Chapter Three) 
that found a discrepancy between self and informant reports of pain for community-dwelling 
people with dementia. Evidence outside of community-dwelling people with dementia also 
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highlighted the challenge of providing an informant report of pain that reflects the self-report 
of pain (Ruben, Blanch-Hartigan & Shipherd, 2018), with the challenge increasing in line with 
the severity of dementia (Hemmingsson et al., 2017; Santos & Castanho, 2014). 
Most GPs reflected upon the importance of self-report, suggesting that this was often their 
first method to investigate pain for people with dementia, however, GPs tended not to use 
standardised pain assessment tools to obtain the pain report, with only a small number of 
GPs reflecting upon a 1 to 10 numerical pain scale. GPs questioned the appropriateness of 
pain assessment tools for people with dementia despite the current UK national pain 
assessment guidelines suggesting that there are a number of valid and reliable self-report 
measures suitable for use with people with mild-to-moderate dementia (Schofield, 2018). In 
previous qualitative studies, observations and interviews were conducted in a hospital 
setting, and alike to the findings of this thesis, many healthcare professionals were cautious 
and did not trust pain assessment scores (Lichtner, Dowding & Closs, 2015; Dowding et al., 
2016). Discordant to these findings, Li et al. (2015) found that pain assessment tools were 
documented in the medical record of 98% of community-dwelling people with dementia, 94% 
of which were standardised self-report pain assessment scales, such as the numerical rating 
scale. However, people with dementia in the Li et al. study were included if they had mild-to-
moderate dementia, and a positive pain screen (by self-report and caregiver’s confirmation). 
These factors (especially the positive pain screen) may have significantly increased the 
likelihood of pain being assessed using a self-report pain assessment tool within a 
healthcare setting.  
Earlier in this chapter, healthcare professionals perceived behavioural changes to be 
inadequately recognised as a symptom of pain (see Section 10.2.1.1.2). This is aligned with 
the finding that most GPs were unaware of dementia-specific behavioural observation pain 
tools. These findings were supported by a previous study in which only 10% of GPs reported 
knowledge of their existence (Jennings et al., 2018b). Similarly, only 2% of pain assessments 
in outpatient medical records were ‘appropriately modified’ (e.g. measured behavioural 
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characteristics) for community-dwelling people with dementia (Li et al., 2015), with similar 
findings in nursing home settings (Allcock, McGarry & Elkan, 2002). However, as discussed 
in the systematic review (see Section 3.5.3), the study by Li et al. (2015) only recruited 
people with mild-to-moderate dementia, in which behavioural observation may not be 
necessary due to the ability to provide a self-report of pain (Schofield, 2018). In previous 
qualitative interviews, nurses and formal caregivers in nursing homes (Tordoff et al., 2017) 
and hospital settings (Lichtner et al., 2015; Harmon et al., 2019) had previously used 
behavioural observation tools for pain, however they reflected that no tool was commonly 
used in this context. The lack of adoption of a behavioural pain assessment tool in practice 
may reflect evidence that there is no one behavioural observation tool more reliable or valid 
than the others (Lichtner et al., 2014), with a clear lack of examination in community-dwelling 
or primary care settings (see Chapter Three).  
In contrast to GPs, in this current study, most psychiatrists were aware of behavioural 
observation pain assessment tools, however similarly to GPs, psychiatrists continued to 
prefer a holistic approach; using alternative markers to identify and assess pain (e.g. medical 
history, caregiver reports, examination), in addition to their clinical experience and 
judgement. In accordance with these findings, research found that behavioural observation 
pain tools were perceived to ‘add no value’ for people with advanced dementia (Tordoff et al., 
2017; Lichtner, Dowding & Closs, 2015; De Witt Jansen et al., 2018). Alternatively, alike to 
the findings of this thesis, healthcare professionals perceived a holistic assessment of pain 
(including examination, collateral history, medical records) as more thorough (De Witt Jansen 
et al., 2018). The limited use of adequately validated pain assessment tools may impede 
optimal pain identification and assessment for people with dementia especially where the 
condition and symptom severity has progressed (McAuliffe et al., 2008). Therefore, these 
qualitative findings may again contribute understanding to the quantitative findings; 
highlighting another potential reason why the incidence and prevalence of musculoskeletal 
consultation was lower for people with dementia compared to older adults without dementia, 
especially over time throughout follow up, based upon the assumption of increasing severity.  
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10.2.2 Management of pain 
This section provides an integrated summary of the key quantitative and qualitative findings 
to meet the following research objective, whilst reflecting upon the previous literature: 
Research objective 2: To investigate the management of pain for community-dwelling 
people with dementia 
Quantitative findings indicated that the five-year prevalence of analgesic prescription for 
people with dementia was 49%, with an annual prevalence ranging from 21.1% to 15.7% 
(depending on the annual period following index date). The systematic review as part of this 
thesis (see Chapter Three) suggests that the prevalence of analgesic prescription ranged 
from 25% to 63% for community-dwelling people with dementia. The majority of the studies 
included in the systematic review were cross-sectional, providing a point prevalence of 
analgesic use for people with dementia. However, two studies provided a 180-day period 
prevalence of 34.9% (Hamina et al., 2016), and a four-year period prevalence of 26% for 
analgesic use for people with dementia (Gallini et al., 2013). Findings from the systematic 
review (see Chapter Three) are comparable to the findings of the prevalence investigation, 
especially those investigating period prevalence of analgesic prescription (Hamina et al., 
2016; Gallini et al., 2013). Similarly, a systematic review of cross-sectional evidence shows 
that the point prevalence of analgesic prescription for people with dementia in nursing home 
settings ranges from 20.2% to 61.2% (Tan et al., 2015). The prevalence rates identified in 
this thesis broadly reflect the prevalence of analgesic prescriptions in previous studies, both 
within the community, and nursing home settings.  
The quantitative findings of this thesis also found that during the five-year period from index 
date, the prevalence of analgesic prescription was 11% lower for people with dementia 
compared to older adults without dementia (49% vs. 60%, respectively). Conditional logistic 
regression testing showed this difference as a significantly lower odds of analgesic 
prescription for people with dementia (adjusted OR 0.82, 95% CI 0.76 to 0.88). This 
investigation included analgesic prescriptions matched to a musculoskeletal consultation. 
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However, in a sensitivity analysis all analgesic prescriptions were included (irrespective of 
matching). This analysis found minimal difference between the five-year prevalence for 
people with and without dementia (76.7% vs. 79%, respectively, adjusted OR 0.97, 95% CI 
0.91 to 1.03). It is important to recognise that although the prevalence rates were similar, the 
prevalence of ‘any analgesic prescription’ was largely influenced by the high and similar 
prevalence of basic analgesic prescription for people with and without dementia (see Section 
10.2.2.3.1.1). Previous literature within community samples (see systematic review in 
Section 3.5.4.1) show a mixed trend, with community-dwelling people with dementia having a 
lower (Mäntyselkä et al., 2004), similar (Hamina et al., 2016), and greater (Haasum et al., 
2011) prevalence of analgesic medication use compared to community-dwelling older adults 
without dementia. The most comparable study to this thesis was by Hamina et al. (2016) who 
examined the period prevalence of analgesic prescription during the first 180-days after 
dementia diagnosis using medical record data. The findings by Hamina et al. reflect the 
sensitivity analysis in this thesis that also found no difference between people with dementia 
and older adults without dementia during the first annual period after index date. Importantly 
however, each of these studies only reported crude prevalence rates for people with and 
without dementia, and did not adjust for potential confounders when examining the 
association between cohort status and analgesic use or prescription. The findings of this 
thesis therefore contribute to the minimal evidence to date comparing the prevalence of 
analgesic medication for people with dementia to older adults without dementia, yet with the 
added robustness of multivariable adjustment and numerous sensitivity analyses.  
In nursing home settings where the evidence is more established, a systematic review and 
meta-analysis revealed that residents with dementia had a significantly lower analgesic 
prevalence compared to residents without dementia (OR 0.58, 95% CI 0.41 to 0.82) (Tan et 
al., 2015). These findings support the main quantitative findings of this thesis suggesting that 
people with dementia have a lower prevalence, and a significantly lower odds of analgesic 
medication than older adults without dementia (yet discordant to the unmatched analgesic 
sensitivity analysis). The similar findings of the review by Tan et al. and this thesis question 
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the potential concern that people with dementia living in nursing homes may be incorrectly 
misclassified to the main analysis, despite wishing to only examine analgesic prescriptions 
for community-dwelling people with dementia (see Section 10.4.2.2). However, additional 
‘strict’ community sensitivity analysis found comparable findings to the main analysis, 
minimising these concerns.   
Importantly, the main analysis and sensitivity analyses found that there was a discrepancy 
between the annual prevalence of analgesic prescription for people with dementia and older 
adults, as the time from dementia diagnosis (index date) increased. Conditional logistic 
regression confirmed these trends showing the odds of analgesic prescription lowered for 
people with dementia compared to older adults without dementia as the time from index date 
increased. Previous literature examining analgesic prescription throughout the progression of 
dementia is limited. Gilmartin et al. (2015) found that the prevalence of analgesic use 
remained relatively consistent at each annual time point from baseline (0 to 5 months after 
dementia diagnosis) to the fifth year of follow up (13.6%, 10.6%, 13.7%, 16.8%, 15.3%, 
respectively). These findings, whilst similar in prevalence rates, are discordant to the findings 
of this thesis in terms of the trend over time. Several differences between the study by 
Gilmartin et al. and this thesis may explain the discordant results. In the study by Gilmartin et 
al. all analgesic medications ‘still in use’ were recorded in an interview with the family 
caregiver. Therefore, the Gilmartin et al. study included prescription and over-the-counter 
medications, whereas the investigation of this thesis only included prescribed analgesics. It 
may be that as time from diagnosis increases there is less consultation activity and therefore 
less chance of prescription, however, the person with dementia and/or their family caregivers 
may compensate by increasing over-the-counter medication. Additionally, the study by 
Gilmartin et al. only included a limited sample (n=236) of people with dementia at baseline, 
lowering to n=73 at five year follow up. Attrition was lower in the study by Gilmartin et al. due 
to the additional exclusion criteria in this thesis throughout follow up (such as cancer 
diagnosis, patient leaving general practice, general practice no longer contributing to CPRD) 
(69% vs. 89% attrition over 5 years, respectively). Despite the lower attrition rate, the small 
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sample in the fifth year of follow up for Gilmartin et al. may lead to less reliable prevalence 
estimates as compared to the large samples utilised within this thesis. As stated previously, 
research on prescription of analgesic medication over time is limited. However, other studies 
have shown that the prevalence of analgesic prescription incrementally lowered with a 
reduction in MMSE score (Neumann-Podczaska et al., 2016; Cornali et al., 2006) and this 
may be reflective of the results presented in this thesis if we are to accept the assertion that 
cognitive ability lowers over time from diagnosis for people with dementia. 
Despite these complementary findings, research examining the temporal trend of analgesic 
prescription rates for people with dementia highlight discordance. In Norwegian nursing 
homes, Sandvik et al. (2016) found that people with dementia had a lower prevalence of 
analgesic prescription compared to nursing home residents without dementia at three cross-
sectional time points (2000, 2004, and 2009), however there was no difference in analgesic 
prescription in 2011. These findings suggest a cohort effect in analgesic prescribing; a shift 
towards equal prescribing rates of analgesic medication for people with and without dementia 
in more recent years. However, this study by Sandvik et al. did not include the same 
participants at each time point, with significant demographic differences across the four 
cohorts. The main findings and sensitivity analyses in this thesis continued to find a 
discrepancy between the prevalence of analgesic prescription between people with dementia 
and older adults without dementia as the time from index date increased, even when each 
model was adjusted for potential cohort effects (the model was adjusted for the calendar year 
of index date). The discordance between the findings of this thesis and the study by Sandvik 
et al. may represent prescribing differences for people with dementia living in nursing homes 
compared to the community or prescribing differences between Norwegian and UK 
healthcare systems.  
10.2.2.1 Pain identification and pain assessment 
It is important to acknowledge that adequate pain identification and pain assessment is a 
prerequisite for optimal pain treatment (Schofield, 2018). Therefore, the challenges 
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associated with pain identification and pain assessment for people with dementia, as already 
discussed (see Section 10.2.1) may explain the lower prevalence of analgesic prescription 
compared to older adults without dementia.  
Communication difficulties were recognised by family caregivers and GPs as a barrier to self-
report (see Section 10.2.1.1.1). Additionally, communication difficulties limit the person with 
dementia’s ability to express their need for pain relief (Corbett et al., 2016). The lack of 
expression for pain relief may be interpreted by family caregivers as a stoical or reticent 
approach to pain. Research has found that of nursing home residents with an MMSE of ≤17, 
residents who were classified as ‘verbal’ had a higher prevalence of analgesic prescription 
compared to residents that were classified as ‘non-verbal’ (Bauer et al., 2016). This finding 
may demonstrate how communication ability may impede optimal analgesic treatment for 
people with dementia. 
Results also show a stoical attitude towards pain was perceived to impede pain identification 
and pain assessment for people with dementia (see Section 10.2.1.1.1). A stoical attitude 
towards pain was also a factor potentially implicating analgesic use, and accessing 
healthcare. This finding has also been recognised in previous research for people with 
dementia living in nursing homes, with stoicism being a key barrier to the administration of 
analgesic medication (Peisah et al., 2014). Earlier in this chapter, the qualitative research by 
Sale et al. was discussed; in which older adults accepted their painful conditions as 
‘tolerable’ and ‘not life threatening’. Such perceptions not only impeded pain identification, 
but also had negative implications for analgesic medication execution and persistence 
because other ‘more important’ medications took priority (Sale et al., 2006).  
10.2.2.2 Non-drug management of pain  
Qualitative findings of this thesis highlighted that people with dementia, family caregivers and 
GPs generally supported the use of non-drug strategies for pain for people with dementia. 
Many GPs recognised the importance of attempting non-drug strategies as a means to 
minimise pharmacological burden and their concerns towards analgesic medication for 
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people with dementia (see Section 10.2.2.3). The findings of this thesis reflect guidance 
recommending non-pharmacological strategies to manage pain for people with dementia 
(AGS Panel, 2009; Abdulla et al., 2013). It is important to note, however, that in this thesis, 
some healthcare professionals believed that there was ‘no place’ for non-pharmacological 
approaches until pain was controlled (using analgesic medication).  
A variety of non-pharmacological approaches were used and supported by people with 
dementia; including exercise, massage, comfort, relaxation, and distraction techniques. 
Despite many acknowledging the benefits of such strategies for their pain, some perceived 
the benefits to be short-lived. Less commonly used non-drug strategies for pain included 
alternative and complementary treatments, such as acupuncture and Reiki; with family 
caregivers seeming sceptical of their efficacy. The use of non-drug strategies has been 
identified in a previous study (Mentes et al. 2004), however, studies to date have failed to 
unravel and explore the person with dementia and family caregiver’s views or perspectives 
towards such strategies for the person with dementia’s pain (i.e. their perspective of whether 
the strategy was useful). Therefore, the findings of this thesis whilst adding to our 
understanding of pharmacological management of pain for people with dementia, also 
provides new understanding about non-pharmacological approaches. Indeed many non-drug 
strategies were used when the person with dementia had concerns towards analgesic 
medication (for the many reasons described previously, see Section 9.4.2). This finding is 
supported in a previous qualitative meta-synthesis, in which older adults preferred the use of 
self-administered, non-drug treatments for their pain due to their resistance to take analgesic 
medication (Crowe et al., 2017b).  
The qualitative findings within this thesis show that GPs generally supported the use of non-
drug treatments for people with dementia; particularly exercise and other simple at-home 
strategies to relieve pain. Despite generally supporting non-drug approaches for pain, GPs’ 
perspective seemed hierarchal, with a lower regard for non-drug treatments perceived as 
‘alternative’ or ‘complementary’. This was primarily due to their perceived unavailability in the 
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NHS (and therefore potential financial burden for the patient), and perceived minimal 
evidence-base. Previous qualitative studies with nurses (Kovach et al., 2000) and nursing 
assistants (Mentes, Teer & Cadogan, 2004; Liu, 2014) also highlighted their positive regard 
towards non-drug management strategies, each reflecting upon their efficacy and 
appropriateness when the person with dementia is reluctant to take analgesic medications 
(Geddis-Regan et al., 2018). Similarly, the findings of this thesis are supported by 
questionnaire studies where the majority of healthcare professionals agreed that non-
pharmacological methods are useful in the management of pain for people with dementia 
(Barry et al., 2012; Barry et al., 2013; Jennings et al., 2018b). Despite support for non-drug 
strategies of pain relief, the systematic review (see Chapter Three) found evidence that non-
drug approaches are underused for people with dementia in primary care (Li et al., 2015), 
however the evidence in this area is limited.  
The current concerns towards analgesic medication for people with dementia as shown in 
the qualitative evidence and in similar literature (see Section 9.4.2 and 10.2.2.3) may lead to 
a preference for non-drug strategies. The lower prevalence of analgesic prescription for 
people with dementia, as found in the quantitative findings, may in part be associated with 
the use of non-drug strategies for pain. 
10.2.2.3 Concerns related to analgesic medication 
Qualitative findings from this thesis found that some people with dementia and family 
caregivers expressed no concerns towards analgesic medication for people with dementia, 
with some even reflecting upon the benefits of their use. This, however, was heavily 
overshadowed by the many concerns held by a number of people with dementia, family 
caregivers, and GPs. The concerns of people with dementia and family caregivers led to a 
reluctance to use analgesic medications, due to side effects, illness burden (the amount of 
conditions and consideration of priority), and treatment burden (the amount of medications 
being taken). Each of these factors are discussed in turn. 
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10.2.2.3.1 Side effects 
This thesis found that potential side effects associated with analgesic medications were a 
key concern for many people with dementia and family caregivers. To support these findings, 
qualitative research also identified potential side effects to increase reluctance to use 
analgesic medication for older adults, with analgesics being a last resort to alleviate pain 
(Crowe et al., 2017b). Concerns relating to the side effects of analgesic medications for older 
adults were intensified with the presence and severity of dementia, due to increased risk of 
constipation, confusion, and nausea (Martin et al., 2005; Kaasalainen et al., 2007). These 
qualitative findings converge well with the quantitative findings, providing explanation for the 
lower prevalence of analgesic medications for people with dementia, especially as the time 
from dementia diagnosis (index date) increased. 
Despite the largely converging findings presented above, it is important to also consider 
divergent findings. As previously highlighted, a minority of people with dementia and family 
caregivers did not express any concerns relating to the side effects of analgesic medications. 
These divergent findings do not provide clear justification or inference to the quantitative 
findings however, do only represent a minority of people with dementia and family caregivers 
whom participated in the qualitative study. Clearly, the quantitative results do show that some 
people with dementia are being prescribed analgesic medication, albeit at a lower rate 
compared to a matched cohort of older adults without dementia. 
In this thesis, people with dementia and family caregivers spoke about their concern towards 
analgesic side effects generally, rather than attributing their concern towards any particular 
medications. In contrast, GPs’ concerns regarding side effects were directly attributed to 
specific analgesic classifications (e.g. NSAID or opioid medications). These concerns are 
discussed and integrated with the quantitative findings in the following sections. 
10.2.2.3.1.1 Basic or simple analgesics 
The five-year prevalence of basic analgesic prescription in this thesis was 36.9% for people 
with dementia. The annual prevalence of basic analgesic prescription was 11.1% to 14.7% 
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(depending upon the annual period after index date) which is at a slightly lower but 
comparable rate to the prevalence range (14% to 32%) found in the systematic review (see 
Chapter Three). The comparability between the annual prevalence in this thesis, and the 
studies included in the systematic review reflect the time period of data collection. For 
example, basic analgesic medications were identified as ‘in use’ at the time of interview 
(Haasum et al., 2011; Barry et al., 2016), during a 180-day period from dementia diagnosis 
(Hamina et al., 2016), or during a one-year period (Brummel‐Smith et al., 2002), and 
therefore comparable to the annual prevalence of this thesis. Furthermore, a previous 
systematic review investigating the cross-sectional prevalence of paracetamol use for people 
with dementia living in nursing homes ranged from 45.2% to 71.0% (Tan et al., 2015; Tan et 
al., 2016). The findings in nursing home settings show a higher prevalence of basic analgesic 
prescription, potentially highlighting differences depending upon residential setting.  
As with the general trend reported for all analgesics, people with dementia had 8% lower 
five-year prevalence of basic analgesic prescription than older adults without dementia 
(36.9% vs. 44.6%, respectively). In line with these findings, during the five-year period from 
index date, people with dementia had a significant 0.84 times lower odds of being prescribed 
a basic analgesic than older adults without dementia. Each of these prevalence rates, 
however, only included analgesic prescriptions matched to a musculoskeletal consultation. 
Sensitivity analysis including all basic analgesic prescriptions (irrespective of matching to a 
musculoskeletal consultation) highlighted alternate findings. The prevalence of basic 
analgesic prescription was similar for people with and without dementia during the five-year 
period from index date (63.5% vs. 62.1%, respectively; adjusted OR 1.03, 95% CI 0.96 to 
1.11). The findings of the sensitivity analysis are more comparable to previous literature. The 
systematic review (see Chapter Three) found that community-dwelling people with dementia 
had a higher prevalence of paracetamol use than community-dwelling people without 
dementia (Haasum et al., 2011; Hamina et al., 2016). In addition, within nursing home 
settings, people with dementia were found to have similar (Tan et al., 2016; Bauer et al., 
2016), or higher (Lövheim et al., 2008; Haasum et al., 2011; Tan et al., 2015) rates of 
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paracetamol use compared to people without dementia. The sensitivity analysis conducted 
as part of this thesis also found that there was no difference in basic analgesic prescription 
between people with and without dementia throughout follow up. The findings of the 
sensitivity analysis were, again, more comparable to previous studies that found an 
increased prevalence of paracetamol use from the first year to the fifth year after dementia 
diagnosis (Gilmartin et al., 2015). This sensitivity analysis suggested that the prevalence of 
basic analgesic prescription for people with dementia was in line with older adults without 
dementia.  
The discrepancy between the main analysis and the sensitivity analysis suggest that when 
prescribing basic analgesics to people with dementia in primary care there is a lack of 
temporal association to a musculoskeletal consultation. This finding may suggest that GPs 
are prescribing basic analgesics even when they have not recently coded for a 
musculoskeletal consultation. This finding may highlight that when GPs are unsure of the 
underlying diagnostic cause of the person with dementia’s presentation, they may use a trial 
and error approach to analgesic treatment, as found in the qualitative findings (see Section 
9.4.2). The idea that prescribing analgesic medication (typically paracetamol due to the high 
safety profile) even when unsure of the underlying diagnostic problem may help to identify if 
the presentation is caused by pain (see Section 2.3.5).   
Qualitative exploration highlights convergence to the sensitivity analysis (yet divergence to 
the main analysis). In particular, healthcare professionals frequently expressed a preference 
for paracetamol for people with dementia due to the good safety profile associated with these 
drugs, thereby minimising their concerns of side effects. In a previous qualitative study using 
semi-structured interviews to generate data, nurses perceived paracetamol as the analgesic 
of choice for mild-to-moderate pain, reflecting upon the benefits of the low side effect profile, 
which was especially beneficial for people with dementia (Kovach et al., 2000). The 
preference towards paracetamol for people with dementia, as found in this thesis and in 
previous literature reflects national recommendations and research (Abdulla et al., 2013; 
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AGS Panel, 2009; McLachlan et al., 2011; Girard et al., 2019). The preference towards 
paracetamol for people with dementia, as identified in the qualitative findings, provides an 
explanation for the similar prevalence of basic analgesic prescription for people with and 
without dementia, as found in the sensitivity analysis.  
Despite the convergence between the sensitivity analysis and the qualitative findings, again 
divergence is important to highlight. One GP reflected upon their concerns of overdose when 
prescribing paracetamol to people with dementia with a low weight. Concerns towards 
paracetamol have also been noted in previous qualitative studies, in which a focus group 
study found that physicians and nurses were particularly concerned about the toxicity, and 
the potential development of liver disease with chronic paracetamol use (Kaasalainen et al., 
2007). This finding reflects recent evidence that questions the safety of paracetamol (Roberts 
et al., 2016), with NICE guidelines no longer recommending paracetamol as the first-line 
treatment for various musculoskeletal-related pain (Wise, 2014; NICE, 2014; NICE, 2016; 
Saragiotto et al., 2016).  
10.2.2.3.1.2 Non-steroidal Anti-Inflammatory Drugs  
The five-year prevalence of non-steroidal anti-inflammatory drug (NSAID) prescription was 
13.4% for people with dementia, with an annual prevalence ranging from 2.6% to 3.7%. The 
sensitivity analysis including all analgesic prescriptions found that the annual prevalence 
ranged from 5% to 7%. The systematic review (see Section 3.5.4.2.2) found that the 
prevalence of NSAID use ranged from 5.9% to 21% for community-dwelling people with 
dementia. In nursing home settings, the prevalence of oral NSAID use for people with 
dementia ranged from 2.0% to 3.8% (Tan et al., 2015; Tan et al., 2016). Each of these 
findings show comparable prevalence estimates to the findings of the main and sensitivity 
analyses included in this thesis.  
Results show the five-year prevalence of NSAID prescription was 7.3% lower for people with 
dementia than older adults without dementia (13.4% vs. 20.7%, respectively, adjusted OR 
0.65, 95% CI 0.57 to 0.75), with similar findings for each sensitivity analyses. These findings 
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are supported by the systematic review (see Chapter Three) which found that the prevalence 
of NSAID use was lower for people with dementia compared to older adults without dementia 
(see Section 3.5.4.2.2). These findings are also supported from evidence in nursing home 
settings that identified a lower prevalence of NSAID use for people with dementia compared 
to older adults without dementia (de Souto Barreto et al., 2013; Tan et al., 2016), with limited 
studies suggesting a similar prevalence of NSAID prescription (Haasum et al., 2011). 
The annual prevalence of NSAID prescription lowered from dementia diagnosis throughout 
follow up for people with dementia. These findings are supported by Gilmartin et al. (2015) 
who also identified a decreased prevalence of NSAID use from the first year to fifth year after 
diagnosis. Similarly, NSAID use for nursing home residents lowered in line with lowered 
MMSE score (indicating increased cognitive impairment) (Bauer et al., 2016). Based on the 
assumption of dementia progression over time, each of these findings indicate that 
increasing cognitive impairment reduces NSAID use for people with dementia. 
These findings converged well with the qualitative findings, providing interpretation to explain 
why people with dementia may be prescribed less NSAIDs than older adults without 
dementia. GPs reflected upon their concerns when prescribing NSAIDs for people with 
dementia due to the increased risk of side effects due to the physiological changes 
associated with ageing. Such concerns were intensified by the presence and severity of 
dementia, especially vascular dementia. Minimal qualitative research has explored concerns 
related to NSAIDs for people with dementia, however Kovach et al. (2000) found that nursing 
assistants in nursing homes reflected upon the potential side effects (e.g. possible bleeding 
problems and stomach upset), and the consideration for preventative measures to minimise 
the risk of such events (e.g. antacids for stomach upset). The concerns towards NSAIDs 
reflect numerous guidelines recommending that such medications should be considered 
rarely for older adults, and only if safer therapies (e.g. paracetamol) have failed to relieve 
pain (AGS Panel, 2009; Abdulla et al., 2013; McLachlan et al., 2011). These findings raise 
the issue of whether GPs are being overly cautious when prescribing NSAIDs to people with 
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dementia, considering their lower prevalence rate compared to matched older adults without 
dementia.  
10.2.2.3.1.3 Opioid prescriptions 
Opioid prescriptions in this thesis were separated into four classifications based upon their 
potency; weak analgesics, moderate analgesics, and strong analgesics (each containing 
increasingly strong opioids used alone or in combination with paracetamol), and very strong 
analgesics (very strong single opioids such as morphine) following previous methodology 
(Bedson et al., 2013). The five-year prevalence of opioid prescription for people with 
dementia ranged from 18.4% for weak analgesic prescriptions (weak combination opioids 
such as codeine + paracetamol) to 1.6% for very strong analgesic prescriptions (e.g. 
morphine and oxycodone). These findings are comparable to the prevalence estimates found 
in the systematic review (see Chapter Three), that found that the prevalence of opioid 
prescription ranged from 3.6% to 27.5% for community-dwelling people with dementia.  
The quantitative findings indicated that the five-year prevalence and odds of weak, moderate, 
and strong analgesic prescription was lower for people with dementia compared to older 
adults without dementia. Additionally, the prevalence and odds of prescription for each of 
these analgesic categories lowered over time from dementia diagnosis (index date) for 
people with dementia compared to older adults without dementia. The findings of this thesis 
build upon the mixed and limited evidence identified in the systematic review that found 
people with dementia had a lower (Bell et al., 2011), similar (Hamina et al., 2016) and a 
higher (Jensen-Dahm et al., 2015) odds of opioid use compared to older adults without 
dementia (see Section 2.4.2.6). Furthermore, the findings of this quantitative investigation 
are supported by a previous systematic review that examined opioid prescription rates for 
people with and without cognitive impairment, irrespective of residential setting (Griffioen et 
al., 2017a). The results of this review showed that 21 studies (out of the total 24 identified) 
found that people with cognitive impairment used equal or less opioids than people without 
cognitive impairment, supporting the findings of this thesis. 
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The qualitative findings support and converge well with the quantitative findings presented 
above. The qualitative findings found that GPs had many concerns related to the side effects 
specifically related to opioid medication. Such concerns increased their reluctance to 
prescribe this classification of analgesic for people with dementia. Importantly, GPs 
perceived such risks to be intensified by the presence of cognitive impairment (such as 
worsening confusion) for people with dementia. This finding was supported in a previous 
meta-review of qualitative studies (Geddis-Regan et al., 2018), with research reiterating that 
the side effects associated with opioid medications increased reluctance to prescribe 
stronger analgesics (Chang et al., 2009; Manias, 2012). So much so that family members, 
nurses, and care workers were resistant for opioids to be taken by the person with dementia 
even when they were prescribed (Peisah et al., 2014). 
The side effects associated with opioid medications for people with dementia may be a 
barrier to optimal pain treatment (McAuliffe et al., 2008; AGS Panel, 2009). These findings 
reflect a ‘negative social stigma’ towards opioid medications for older adults, including people 
with dementia (AGS Panel, 2009) due to the well documented potential harms of opioid 
medications (AGS Panel, 2002; Abdulla et al., 2013; McLachlan et al., 2011). The findings in 
this thesis suggest that concerns specifically related to people with dementia (e.g. confusion) 
are added to an overall general concern of prescribing opioids in older adults. Recent UK 
guidelines recommend that GPs reduce opioid prescriptions, due to the rise in opioid 
prescription rates in recent years (Bedson et al., 2013; Bedson et al., 2016; Curtis et al., 
2019; British Medical Association, 2017). These additional concerns further contribute to 
GPs’ cautious approach to prescribing opioids. The qualitative findings, along with the 
previous literature provide a potential explanation to understand why people with dementia 
had a lower prevalence of opioid prescription (with the exception of very strong opioids), 
compared to older adults without dementia.  
When focusing upon very strong opioids specifically, the quantitative findings indicated that 
the five-year prevalence was only slightly lower for people with dementia compared to older 
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adults without dementia (1.6% vs. 1.9%, respectively), somewhat diverging from the 
qualitative findings. When examining the odds of very strong analgesic prescription, people 
with dementia had a statistically significant 0.57 lower odds than older adults without 
dementia (adjusted OR 0.57 95% CI 0.33 to 0.98), however, the confidence intervals around 
this effect are noticeably wide suggesting some unreliability. Indeed, when considering the 
absolute difference between prevalence estimates it is only 0.3%. One potential reason for 
the lack of difference between people with and without dementia as reported in these results 
is that pain warranting such a strong analgesic may be more easily identifiable. One key 
challenge of pain identification and pain assessment was determining the underlying 
pathology of the changed presentation. However, very strong opioid prescriptions (such as 
morphine or Oxycodone) might be warranted when the pain source was more severe and 
easily identifiable (e.g. an acute injury). In this situation, the presence or absence of cognitive 
impairment was less likely to impede the identification of pain. A second potential reason 
relates to the small sample of people with and without dementia receiving a very strong 
analgesic prescription. To illustrate, during the five-year period from index date, only 63 (out 
of n=3893) people with dementia, and 238 (out of n=12,276) older adults without dementia 
were prescribed a very strong opioid. The rarity of very strong analgesic prescription in 
primary care may reduce the precision of the prevalence estimates, and make the absolute 
difference between people with and without dementia minimal.   
10.2.2.3.2  Illness and treatment burden  
Another concern expressed by people with dementia, family caregivers, and GPs towards 
analgesic medication was illness and treatment burden. The amount of health conditions 
(illness burden) and the amount of medications being taken by the person with dementia 
(treatment burden) lead to additional concerns towards analgesic medication. Comorbid 
conditions, or potential drug interactions from medications used to treat them, may mean that 
analgesics are contraindicated. Additionally, comorbidities may also increase the number of 
medications being prescribed and taken, again, increasing the risk of drug-drug interactions, 
as well as concerns regarding polypharmacy. In some of the interviews, it was expressed 
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that the amount of medications being taken by the person with dementia had reached 
maximum capacity, meaning that people with dementia were reluctant to take ‘lower priority’ 
medications, such as analgesics. In support of these findings, a meta-synthesis of qualitative 
research found that older adults were reluctant to take multiple medications for multiple 
health problems (Crowe et al., 2017b), illustrating the challenge of managing an extensive 
medication regimen, especially for people with dementia where execution and persistent with 
medications may be more challenging (Arlt et al., 2008). Additionally, previous qualitative 
interviews with staff in residential aged care facilities found that pain medication was rarely 
prioritised over physical care medications for people with dementia refusing medications 
(Peisah et al., 2014). The challenge of illness disease and treatment burden for people with 
dementia was explored by emergency nurses' whom reflected upon comorbidity and 
polypharmacy as an additional concern that limited the number of available and appropriate 
analgesic treatments (Fry, Chenoweth & Arendts, 2016). The findings of this thesis, along 
with the previous literature highlight the challenge for healthcare professionals to identify an 
effective, yet safe analgesic medication, whilst considering potential contraindications. This 
finding may provide further explanation for the discrepancy of analgesic prescribing between 
people with dementia and older adults without dementia, identified in the quantitative 
findings.  
10.2.2.3.3 Weighing up the concerns 
The concerns relating to side effects (see Section 10.2.2.3.1), and illness and treatment 
burden (see Section 10.2.2.3.2) each contributed to a sense of reluctance to use analgesic 
medication for people with dementia. Healthcare professionals perceived dementia as a 
factor providing additional complexity to an already challenging task; prescribing analgesic 
medication for an older adult. These findings, in addition to the challenges of pain 
identification and assessment described previously provide greater understanding to why 
analgesic prescription prevalence was significantly lower for people with dementia than older 
adults without dementia at a population level. 
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The multifactorial concerns towards analgesic medications for people with dementia often 
meant that GPs had the challenging task of weighing up and determining the most effective 
analgesic, whilst also considering potential side effects, drug-drug, and drug-disease 
interactions. The multifactorial considerations inherent in analgesic prescribing led to many 
GPs feeling limited or restricted when prescribing analgesic medication to people with 
dementia. This finding was supported in previous qualitative studies, in which analgesic 
prescription was perceived as ‘complex’ and ‘restricted’ for people with dementia (Corbett et 
al., 2016; Griffioen et al., 2017a; Martin et al., 2005).  
To identify or ‘weigh up’ the ‘most appropriate’ analgesic, GPs recognised the importance of 
upwards titration, or as commonly referred ‘starting low and going slow’, until the person with 
dementia was comfortable with their pain. Previous studies support these findings; with many 
healthcare professionals following a stepped approach to analgesic treatment for people with 
dementia as a means to assess potential side effects and interactions (Barry et al., 2012; 
Barry et al., 2013; Kovach et al., 2000; Kaasalainen et al., 2007). In line with the principles of 
upwards titration, GPs had a preference towards paracetamol, for reasons outlined 
previously, however paracetamol was not always perceived effective depending upon the 
severity of the pain experienced. When considering escalation and upwards titration to 
alternative analgesic medications (e.g. NSAIDs or opioids), GPs reported many concerns, 
such as their association with side effects and potential drug-drug or drug-disease 
interactions. GPs weighed up their concerns related to each analgesic, sometimes trialling 
analgesic medications to identify the most ‘appropriate’ treatment. In previous research, 
nurses described this process as a ‘balancing act’ (Fry et al., 2016; Kaasalainen et al., 2007).  
Importantly, GPs perceived the complexity and perceived ‘limited choice’ of appropriate 
treatments to have negative implications; leading to the under treatment of pain for people 
with dementia, due to the concern of ‘doing more harm than good’. These findings therefore 
contribute to the understanding of the quantitative findings that indicate people with dementia 
were prescribed less analgesic medication than older adults without dementia. 
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10.2.2.4 Responsibility of the caregiver to manage pain 
The qualitative findings of this thesis suggest that family caregivers were often responsible to 
manage the pain experienced by the person with dementia in the community by prompting 
them to engage with non-drug strategies and to take analgesic medication. Additionally, GPs 
were often reliant upon the presence of a family caregiver to manage analgesic medications 
in the community; with the presence of a family caregiver minimising many of the concerns 
discussed throughout this chapter. To exemplify, GPs were resistant to prescribe opioids to 
people with dementia in the absence of a family caregiver or support in the community. The 
presence of family caregivers reduced the perceived risk of opioids (and other analgesics) 
being incorrectly managed. This was a concern for opioids in particular due to the risk of side 
effects, addiction, and overdose, providing further explanation for the discrepancy of opioid 
prescription between older adults with and without dementia. 
The responsibility for family caregivers to manage pain was, however, sometimes perceived 
as burdensome. To counteract the burden, family caregivers and GPs recognised the 
benefits of medication management strategies (e.g. blister packs, dosette boxes, and 
automatic pill dispensers) to reduce the sense of responsibility felt by the family caregiver to 
correctly administer medications. Conversely, this thesis also found that some family 
caregivers expressed relief (rather than burden) to take control of the medication taken by 
the person with dementia. Qualitative research exploring pain treatment for community-
dwelling people with dementia is lacking; with this thesis highlighting the unique challenges 
of pain management in the community. Despite the lack of directly comparable findings, 
Maidment et al. (2017) explored medication management (without a specific focus upon 
analgesic medications) from the perspective of people with dementia, family caregivers, and 
health and social care professionals using semi-structured interviews. This study by 
Maidment et al. also highlighted the utility of compliance packs to manage medication 
regimens, and reflected upon the emotional burden felt by family caregivers when managing 
multiple medications in the community. This thesis built upon the findings of Maidment et al. 
by focusing upon pain management specifically and by also illuminating the potential relief 
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felt by some family caregivers when managing the person with dementia’s analgesic 
medication regimen to avoid adverse events (e.g. overdose). 
The findings of this thesis show that many GPs were cautious to prescribe analgesic 
medications (especially strong medications) in the absence of a family caregiver, or close 
support in the community. Such findings may contribute additional understanding to the 
reported lower prevalence of analgesic prescriptions for people with dementia compared to 
older adults without dementia, as identified in the quantitative findings, especially if a family 
caregiver is not present in the community to take on this role.  
10.3 Unique contributions 
This thesis provides the first mixed methods investigation into pain identification, 
assessment, and pain management for community-dwelling people with dementia. Previous 
research focusing upon community-dwelling people with dementia is limited, of low quality, 
with particularly limited research conducted in the UK (see Chapter Three).  
This thesis was also the first to examine pain identification, assessment, and treatment for 
community-dwelling people with dementia, using UK primary care electronic health record 
data, especially concerning the trend of musculoskeletal consultation and analgesic 
prescription over time, with the presumption of disease progression. Unlike many of the 
studies included in the systematic review (see Chapter Three), this study also identified a 
matched older adult cohort, to allow for direct comparison. The quantitative findings of this 
study therefore build upon previous evidence, providing unique insights into musculoskeletal 
consultation and analgesic prescriptions in a large population of people with dementia in 
primary care likely to be representative of the primary care population as a whole.   
Previous research that aimed to explore pain identification, assessment, and treatment for 
people with dementia has only interviewed older adults without dementia (i.e. formal/informal 
caregivers; Martin et al., 2005), or only included the person with dementia in observational 
based designs (Lichtner et al., 2015; Lichtner et al., 2016). A previous study which included 
family caregivers and persons with dementia in dyadic interviews explored medication 
Chapter Ten: Discussion 
 
 
374 
 
management generally (Maidment et al., 2017) and did not consider the specifics of 
managing pain. It is well established that pain and emotion are linked (Lumley et al., 2011) 
and it may be argued that the experience of pain and emotional expression within a dyadic 
relationship is different to the experience of other medical problems or issues, certainly 
research has shown emotional influences between couples and family members when one 
member expresses pain (Campbell, Shraim, Jordan & Dunn, 2015; Campbell, Jordan & 
Dunn, 2012). Importantly this thesis was the first to explore the person with dementia’s 
perspective and experience of their own pain identification, assessment, and management, 
irrespective of setting (Geddis-Regan et al., 2018). 
A small number of qualitative studies have explored pain identification, assessment, and 
treatment from the perspective of family caregivers of people with dementia (Lichtner et al., 
2015; Lichtner et al., 2016; Martin et al., 2005; Mentes et al., 2004). In these studies, 
however, the family caregivers reflected upon their relative with dementia currently living in a 
nursing home setting, or during a hospital stay. In nursing home and hospital settings, pain 
identification, assessment, and treatment are different from a community or primary care 
perspective. For example, in nursing home and hospital settings, healthcare professionals 
are regularly available and responsible to manage pain for the person with dementia. 
Alternatively, this thesis provides novel insights into the experience and perspective of family 
caregivers who felt responsible to provide the primary source of care and support for their 
community-dwelling relative with dementia. 
Previous qualitative studies have examined pain identification, assessment, and treatment 
for people with dementia from the perspective of healthcare professionals (Geddis-Regan et 
al., 2018). The majority of these studies investigated nurses, nursing assistants, and 
healthcare assistants’ perspective of pain for people with dementia living in formal care 
settings (including nursing home, palliative, and acute care settings; Geddis-Regan et al., 
2018). Only two studies provide an insight into pain identification, assessment, and treatment 
for community-dwelling people with dementia (Karlsson et al., 2014; Karlsson et al., 2012), 
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with both studies only exploring a nurse perspective. In the community, GPs often provide 
ongoing care and support for people with dementia, including the identification and 
assessment of pain, and the prescription of analgesic medications. When GPs consider the 
need for specialist input, the GP acts as a gatekeeper to secondary care services such as 
old age psychiatrists. Despite their direct involvement in pain care and the management of 
behavioural and psychological changes for people with dementia living in the community, 
limited previous research has explored the perspective of GPs and old age psychiatrists. 
This research therefore provides unique, and much needed insight into the perspective and 
experience of GPs and psychiatrists, with a focus upon pain identification, assessment, and 
treatment for community-dwelling people with dementia (Jennings et al., 2018b). 
10.4 Strengths, challenges, and limitations 
The following sections discuss the strengths, challenges, and limitations of this thesis, 
focusing upon the mixed methods approach as a whole, followed by the quantitative and 
qualitative elements in turn.  
10.4.1 Mixed Methods 
The mixed methods approach to this thesis allowed the quantitative findings to provide a 
clear picture of pain identification, assessment, and treatment for a large population of 
people with dementia. Whereas the qualitative semi-structured interviews provided a detailed 
exploration and discussion of the participants’ perspectives, providing rich detail to the 
picture. The use of both quantitative and qualitative methods therefore allowed for a more 
complete understanding of the phenomena. 
Of the three core mixed method designs outlined by Creswell and Plano Clark (2018), a 
convergent mixed methods design was chosen to investigate pain identification, assessment, 
and management for people with dementia. A convergent mixed methods design allowed the 
quantitative and qualitative data to be collected and analysed concurrently, using traditional 
methods most suitable for the data (e.g. statistical analysis for quantitative data, and 
thematic analysis for qualitative data). The convergent design (rather than a sequential 
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design; see Section 5.4.2) therefore had pragmatic benefits within a time restricted project. 
For a convergent mixed methods design, Creswell and Plano Clark recommend that the 
quantitative and qualitative approaches should investigate similar concepts to facilitate 
integration. Quantitative and qualitative findings were integrated in a narrative discussion 
throughout this chapter (see Section 10.2). The integration found that the qualitative findings 
supported, explained, and contributed to an in-depth understanding of the quantitative results 
and vice versa. However, there was instances where the quantitative and qualitative findings 
could not be integrated as easily. For example, the qualitative findings highlighted non-drug 
strategies to manage pain, however information about non-drug strategies were unavailable 
for investigation in the CPRD hindering complete integration. 
Finally, Creswell and Plano Clark (2018) reiterate the potential consequences of integrating 
quantitative and qualitative approaches that have vastly different sample sizes. In this study, 
the different sample sizes had no negative consequences for integration. The quantitative 
and qualitative findings provide a ‘complementary picture about the phenomenon’ (Creswell 
& Plano Clark, 2018, p. 188). In fact, different sample sizes are essential to ensure a rigorous 
high-powered quantitative, and a rigorous in-depth qualitative investigation. 
10.4.2 Quantitative methods 
10.4.2.1 Study design 
The general strengths and limitations of electronic healthcare record databases, including 
CPRD were outlined in Table 6.1. CPRD data provided the opportunity to examine 
longitudinal consultation and treatment trends in primary care, using a representative sample 
of people with dementia and older adults in the UK.  
Electronic health records are frequently used in research (Cowie et al., 2017; Herrett et al., 
2015), however data is not recorded with research purposes in mind. Secondary analysis of 
CPRD data therefore required an iterative process driven by the aim of the research followed 
by the available data (Cheng & Phillips, 2014). For this study, the analysis was initially driven 
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by the first research objective: to investigate pain identification and assessment for 
community-dwelling people with dementia; however, CPRD does not provide explicit pain 
identification or assessment details. Therefore, the analysis was partially driven by the 
available data, utilising Read codes indicative of a musculoskeletal consultation to illustrate 
that a potentially painful condition was identified, investigated, and coded by the clinician in 
accordance with previous methodology (Richardson et al., 2018; see Section 6.2.9.1). 
Although this method provided an insight into (often painful) musculoskeletal condition 
identification and assessment in primary care, pain caused by other factors (e.g. head pain) 
and the severity of the pain could not be examined, potentially underestimating the 
prevalence of pain for people with dementia. To avoid this limitation, I could have collected 
data that was designed with the objective of the research in mind (e.g. using a survey design 
to ask GPs about pain identification and assessment for people with dementia). However, 
primary collected data would have obtained a smaller sample (as the set-up of a multisite 
recruitment design may have taken time and organisation beyond the expectation for a PhD 
study), it would not have covered the five year period as used in this current analysis (with 
the constraints of a 3 year PhD), there would have been considerable cost associated with 
this more traditional research recruitment approach (beyond the funding structure), and it 
may not be representative of older adults in primary care at a population level. For example, 
on this last point, people that respond to surveys may be inherently the same as each other, 
but different from the rest of the population (selection bias). 
10.4.2.2 Sample 
Approximately 98% of people in the UK are registered with a general practice, with primary 
care being the first point of healthcare contact in the community (Herrett et al., 2015). 
Research has found that CPRD is representative of the UK population in relation to age, 
gender, and ethnicity (Herrett et al., 2015), making CPRD an ideal representative sample 
base for health service research at a population level.  
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Patients in the dementia cohort were identified using Read codes and product codes 
indicative of a dementia diagnosis (see Section 6.2.6.1.1). The recorded rate of dementia 
diagnosis in UK primary care data has increased from 40% in 2009 to 67% in 2015, with a 
concomitant increase in the prescription of anti-dementia drugs (Mukadam, Livingston, 
Rantell & Rickman, 2014). Despite improvements in detection rates (Donegan et al., 2017), 
there may be a large proportion of people with dementia residing in the community that were 
not recorded as having a diagnosis, or anti-dementia drug in primary care records. This has 
implications for this study, as people with dementia without a recorded dementia diagnostic 
Read code, or anti-dementia drug prescription may have been misclassified to the older adult 
cohort, especially so during the earlier years of the study period (i.e. 1997) where reporting 
and detection rates have been shown to be lowest. Despite this limitation, this study ensured 
that all older adults were ‘active consulters’ (consulting within a 90 day pre-and-post window 
of index date), minimising the chance that the older adult had dementia unknowingly to the 
healthcare professional. Additionally, the cohort design of this study allowed dementia 
diagnosis to be investigated over a long period (up to 20 years). This period of investigation 
minimised the chance that people with dementia were misclassified into the older adult 
cohort (and vice versa), compared to alternative epidemiological designs (e.g. cross-
sectional designs) which would rely upon a much shorter period of time (often a single time-
point) to identify evidence (or absence) of dementia. Finally, to mitigate these limitations, 
recent research has found a high agreement between dementia identified in CPRD, Hospital 
Episode Statistics data, and GP survey data; suggesting acceptable identification of people 
with dementia in CPRD (Brown et al., 2016). 
The focus of this project was community-dwelling populations, defined as people living at 
home alone or with family members, in assisted living facilities, retirement communities, or in 
a residential home (Hunt et al., 2015; see Section 1.7). This definition was strictly 
implemented in the systematic review and qualitative recruitment. However, important 
limitations are essential to consider regarding the CPRD investigation. Firstly, all patients 
with a Read code indicative of formal care residence were excluded, as this was a definitive 
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marker of formal care residence in line with previous EHR research (Shah et al., 2010). It 
became evident, however, that clinicians inconsistently used these specific status codes (as 
opposed to diagnosis codes for example); therefore, people living in formal care settings may 
(incorrectly) remain in the main analysis. To investigate the implication of this potential 
misclassification bias, sensitivity analysis was conducted, with two additional markers to 
identify and exclude people living in a formal care residence i) a household of greater than 
two people over the age of 50 and ii) a consultation location in a formal care setting (see 
Section 6.2.13.5.1). Excluding patients with evidence of these additional markers allowed for 
the identification of a ‘strict’ or ‘hard’ population of older adults with and without dementia 
with a higher likelihood of living in the community. The sensitivity analysis findings reflected 
the main analysis findings, showing limited impact of potential misclassification. Secondly, 
information was often unavailable in CPRD to distinguish between people living in a nursing 
home and people living in a residential home. For example, Read codes often referred to 
‘care homes’ or ‘institutions’ rather than explicitly coding if the person lived in a residential or 
nursing home, with further complexity for dual-registered homes (providing residential and 
nursing care). Furthermore, households with greater than two people over the age of 50 were 
excluded from the sensitivity analysis. Both of these methods facilitated the identification and 
exclusion of nursing home residents; however, people living in residential homes may have 
been incorrectly excluded from the main and sensitivity analysis.  
10.4.2.3 Analysis 
This research aimed to investigate the pattern of musculoskeletal consultation and analgesic 
prescriptions in conjunction to expected dementia progression over time. To investigate this 
trend, the incidence and prevalence analysis was stratified into annual periods from the index 
date, defined as the incident dementia-related clinical code (or equivalent matched date for 
older adults without dementia). Research and UK policy have highlighted the untimely coding 
of a dementia diagnosis in primary care records, with a small number of patients only 
receiving a recording of dementia during the latter, and more severe stages of the condition 
(Bradford, Kunik, Schulz, Williams & Singh, 2009; Department of Health, 2009). The untimely 
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diagnosis of dementia in primary care may implicate the accuracy of longitudinal temporal 
analysis starting from an index date representing ‘dementia diagnosis’ (Russell et al., 2013). 
Additionally, the temporal interpretation in this thesis relies upon the assumption that 
cognitive ability of people with dementia declines during the five-year period from their first 
dementia-related clinical code, in line with similar studies (Gilmartin et al., 2015). This 
method was used due to the unavailability of codes to determine cognitive ability (e.g. MMSE 
score) within consultation records. I acknowledge that this approach does not take into 
account that the progression of cognitive impairment for people with dementia is individual to 
the person, and the subtype of dementia. 
The results show that the dementia cohort had a shorter follow up from index date than the 
older adult cohort (see Table 7.5). The dementia cohort also had a reduced incidence and 
prevalence of musculoskeletal consultation and analgesic prescription, especially as time 
from index date increased. The difference between the dementia cohort and the older adult 
cohort may be explained by immortal time bias; meaning that the ‘period of follow-up during 
which, by design, death or the study outcome cannot occur’ (Lévesque et al., 2010). In other 
words, ‘unhealthier’ patients in the dementia cohort may have left the study (e.g. due to 
death, transfer to nursing home), leaving a healthier cohort of patients with dementia that did 
not have musculoskeletal pain, or require analgesic medication. Despite this being an 
important consideration, it was found that the dementia cohort and the older adult cohort that 
remained in the study during the last annual time period from index date (year four to five) 
were similar concerning a range of baseline characteristics as people included in the first 
year after index date (see Table 7.5). This finding indicates that the dementia cohort and 
older adult cohort did not seem to become progressively ‘healthier’ throughout follow up 
because of attrition.  
Musculoskeletal conditions are the most prevalent cause of pain for older adults with and 
without dementia (Corbett et al., 2012; Corbett et al., 2014; Husebo et al., 2010). For this 
reason, and many others (see Section 6.2.9.1), musculoskeletal consultation Read codes 
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were used as a proxy indicator for the identification and assessment of a painful condition in 
primary care. Earlier in this Chapter, the priority of health conditions and coding was 
discussed (see Section 10.2.2.3.2), with research finding that codes for musculoskeletal 
conditions were only coded when other comorbid conditions were no longer a priority 
(Bedson et al., 2011). For people with dementia, this may mean that other health problems 
that have ‘clinical dominance’ may be coded by the GP (such as BPSD) even when pain has 
been identified and assessed (Jørgensen et al., 2018). This may contribute to the lower 
incidence and prevalence of musculoskeletal consultations for people with dementia 
compared to older adults. 
CPRD only captures musculoskeletal consultations and analgesic prescriptions occurring in 
primary care (Herrett et al., 2015). Therefore, the absence of a musculoskeletal consultation 
does not necessarily mean an absence of musculoskeletal condition for the individual. 
People with dementia may consult less (although this was not the case at baseline; see 
Table 7.4) due to restricted access to primary care (Pratt, Clare & Kirchner, 2006; Bunn et 
al., 2016) resulting in a lower rate of musculoskeletal consultation and analgesic 
prescriptions. Similarly, CPRD does not capture over-the-counter analgesic medications. 
Older adults regularly obtain paracetamol over-the-counter to self-manage pain (Roumie & 
Griffin, 2004), with many family caregivers choosing to manage the pain experienced by the 
person with dementia using over-the-counter analgesics when living in the community 
(Mentes et al., 2004). The prevalence estimates of analgesic prescription in this study are 
therefore likely to under estimate the true prevalence of analgesic medications that are 
widely available over-the-counter (e.g. paracetamol and some NSAIDs).  
Finally, this study only included medications with a primary analgesic property (defined as 
drugs within the Anatomical Therapeutic Chemical (ATC) groups N02 or M01A). Pain may, 
however, also be treated using gabapentinoids (e.g. gabapentin and pregabalin) (Appleyard 
et al., 2019). This may be especially true for people with dementia, as gabapentinoids are 
perceived as a ‘dual-action’ medication to target both pain and anxiety (Appleyard et al., 
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2019). The ‘off-label’ prescription of gabapentinoids (which may be more likely for people 
with dementia) may explain the discrepancy in analgesic prescription for people with and 
without dementia.   
10.4.3 Qualitative methods 
The strengths and limitations of qualitative study designs are discussed throughout Chapter 
Six. This section reflects upon some of the pertinent strengths, challenges and limitations 
identified when reflecting upon the study design, sample, and analysis. 
10.4.3.1 Study design 
Unlike previous research (see Section 10.3), this thesis wished to include people with 
dementia to explore their perspective and experience of pain identification, assessment, and 
management. Dyadic interviews including the person with dementia and their family 
caregivers have been praised in previous research, with the dyadic interview facilitating a 
safe and comfortable environment for open and honest discussion (Morgan et al., 2013; 
Pesonen et al., 2011). Dyadic interviews also overcome many ethical concerns (see Section 
6.3.5). Despite the positives of dyadic interviews for people with dementia, dyadic interviews 
sometimes ‘interfered’ with the person with dementia’s voice being heard (Morgan et al., 
2013; Pesonen et al., 2011 p. 656). To balance the power dynamics in dyadic interviews, I 
employed various techniques to illuminate and focus upon the perspective of the person with 
dementia (see Section 6.3.5). However, I acknowledge that such techniques may not have 
fully addressed the imbalance of power, with some family caregivers continuing to take 
control of the interview. Consequently, the perspective of the person with dementia was 
sometimes expressed by the family caregiver, on behalf of the person with dementia, despite 
the person with dementia having the ability to describe their own thoughts and experiences. 
Although dyadic interviews may have meant that the family caregiver perspective over-
powered the voice of the person with dementia, I viewed this as a worthy compromise to 
ensure the safety and wellbeing for the person with dementia, in line with previous research 
in this area (Pesonen et al., 2011).  
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Additionally, two GPs completed a telephone interview. The convenience of telephone 
interviews improved the recruitment of healthcare professionals in this study. Telephone 
interviews seemed shorter, and felt more procedural (rather than exploratory) due to lost 
nuances, the challenge of building rapport, and lack of non-verbal cues (Irvine et al., 2012).   
10.4.3.2 Sample 
People with dementia were only eligible for the study if they had a family caregiver that was 
also willing to be interviewed, as part of a dyadic interview, for reasons previously discussed 
(see Section 6.3.5). Although this study did not stipulate that the person with dementia must 
live with a family caregiver, due to the nature of recruitment, none of the people with 
dementia lived alone. Therefore, this study was unable to explore the unique perspectives, 
experiences, and challenges of pain identification, assessment, and management for people 
with dementia that did not live with a close family caregiver.  
Similarly, inclusion criteria stipulated that the person with dementia must be able to 
communicate their experiences verbally, as part of the interview methodology. This meant, 
however, that the unique challenges of pain identification, assessment, and management for 
people with advanced dementia that could no longer verbally communicate were not 
explored. It cannot be assumed that the experiences of people with dementia in this study 
reflect the experiences of people with advanced dementia that are unable to contribute to an 
interview. It is important to remain mindful that the findings of this study therefore reflect the 
experiences of a sub-group of people with dementia. For example, in this study, a stoical 
attitude towards pain was viewed as a factor impeding the self-report of pain. However, this 
may only affect people with dementia that have ‘relatively intact insight’ during the early 
stages of dementia progression according to previous research (Chopra & Smith, 2006). 
When interviewing people with dementia and family caregivers, all but one of the dyadic 
relations were husband and wife dyads. Furthermore, all people with dementia and their 
family caregivers were white British, meaning that the unique experiences for other cultures 
and ethnic groups could not be explored. The restricted nature of the sample may limit the 
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transferability of the findings to alternative dyadic relationships (e.g. parent and child) and 
ethnic groups. 
In terms of recruitment, all people with dementia and their family caregivers were recruited 
through Join Dementia Research (JDR). Therefore, the person with dementia or their family 
caregiver must be actively interested in participating in research. Additionally, healthcare 
professionals were recruited using a snowball sample through existing clinical networks 
within the School of Primary, Community and Social Care. Healthcare professionals recruited 
in this study may have had an increased awareness of pain research due to their 
connections with the School. Each of these recruitment strategies are important when 
considering the transferability of findings to other populations. 
10.4.3.3 Analysis 
This study used thematic analysis to explore the collective meanings of pain identification, 
assessment, and management for people with dementia, offering an insight into patterns of 
meaning across the dataset (Braun & Clarke, 2012). Thematic analysis therefore does not 
facilitate the exploration of unique and idiosyncratic perspectives and experiences found only 
within a single data item (rather than across the dataset), like other alternative analytical 
approaches (e.g. narrative analysis, Interpretative Phenomenological Analysis). However, to 
reflect the research questions (see Section 4.2), it was important to identify the collective 
meaning of the key parties involved in the care of community-dwelling people with dementia, 
making thematic analysis an appropriate analytical approach. When choosing thematic 
analysis, there was a number of theoretical and analytical decisions to make (see Section 
6.3.9). The analysis in this thesis was underpinned by a critical realist theoretical perspective 
(see Section 5.3.2), and thus the interpretation was directly focused upon the explicit or 
surface meanings of the data. Therefore, it was not the purpose of this analysis to 
conceptually interrogate the underlying meaning of the data, however research of this nature 
may be useful.   
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10.5 Reflections on the study 
I approached this study with a background in Health Psychology. This equipped me with the 
knowledge and experience of both quantitative and qualitative methods, but also an 
understanding of the detrimental impact of persistent pain. Before starting the PhD, I 
provided day care support to people with dementia living in the community at a local charity. 
Alongside this role, I worked in the NHS as a Clinical Studies Assistant regularly collecting 
data for a number of dementia and mental health studies. During this employment, I collected 
data for the MARQUE project (based at University College London) which aimed to increase 
knowledge about agitation or distress behaviours for people with dementia in nursing home 
settings. Despite having previous experience of witnessing the challenges of living with 
dementia (as part of my day care role), and being aware of the agitation or distress 
behaviours in nursing homes (as part of my employment), my understanding of pain for 
people with dementia was limited.  
This study was underpinned by the theoretical perspective of critical realism. Therefore, I 
believe that pain, musculoskeletal conditions, and analgesic medications are external 
realities that exist independent of our construction of them. I also believe that each 
participant had their own subjective, real-world lived accounts of pain identification, 
assessment, and treatment shaped by culture, history, and experience (Maxwell, 2012; 
McEvoy & Richards, 2006). The use of quantitative methods allowed musculoskeletal 
conditions and analgesic medications to be measured as an ‘external reality’. Qualitative 
methods allowed insight and exploration into participants’ individual perspectives. This 
perspective was shaped by my own beliefs, experiences in education, employment, and the 
specific interests and expertise of my supervisory team.  
Despite having a knowledge of quantitative methods, I had not previously worked with ‘big 
data’ or EHR. This thesis therefore gave me the opportunity to advance my understanding 
and skills ‘cleaning’ and analysing population-level data using epidemiological principles. My 
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experience working with health record data as part of this thesis has given me the confidence 
to use this data as part of future projects.  
I have conducted qualitative interviews previously as part of my education and employment, 
however, this study was the first time that I had conducted qualitative interviews with people 
with dementia. Immersing myself within the literature related to interviewing people with 
dementia (a review of which is provided by Novek and Wilkinson, 2019), and gaining advice 
from PPIE members was important to gain an understanding of the potential encounters that 
I may face during the interviews. Although I had not previously conducted qualitative 
interviews with people with dementia, my previous involvement in dementia research means 
that I have determined if a person with dementia has the capacity to consent in research. I 
have previously undertaken training courses such as ‘An Introduction to the Valid Informed 
Consent Process’, and ‘Informed Consent with Adults Lacking Capacity’ (both through the 
Clinical Research Network). Additionally, in previous employment, I was supervised when 
determining capacity to consent, and was deemed competent by senior research staff. 
Despite the training and experiences gained before the PhD, it was essential to remain 
continually reflexive before, during, and after the consent process (using the methods 
outlined in Section 6.3.11).  
Before conducting interviews with people with dementia and their family caregivers, I 
preconceived that participants may view me as the ‘young lady from the university’. This 
preconception in hindsight was formed based upon my previous caregiving role, in which I 
felt I had a granddaughter-like relationship with the people with dementia that attended the 
day care service. Additionally, I felt that my ‘student’ status may have influenced the data 
collected; with some participants questioning my interest in dementia by asking ‘do you have 
a grandparent with dementia?’. In contrast, however, some people with dementia and family 
caregivers viewed me as an ‘expert’ in dementia, asking for my opinion on the symptoms 
experienced and the care provided to the person with dementia. Such questions highlighted 
the blurred role of the researcher. In such circumstances, I re-established my role as a 
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researcher, and the kinds of questions that I could, and could not answer. Similarly, I also 
preconceived that my ‘student’ status and social science background (rather than being a 
qualified health professional) would place me as an ‘inferior’ in the eyes of GPs and 
psychiatrists. Before entering my first GP interview, I perceived the GP as the ‘expert’ and 
myself merely as an interested PhD student. This preconception was quickly readdressed as 
many GPs viewed me as the expert in pain for people with dementia, using phrases such as 
‘you probably already know all of this’ and ‘you're going to tell me that there's a dementia 
pain scale’. When reflecting upon the data, my ‘expert’ status seemed to make GPs cautious 
to express their feelings, thoughts and experiences that deviated from the ‘right answer’. In 
an attempt to overcome this, at the start of each interview I explained to all participants that 
there was ‘no right or wrong answers’, rather I was interested in their thoughts, feelings, 
perspectives and experiences. 
10.6 Implications  
The findings of this study have implications for family caregivers, healthcare professionals, 
and policy, each of which are discussed in turn.  
10.6.1 Family caregivers 
UK policy and guidance recognised that family caregivers provide the majority of care to 
people with dementia (Department of Health, 2009). Therefore, family caregivers should 
receive the support that will enable them to assist the person with dementia to live as well as 
possible with dementia (Thompson et al., 2007). However, this study continues to highlight 
the responsibility and potential burden upon family caregivers to identify, assess, evaluate, 
treat, and monitor pain in the community. It is therefore essential that we equip family 
caregivers with the knowledge and support to identify and manage pain for the person with 
dementia (Napp Pharmaceuticals, 2014). This may involve exploring the person with 
dementia and the family caregiver’s beliefs and attitudes towards pain, and their 
understanding of pain for people with dementia. This would allow potential misconceptions to 
be explored and allow a basis for further education. For example, it might be helpful to 
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educate family caregivers about the signs of pain (and other unmet needs), especially for 
people with dementia that may have difficulty verbally communicating their pain. This is 
especially important for signs that are behavioural or psychological in nature that may be 
incorrectly attributed to dementia itself. 
10.6.2 Healthcare professionals 
This study, in line with previous literature, found that some family caregivers and healthcare 
professionals questioned if the self-reported pain of the person with dementia reflected their 
pain experience. Such beliefs contributed to the perspective that self-reported tools for 
people with dementia are inappropriate. Such findings are concerning considering that 
guidance recommends that self-report tools should be attempted to identify and assess pain 
for people with dementia irrespective of the severity of cognitive impairment (Schofield, 
2018). Recommendations should continue to emphasise the importance of attempting self-
report for people with dementia as part of a multidimensional assessment.  
Many healthcare professionals reflected upon the importance of investigating ‘behavioural 
and psychological symptoms’ as a potential indication of pain for people with dementia. 
Despite this, many expressed concern that behaviours associated with pain continue to be 
incorrectly attributed as a symptom of dementia. In accordance with this finding, in large, 
healthcare professionals were unaware of, or chose not to use dementia-specific 
assessment tools, despite recent UK pain management guidelines recommending the 
incorporation of behavioural observation tools in clinical practice (Schofield, 2018; NICE, 
2018). These findings highlight a disconnection between policy, research, and clinical 
practice when assessing pain for people with dementia in UK primary and secondary care. 
Healthcare professionals should be given the necessary support and training to implement 
behavioural observation pain tools in primary and secondary care as part of the 
multidimensional assessment of pain.  
This research identified many concerns relating to analgesic medications for people with 
dementia, including side effects, illness burden, and treatment burden. This was reflected in 
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the potential under treatment of pain, as identified in the quantitative findings. To address this 
issue, healthcare professionals should:  
 Engage with non-drug strategies as a first-line or combined approach for pain  
 Identify the optimal analgesic treatment that balances the benefits of pain relief 
against the risk of side effects, drug-disease and drug-drug interactions  
 Regularly assess the efficacy of the analgesic medication, along with the evaluation 
of potential side effects, interactions, and functioning  
Despite the importance of regularly assessing and evaluating pain for people with dementia 
(as discussed above), GPs viewed this as challenging in the time-limited context of primary 
care. The responsibility (and sometimes burden) of pain assessment, evaluation, monitoring, 
and feedback often fell upon the shoulders of family caregivers in the community. It is 
therefore essential to promote a ‘whole system’ approach in the community, including 
primary and secondary care teams and family caregivers, but also other community services, 
such as pharmacists, home care, third sector services, admiral and district nurses. Each of 
these professions have the opportunity to play a role in pain care, with the inclusion and 
consideration of pain in care plans for people with dementia (Department of Health, 2009; 
Maidment et al., 2017), given adequate support, education, and training is in place.  
10.6.3 Policy 
The UK Dementia Strategy emphasised the importance of supporting people with dementia 
to continue living in their own homes for as long as possible (Department of Health, 2009).  
BPSD are often recognised as the primary reason for nursing home and hospital admission 
(Finkell, 2000; Luppa et al., 2010), largely due to the impact on family caregivers of people 
with dementia (Chiao, Wu & Hsiao, 2015). BPSD is commonly treated using anti-psychotic 
medication despite risks of mortality and evidence of limited efficacy (Kales et al., 2012; 
Forester & Vahia, 2019). To reflect this, research and policy suggests that anti-psychotic 
medications should only be prescribed to people with dementia in exceptional circumstances 
(Department of Health, 2015). In addition, policy recommends that pain should be 
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investigated as a potential driver of BPSD for people with dementia (Department of Health, 
2015) with trial evidence (nursing home based) indicating that the administration of analgesic 
medication can lead to reductions in BPSD (see Section 1.2.3; Husebo et al., 2011a; Pieper 
et al., 2013). This thesis found that the identification and assessment of painful conditions 
was lower for people with dementia at a primary care population level, with qualitative 
findings highlighting the difficulty of determining if changes in presentation were related to 
pain, an alternative unmet need, or were a direct symptom of dementia. Clearly from the 
evidence presented, pain and pain conditions are very common in people with dementia and 
in line with these findings, guidance has called for a national public health campaign to 
educate people about the signs of pain in people with dementia (Napp Pharmaceuticals, 
2014). A campaign of this nature would aim to improve the recognition of pain, and its role as 
a potential driver of BPSD. Such action would possibly reduce inappropriate referral to 
secondary care services (e.g. old age psychiatry), and potentially lower the use of harmful 
anti-psychotic prescriptions; increasing quality of life for people with dementia and family 
caregivers.  
10.7 Future research 
The findings from this thesis indicates that the following research is needed: 
1. To test the psychometric properties and clinical utility of behavioural observation pain 
tools for people with dementia in primary care settings. Behavioural observation tools 
are recommended by UK guidelines (Schofield, 2018), however research has yet to 
investigate the clinical utility, suitability, and appropriateness of these pain 
assessment methods for a GP in a primary care setting (Corbett et al., 2014; see 
Section 2.3.3.1). Research of this nature is essential when implementing a 
behavioural observation tool in clinical practice.  
2. To examine pain management for community-dwelling people with dementia in the 
UK. This study would use a nationwide longitudinal interview survey design. Such 
research should overcome the limitations associated with longitudinal primary care 
Chapter Ten: Discussion 
 
 
391 
 
consultation data, particularly the restrictive nature of using EHR (as outlined 
elsewhere, see Section 10.4.2.1). Surveys would be facilitated by a research 
assistant, with information obtained by the person with dementia (where able) or the 
caregiver (informal or formal). The survey could include a detailed investigation of:  
 The general health of the person with dementia  
 The stage and severity of dementia  
 Examination of pain (e.g. measures of severity and impact)  
 Pharmacological pain management  
 Non-pharmacological strategies for pain 
Importantly (and currently missing from the literature), surveys would be completed 
during the first year following dementia diagnosis, and each year there onwards until 
nursing home admission, death, or the end of the study period. Although survey 
designs come with their own limitations (see Section 10.4.2.1) this method would 
allow for the first longitudinal investigation of pharmacological (including over-the-
counter and prescribed medication) and non-pharmacological management for 
people with dementia in the UK throughout the progression of their condition. This 
may help to identify individuals at an increased risk of a poor outcome (early nursing 
home admission, mortality) and whether pain and complications about the 
assessment and management of pain contribute to those outcomes. Having 
knowledge about risk factors is the first step for future intervention design. 
3. A mixed methods investigation of an educational intervention to improve pain 
identification and pain assessment for people with dementia in primary care. Primary 
care team members (e.g. GPs, nursing staff, healthcare members) would receive a 
training package based upon up to date UK guidelines and evidence (Abdulla et al., 
2013; Schofield, 2018). The training package would include information and practical 
guidance on:  
 Self-report (The Numerical Rating Scale or verbal descriptors; Schofield, 
2018)  
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 Behavioural observation (PAINAD and Doloplus-2 scale; Schofield, 2018) 
 Clinical guidelines for non-pharmacological and analgesic prescription for 
people with dementia (AGS Panel, 2009; Abdulla et al., 2013).  
Primary care team members would be provided with educational resources reiterating 
the messages provided in the training. A qualitative evaluation, with interviews with 
trainees would assess the feasibility and appropriateness of the intervention as a 
process evaluation to determine integration and implementation of the educational 
intervention into practice. Quantitative analysis would examine the prescription of 
analgesics for people with dementia prior to and after the intervention.  
10.8 Conclusion  
This chapter provided an overview of the key findings of this thesis, organised by each 
research objective, with comparison to previous relevant literature identified throughout the 
literature and systematic review. An overview of the strengths, challenges, and limitations 
pertaining to the mixed methods approach, including the quantitative and qualitative 
elements were considered. Key reflections on the study, and implications of this research for 
family caregivers, practice, and policy were highlighted, with suggestions for future research.  
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Appendix 1: Medline Ovid Search Strategy 
1 exp Analgesics/ 
2 analgesi*.ti,ab. 
3 drug*.ti,ab. 
4 ("drug*" adj3 "trial").ti,ab. 
5 medication*.ti,ab. 
6 prescription*.ti,ab. 
7 pharmacolog*.ti,ab. 
8 ("pain" adj3 "manag*").ti,ab. 
9 assess*.ti,ab. 
10 treat*.ti,ab. 
11 opioid*.ti,ab. 
12 paracetamol.ti,ab. 
13 acetaminophen.ti,ab. 
14 tylenol.ti,ab. 
15 panadol.ti,ab. 
16 NSAIDS.ti,ab. 
17 (non?steroidal adj3 anti?inflammatory).ti,ab. 
18 morphine.ti,ab. 
19 codeine.ti,ab. 
20 narcotic.ti,ab. 
21 opium.ti,ab. 
22 buprenorphine.ti,ab. 
23 dextromoramide.ti,ab. 
24 diphenoxylate.ti,ab. 
25 dipipanone.ti,ab. 
26 dextropropoxyphene.ti,ab. 
27 propoxyphene.ti,ab. 
28 diamorphine.ti,ab. 
29 dihydrocodeine.ti,ab. 
30 alfentanil.ti,ab. 
31 fentanyl.ti,ab. 
32 remifentanil.ti,ab. 
33 meptazinol.ti,ab. 
34 methadone.ti,ab. 
35 nalbuphine.ti,ab. 
36 oxycodone.ti,ab. 
37 papaveretum.ti,ab. 
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38 pentazocine.ti,ab. 
39 meperidine.ti,ab. 
40 pethidine.ti,ab. 
41 phenazocine.ti,ab. 
42 hydrocodone.ti,ab. 
43 hydromorphone.ti,ab. 
44 levorphanol.ti,ab. 
45 oxymorphone.ti,ab. 
46 butorphanol.ti,ab. 
47 dezocine.ti,ab. 
48 sufentanil.ti,ab. 
49 ketobemidone.ti,ab. 
50 Gabapentin.ti,ab. 
51 Pregabalin.ti,ab. 
52 Amitriptyline.ti,ab. 
53 Duloxetine.ti,ab. 
54 Capsaicin cream.ti,ab. 
55 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 
or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 
56 exp Exercise/ 
57 exp Cognitive Therapy/ 
58 therap*.ti,ab. 
59 non?pharmacol*.ti,ab. 
60 physiotherap*.ti,ab. 
61 rehabilitation.ti,ab. 
62 aromatherap*.ti,ab. 
63 art therap*.ti,ab. 
64 acoustic stimulation.ti,ab. 
65 (colo?r adj3 therap*).ti,ab. 
66 music.ti,ab. 
67 (play adj3 therap*).ti,ab. 
68 movement.ti,ab. 
69 role play.ti,ab. 
70 tai chi.ti,ab. 
71 Qigong.ti,ab. 
72 motion.ab,ti. 
73 aerobic*.ti,ab. 
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74 strength*.ti,ab. 
75 reminisc*.ti,ab. 
76 guided imag*.ti,ab. 
77 mindful*.ti,ab. 
78 re?ki.ti,ab. 
79 biofeedback.ti,ab. 
80 transcutaneous electric* nerve stimulation.ti,ab. 
81 TENS.ti,ab. 
82 physical therap*.ti,ab. 
83 cognitive behavio?ral therap*.ti,ab. 
84 CBT.ti,ab. 
85 acupuncture.ti,ab. 
86 psychosocial.ti,ab. 
87 massage.ti,ab. 
88 danc*.ti,ab. 
89 hypnosis.ti,ab. 
90 (hot adj3 therap*).ti,ab. 
91 (cold adj3 therap*).ti,ab. 
92 (watching adj3 TV).ti,ab. 
93 (watching adj3 television).ti,ab. 
94 rest*.ti,ab. 
95 breath*.ti,ab. 
96 (nutrition* adj3 supplement*).ti,ab. 
97 herbal preparation*.ti,ab. 
98 self management.ti,ab. 
99 educati*.ti,ab. 
100 exercis*.ti,ab. 
101 physical activit*.ti,ab. 
102 cycling.ti,ab. 
103 swim*.ab,ti. 
104 gym*.ab,ti. 
105 walk*.ti,ab. 
106 treadmill*.ti,ab. 
107 yoga*.ti,ab. 
108 program*.ti,ab. 
109 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 
or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 
85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 
or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 
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110 exp Pain Measurement/ 
111 (pain adj3 tool).ti,ab. 
112 (rating adj3 pain).ti,ab. 
113 (scale* adj3 pain).ti,ab. 
114 (measur* adj3 pain).ti,ab. 
115 (assess* adj3 pain).ti,ab. 
116 (pain adj3 behavio?r).ti,ab. 
117 (observat* adj3 pain).ti,ab. 
118 (identif* adj3 pain).ti,ab. 
119 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 
120 exp Pain/ 
121 discomfort.ti,ab. 
122 nociception.ti,ab. 
123 pain*.ti,ab. 
124 120 or 121 or 122 or 123 
125 exp Primary Health Care/ 
126 exp General Practitioners/ 
127 exp Community Health Services/ 
128 communit*.ti,ab. 
129 community dwelling.ti,ab. 
130 domestic.ti,ab. 
131 (home adj3 dwelling).ti,ab. 
132 general practi*.ti,ab. 
133 family practi*.ti,ab. 
134 family doctor.ti,ab. 
135 GP.ti,ab. 
136 GPs.ti,ab. 
137 doctor*.ti,ab. 
138 outpatient*.ti,ab. 
139 physician.ti,ab. 
140 (practice adj3 nurse).ti,ab. 
141 (primary adj3 care).ti,ab. 
142 (primary adj3 health adj3 care).ti,ab. 
143 (district adj3 nurse).ti,ab. 
144 clinician*.ti,ab. 
145 psychiatr*.ti,ab. 
146 pharmac*.ti,ab. 
147 (community adj3 nurse).ti,ab. 
148 occupational therap*.ti,ab. 
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149 (ambulatory adj3 care).ti,ab. 
150 physiotherap*.ti,ab. 
151 Community Health Service*.ti,ab. 
152 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 
137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 
149 or 150 or 151 
153 exp Dementia/ 
154 dement*.ti,ab. 
155 (cognitive* adj3 impair*).ti,ab. 
156 Alzheimer*.ti,ab. 
157 lewy* bod*.ti,ab. 
158 pick* disease.ti,ab. 
159 creutzfeldt.ti,ab. 
160 huntington*.ti,ab. 
161 binswanger*.ti,ab. 
162 Wernicke Korsakoff.ti,ab. 
163 153 or 154 or 155 or 156 or 157 or 158 or 159 or 160 or 161 or 162 
164 55 or 109 or 119 
165 164 and 124 and 152 and 163 
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Appendix 2: Systematic review quality assessment 
Quality of observational studies using the National Institute of Health Quality Assessment 
Tool for Observational Cohort and Cross-Sectional Studies  
Study Quality assessment criteriaa 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
Overal
l 
Barry et al   -     -   - - -  Fair 
Bell et al            - -  Fair 
Breland,et al    -        - - - - Fair 
Brummel-Smith et 
al 
   -  -      - - - Poor 
Gallini et al            - -   Fair 
Gilmartin et al             -   Good 
Grace et al        -   - - - - Fair 
Haasum, et al            - -  Fair 
Hamina et al 
(2016) 
           -  - Fair 
Hamina et al 
(2017) 
           -   Good 
Hamina et al 
(2018) 
            - - Good 
Hartikainel et al 
(2005b) 
           - - - Fair 
Hartikainen et al 
(2005a) 
           - -  Fair 
Hunt et al        -   - - -  Poor 
Jensen-Dahm, et al 
(2012) 
           - -  Fair 
Jensen-Dahm, et al 
(2015) 
 -      -   - - - - Fair 
Krulewitch et al   -  -    -     - - Poor 
Li et al (2015)   -         - - - Fair 
Mäntyselkä, et al        -   - - -  Fair 
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Orgeta et al   - -        - -  Fair 
Reigier & Gitlin   - - -   -   - - - - Fair 
Schmader et al      -     - - - - Fair 
Shega et al (2006)    -        - - - Fair 
Shega, et al (2004)    -        - - - Fair 
Shega, et al (2005)    -  -       - - Fair 
Snow et al            -  - Good 
Thakur et al    -       - - - - Fair 
“”, yes; “”, no; “-“, not applicable, not known, cannot determine. 
a (1) Was the research question or objective in this paper clearly stated? (2) Was the study population 
clearly specified and defined? (3) Was the participation rate of eligible persons at least 50%? (4) 
Were all the subjects selected or recruited from the same or similar populations? Were inclusion and 
exclusion criteria for being in the study prespecified and applied uniformly to all participants? (5) Was 
a sample size justification, power description, or variance and effect estimates provided? (6) For the 
analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being 
measured? (7) Was the timeframe sufficient so that one could reasonably expect to see an 
association between exposure and outcome if it existed? (8) For exposures that can vary in amount 
or level, did the study examine different levels of the exposure as related to the outcome (e.g., 
categories of exposure, or exposure measured as continuous variable)? (9) Were the exposure 
measures (independent variables) clearly defined, valid, reliable, and implemented consistently 
across all study participants? (10) Was the exposure(s) assessed more than once over time? (11) 
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? (12) Were the outcome assessors blinded to the exposure 
status of participants? (13) Was loss to follow-up after baseline 20% or less? (14) Were key potential 
confounding variables measured and adjusted statistically for their impact on the relationship 
between exposure(s) and outcome(s)? 
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Quality of observational studies using the National Institute of Health Quality Assessment 
Tool for Case-Control Studies 
Study Quality assessment criteriaa 
1 2 3 4 5 6 7 8 9 10 11 12 Overall 
Gallini, et 
al  
            Fair 
“”, yes; “”, no; “-“, not applicable, not known, cannot determine. 
a1. Was the research question or objective in this paper clearly stated and appropriate? 2. Was 
the study population clearly specified and defined? 3. Did the authors include a sample size 
justification? 4. Were controls selected or recruited from the same or similar population that gave 
rise to the cases (including the same timeframe)? 5. Were the definitions, inclusion and 
exclusion criteria, algorithms or processes used to identify or select cases and controls valid, 
reliable, and implemented consistently across all study participants? 6. Were the cases clearly 
defined and differentiated from controls? 7. If less than 100 percent of eligible cases and/or 
controls were selected for the study, were the cases and/or controls randomly selected from 
those eligible? 8. Was there use of concurrent controls? 9. Were the investigators able to confirm 
that the exposure/risk occurred prior to the development of the condition or event that defined a 
participant as a case? 10. Were the measures of exposure/risk clearly defined, valid, reliable, 
and implemented consistently (including the same time period) across all study participants? 11. 
Were the assessors of exposure/risk blinded to the case or control status of participants? 12. 
Were key potential confounding variables measured and adjusted statistically in the analyses? If 
matching was used, did the investigators account for matching during study analysis? 
**Study by Gallini is a nested case-control within a cohort design, and therefore quality 
assessment was conducted using two assessment tools.  
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National Institute of Health Quality Assessment Tool for Before-After (Pre-Post) Studies with 
No Control Group 
Study Quality assessment criteria a 
1 2 3 4 5 6 7 8 9 10 11 Overall 
Elliott & Horgas   - -       - Poor  
Park   - - -      - Poor 
Nakanishi et al    -  -     - Poor 
“”, yes; “”, no; “-“, not applicable, not known, cannot determine. 
a 1. Was the study question or objective clearly stated? 2. Were eligibility/selection criteria for the 
study population prespecified and clearly described? 3. Were the participants in the study 
representative of those who would be eligible for the test/service/intervention in the general or 
clinical population of interest? 4. Were all eligible participants that met the prespecified entry 
criteria enrolled? 5. Was the sample size sufficiently large to provide confidence in the findings? 
6. Was the test/service/intervention clearly described and delivered consistently across the study 
population? 7. Were the outcome measures prespecified, clearly defined, valid, reliable, and 
assessed consistently across all study participants? 8. Were the people assessing the outcomes 
blinded to the participants' exposures/interventions? 9. Was the loss to follow-up after baseline 
20% or less? Were those lost to follow-up accounted for in the analysis? 10. Did the statistical 
methods examine changes in outcome measures from before to after the intervention? Were 
statistical tests done that provided p values for the pre-to-post changes? 11. Were outcome 
measures of interest taken multiple times before the intervention and multiple times after the 
intervention (i.e., did they use an interrupted time-series design)? 12. If the intervention was 
conducted at a group level (e.g., a whole hospital, a community, etc.) did the statistical analysis 
take into account the use of individual-level data to determine effects at the group level? 
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National Institute of Health Quality Assessment Tool for Controlled Intervention Studies 
Study Quality assessment criteriaa 
 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
Overal
l 
Benedetti et al     - - -    -     Fair 
Kunik et al       -        Poor 
“”, yes; “”, no; “-“, not applicable, not known, cannot determine. 
a 1. Was the study described as randomized, a randomized trial, a randomized clinical trial, or an 
RCT? 2. Was the method of randomization adequate (i.e., use of randomly generated 
assignment)? 3. Was the treatment allocation concealed (so that assignments could not be 
predicted)? 4. Were study participants and providers blinded to treatment group assignment? 5. 
Were the people assessing the outcomes blinded to the participants' group assignments? 6. Were 
the groups similar at baseline on important characteristics that could affect outcomes (e.g., 
demographics, risk factors, co-morbid conditions)? 7. Was the overall drop-out rate from the study 
at endpoint 20% or lower of the number allocated to treatment? 8. Was the differential drop-out rate 
(between treatment groups) at endpoint 15 percentage points or lower? 9. Was there high 
adherence to the intervention protocols for each treatment group? 10. Were other interventions 
avoided or similar in the groups (e.g., similar background treatments)? 11. Were outcomes 
assessed using valid and reliable measures, implemented consistently across all study 
participants? 12. Did the authors report that the sample size was sufficiently large to be able to 
detect a difference in the main outcome between groups with at least 80% power? 13. Were 
outcomes reported or subgroups analyzed prespecified (i.e., identified before analyses were 
conducted)? 14. Were all randomized participants analyzed in the group to which they were 
originally assigned, i.e., did they use an intention-to-treat analysis? 
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Appendix 3: ISAC CPRD study approval 
 
ISAC EVALUATION OF PROTOCOLS FOR RESEARCH INVOLVING CPRD DATA 
 
FEEDBACK TO APPLICANTS 
 
12.1 CONFIDENTIAL                                                                       by e-mail 
12.2 PROTOCOL NO: 12.3 17_240RA 
12.4 PROTOCOL 
TITLE:  
Dementia and Musculoskeletal Pain: Consultation and Treatment Patterns in 
Primary Care 
12.5 APPLICANT:  Dr John Bedson 
Keele University 
j.bedson@keele.ac.uk 
12.5.1 APPROV
ED  
12.5.2   
APPROVED WITH COMMENTS  
(resubmission not required)  
  
REVISION/ 
RESUBMISSION 
REQUESTED  
  
REJECTED  
 
 
INSTRUCTIONS: 
Protocols with an outcome of ‘Approved’ or ‘Approved with comments’ do not require 
resubmission to the ISAC. 
 
REVIEWER  COMMENTS: 
It isn’t completely clear how the family number will be used, this is an identifier that links individuals in 
the same ‘household’ rather than a number indicating how many people are resident. Presumably the 
applicants will be deriving the information they need from this variable.  
DATE OF ISAC FEEDBACK: 11/12/18 
DATE OF APPLICANT FEEDBACK:  
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Appendix 4: Clinical code lists 
Each table below includes clinical codes (starting from the most commonly recorded to least 
commonly recorded) for each clinical entity. If the code list included more than 100 codes, 
only the first 100 are included below. Full clinical codes available upon request.  
 
i. Dementia diagnostic and product codes 
ii. Musculoskeletal condes 
iii. Analgesic prescription codes 
iv. Cancer codes 
v. Formal residence codes 
vi. Cardiovascular-related codes 
vii. Depression/bipolar codes 
viii. Diabetes codes 
i. Dementia diagnostic codes 
Dementia diagnosis codes 
Medcode Read code Read term 
12710 6AB..00 
Dementia annual review 
1350 E00..12 
Senile/presenile dementia 
1917 F110.00 
Alzheimer's disease 
6578 Eu01.00 
[X]Vascular dementia 
4693 Eu02z00 
[X] Unspecified dementia 
1916 E00..11 
Senile dementia 
7664 Eu00.00 
[X]Dementia in Alzheimer's disease 
7323 E000.00 
Uncomplicated senile dementia 
5931 1461 
H/O: dementia 
2882 E00z.00 
Senile or presenile psychoses NOS 
4357 Eu02z14 
[X] Senile dementia NOS 
55023 66h..00 
Dementia monitoring 
2731 F11z.11 
Cerebral atrophy 
8195 Eu00z11 
[X]Alzheimer's dementia unspec 
8634 E004.11 
Multi infarct dementia 
33707 E00..00 
Senile and presenile organic psychotic conditions 
26270 Eu02500 
[X]Lewy body dementia 
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19477 E004.00 
Arteriosclerotic dementia 
30706 Eu00200 
[X]Dementia in Alzheimer's dis, atypical or mixed type 
5651 F11z.00 
Cerebral degeneration NOS 
15249 E00y.00 
Other senile and presenile organic psychoses 
9509 Eu02300 
[X]Dementia in Parkinson's disease 
15165 E001.00 
Presenile dementia 
25386 E041.00 
Dementia in conditions EC 
7572 F116.00 
Lewy body disease 
11379 Eu00112 
[X]Senile dementia,Alzheimer's type 
11175 Eu01100 
[X]Multi-infarct dementia 
29386 Eu00z00 
[X]Dementia in Alzheimer's disease, unspecified 
31016 Eu01300 
[X]Mixed cortical and subcortical vascular dementia 
19393 Eu01z00 
[X]Vascular dementia, unspecified 
9565 Eu01.11 
[X]Arteriosclerotic dementia 
32057 F110100 
Alzheimer's disease with late onset 
38678 Eu00100 
[X]Dementia in Alzheimer's disease with late onset 
12621 Eu02.00 
[X]Dementia in other diseases classified elsewhere 
27342 E012.11 
Alcoholic dementia NOS 
16797 F110000 
Alzheimer's disease with early onset 
21887 E002100 
Senile dementia with depression 
29512 F112.00 
Senile degeneration of brain 
26323 Eu10711 
[X]Alcoholic dementia NOS 
18386 E002000 
Senile dementia with paranoia 
37015 E003.00 
Senile dementia with delirium 
49263 Eu00000 
[X]Dementia in Alzheimer's disease with early onset 
42279 E004z00 
Arteriosclerotic dementia NOS 
11136 F111.00 
Pick's disease 
27935 Eu02z15 
[X] Senile psychosis NOS 
23835 E040.11 
Korsakoff's non-alcoholic psychosis 
8934 Eu01200 
[X]Subcortical vascular dementia 
44674 E002.00 
Senile dementia with depressive or paranoid features 
55313 Eu01y00 
[X]Other vascular dementia 
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38438 E001z00 
Presenile dementia NOS 
9415 R201.00 
[D]Senescence 
37014 Eu02200 
[X]Dementia in Huntington's disease 
28402 Eu02000 
[X]Dementia in Pick's disease 
27759 Eu02z16 
[X] Senile dementia, depressed or paranoid type 
30032 E001200 
Presenile dementia with paranoia 
27677 E001300 
Presenile dementia with depression 
43089 E004000 
Uncomplicated arteriosclerotic dementia 
53446 Eu04100 
[X]Delirium superimposed on dementia 
34944 Eu02z13 
[X] Primary degenerative dementia NOS 
49513 E001100 
Presenile dementia with delirium 
48531 F11x700 
Cerebral degeneration due to Jakob - Creutzfeldt disease 
64267 Eu02y00 
[X]Dementia in other specified diseases classif elsewhere 
38286 A411.00 
Jakob-Creutzfeldt disease 
43292 E004300 
Arteriosclerotic dementia with depression 
43346 Eu00113 
[X]Primary degen dementia of Alzheimer's type, senile onset 
48501 Eu02z11 
[X] Presenile dementia NOS 
47555 F11x000 
Cerebral degeneration due to alcoholism 
46488 Eu01000 
[X]Vascular dementia of acute onset 
46762 Eu00111 
[X]Alzheimer's disease type 1 
25704 Eu00011 
[X]Presenile dementia,Alzheimer's type 
47619 Eu02z12 
[X] Presenile psychosis NOS 
54106 Eu02100 
[X]Dementia in Creutzfeldt-Jakob disease 
96860 F11x900 
Cerebral degeneration in Parkinson's disease 
55467 E004200 
Arteriosclerotic dementia with paranoia 
54744 F11x200 
Cerebral degeneration due to cerebrovascular disease 
42602 E001000 
Uncomplicated presenile dementia 
41089 E002z00 
Senile dementia with depressive or paranoid features NOS 
55838 Eu01111 
[X]Predominantly cortical dementia 
34976 F11y.00 
Other cerebral degeneration 
31524 F11yz00 
Other cerebral degeneration NOS 
56912 E004100 
Arteriosclerotic dementia with delirium 
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60059 Eu00012 
[X]Primary degen dementia, Alzheimer's type, presenile onset 
62056 BBC9.11 
[M]Pick's tubular adenoma 
61528 Eu00013 
[X]Alzheimer's disease type 2 
59122 Fyu3000 
[X]Other Alzheimer's disease 
55222 ZS7C500 
Language disorder of dementia 
44592 F11xz00 
Cerebral degeneration other disease NOS 
47658 F11x500 
Cerebral degeneration due to myxoedema 
93372 F103.00 
Cerebral degeneration in diseases EC 
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Dementia drug product codes 
Prodcode 
Product name 
2931 
Donepezil 10mg tablets 
2930 
Donepezil 5mg tablets 
39240 
Memantine 20mg tablets 
6225 
Memantine 10mg tablets 
7361 
Galantamine 24mg modified-release capsules 
5247 
Aricept 10mg tablets (Eisai Ltd) 
14309 
Galantamine 16mg modified-release capsules 
11751 
Rivastigmine 3mg capsules 
37132 
Rivastigmine 9.5mg/24hours transdermal patches 
4597 
Rivastigmine 1.5mg capsules 
5400 
Aricept 5mg tablets (Eisai Ltd) 
11635 
Galantamine 12mg tablets 
10255 
Galantamine 8mg modified-release capsules 
11654 
Galantamine 8mg tablets 
36976 
Rivastigmine 4.6mg/24hours transdermal patches 
11752 
Rivastigmine 4.5mg capsules 
9786 
Rivastigmine 6mg capsules 
35088 
Donepezil 10mg orodispersible tablets sugar free 
11837 
Memantine 10mg/ml oral solution sugar free 
35179 
Donepezil 5mg orodispersible tablets sugar free 
24088 
Reminyl XL 24mg capsules (Shire Pharmaceuticals Ltd) 
10187 
Galantamine 4mg tablets 
48443 
Donepezil 10mg orodispersible tablets 
20140 
Reminyl XL 16mg capsules (Shire Pharmaceuticals Ltd) 
37957 
Exelon 9.5mg/24hours transdermal patches (Novartis Pharmaceuticals UK Ltd) 
18800 
Ebixa 10mg tablets (Lundbeck Ltd) 
55720 
Gatalin XL 24mg capsules (Aspire Pharma Ltd) 
56709 
Gatalin XL 16mg capsules (Aspire Pharma Ltd) 
7329 
Galantamine 20mg/5ml oral solution sugar free 
48442 
Donepezil 5mg orodispersible tablets 
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18587 
Reminyl XL 8mg capsules (Shire Pharmaceuticals Ltd) 
5334 
Reminyl 12mg tablets (Shire Pharmaceuticals Ltd) 
11827 
Rivastigmine 2mg/ml oral solution sugar free 
18062 
Reminyl 8mg tablets (Shire Pharmaceuticals Ltd) 
39363 
Ebixa 20mg tablets (Lundbeck Ltd) 
11716 
Exelon 3mg capsules (Novartis Pharmaceuticals UK Ltd) 
37444 
Exelon 4.6mg/24hours transdermal patches (Novartis Pharmaceuticals UK Ltd) 
39362 
Ebixa tablets treatment initiation pack (Lundbeck Ltd) 
11546 
Exelon 1.5mg capsules (Novartis Pharmaceuticals UK Ltd) 
9966 
Ebixa 5mg/0.5ml pump actuation oral solution (Lundbeck Ltd) 
61921 
Luventa XL 24mg capsules (Fontus Health Ltd) 
37188 
Aricept Evess 10mg orodispersible tablets (Eisai Ltd) 
38976 
Memantine 5mg+10mg+15mg+20mg Tablet 
56421 
Gatalin XL 8mg capsules (Aspire Pharma Ltd) 
9854 
Reminyl 4mg tablets (Shire Pharmaceuticals Ltd) 
56631 
Rivastigmine 13.3mg/24hours transdermal patches 
5616 
Exelon 6mg capsules (Novartis Pharmaceuticals UK Ltd) 
29288 
Reminyl 4mg/ml oral solution (Shire Pharmaceuticals Ltd) 
20404 
Exelon 4.5mg capsules (Novartis Pharmaceuticals UK Ltd) 
53882 
Rivastigmine 2mg/ml oral solution 
62164 
Alzest 9.5mg/24hours transdermal patches (Dr Reddy's Laboratories (UK) Ltd) 
61676 
Donepezil 1mg/ml oral solution sugar free 
66899 
Memantine 20mg orodispersible tablets sugar free 
63360 
Luventa XL 16mg capsules (Fontus Health Ltd) 
36848 
Aricept Evess 5mg orodispersible tablets (Eisai Ltd) 
61920 
Luventa XL 8mg capsules (Fontus Health Ltd) 
59993 
Galzemic XL 16mg capsules (Creo Pharma Ltd) 
60493 
Galzemic XL 24mg capsules (Creo Pharma Ltd) 
66934 
Memantine 10mg orodispersible tablets sugar free 
62780 
Alzest 4.6mg/24hours transdermal patches (Dr Reddy's Laboratories (UK) Ltd) 
18556 
Exelon 2mg/ml oral solution (Novartis Pharmaceuticals UK Ltd) 
58780 
Voleze 9.5mg/24hours transdermal patches (Focus Pharmaceuticals Ltd) 
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62868 
Gazylan XL 24mg capsules (Teva UK Ltd) 
61618 
Nemdatine 20mg tablets (Actavis UK Ltd) 
48015 
Galsya XL 24mg capsules (Consilient Health Ltd) 
60192 
Galzemic XL 8mg capsules (Creo Pharma Ltd) 
57171 
Erastig 9.5mg/24hours transdermal patches (Teva UK Ltd) 
63226 Prometax 9.5mg/24hours transdermal patches (Novartis Pharmaceuticals UK 
Ltd) 
61385 
Nemdatine 10mg tablets (Actavis UK Ltd) 
63405 
Galsya XL 16mg capsules (Consilient Health Ltd) 
61476 
Acumor XL 24mg capsules (Mylan Ltd) 
57627 
Erastig 4.6mg/24hours transdermal patches (Teva UK Ltd) 
64982 
Memantine 20mg tablets (Teva UK Ltd) 
48482 
Galsya XL 8mg capsules (Consilient Health Ltd) 
62867 
Gazylan XL 16mg capsules (Teva UK Ltd) 
68792 
Memantine 10mg/ml oral solution sugar free (Chanelle Medical UK Ltd) 
69638 Memantine 5mg/10mg/15mg/20mg 4 week treatment initiation pack (Lupin 
(Europe) Ltd) 
65573 
Gazylan XL 8mg capsules (Teva UK Ltd) 
62925 
Acumor XL 16mg capsules (Mylan Ltd) 
59330 
Voleze 4.6mg/24hours transdermal patches (Focus Pharmaceuticals Ltd) 
65501 
Eluden 4.6mg/24hours transdermal patches (Mylan Ltd) 
63951 
Rivastigmine 9.5mg/24hours transdermal patches (Actavis UK Ltd) 
68493 
Nemdatine tablets treatment initiation pack (Actavis UK Ltd) 
58937 
Exelon 13.3mg/24hours transdermal patches (Novartis Pharmaceuticals UK Ltd) 
68845 
Memantine 10mg/ml oral solution sugar free (A A H Pharmaceuticals Ltd) 
65761 
Eluden 9.5mg/24hours transdermal patches (Mylan Ltd) 
65333 Memantine 10mg/ml oral solution sugar free (Alliance Healthcare (Distribution) 
Ltd) 
69595 
Marixino 20mg tablets (Consilient Health Ltd) 
59871 
Donepezil 10mg/5ml oral suspension 
53842 
Aricept 5mg tablets (Waymade Healthcare Plc) 
53922 
Donepezil 10mg orodispersible tablets (Consilient Health Ltd) 
58709 
Donepezil 10mg tablets (A A H Pharmaceuticals Ltd) 
56600 
Donepezil 5mg tablets (Zentiva) 
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57139 
Ebixa 10mg tablets (DE Pharmaceuticals) 
55928 
Exelon 4.5mg capsules (Waymade Healthcare Plc) 
56771 
Rivastigmine 3mg capsules (Dr Reddy's Laboratories (UK) Ltd) 
60723 
Rivastigmine 6mg capsules (Waymade Healthcare Plc) 
68802 
Donepezil 5mg tablets (Waymade Healthcare Plc) 
68494 
Rivastigmine 6mg capsules (A A H Pharmaceuticals Ltd) 
69564 Prometax 4.6mg/24hours transdermal patches (Novartis Pharmaceuticals UK 
Ltd) 
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ii. Musculoskeletal codes 
Medcode Readcode Read term 
154 N142.11 Low back pain 
123 N131.00 Cervicalgia - pain in neck 
198 N245.17 Shoulder pain 
9517 1M10.00 Knee pain 
3324 16C6.00 Back pain without radiation NOS 
313 N143.00 Sciatica 
153 16C2.00 Backache 
3763 16C5.00 C/O - low back pain 
554 N094611 Knee joint pain 
396 N05..11 Osteoarthritis 
286 N094K12 Hip pain 
557 N145.00 Backache, unspecified 
1219 N245.16 Leg pain 
855 N245.13 Foot pain 
5864 N094.00 Pain in joint - arthralgia 
360 N213211 Tennis elbow 
1258 N245.11 Ankle pain 
5780 N245200 Pain in leg 
734 N217900 Plantar fasciitis 
1330 N094512 Hip joint pain 
822 N245.12 Arm pain 
17799 1M11.00 Foot pain 
587 N06z.11 Arthritis 
2786 16C..00 Backache symptom 
202 N094000 Arthralgia of unspecified site 
3518 R065A00 [D]Musculoskeletal chest pain 
874 N210.12 Frozen shoulder 
3057 N05..00 Osteoarthritis and allied disorders 
2519 182B.00 Rib pain 
5787 N245700 Shoulder pain 
2025 N245.14 Hand pain 
2487 N05zL00 Osteoarthritis NOS, of knee 
1946 N245111 Toe pain 
665 N05z611 Knee osteoarthritis NOS 
771 N110.11 Cervical spondylosis 
2881 N110.00 Cervical spondylosis without myelopathy 
2521 N094311 Wrist joint pain 
1338 N241000 Myalgia unspecified 
1497 R00z211 [D]General aches and pains 
2494 N245.15 Heel pain 
5762 N245300 Pain in arm 
1209 N217400 Achilles tendinitis 
495 N213300 Olecranon bursitis 
5440 N241012 Muscle pain 
2532 N245400 Calf pain 
1335 N142.00 Pain in lumbar spine 
2284 N242000 Neuralgia unspecified 
5776 N05z.00 Osteoarthritis NOS 
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Medcode Readcode Read term 
6044 N094M00 Arthralgia of knee 
6496 N14z.00 Back disorders NOS 
3677 N0z..00 Arthropathies NOS 
743 N236.00 Dupuytren's contracture 
3322 N245012 Finger pain 
1129 N221.00 Bunion 
3252 N224.00 Ganglion and cyst of synovium, tendon and bursa 
3546 N215700 Trochanteric bursitis 
6520 N245000 Hand pain 
4544 N245.00 Pain in limb 
1339 N245011 Thumb pain 
4795 N213200 Lateral epicondylitis of the elbow 
1104 N053512 Hip osteoarthitis NOS 
12189 16CA.00 Mechanical low back pain 
864 N21z211 Tendonitis NOS 
1212 N147200 Coccygodynia 
827 N210.00 Adhesive capsulitis of the shoulder 
10231 16C9.00 Chronic low back pain 
1166 N074.00 Chondromalacia patellae 
1287 N217200 Metatarsalgia NOS 
1418 N094900 Arthralgia of multiple joints 
237 N224300 Ganglion unspecified 
1646 N094211 Elbow joint pain 
11962 1M00.00 Pain in elbow 
1455 R01z200 [D]Musculoskeletal pain 
1604 N324400 Osgood-Schlatter's dis - osteochondrosis of tibial tubercle 
1866 N245.18 Thigh pain 
6704 N145.12 Back pain, unspecified 
471 N350.00 Hallux valgus - acquired 
2380 N220300 Trigger finger - acquired 
99477 1M01.00 Pain in wrist 
1726 N211.00 Rotator cuff shoulder syndrome and allied disorders 
4948 N141.00 Pain in thoracic spine 
4353 N050.00 Generalised osteoarthritis - OA 
1720 N142.14 Lumbago 
5489 N212500 Shoulder tendonitis 
717 N248.00 Fibromyalgia 
332 N216500 Prepatellar bursitis 
6695 1D22.11 C/O - a chest wall symptom 
5999 N094F00 Arthralgia of wrist 
1606 N146z11 Sacroiliac strain 
443 N090611 Knee joint effusion 
5916 N141.11 Acute back pain - thoracic 
3536 N135.00 Torticollis unspecified 
6166 N094W00 Anterior knee pain 
730 N213111 Golfer's elbow 
14823 R065200 [D]Anterior chest wall pain 
2175 Nz...00 Musculoskeletal and connective tissue diseases NOS 
19322 1M13.00 Ankle pain 
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Medcode Readcode Read term 
5923 N145.11 Acute back pain - unspecified 
1355 16A2.00 Stiff neck 
6313 1D13111 C/O - pain in big toe 
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iii. Analgesic prescription codes 
Basic analgesic 
Prodcode Product name Substance strength 
7 Paracetamol 500mg tablets 500mg 
15 Ibuprofen 400mg tablets 400mg 
139 Paracetamol 500mg capsules 500mg 
332 Ibuprofen 5% gel 50mg/1gram 
1609 Paracetamol 500mg soluble tablets 500mg 
156 Diclofenac 1.16% gel 11.6mg/1gram 
416 Ibuprofen 200mg tablets 200mg 
1113 Movelat cream (Genus Pharmaceuticals Ltd) 
2mg/1gram + 
20mg/1gram 
434 Aspirin 300mg gastro-resistant tablets 300mg 
1544 Piroxicam 0.5% gel 5mg/1gram 
377 Aspirin 300mg dispersible tablets 300mg 
1653 Movelat gel (Genus Pharmaceuticals Ltd) 
20mg/1gram + 
2mg/1gram 
827 
Voltarol 1.16% Emulgel (GlaxoSmithKline Consumer 
Healthcare) 11.6mg/1gram 
262 Paracetamol 250mg/5ml oral suspension 50mg/1ml 
5701 Algesal cream (Thornton & Ross Ltd) 100mg/1gram 
2938 Ibuprofen 100mg/5ml Oral suspension 100mg/5ml 
559 Traxam 3% gel (AMCo) 30mg/1gram 
4186 Paracetamol 250mg/5ml oral suspension sugar free 250mg/5ml 
254 Aspirin 300mg tablets 300mg 
5767 Ibuprofen 10% gel 100mg/1gram 
1156 Ibugel 5% gel (Dermal Laboratories Ltd) 50mg/1gram 
2858 Feldene 0.5% gel (Pfizer Ltd) 5mg/1gram 
2606 Ketoprofen 2.5% gel 25mg/1gram 
1739 Brufen 400mg tablets (Mylan Ltd) 400mg 
6231 Capsaicin 0.025% cream 250microgram/1gram 
3587 Felbinac 3% gel 30mg/1gram 
10265 Fenbid 5% gel (AMCo) 50mg/1gram 
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5393 Intralgin gel (3M Health Care Ltd) 
50mg/1gram + 
20mg/1gram 
10093 Diethylamine salicylate 10% cream 10% 
1137 
Nu-seals aspirin ec 300mg Gastro-resistant tablet (Eli Lilly 
and Company Ltd) 300mg 
1270 Ibuleve 5% gel (Dendron Ltd) 50mg/1gram 
48326 Ibuprofen 100mg/5ml oral suspension sugar free 20mg/1ml 
9421 
Powergel 2.5% gel (A. Menarini Farmaceutica 
Internazionale SRL) 25mg/1gram 
112 Ibuprofen 5% cream 50mg/1gram 
7141 Ibugel Forte 10% gel (Dermal Laboratories Ltd) 100mg/1gram 
3077 Oruvail 2.5% gel (Sanofi) 25mg/1gram 
33710 Paracetamol 500mg caplets (A A H Pharmaceuticals Ltd) 500mg 
6115 Diclofenac sodium 3% gel 30mg/1gram 
7817 Benzydamine 3% cream 30mg/1gram 
1808 Capsaicin 0.075% cream 750microgram/1gram 
5748 
Salicylic acid 2% / Mucopolysaccharide polysulfate 0.2% 
cream 
2mg/1gram + 
20mg/1gram 
1621 Brufen 200mg tablets (Abbott Laboratories Ltd) 200mg 
6208 
Voltarol 1.16% Emulgel P (GlaxoSmithKline Consumer 
Healthcare) 11.6mg/1gram 
1339 Ditropan 5mg tablets (Sanofi) 5mg 
4980 
Salicylic acid 2% / Mucopolysaccharide polysulfate 0.2% 
gel 
20mg/1gram + 
2mg/1gram 
2693 Proflex 5% cream (Novartis Consumer Health UK Ltd) 50mg/1gram 
8510 Ibuprofen 5% spray 50mg/1ml 
5025 Zacin 0.025% cream (Teva UK Ltd) 250microgram/1gram 
26159 Fenbid Forte 10% gel (AMCo) 100mg/1gram 
1862 Paracetamol 500mg/5ml oral suspension sugar free 500mg/5ml 
43479 Paracetamol 500mg caplets (Actavis UK Ltd) 500mg 
10338 Felbinac 3.17% foam 31.7mg/1gram 
13083 Deep Relief gel (The Mentholatum Company Ltd) 
50mg/1gram + 
30mg/1gram 
10149 Ibuprofen 200mg capsules 200mg 
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5896 Ibuleve Maximum Strength 10% gel (Dendron Ltd) 100mg/1gram 
484 Equagesic Tablet (Wyeth Pharmaceuticals)  
15930 Ibuprofen 5% / Levomenthol 3% gel 
50mg/1gram + 
30mg/1gram 
7692 Axsain 0.075% cream (Teva UK Ltd) 750microgram/1gram 
3520 Movelat Relief gel (Genus Pharmaceuticals Ltd) 
20mg/1gram + 
2mg/1gram 
4648 Ibuspray 5% spray (Dermal Laboratories Ltd) 50mg/1ml 
5243 Paracetamol 500mg suppositories 500mg 
360 Brufen 100mg/5ml syrup (Mylan Ltd) 20mg/1ml 
56558 
Voltarol 12 Hour Emulgel P 2.32% gel (GlaxoSmithKline 
Consumer Healthcare) 23.2mg/1gram 
2794 Co-codamol 30mg/500mg tablets (Wockhardt UK Ltd) 30mg + 500mg 
9201 Ibuleve 5% spray (Dendron Ltd) 50mg/1ml 
784 Ibuprofen 300mg modified-release capsules 300mg 
27459 Paracetamol 500mg caplets (Zentiva) 500mg 
48597 
Paracetamol 500mg caplets (Alliance Healthcare 
(Distribution) Ltd) 500mg 
11540 Diclofenac 16mg/ml topical solution 16mg/1ml 
49105 Paracetamol 500mg caplets (Teva UK Ltd) 500mg 
4196 Paracetamol 240mg suppositories 240mg 
9712 Paracetamol 250mg orodispersible tablets sugar free 250mg 
5323 Paracetamol 250mg suppositories 250mg 
9176 Movelat Relief cream (Genus Pharmaceuticals Ltd) 
2mg/1gram + 
20mg/1gram 
15178 Radian B Pain Relief spray (Thornton & Ross Ltd) 
14mg/1ml + 10mg/1ml + 
5.4mg/1ml + 6mg/1ml 
23716 
Paracetamol 500mg caplets (IVAX Pharmaceuticals UK 
Ltd) 500mg 
6435 Pennsaid 16mg/ml cutaneous solution (Movianto UK Ltd) 16mg/1ml 
11074 Ralgex Heat spray (G.R. Lane Health Products Ltd) 60mg/1ml + 16mg/1ml 
208 Tensoplast bandage 5cm x 4.5m (BSN medical Ltd) 5cm 
14901 Diclofenac 1% transdermal patches 10mg/1gram 
49417 Paracetamol 500mg caplets (Kent Pharmaceuticals Ltd) 500mg 
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14964 Solpadeine Plus soluble tablets (Omega Pharma Ltd) 8mg + 500mg + 30mg 
49575 Paracetamol 500mg caplets (Vantage) 500mg 
31257 Paracetamol 500mg caplets (Galpharm International Ltd) 500mg 
18151 
Voltarol Pain-eze 1.16% Emulgel (GlaxoSmithKline 
Consumer Healthcare) 11.6mg/1gram 
8882 Feldene 0.50% Sports gel (Pfizer Ltd) 5mg/1gram 
11805 Ralgex Freeze spray (G.R. Lane Health Products Ltd) 
677.7mg/1gram + 
144.1mg/1gram + 
100mg/1gram 
28344 Paracetamol 500mg caplets (Wockhardt UK Ltd) 500mg 
31054 Phorpain Maximum Strength 10% gel (AMCo) 100mg/1gram 
20068 Paracetamol 250mg/5ml oral suspension sugar free 250mg/5ml 
11550 
Nurofen Meltlets 200mg tablets (Reckitt Benckiser 
Healthcare (UK) Ltd) 200mg 
9630 Feldene P 0.5% gel (Pfizer Ltd) 5mg/1gram 
1468 Ibuprofen 200mg Soluble tablet 200mg 
20967 Phorpain 5% gel (AMCo) 50mg/1gram 
7261 Cuprofen 5% gel (SSL International Plc) 50mg/1gram 
39708 Diclofenac 4% cutaneous spray 4% 
48535 Paracetamol 500mg caplets (Rusco Ltd) 500mg 
37972 Ibuleve Speed Relief 5% gel (Dendron Ltd) 50mg/1gram 
207 Clindamycin 75mg capsules 75mg 
56566 Paracetamol 500mg caplets (J M McGill Ltd) 500mg 
Weak analgesics  
Prodcode Product name Substance strength 
11 
Co-dydramol 10mg/500mg tablets 
500mg + 10mg 
19 
Co-codamol 8mg/500mg tablets 
500mg + 8mg 
57 
Co-codamol 8mg/500mg effervescent tablets 
8mg + 500mg 
58 
Bendroflumethiazide 5mg tablets 
5mg 
625 
Co-codamol 8mg/500mg capsules 
500mg + 8mg 
687 
Tramacet 37.5mg/325mg tablets (Grunenthal Ltd) 
37.5mg + 325mg 
6558 
Tramadol 37.5mg / Paracetamol 325mg tablets 
37.5mg + 325mg 
9457 
Paracetamol 500mg with codeine phosphate 8mg tablet 
500mg + 8mg 
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2986 
Co-codaprin 8mg/400mg dispersible tablets 
8mg + 400mg 
2047 
Co-codaprin 8mg with 400mg tablets 
8mg+400mg 
37904 
Co-codamol 12.8mg/500mg tablets 
12.8mg + 500mg 
42332 Tramacet 37.5mg/325mg effervescent tablets (Grunenthal 
Ltd) 
37.5mg + 325mg 
7063 
Co-dydramol 10mg/500mg/5ml oral suspension 
2mg/1ml + 100mg/1ml 
28780 Co-dydramol 10mg/500mg tablets (A A H Pharmaceuticals 
Ltd) 
500mg + 10mg 
42280 Tramadol 37.5mg / Paracetamol 325mg effervescent 
tablets sugar free 
37.5mg + 325mg 
11945 
Syndol Tablet (SSL International Plc) 
 
10122 Dihydrocodeine 10mg with paracetamol 500mg/5ml oral 
suspension sugar free 
10mg + 500mg/5ml 
34229 Co-codamol 8mg+500mg Dispersible tablet (Rhone-
Poulenc Rorer Ltd) 
8mg + 500mg 
7469 Df118 10mg/5ml Oral solution (Martindale Pharmaceuticals 
Ltd) 
2mg/1ml 
47071 Co-dydramol (dihydrocodeine and paracetamol) 10mg with 
500mg/5ml oral suspension 
10mg + 500mg/5ml 
Moderate analgesics  
Prodcode Prodcode Substance Strength 
4 
Paracetamol/Dextropropoxyphene hydrochloride 
325mg + 32.5mg 
382 
Codeine phosphate 
15mg 
7072 
Codeine phosphate/Paracetamol 
15mg + 500mg 
152 
Codeine phosphate 
3mg/1ml 
2871 
Pholcodine 
1mg/1ml 
7555 
Buprenorphine 
5microgram/1hour 
10205 
Buprenorphine 
10microgram/1hour 
4016 
Nefopam hydrochloride 
30mg 
7236 
Buprenorphine 
10microgram/1hour 
7334 
Buprenorphine 
5microgram/1hour 
5955 
Dihydrocodeine tartrate/Paracetamol 
30mg + 500mg 
9855 
Paracetamol/Dihydrocodeine tartrate 
500mg + 20mg 
1617 
Codeine phosphate 
3mg/1ml 
396 
Buprenorphine hydrochloride 
200microgram 
2040 
Paracetamol/Dihydrocodeine tartrate 
500mg + 20mg 
46729 
Codeine Phosphate/paracetamol 
15mg + 500mg 
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3522 
Buprenorphine hydrochloride 
200microgram 
3794 
Nefopam hydrochloride 
30mg 
1708 
Ibuprofen/Codeine phosphate 
300mg + 20mg 
6547 
Buprenorphine hydrochloride 
2mg 
6056 
Buprenorphine hydrochloride 
8mg 
10176 
Codeine phosphate/Paracetamol 
15mg + 500mg 
46511 
Codeine phosphate/Paracetamol 
15mg + 500mg 
4805 
Codeine Phosphate 
15mg/5ml 
37979 
Nefopam hydrochloride 
30mg 
12076 
Dextropropoxyphene Napsylate 
60mg 
46898 
Codeine Phosphate/paracetamol 
15mg + 500mg 
124 
Paracetamol/Dextropropoxyphene hydrochloride 
325mg + 32.5mg 
35681 
Buprenorphine hydrochloride/Naloxone hydrochloride 
2mg + 500microgram 
35682 
Buprenorphine Hydrochloride/naloxone Hydrochloride 
8mg + 2mg 
Strong analgesics 
Prodcode Product name Substance strength 
86 
Tramadol 50mg capsules 
50mg 
96 
Co-codamol 30mg/500mg tablets 
30mg + 500mg 
53 
Dihydrocodeine 30mg tablets 
30mg 
158 
Codeine 30mg tablets 
30mg 
800 
Co-codamol 30mg/500mg capsules 
30mg + 500mg 
11665 
Zapain 30mg/500mg tablets (AMCo) 
30mg + 500mg 
810 
Co-codamol 30mg/500mg effervescent tablets 
30mg + 500mg 
656 
Tylex 30mg/500mg capsules (UCB Pharma Ltd) 
30mg + 500mg 
4114 
Tramadol 100mg modified-release capsules 
100mg 
1640 
Kapake 30mg/500mg tablets (Galen Ltd) 
30mg + 500mg 
2211 
Solpadol 30mg/500mg effervescent tablets (Sanofi) 
30mg + 500mg 
3156 
Solpadol 30mg/500mg caplets (Sanofi) 
30mg + 500mg 
2041 
Dihydrocodeine 60mg modified-release tablets 
60mg 
21880 
Zapain 30mg/500mg capsules (AMCo) 
30mg + 500mg 
6215 
Tramadol 200mg modified-release capsules 
200mg 
4115 
Tramadol 100mg modified-release tablets 
100mg 
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701 
Tramadol 50mg modified-release capsules 
50mg 
8456 
DHC Continus 60mg tablets (Napp Pharmaceuticals Ltd) 
60mg 
9516 
Kapake 30mg/500mg capsules (Galen Ltd) 
30mg + 500mg 
3239 
Meptazinol 200mg tablets 
200mg 
5955 
Paracetamol 500mg / Dihydrocodeine 30mg tablets 
30mg + 500mg 
13300 BuTrans 20micrograms/hour transdermal patches (Napp 
Pharmaceuticals Ltd) 
20micrograms/hour 
4834 
Tramadol 150mg modified-release capsules 
150mg 
2450 
Pethidine 50mg tablets 
50mg 
6234 
Dihydrocodeine 120mg modified-release tablets 
120mg 
539 
Codeine 60mg tablets 
60mg 
7238 
Buprenorphine 20micrograms/hour transdermal patches 
20micrograms/hour 
187 
Zydol 50mg capsules (Grunenthal Ltd) 
50mg 
9313 
Dihydrocodeine 90mg modified-release tablets 
90mg 
767 
Solpadol 30mg/500mg capsules (Sanofi) 
30mg + 500mg 
3644 
Zydol SR 100mg tablets (Grunenthal Ltd) 
100mg 
9001 
Diconal tablets (Amdipharm Plc) 
30mg + 10mg 
3378 
Tramadol 50mg soluble tablets sugar free 
50mg 
40249 
Maxitram SR 100mg capsules (Chiesi Ltd) 
100mg 
8447 
Meptid 200mg Tablet (Shire Pharmaceuticals Ltd) 
200mg 
4823 
Dihydrocodeine 40mg tablets 
40mg 
6879 
Buprenorphine 35micrograms/hour transdermal patches 
35microgram/1hour 
9275 
DHC Continus 120mg tablets (Napp Pharmaceuticals Ltd) 
120mg 
3064 Buprenorphine 400microgram sublingual tablets sugar 
free 
400microgram 
3435 
Tylex 30mg/500mg effervescent tablets (UCB Pharma Ltd) 
30mg + 500mg 
5936 Transtec 35micrograms/hour transdermal patches (Napp 
Pharmaceuticals Ltd) 
35microgram/1hour 
9209 
DHC Continus 90mg tablets (Napp Pharmaceuticals Ltd) 
90mg 
38950 
Remedeine Forte tablets (Crescent Pharma Ltd) 
30mg + 500mg 
40254 
Maxitram SR 50mg capsules (Chiesi Ltd) 
50mg 
3029 
CO-CODAMOL EFF 30MG/500MG TAB 
 
39811 
Maxitram SR 200mg capsules (Chiesi Ltd) 
200mg 
6917 
Buprenorphine 52.5micrograms/hour transdermal patches 
52.5microgram/1hour 
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11584 
Buprenorphine 70micrograms/hour transdermal patches 
70microgram/1hour 
6040 Transtec 52.5micrograms/hour transdermal patches (Napp 
Pharmaceuticals Ltd) 
52.5microgram/1hour 
1929 
GranuGEL Hydrocolloid Gel dressing (ConvaTec Ltd) 
 
6181 Transtec 70micrograms/hour transdermal patches (Napp 
Pharmaceuticals Ltd) 
70microgram/1hour 
2367 
Pentazocine 25mg tablets 
25mg 
37021 
Tramadol 200mg modified-release tablets 
200mg 
328 
Pentazocine 50mg capsules 
50mg 
5169 
Zydol SR 200mg tablets (Grunenthal Ltd) 
200mg 
8017 Temgesic 400microgram sublingual tablets (Indivior UK 
Ltd) 
400microgram 
9396 
Zamadol SR 100mg capsules (Meda Pharmaceuticals Ltd) 
100mg 
57900 Co-codamol 30mg/500mg caplets (A A H Pharmaceuticals 
Ltd) 
30mg + 500mg 
50862 
Marol 200mg modified-release tablets (Teva UK Ltd) 
200mg 
2794 
Co-codamol 30mg/500mg tablets (Wockhardt UK Ltd) 
30mg + 500mg 
36993 
Co-codamol 30mg/500mg capsules (Teva UK Ltd) 
30mg + 500mg 
1261 Co-codamol 30mg/500mg effervescent powder sachets 
sugar free 
30mg + 500mg 
13813 
Zamadol 50mg capsules (Meda Pharmaceuticals Ltd) 
50mg 
46021 
Tapentadol 50mg modified-release tablets 
50mg 
11734 
Tramadol 50mg orodispersible tablets sugar free 
50mg 
36732 
Tramadol 50mg modified-release tablets 
50mg 
9917 Kapake Insts 30mg/500mg effervescent powder sachets 
(Galen Ltd) 
30mg + 500mg 
39709 Marol 200mg modified-release tablets (Morningside 
Healthcare Ltd) 
200mg 
21797 
Zamadol SR 200mg capsules (Meda Pharmaceuticals Ltd) 
200mg 
37020 
Tramadol 150mg modified-release tablets 
150mg 
4236 
Palfium 5mg tablets (Roche Products Ltd) 
5mg 
7104 
Kapake 30mg/500mg effervescent tablets (Galen Ltd) 
30mg + 500mg 
11748 
Tramadol 400mg modified-release tablets 
400mg 
49323 
Marol 150mg modified-release tablets (Teva UK Ltd) 
150mg 
9389 
Zamadol SR 50mg capsules (Meda Pharmaceuticals Ltd) 
50mg 
11746 
Tramadol 300mg modified-release tablets 
300mg 
11559 
Tramadol 50mg effervescent powder sachets sugar free 
50mg 
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39750 Marol 150mg modified-release tablets (Morningside 
Healthcare Ltd) 
150mg 
23981 
Zamadol SR 150mg capsules (Meda Pharmaceuticals Ltd) 
150mg 
11101 
Zydol 50mg soluble tablets (Grunenthal Ltd) 
50mg 
35656 
Tradorec XL 100mg tablets (Endo Ventures Ltd) 
100mg 
35651 
Tradorec XL 200mg tablets (Endo Ventures Ltd) 
200mg 
9739 
Tramadol 100mg effervescent powder sachets sugar free 
100mg 
38970 DF 118 Forte 40mg tablets (Martindale Pharmaceuticals 
Ltd) 
40mg 
38013 
Pethidine 50mg capsules 
50mg 
29860 
Tramadol 50mg capsules (IVAX Pharmaceuticals UK Ltd) 
50mg 
20310 
Zamadol Melt 50mg tablets (Meda Pharmaceuticals Ltd) 
50mg 
21397 
Zydol XL 400mg tablets (Grunenthal Ltd) 
400mg 
15871 Kapake Insts 60mg/1000mg effervescent powder sachets 
(Galen Ltd) 
60mg + 1gram 
44210 
Kapake 15mg/500mg tablets (Galen Ltd) 
15mg + 500mg 
36035 
Tradorec XL 300mg tablets (Endo Ventures Ltd) 
300mg 
4518 
DF 118 30 MG TAB 
 
14490 
Tramake 50mg capsules (Galen Ltd) 
50mg 
19993 
Dromadol SR 100mg tablets (Teva UK Ltd) 
100mg 
21947 
Zydol XL 150mg tablets (Grunenthal Ltd) 
150mg 
24383 
Tramake Insts 100mg sachets (Galen Ltd) 
100mg 
14602 Co-codamol 60mg/1000mg effervescent powder sachets 
sugar free 
60mg + 1gram 
16271 
Zydol XL 300mg tablets (Grunenthal Ltd) 
300mg 
23625 
Dromadol SR 150mg tablets (Teva UK Ltd) 
150mg 
11549 
Tramadol 75mg modified-release tablets 
75mg 
Very strong analgesics 
Prodcode Product name Substance Strength 
1503 Oramorph 10mg/5ml oral solution (Boehringer Ingelheim 
Ltd) 
2mg/1ml 
495 
MST Continus 10mg tablets (Napp Pharmaceuticals Ltd) 
10mg 
2957 
MST Continus 30mg tablets (Napp Pharmaceuticals Ltd) 
30mg 
13114 Zomorph 10mg modified-release capsules (Ethypharm UK 
Ltd) 
10mg 
5840 
Morphine sulfate 10mg/5ml oral solution 
2mg/1ml 
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13117 Zomorph 30mg modified-release capsules (Ethypharm UK 
Ltd) 
30mg 
4477 
MST Continus 60mg tablets (Napp Pharmaceuticals Ltd) 
60mg 
5599 OxyContin 10mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
10mg 
3919 
Sevredol 10mg tablets (Napp Pharmaceuticals Ltd) 
10mg 
7389 OxyContin 20mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
20mg 
5681 
Morphine 10mg modified-release tablets 
10mg 
5714 
MST Continus 15mg tablets (Napp Pharmaceuticals Ltd) 
15mg 
4280 
MST Continus 5mg tablets (Napp Pharmaceuticals Ltd) 
5mg 
5843 
Oxycodone 10mg modified-release tablets 
10mg 
6557 
OxyNorm 5mg capsules (Napp Pharmaceuticals Ltd) 
5mg 
6608 
Oxycodone 20mg modified-release tablets 
20mg 
5585 
Oxycodone 10mg capsules 
10mg 
6790 
Oxycodone 5mg capsules 
5mg 
15964 Zomorph 60mg modified-release capsules (Ethypharm UK 
Ltd) 
60mg 
5991 
MST Continus 100mg tablets (Napp Pharmaceuticals Ltd) 
100mg 
9973 
OxyNorm 10mg capsules (Napp Pharmaceuticals Ltd) 
10mg 
4266 
Morphine 10mg tablets 
10mg 
9927 OxyContin 40mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
40mg 
7875 
Morphine 30mg modified-release tablets 
30mg 
5907 
Lamotrigine 100mg dispersible tablets sugar free 
100mg 
6002 
Morphine 10mg modified-release capsules 
10mg 
9874 OxyNorm liquid 5mg/5ml oral solution (Napp 
Pharmaceuticals Ltd) 
1mg/1ml 
7167 OxyContin 5mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
5mg 
5670 Diamorphine hydrochloride 10mg powder for injection 
solution 
10mg 
6708 
Oxycodone 40mg modified-release tablets 
40mg 
4693 Oramorph 10mg/5ml oral solution unit dose vials 
(Boehringer Ingelheim Ltd) 
2mg/1ml 
6609 
Oxycodone 5mg/5ml oral solution sugar free 
1mg/1ml 
7275 
Oxycodone 20mg capsules 
20mg 
7372 
OxyNorm 20mg capsules (Napp Pharmaceuticals Ltd) 
20mg 
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14063 Zomorph 100mg modified-release capsules (Ethypharm 
UK Ltd) 
100mg 
10021 OxyContin 80mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
80mg 
6769 
Oxycodone 5mg modified-release tablets 
5mg 
18881 
Morphgesic SR 10mg tablets (AMCo) 
10mg 
8822 
Morphine 60mg modified-release tablets 
60mg 
6948 
Oxycodone 80mg modified-release tablets 
80mg 
8876 Oramorph 20mg/ml concentrated oral solution (Boehringer 
Ingelheim Ltd) 
20mg/1ml 
7197 
Morphine sulphate 12 30mg Modified-release capsule 
30mg 
9602 
Morphine 5mg modified-release tablets 
5mg 
9557 
Morphine 15mg modified-release tablets 
15mg 
19449 
Morphgesic SR 30mg tablets (AMCo) 
30mg 
9137 
Morphine 20mg tablets 
20mg 
45745 OxyContin 30mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
30mg 
39477 Targinact 10mg/5mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
10mg + 5mg 
8039 
MST Continus 200mg tablets (Napp Pharmaceuticals Ltd) 
200mg 
39478 Targinact 20mg/10mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
10mg + 20mg 
9183 
Morphine 100mg modified-release tablets 
100mg 
655 Morphine sulfate 10mg/5ml oral solution unit dose vials 
sugar free 
2mg/1ml 
45827 
Oxycodone 30mg modified-release tablets 
30mg 
39475 Oxycodone 10mg / Naloxone 5mg modified-release 
tablets 
10mg + 5mg 
6366 
Sevredol 50mg tablets (Napp Pharmaceuticals Ltd) 
50mg 
9960 
Morphine sulphate 12 60mg Modified-release capsule 
60mg 
40645 Targinact 5mg/2.5mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
5mg + 2.5mg 
45788 OxyContin 15mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
15mg 
19471 
Morphgesic SR 60mg tablets (AMCo) 
60mg 
7406 OxyNorm 10mg/ml concentrate oral solution (Napp 
Pharmaceuticals Ltd) 
10mg/1ml 
607 MST Continus Suspension 20mg granules sachets (Napp 
Pharmaceuticals Ltd) 
20mg 
6269 
Morphine sulfate 20mg/ml oral solution sugar free 
20mg/1ml 
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39498 Oxycodone 20mg / Naloxone 10mg modified-release 
tablets 
10mg + 20mg 
9342 
MXL 60mg capsules (Napp Pharmaceuticals Ltd) 
60mg 
15950 Zomorph 200mg modified-release capsules (Ethypharm 
UK Ltd) 
200mg 
9337 
MXL 30mg capsules (Napp Pharmaceuticals Ltd) 
30mg 
11342 Oramorph 30mg/5ml oral solution unit dose vials 
(Boehringer Ingelheim Ltd) 
6mg/1ml 
11405 
Oxycodone 10mg/ml oral solution sugar free 
10mg/1ml 
40961 Targinact 40mg/20mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
40mg + 20mg 
9371 
MXL 120mg capsules (Napp Pharmaceuticals Ltd) 
120mg 
9381 
MXL 90mg capsules (Napp Pharmaceuticals Ltd) 
90mg 
45929 
Oxycodone 60mg modified-release tablets 
60mg 
40616 Oxycodone 5mg / Naloxone 2.5mg modified-release 
tablets 
5mg + 2.5mg 
5138 
Hydromorphone 1.3mg capsules 
1.3mg 
15815 
Morphine 50mg tablets 
50mg 
12900 MST Continus Suspension 30mg granules sachets (Napp 
Pharmaceuticals Ltd) 
30mg 
14050 
Morphine sulphate 12 100mg Modified-release capsule 
100mg 
5137 
Hydromorphone 2.6mg capsules 
2.6mg 
19477 
Morphgesic SR 100mg tablets (AMCo) 
100mg 
9325 
Hydromorphone 4mg modified-release capsules 
4mg 
17936 
MXL 200mg capsules (Napp Pharmaceuticals Ltd) 
200mg 
45830 OxyContin 120mg modified-release tablets (Napp 
Pharmaceuticals Ltd) 
120mg 
40785 Oxycodone 40mg / Naloxone 20mg modified-release 
tablets 
40mg + 20mg 
15798 
Hydromorphone 8mg modified-release capsules 
8mg 
4476 MST Continus Suspension 60mg granules sachets (Napp 
Pharmaceuticals Ltd) 
60mg 
15792 
Hydromorphone 2mg modified-release capsules 
2mg 
3990 
Dextromoramide 5mg tablets 
5mg 
5555 Sevredol 10mg/5ml oral solution (Napp Pharmaceuticals 
Ltd) 
2mg/1ml 
5563 
Morphine sulphate 12 20mg Modified-release capsule 
20mg 
11838 
Morphine 200mg modified-release tablets 
200mg 
6736 Morphine 20mg modified-release granules sachets sugar 
free 
20mg 
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14156 Morphine sulfate 30mg/5ml oral solution unit dose vials 
sugar free 
6mg/1ml 
12604 MST Continus Suspension 100mg granules sachets 
(Napp Pharmaceuticals Ltd) 
100mg 
9332 
Palladone SR 2mg capsules (Napp Pharmaceuticals Ltd) 
2mg 
9331 
Palladone SR 4mg capsules (Napp Pharmaceuticals Ltd) 
4mg 
26283 
Filnarine SR 10mg tablets (Teva UK Ltd) 
10mg 
9615 
Palladone 1.3mg capsules (Napp Pharmaceuticals Ltd) 
1.3mg 
22756 
Filnarine SR 30mg tablets (Teva UK Ltd) 
30mg 
9330 
Palladone 2.6mg capsules (Napp Pharmaceuticals Ltd) 
2.6mg 
21275 
Palladone SR 8mg capsules (Napp Pharmaceuticals Ltd) 
8mg 
NSAIDs 
Prodcode Product name Substance strength 
40 
Diclofenac sodium 50mg gastro-resistant tablets 
50mg 
807 
Naproxen 500mg tablets 
500mg 
661 
Naproxen 250mg tablets 
250mg 
1086 
Ibuprofen 600mg tablets 
600mg 
2243 
Meloxicam 7.5mg tablets 
7.5mg 
1469 
Meloxicam 15mg tablets 
15mg 
162 
Arthrotec 50 gastro-resistant tablets (Pfizer Ltd) 
50mg + 200microgram 
1073 
Mefenamic acid 500mg tablets 
500mg 
3053 
Naproxen 500mg gastro-resistant tablets 
500mg 
580 
Diclofenac sodium 75mg modified-release tablets 
75mg 
5254 
Celecoxib 200mg capsules 
200mg 
474 
Celecoxib 100mg capsules 
100mg 
2386 Voltarol Retard 100mg tablets (Novartis Pharmaceuticals 
UK Ltd) 
100mg 
917 
Diclofenac sodium 50mg tablets 
50mg 
177 
Indometacin 25mg capsules 
25mg 
649 
Diclofenac sodium 25mg gastro-resistant tablets 
25mg 
5455 
Etodolac 600mg modified-release tablets 
600mg 
259 
Mefenamic acid 250mg capsules 
250mg 
3431 
Naproxen 250mg gastro-resistant tablets 
250mg 
518 
Rofecoxib 12.5mg tablets 
12.5mg 
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1392 
Ibuprofen 800mg modified-release tablets 
800mg 
1984 
Diclofenac sodium 100mg modified-release tablets 
100mg 
706 
Rofecoxib 25mg tablets 
25mg 
2387 
Arthrotec 75 gastro-resistant tablets (Pfizer Ltd) 
75mg + 200microgram 
4880 Diclofenac sodium 75mg gastro-resistant / Misoprostol 
200microgram tablets 
75mg + 200microgram 
650 
Etoricoxib 60mg tablets 
60mg 
736 
Indometacin 50mg capsules 
50mg 
1233 
Diclofenac sodium 75mg modified-release tablets 
75mg 
2234 
Nabumetone 500mg tablets 
500mg 
5812 
Etoricoxib 90mg tablets 
90mg 
1446 
Voltarol 50mg Tablet (Novartis Pharmaceuticals UK Ltd) 
50mg 
977 
Minulet tablets (Wyeth Pharmaceuticals) 
75microgram + 
30microgram 
838 
Oruvail 200mg Modified-release capsule (Hawgreen Ltd) 
200mg 
141 
Piroxicam 10mg capsules 
10mg 
1755 
Piroxicam 20mg capsules 
20mg 
296 
Ponstan Forte 500mg tablets (Chemidex Pharma Ltd) 
500mg 
417 
Diclofenac 50mg dispersible tablets sugar free 
50mg 
1210 
Indometacin 75mg modified-release capsules 
75mg 
1866 
Naprosyn 500mg tablets (Atnahs Pharma UK Ltd) 
500mg 
4506 
Volsaid Retard 75 tablets (Chiesi Ltd) 
75mg 
3043 
Ketoprofen 200mg modified-release capsules 
200mg 
928 
Diclofenac sodium 25mg tablets 
25mg 
1116 
Diclofenac 100mg suppositories 
100mg 
2904 Diclofenac sodium 75mg gastro-resistant modified-release 
capsules 
75mg 
341 
Feldene 10mg capsules (Pfizer Ltd) 
10mg 
2257 
Surgam SA 300mg capsules (Sanofi) 
300mg 
2235 
Relifex 500mg tablets (Meda Pharmaceuticals Ltd) 
500mg 
5080 
Celebrex 200mg capsules (Pfizer Ltd) 
200mg 
1766 Voltarol sr 75mg Modified-release tablet (Novartis 
Pharmaceuticals UK Ltd) 
75mg 
2288 
Naprosyn 250mg tablets (Atnahs Pharma UK Ltd) 
250mg 
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5175 
Celebrex 100mg capsules (Pfizer Ltd) 
100mg 
4625 Voltarol 75mg SR tablets (Novartis Pharmaceuticals UK 
Ltd) 
75mg 
126 
Ponstan 250mg capsules (Chemidex Pharma Ltd) 
250mg 
3852 Diclomax 100mg Modified-release capsule (Provalis 
Healthcare Ltd) 
100mg 
1496 
Indocid R 75mg capsules (Merck Sharp & Dohme Ltd) 
75mg 
850 
Mobic 7.5mg tablets (Boehringer Ingelheim Ltd) 
7.5mg 
526 
Aceclofenac 100mg tablets 
100mg 
120 
Indocid 25mg capsules (Merck Sharp & Dohme Ltd) 
25mg 
666 
Vioxx 25mg tablets (Merck Sharp & Dohme Ltd) 
25mg 
3935 
Feldene 20 capsules (Pfizer Ltd) 
20mg 
1139 
Voltarol 25mg Tablet (Novartis Pharmaceuticals UK Ltd) 
25mg 
5938 
Etoricoxib 120mg tablets 
120mg 
6464 
Arcoxia 60mg tablets (Grunenthal Ltd) 
60mg 
11168 
Volsaid Retard 100 tablets (Chiesi Ltd) 
100mg 
4216 
Brufen 600mg tablets (Mylan Ltd) 
600mg 
3275 
Benoral 2g/5ml oral suspension (Sanofi-Synthelabo Ltd) 
400mg/1ml 
3326 
Oruvail 100mg Modified-release capsule (Hawgreen Ltd) 
100mg 
3901 
Naprosyn EC 500mg tablets (Atnahs Pharma UK Ltd) 
500mg 
919 
Indometacin 100mg suppositories 
100mg 
5266 Lodine sr 600mg Modified-release tablet (Shire 
Pharmaceuticals Ltd) 
600mg 
10033 
Etodolac 300mg capsules 
300mg 
1571 
Ketoprofen 100mg modified-release capsules 
100mg 
2382 
Tiaprofenic acid 300mg modified-release capsules 
300mg 
9409 Ethilon suture 2gauge 45cm length with 26mm curved 
reverse cutting needle W320 Blue (Ethicon Ltd) 
Gauge 2.0/45cm (blue) 
3974 
Tenoxicam 20mg tablets 
20mg 
344 
Acemetacin 60mg capsules 
60mg 
6498 
Arcoxia 90mg tablets (Grunenthal Ltd) 
90mg 
3939 
Napratec OP tablets (Pfizer Ltd) 
 
12075 
Mobiflex 20mg Tablet (Roche Products Ltd) 
20mg 
499 
Diclofenac 50mg suppositories 
50mg 
3182 
Froben 50mg tablets (Abbott Laboratories Ltd) 
50mg 
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8544 
Fenbufen 450mg tablets 
450mg 
920 
Indocid 100mg suppositories (Aspen Pharma Trading Ltd) 
100mg 
2258 
Emflex 60mg capsules (Merck Serono Ltd) 
60mg 
1470 
Mobic 15mg tablets (Boehringer Ingelheim Ltd) 
15mg 
6249 
Froben 100mg tablets (Abbott Laboratories Ltd) 
100mg 
37587 
Etoricoxib 30mg tablets 
30mg 
3266 
Flurbiprofen 50mg tablets 
50mg 
589 Voltarol 50mg dispersible tablets (Novartis 
Pharmaceuticals UK Ltd) 
50mg 
2366 
Flurbiprofen 100mg tablets 
100mg 
7688 
Rheumox 600mg tablets (Mercury Pharma Group Ltd) 
600mg 
7522 
Lederfen 300mg Tablet (Wyeth Pharmaceuticals) 
300mg 
3972 
Naprosyn EC 250mg tablets (Atnahs Pharma UK Ltd) 
250mg 
10558 
Flexin-75 Continus tablets (Napp Pharmaceuticals Ltd) 
75mg 
389 
Ketoprofen 50mg capsules 
50mg 
8062 Motifene 75mg modified-release capsules (Daiichi Sankyo 
UK Ltd) 
75mg 
1231 
Ketoprofen 100mg capsules 
100mg 
3739 
Rheumox 300mg capsules (Mercury Pharma Group Ltd) 
300mg 
2622 
Ibuprofen 800mg tablets 
800mg 
157 Voltarol 100mg Suppository (Novartis Pharmaceuticals 
UK Ltd) 
100mg 
 
  
  
497 
 
v. Cancer codes 
Medcode Readcode Read term 
3968 B34..00 
Malignant neoplasm of female breast 
780 B46..00 
Malignant neoplasm of prostate 
348 B34..11 
Ca female breast 
1624 BB2A.00 
[M]Squamous cell carcinoma NOS 
779 B49..00 
Malignant neoplasm of urinary bladder 
1220 B13..00 
Malignant neoplasm of colon 
2587 B22z.11 
Lung cancer 
3903 B22z.00 
Malignant neoplasm of bronchus or lung NOS 
865 B32..00 
Malignant melanoma of skin 
2272 BB5..11 
[M]Adenocarcinomas 
3445 B33..16 
Epithelioma basal cell 
3197 BB03.00 
Malignant neoplasm of female breast 
1800 B141.00 
Malignant neoplasm of prostate 
1940 B33..13 
Ca female breast 
13569 B590.00 
[M]Squamous cell carcinoma NOS 
93352 B338.00 
Malignant neoplasm of urinary bladder 
8625 B641.00 
Malignant neoplasm of colon 
1062 B10..00 
Lung cancer 
4944 B630.00 
Malignant neoplasm of bronchus or lung NOS 
3604 B627.00 
Malignant melanoma of skin 
8166 B17..00 
[M]Adenocarcinomas 
4632 B33..00 
Epithelioma basal cell 
4403 B577.11 
[M]Neoplasm, metastatic 
3152 BB13.00 
Malignant neoplasm of rectum 
1483 BBg1.11 
Rodent ulcer 
1986 B440.11 
Disseminated malignancy NOS 
9470 B34z.00 
Squamous cell carcinoma of skin 
6170 B590.11 
Chronic lymphoid leukaemia 
7967 BB2..12 
Malignant neoplasm of oesophagus 
13243 B22..00 
Multiple myeloma 
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Medcode Readcode Read term 
2462 B61..00 
Non - Hodgkin's lymphoma 
8386 B11..00 
Malignant neoplasm of pancreas 
2492 B33z.00 
Other malignant neoplasm of skin 
7805 B440.00 
Liver metastases 
5901 B141.12 
[M]Carcinoma, metastatic, NOS 
579 BBE1.00 
[M]Lymphoma NOS 
1056 B5z..00 
Cancer of ovary 
4865 B10z.11 
Malignant neoplasm of female breast NOS 
7483 BBE1.12 
Carcinomatosis 
2890 B430200 
[M]Squamous cell neoplasms 
7654 B585.00 
Malignant neoplasm of trachea, bronchus and lung 
2747 B41..00 
Hodgkin's disease 
5842 B58..00 
Malignant neoplasm of stomach 
3672 BBn0.12 
Malignant neoplasm of skin NOS 
9118 B13z.11 
Malignant neoplasm of ovary 
8695 BB12.00 
Rectal carcinoma 
3811 B134.00 
[M]Malignant melanoma NOS 
12335 B62y.00 
Malignant neoplasm of other and unspecified site NOS 
4413 B650.00 
Oesophageal cancer 
2815 B133.00 
[M]Melanoma NOS 
5199 B583200 
Malignant neoplasm of endometrium of corpus uteri 
5637 B53..00 
Secondary malignant neoplasm of bone and bone marrow 
11628 B1z0.11 
Malignant neoplasm of cervix uteri 
4137 B570.00 
Secondary malignant neoplasm of other specified sites 
14800 B11z.00 
[M]Myeloma NOS 
14825 BA0..00 
Colonic cancer 
8930 BB52.00 
[M]Carcinoma NOS 
15103 B577.00 
Malignant neoplasm of caecum 
31102 B49z.00 
Malignant lymphoma NOS 
319 B21..00 
Acute myeloid leukaemia 
7484 B226.00 
Malignant neoplasm of sigmoid colon 
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Medcode Readcode Read term 
1599 B4A0.00 
Cerebral metastasis 
3230 B41..11 
Malignant neoplasm of thyroid gland 
8523 BBb0.11 
Cancer of bowel 
6436 BB43.00 
Secondary malignant neoplasm of lung 
2744 B40..00 
Malignant neoplasm of stomach NOS 
18617 B51..00 
Neoplasm of unspecified nature 
6115 B6y0.00 
[M]Adenocarcinoma NOS 
8711 BB5D100 
Secondary malignant neoplasm of liver 
10395 BBm7.00 
Malignant neoplasm of urinary bladder NOS 
9575 BBbL.11 
Malignant neoplasm of larynx 
68236 B550.00 
Mesothelioma 
13559 B4A..00 
Malignant neoplasm of kidney parenchyma 
10726 B651.00 
Cervical carcinoma (uterus) 
93490 B33z.11 
[M]Glioma NOS 
10283 B01..00 
[M]Transitional cell carcinoma NOS 
4250 B68z.00 
Malignant neoplasm of uterus, part unspecified 
3371 BBg2.11 
Malignant neoplasm of brain 
8547 BBbB.00 
Myeloproliferative disorder 
5198 B583000 
[M]Cholangiocarcinoma 
8085 BBF1.00 
[M] Monoclonal gammopathy 
7693 BBE..00 
[M]Glioblastoma multiforme 
3923 BB5R.00 
Malignant neoplasm of head, neck and face 
7046 B43..00 
Malig neop of kidney and other unspecified urinary organs 
8101 BB5a.00 
Chronic myeloid leukaemia 
30700 B10z.00 
Squamous cell carcinoma of skin NOS 
4251 B640.00 
Malignant neoplasm of tongue 
12870 B221.00 
Leukaemia NOS 
1044 BA06.00 
[M]Non Hodgkins lymphoma 
5455 BB53.00 
[M]Astrocytoma NOS 
25886 B222100 
Secondary malignant neoplasm of brain 
15148 B47..00 
[M]Sarcoma NOS 
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Medcode Readcode Read term 
21868 BB02.00 
[M]Naevi and melanomas 
28163 B13z.00 
[M]Carcinoid tumours 
5034 B33..12 
Malignant neoplasm of body of uterus 
7219 B141.11 
[M]Renal adenoma and carcinoma 
7176 B65..00 
Malignant neoplasm of oesophagus NOS 
9291 BB1J.00 
Acute lymphoid leukaemia 
12006 B621.00 
Malignant neoplasm of main bronchus 
22187 B150300 
Neoplasm of unspecified nature of brain 
100 of the most commonly recorded cancer clinical codes (of a total 2152) 
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vii. Formal residence codes 
Medcode Read codes Read terms 
13359 
13F6100 Lives in a nursing home 
49681 
13FX.00 Lives in care home 
93998 
9b0i.00 Residential home visit note 
24956 
13FK.00 Lives in a residential home 
13360 
13F6.00 Nursing/other home 
101003 
9NFR.00 Home visit request by residential institution 
11419 
13F7200 Lives in an old peoples home 
107602 
9NFW100 Care home visit for follow-up patient review 
100080 
8Ce5.00 Preferred place of care - residential home 
7101 
9N1F.12 Seen in old people's home 
107443 
9NFW000 Care home visit for initial patient assessment 
107757 
9NFW.00 Care home visit 
73321 
9b1P.00 Nursing home 
101078 
949D.00 Patient died in care home 
107390 
8Ce5.11 Preferred place of care - care home 
27425 
13F5.00 Part III accommodation 
101152 
94ZC.00 Preferred place of death: care home 
45650 
T704.00 Place of occurrence of accident/poisoning, residential house 
73083 
9b0Y.00 Nursing home visit note 
42191 
ZLG3.00 Discharge to residential home 
24828 
Z177F00 Nursing home care 
104115 
94ZE.00 Preferred place of death: residential home 
24816 
Z177C00 Residential care 
59548 
13FT.00 Lives in an old peoples home 
98758 
13Zo.00 Previously lived in care home 
27360 
13F5100 Part III accomodation arranged 
43709 
ZV70H00 [V]Examination for admission to residential institutions 
36096 
13F5.11 Part 3 accomodation 
68005 
13FV.00 Lives in a welfare home 
47609 
T77..00 Place of accident or poisoning, residential institution 
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Medcode Read codes Read terms 
56326 
U3K1.00 [X]Assault by bodily force occurrn in residential institut'n 
61569 
TK70.00 Suicide+selfinflicted injury-jump from residential premises 
102230 
M270100 Nursing home acquired pressure ulcer 
48549 
ZLG3100 Discharge to private residential home 
66371 
TN70.00 Injury ?accidental, fall from residential premises 
56969 
T77z.00 Accident/poisoning occurred in residential institution NOS 
46642 
9b79.00 Other residential care homes managed by local authority 
46222 
T774.00 Place of occurrence of accident/poisoning, old people's home 
53140 
Z177D00 Local authority residential care 
69028 
ZLG3200 Discharge to part III residential home 
69762 
U106100 [X]Fall involving bed occurrence in residential institution 
66122 
13F5111 Part 3 accomodation arranged 
67903 
U105100 [X]Fall involvng wheelchair occurrence residential instit'n 
100389 
U321.00 [X]Assault by pesticides occurrn in residential institution 
99120 
U193100 [X]Victim of lightning, occurrn in residential institution 
48733 
U198100 [X]Victim of flood, occurrence in residential institution 
107927 
U1B4100 [X]Lack of water, occurrence in residential institution 
99110 
U10F100 [X]Fall from cliff, occurrence in residential institution 
111109 
U124100 [X]Bitten/struck by dog occurrnce in residential institut'n 
111795 
U1B3100 [X]Lack of food, occurrence in residential institution 
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ix. Cardiovascular-related codes 
Medcode Read code Read term 
1430 
G33..00 Angina pectoris 
240 
G3...00 Ischaemic heart disease 
1469 
G66..00 Stroke and cerebrovascular accident unspecified 
241 
G30..00 Acute myocardial infarction 
1792 
G3...13 IHD - Ischaemic heart disease 
1517 
G73z000 Intermittent claudication 
1298 
G66..11 CVA unspecified 
1677 
G30..15 MI - acute myocardial infarction 
14658 
G30z.00 Acute myocardial infarction NOS 
10562 
G307100 Acute non-ST segment elevation myocardial infarction 
3530 
G73z.00 Peripheral vascular disease NOS 
2760 
G73zz00 Peripheral vascular disease NOS 
1344 
G340.12 Coronary artery disease 
1431 
G311.13 Unstable angina 
1676 
G3z..00 Ischaemic heart disease NOS 
11983 
G311500 Acute coronary syndrome 
3149 
G64z.00 Cerebral infarction NOS 
7347 
G311100 Unstable angina 
5943 
G73..00 Other peripheral vascular disease 
12229 
G30X000 Acute ST segment elevation myocardial infarction 
6116 
G66..13 CVA - Cerebrovascular accident unspecified 
5051 
G61..00 Intracerebral haemorrhage 
2099 
G575.00 Cardiac arrest 
6853 
G73z011 Claudication 
28554 
G33zz00 Angina pectoris NOS 
1678 
G308.00 Inferior myocardial infarction NOS 
1826 
G73..12 Ischaemia of legs 
6960 
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
4017 
G32..00 Old myocardial infarction 
1655 
G340.11 Triple vessel disease of the heart 
  
504 
 
Medcode Read code Read term 
4325 
G73yz00 Other specified peripheral vascular disease NOS 
5413 
G340.00 Coronary atherosclerosis 
1414 
G33z300 Angina on effort 
25842 
G33z.00 Angina pectoris NOS 
5602 
G64z.12 Cerebellar infarction 
12804 
G33z700 Stable angina 
5640 
G70..00 Atherosclerosis 
6253 
G66..12 Stroke unspecified 
3999 
G340000 Single coronary vessel disease 
7780 
G667.00 Left sided CVA 
4656 
G311.11 Crescendo angina 
6155 
G64..13 Stroke due to cerebral arterial occlusion 
12833 
G668.00 Right sided CVA 
569 
G64..12 Infarction - cerebral 
5254 
G340100 Double coronary vessel disease 
2491 
G30..12 Coronary thrombosis 
16517 
G640.00 Cerebral thrombosis 
3704 
G307.00 Acute subendocardial infarction 
14897 
G301z00 Anterior myocardial infarction NOS 
36523 
G311.00 Preinfarction syndrome 
9276 
G31y000 Acute coronary insufficiency 
20095 
G330.00 Angina decubitus 
20416 
G3...12 Atherosclerotic heart disease 
1318 
G700.00 Aortic atherosclerosis 
7320 
G343.00 Ischaemic cardiomyopathy 
33543 
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
5387 
G301.00 Other specified anterior myocardial infarction 
9985 
G64z200 Left sided cerebral infarction 
18604 
G61..12 Stroke due to intracerebral haemorrhage 
10504 
G64z300 Right sided cerebral infarction 
3535 
G61z.00 Intracerebral haemorrhage NOS 
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Medcode Read code Read term 
12139 
G300.00 Acute anterolateral infarction 
52517 
Gyu3.00 [X]Ischaemic heart diseases 
17307 
G311200 Angina at rest 
13564 
G613.00 Cerebellar haemorrhage 
17322 
G664.00 Cerebellar stroke syndrome 
8935 
G302.00 Acute inferolateral infarction 
23671 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
17464 
G32..12 Personal history of myocardial infarction 
8443 
G663.00 Brain stem stroke syndrome 
15019 
G641.00 Cerebral embolism 
23078 
G34y100 Chronic myocardial ischaemia 
36854 
G332.00 Coronary artery spasm 
32450 
G33z400 Ischaemic chest pain 
26424 
G64z400 Infarction of basal ganglia 
17872 
G301100 Acute anteroseptal infarction 
18889 
G34z000 Asymptomatic coronary heart disease 
9507 
G307000 Acute non-Q wave infarction 
36717 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
12986 
G331.00 Prinzmetal's angina 
8610 
G76z000 Iliac artery occlusion 
24783 
G3...11 Arteriosclerotic heart disease 
22383 
G3y..00 Other specified ischaemic heart disease 
25407 
G575.11 Cardio-respiratory arrest 
28138 
G34..00 Other chronic ischaemic heart disease 
23892 
G304.00 Posterior myocardial infarction NOS 
21195 
G575100 Sudden cardiac death, so described 
25615 
G64z000 Brainstem infarction 
30202 
G617.00 Intracerebral haemorrhage, intraventricular 
19655 
G311.14 Angina at rest 
29421 
G344.00 Silent myocardial ischaemia 
14898 
G305.00 Lateral myocardial infarction NOS 
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Medcode Read code Read term 
15661 
G310.11 Dressler's syndrome 
26863 
G33z600 New onset angina 
29643 
G303.00 Acute inferoposterior infarction 
53745 
Gyu6400 [X]Other cerebral infarction 
33499 
G665.00 Pure motor lacunar syndrome 
33899 
G575000 Cardiac arrest with successful resuscitation 
17689 
G30..17 Silent myocardial infarction 
13571 
G30..16 Thrombosis - coronary 
100 of 190 clinical codes  
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xi. Depression codes 
Medcode Read code Read term 
324 E2B..00 
Depressive disorder NEC 
655 E200300 
Anxiety with depression 
543 Eu32z11 
[X]Depression NOS 
1996 1B17.00 
Depressed 
4639 Eu32.00 
[X]Depressive episode 
1131 E204.00 
Neurotic depression reactive type 
1908 2257 
O/E - depressed 
9211 Eu32100 
[X]Moderate depressive episode 
2970 Eu32z00 
[X]Depressive episode, unspecified 
6932 E113.11 
Endogenous depression - recurrent 
5987 Eu32z14 
[X] Reactive depression NOS 
6950 E112.13 
Endogenous depression first episode 
595 E112.14 
Endogenous depression 
4323 E2B1.00 
Chronic depression 
6482 E113700 
Recurrent depression 
10610 E112.00 
Single major depressive episode 
5879 E112.11 
Agitated depression 
6874 Eu31.00 
[X]Bipolar affective disorder 
1055 E135.00 
Agitated depression 
11717 Eu32000 
[X]Mild depressive episode 
3292 Eu33.00 
[X]Recurrent depressive disorder 
11913 Eu41200 
[X]Mixed anxiety and depressive disorder 
9667 Eu32200 
[X]Severe depressive episode without psychotic symptoms 
15099 E113.00 
Recurrent major depressive episode 
3291 Eu32z12 
[X]Depressive disorder NOS 
10667 Eu32400 
[X]Mild depression 
2741 Eu30000 
[X]Hypomania 
6546 E112.12 
Endogenous depression first episode 
5726 Eu3..00 
[X]Mood - affective disorders 
16889 6657.11 
Lithium monitoring 
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Medcode Read code Read term 
2923 62T1.00 
Puerperal depression 
7953 Eu34100 
[X]Dysthymia 
9055 Eu32.11 
[X]Single episode of depressive reaction 
14709 E113200 
Recurrent major depressive episodes, moderate 
1531 Eu31.11 
[X]Manic-depressive illness 
15155 E112200 
Single major depressive episode, moderate 
29520 Eu33100 
[X]Recurrent depressive disorder, current episode moderate 
8567 E11..11 
Bipolar psychoses 
7604 Eu32.13 
[X]Single episode of reactive depression 
14784 E117.00 
Unspecified bipolar affective disorder 
16506 E112100 
Single major depressive episode, mild 
22564 6657 
On lithium 
2560 E11..12 
Depressive psychoses 
15220 Eu34114 
[X]Persistant anxiety depression 
7749 Eu41211 
[X]Mild anxiety depression 
14656 E11..00 
Affective psychoses 
12099 Eu32300 
[X]Severe depressive episode with psychotic symptoms 
1533 E290.00 
Brief depressive reaction 
8826 Eu33.15 
[X]SAD - Seasonal affective disorder 
13307 Eu53011 
[X]Postnatal depression NOS 
14728 E110100 
Single manic episode, mild 
10825 E118.00 
Seasonal affective disorder 
9183 E11z200 
Masked depression 
8902 Eu33.13 
[X]Recurrent episodes of reactive depression 
7737 Eu34113 
[X]Neurotic depression 
44300 Eu33z00 
[X]Recurrent depressive disorder, unspecified 
8851 Eu33.11 
[X]Recurrent episodes of depressive reaction 
7011 E112z00 
Single major depressive episode NOS 
22806 Eu32212 
[X]Single episode major depression w'out psychotic symptoms 
16632 E291.00 
Prolonged depressive reaction 
6854 Eu32y00 
[X]Other depressive episodes 
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Medcode Read code Read term 
12173 Eu30.00 
[X]Manic episode 
98414 Eu32700 
[X]Major depression, severe without psychotic symptoms 
25563 E113z00 
Recurrent major depressive episode NOS 
4678 Eu30z11 
[X]Mania NOS 
11548 146D.00 
H/O: manic depressive disorder 
15219 E112300 
Single major depressive episode, severe, without psychosis 
21540 Eu34000 
[X]Cyclothymia 
29784 Eu33000 
[X]Recurrent depressive disorder, current episode mild 
29342 E113100 
Recurrent major depressive episodes, mild 
33469 Eu33200 
[X]Recurr depress disorder cur epi severe without psyc sympt 
98252 Eu32600 
[X]Major depression, moderately severe 
27584 Eu31700 
[X]Bipolar affective disorder, currently in remission 
31316 E116.00 
Mixed bipolar affective disorder 
6710 Eu31.12 
[X]Manic-depressive psychosis 
2972 E2B0.00 
Postviral depression 
34390 E112000 
Single major depressive episode, unspecified 
37070 E110.00 
Manic disorder, single episode 
8584 Eu34111 
[X]Depressive neurosis 
25697 E113300 
Recurrent major depressive episodes, severe, no psychosis 
20110 E110000 
Single manic episode, unspecified 
18909 E110.11 
Hypomanic psychoses 
16808 Eu31000 
[X]Bipolar affective disorder, current episode hypomanic 
13024 Eu30100 
[X]Mania without psychotic symptoms 
11329 Eu33211 
[X]Endogenous depression without psychotic symptoms 
12831 E115.11 
Manic-depressive - now depressed 
47009 Eu33300 
[X]Recurrent depress disorder cur epi severe with psyc symp 
11596 E11y000 
Unspecified manic-depressive psychoses 
21065 Eu30200 
[X]Mania with psychotic symptoms 
9521 Eu30.11 
[X]Bipolar disorder, single manic episode 
26161 E11..13 
Manic psychoses 
33751 Eu31z00 
[X]Bipolar affective disorder, unspecified 
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Medcode Read code Read term 
19696 Eu33.12 
[X]Recurrent episodes of psychogenic depression 
22116 Eu33400 
[X]Recurrent depressive disorder, currently in remission 
24112 Eu32313 
[X]Single episode of psychotic depression 
101054 Eu32900 
[X]Single major depr ep, severe with psych, psych in remiss 
17385 E114.11 
Manic-depressive - now manic 
4677 E115.00 
Bipolar affective disorder, currently depressed 
98346 Eu32500 
[X]Major depression, mild 
3702 E114.00 
Bipolar affective disorder, currently manic 
100 of 216 clincial codes 
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xiii. Diabetes codes 
Medcode Readcode Read term 
9897 9OL..00 
Diabetes monitoring admin. 
3550 66A..00 
Diabetic monitoring 
6125 66AS.00 
Diabetic annual review 
2379 9N1Q.00 
Seen in diabetic clinic 
13194 9OL4.00 
Diabetes monitoring 1st letter 
26666 2G5E.00 
O/E - Right diabetic foot at low risk 
26667 2G5I.00 
O/E - Left diabetic foot at low risk 
758 C10F.00 
Type 2 diabetes mellitus 
711 C10..00 
Diabetes mellitus 
608 66A2.00 
Follow-up diabetic assessment 
11094 9NND.00 
Under care of diabetic foot screener 
11471 8B3l.00 
Diabetes medication review 
1684 66A4.00 
Diabetic on oral treatment 
13195 9OL5.00 
Diabetes monitoring 2nd letter 
31157 2G5F.00 
O/E - Right diabetic foot at moderate risk 
31156 2G5J.00 
O/E - Left diabetic foot at moderate risk 
18311 68A7.00 
Diabetic retinopathy screening 
13197 9OL1.00 
Attends diabetes monitoring 
101801 66At100 
Type II diabetic dietary review 
10977 66Ac.00 
Diabetic peripheral neuropathy screening 
13067 66AZ.00 
Diabetic monitoring NOS 
8836 66AR.00 
Diabetes management plan given 
2378 66AJ.00 
Diabetic - poor control 
11348 9h42.00 
Excepted from diabetes quality indicators: Informed dissent 
7563 66A3.00 
Diabetic on diet only 
12213 8BL2.00 
Patient on maximal tolerated therapy for diabetes 
12030 9OL6.00 
Diabetes monitoring 3rd letter 
1323 F420.00 
Diabetic retinopathy 
506 C100112 
Non-insulin dependent diabetes mellitus 
1549 C10E.00 
Type 1 diabetes mellitus 
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Medcode Readcode Read term 
4513 C109.00 
Non-insulin dependent diabetes mellitus 
7069 F420000 
Background diabetic retinopathy 
11433 2BBP.00 
O/E - right eye background diabetic retinopathy 
11041 9h41.00 
Excepted from diabetes qual indicators: Patient unsuitable 
13192 9OLA.00 
Diabetes monitor. check done 
11129 2BBQ.00 
O/E - left eye background diabetic retinopathy 
9974 9N1v.00 
Seen in diabetic eye clinic 
9145 9N4I.00 
DNA - Did not attend diabetic clinic 
13074 13B1.00 
Diabetic diet 
47032 8CS0.00 
Diabetes care plan agreed 
8842 66A5.00 
Diabetic on insulin 
13057 679L.00 
Health education - diabetes 
83532 66Ao.00 
Diabetes type 2 review 
10983 C11y300 
Impaired fasting glycaemia 
12675 66AQ.00 
Diabetes: shared care programme 
13071 66AI.00 
Diabetic - good control 
31171 2G5G.00 
O/E - Right diabetic foot at high risk 
31172 2G5K.00 
O/E - Left diabetic foot at high risk 
13196 66AD.00 
Fundoscopy - diabetic check 
8414 8CA4100 
Pt advised re diabetic diet 
17859 C109.12 
Type 2 diabetes mellitus 
6813 1434 
H/O: diabetes mellitus 
22823 66Ab.00 
Diabetic foot examination 
31141 9OL8.00 
Diabetes monitor.phone invite 
47144 2BBM.00 
O/E - diabetic maculopathy absent both eyes 
47011 8Hj0.00 
Referral to diabetes structured education programme 
10042 R10E.00 
[D]Impaired glucose tolerance 
1038 C100011 
Insulin dependent diabetes mellitus 
30648 9N4p.00 
Did not attend diabetic retinopathy clinic 
93854 9OLM.00 
Diabetes structured education programme declined 
50175 66AW.00 
Diabetic foot risk assessment 
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Medcode Readcode Read term 
11677 8H7r.00 
Refer to diabetic foot screener 
38078 66A9.00 
Understands diet - diabetes 
12307 66AU.00 
Diabetes care by hospital only 
31240 9OL7.00 
Diabetes monitor.verbal invite 
1789 R105712 
[D]Hyperglycaemia 
31241 9OLZ.00 
Diabetes monitoring admin.NOS 
8446 L180811 
Gestational diabetes mellitus 
6430 9NM0.00 
Attending diabetes clinic 
9958 42W..00 
Hb. A1C - diabetic control 
3837 F420400 
Diabetic maculopathy 
1647 C108.00 
Insulin dependent diabetes mellitus 
21689 13AB.00 
Diabetic lipid lowering diet 
12262 8I3X.00 
Diabetic retinopathy screening refused 
18824 8I3W.00 
Diabetic foot examination declined 
10642 ZC2C800 
Dietary advice for diabetes mellitus 
14889 C100111 
Maturity onset diabetes 
10824 9N1i.00 
Seen in diabetic foot clinic 
93657 8Hj4.00 
Referral to DESMOND diabetes structured education programme 
12247 8I6G.00 
Diabetic foot examination not indicated 
13191 9OL..11 
Diabetes clinic administration 
10791 R10D000 
[D]Impaired fasting glycaemia 
13069 66A8.00 
Has seen dietician - diabetes 
35383 9OLD.00 
Diabetic patient unsuitable for digital retinal photography 
20900 9OLA.11 
Diabetes monitored 
18167 66AT.00 
Annual diabetic blood test 
28769 66AV.00 
Diabetic on insulin and oral treatment 
93870 8Hj5.00 
Referral to XPERT diabetes structured education programme 
17236 14P3.00 
H/O: insulin therapy 
14803 C100100 
Diabetes mellitus, adult onset, no mention of complication 
10755 F420600 
Non proliferative diabetic retinopathy 
1407 C10FJ00 
Insulin treated Type 2 diabetes mellitus 
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Medcode Readcode Read term 
1682 C101.00 
Diabetes mellitus with ketoacidosis 
22130 9OL3.00 
Diabetes monitoring default 
16230 C106.00 
Diabetes mellitus with neurological manifestation 
26604 66AY.00 
Diabetic diet - good compliance 
20696 66AA.11 
Injection sites - diabetic 
52237 9360 
Patient held diabetic record issued 
19739 68A9.00 
Diabetic retinopathy screening offered 
13108 2BBX.00 
O/E - left eye diabetic maculopathy 
100 of 580 clinical codes 
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Appendix 5: NHS Research Ethics Committee (REC) and Health Research Authority (HRA) 
approval 
a. NHS REC approval 
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b. HRA Approval 
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Appendix 6: Interview guides 
a. Person with dementia and family caregiver interview guide 
General: 1. Tell me a bit about yourself? 
If not covered: 
Age: 1. If you don’t mind me asking, how old are you? 
Occupation: 1. Do you currently work? 
2. What did you used to do? 
Living 
situation: 
1. Tell me a little about where you both live?  
2. Have you lived in this house for long?  
3. Who lives with you? 
Comorbidity: 1. Do you have any health problems? Do these cause you any pain? 
2. When did this come about? How long have you had ________ for? 
Dementia 1. So you’ve mentioned memory problems, can you tell me more about this? 
2. How long have you/they experienced this?  
3. Tell me about how much this affects you?  
4. Have seen a doctor about your memory problems in the past? 
5. Have you been given a diagnosis? When was this? 
6. Do you currently see a healthcare professional about your memory 
problems? 
The current or previous experience of pain 
Iowa Pain Thermometer  
 Point to the word that best describes how bad their pain is now  
 Point to the word that best describes how bad their pain has been in the past 4 weeks 
Person with dementia Family caregiver 
Tell me about your pain 
How would you describe the pain? 
Tell me about _______’s pain 
How would you describe their pain? 
The impact of pain 
How do you think that pain affects you? 
 What kind of things do you do 
differently now? 
How do you think that pain affects 
___________? 
 What kind of things do they do 
differently now? 
Experience of pain assessment 
Tell me about how you both communicate 
about pain 
 
Tell me about how you both communicate 
about pain 
 
  
519 
 
Tell me what you do when you’re in pain or 
are uncomfortable 
 
In your opinion, can other people (e.g. 
professionals) see when you’re in pain? 
  
How you tell when they’re in pain or are 
uncomfortable? What sort of signs do you look 
for? 
 
What makes it difficult to tell if they are in pain? 
 
In your opinion, can other people (e.g. 
professionals) see when _______ is in pain? 
Do they ask you? 
Experience of pain management 
What do professionals do when you tell them 
about your pain? 
 
What do you do to help when you are in pain? 
How do you tell if they have worked? 
 
What other things help you to feel better when 
you’re in pain? 
What do professionals do when you tell them 
about _______’s pain? 
 
What do you do to help when ____ is in pain? 
How do you tell if they have worked? 
 
What do you think could have been done better 
to help with their pain/discomfort? 
 
What other things help them to feel better when 
they’re in pain? 
Healthcare and support 
Support for your pain? Support for their pain? 
 
Is there anything else you’d like to say? 
 
Before we finish, I will just check if there is anything that we have forgotten to discuss. 
 
Close the interview and thank the interviewee for their participation.  
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b. Healthcare professional interview guide 
General: So, tell me about yourself?  
If not covered: 
Occupation: What is your profession? How long have you worked as __________ for? 
What is your role in regard to pain for people with dementia? 
  
The impact of pain 
How does pain can affect a person with dementia? 
Experience of pain assessment 
Could you talk me through your typical method to assess pain in people with dementia? 
 
What factors may flag to you that a person with dementia might be experiencing pain? 
 
 Tell me about self-reported pain for patients with dementia 
 What if the person with dementia cannot communicate? 
 What things would you be looking for to indicate a person with dementia may be in 
pain? 
 How does this method differ from older populations without dementia?  
 
Any tools in use for pain assessment, and if any, for use with patients with dementia? 
 
The role of carers in the process? 
 
How comfortable/confident are you when assessing pain in people with dementia? 
 What factors increase/decrease your confidence? 
Experience of pain management 
Could you talk me though your typical response for a patient with dementia who you believe 
is experiencing pain?  
 Analgesia 
o What are the treatment options? 
o When would treatment be offered? 
o What other treatment options are available? 
o Does this differ to people without dementia? 
 Other pain management techniques?  
How do you decide which treatments to offer?  
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The role of carers in the process? 
How comfortable/confident are you when treating pain in people diagnosed with dementia? 
 What factors increase/decrease your confidence? 
Healthcare and Support 
What are the challenges for you as a practitioner?   
What things would be helpful for you, or your colleagues to support the management of pain 
in people with dementia? 
What are the challenges for services more broadly?   
 
Is there anything else you’d like to say? 
 
Before we finish, I will just check if there is anything that we have forgotten to discuss 
 
Close the interview and thank the interviewee for their participation. 
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Appendix 7: Pre-interview checklist  
 
Pre Interview Checklist 
 
Caregiver name: ___________________________ 
 
Person with dementia participating: Yes / No 
 
Person with dementia name: ___________________  
 
Location:   Home      Keele University 
  
 
Address:_____________________________________
_____________________________________________
_____________________________________________ 
Time: ______________am/pm 
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Any special requirements?* Is the person with dementia aware of 
their diagnosis? Will the person with dementia be present (if caregiver is participating 
alone)? Parking? Other? 
_____________________________________________
_____________________________________________ 
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Appendix 8: Study pack 
a. Person with dementia and family caregiver invitation letter 
 
Pain in People with Dementia Study 
Dear Sir/Madam, 
My name is Laurna Bullock and I am a PhD student at the Research Institute 
of Primary Care and Health Sciences at Keele University. I am very interested 
in understanding normal everyday aches and pains experienced by people 
with dementia (e.g. osteoarthritis, headache, back pain, knee pain), and how 
this is recognised, assessed, and treated. I would like to talk to people with 
dementia and carers of those with dementia about their experiences. This 
research will allow people with dementia and carers of people with dementia a 
voice into something that directly affects their life, with the aim to improve pain 
management and treatment for people with dementia. 
I have learned your name and contact details as you were recommended for 
the study by Approach Staffordshire, or through Join Dementia Research. 
If you are interested in taking part, you can call or email me (contact details 
are at the end of this letter). Alternatively, you can complete the contact slip 
(enclosed with this pack) and return it to me using the pre-paid envelope 
included in this pack, and I will call you back at a convenient time. During this 
conversation, we will discuss the research further, answer any questions, and 
arrange a time/place convenient to you to complete the interview (including 
your own home if you prefer). On the day of the interview, I will call 
approximately one hour before, to check that the interview can go ahead. The 
visit is likely to last approximately 60-90 minutes and will involve talking about 
the person with dementia’s pain experience. The researcher would be 
interested to chat to the carer of the person with dementia and the person 
with dementia together. This may mean that the carer agrees that the 
person with dementia would wish to take part. However, if the person with 
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dementia cannot, or does not wish to take part, the interview can be 
completed alone with the carer. The interview can be flexible to suit your 
needs. 
I have included two information leaflets (one for the carer and one for the 
person with dementia) about the study with this letter. These leaflets contain 
more information about the study to help you to decide if you would wish to 
take part.   
If you are interested in taking part or have any questions, please 
contact me.  
Yours sincerely, 
Laurna Bullock 01782 734985  /  l.bullock@keele.ac.uk
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b. Person with dementia information leaflet 
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c. Family caregiver information leaflet  
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d. Person with dementia informed consent form 
 
    
 
 
 
PIP-D Study Person with Dementia Interview Consent Form 
 
Name and contact details of Principal Investigator: 
Laurna Bullock, Research Institute for Primary Care & Health Sciences, Keele 
University, Staffordshire, ST5 5BG, 01782 734889, l.bullock@keele.ac.uk 
               Please initial 
1. I confirm that I have read and understand the information leaflet  
(version 1.1, dated 04/10/2017)............................................................................ 
 
2. I understand that my participation is voluntary, and that I am free to  
withdraw at any time.............................................................................................  
 
3. I have had the opportunity to ask questions, and have had these answered  
by the researcher.................................................................................................  
 
4. I understand that personal information I provide will be made anonymous for  
research results and will remain confidential.……………………………………..…… 
 
5. I agree to take part in an interview……………................................................... 
 
6. I agree to keep the issues discussed by the other participant confidential……………........... 
 
7. I understand that the content of the interview will be recorded and written  
up for analysis used to form our results ………………………………………...… 
 
  
 
 
 
 
Study ID Number 
 
 
 
 
 
 
 
 
  
 
8. I agree for my anonymised quotes to be used in research results (e.g.  
publications, presentations)…..……………………………………………………. 
 
9. I agree for the information that has been made anonymous to be stored and  
to be used for further analysis ……………………………..….……………………... 
 
10. I wish to receive a copy of the results when the project is completed……………….. 
 
Please sign and date on the line below: 
 
 
i. Name of Participant 
(Please Print) 
 ii. Date  iii. Signature 
 
 
 
    
iv. Name of Researcher 
(Please Print) 
 v. Date   
Signature 
 
Thank you for your help with this research study
 
 
  
 
e. Family caregiver informed consent form 
 
 
 
 
PIP-D Study Caregiver Interview Consent Form 
 
Name and contact details of Principal Investigator: 
Laurna Bullock, Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, 
ST5 5BG, 01782 734889, l.bullock@keele.ac.uk 
               Please initial 
1. I confirm that I have read and understand the information leaflet  
(version 1.0, dated 15/05/2017).............................................................................. 
 
2. I understand that my participation is voluntary, and that I am free to withdraw  
at any time............................................................................................................  
 
3. I have had the opportunity to ask questions, and have had these answered  
to my satisfaction by the researcher.......................................................................... 
 
4. I understand that personal information I provide will be made anonymous for  
research outputs and will remain confidential.………………………………………… 
 
5. I agree to take part in an interview……………................................................... 
 
6. I understand that the content of the interview will be recorded and written up  
for analysis and used to form the study results……………………………………………….. 
 
7. I agree for my anonymous quotes to be used in research results (e.g.  
publications, presentations)……………………………………………………………. 
 
8. I agree for the information that has been made anonymous to be stored and  
  
 
 
 
 
Study ID Number: 
 
 
 
 
 
 
 
 
  
 
to be used for further analysis ……………………………….……………………… 
 
9. I wish to receive a copy of the results when the project is completed……………….. 
 
If completing the interview with a relative/friend with dementia: 
10. If participating in a joint interview, I agree to keep the issues discussed by the  
other participant confidential………………................................................................... 
 
General Practitioner’s name: ________________________________________________ 
 
General Practice: __________________________________________________________ 
 
Please sign and date on the line below: 
 
 
i. Name of Participant 
(Please Print) 
 ii. Date  iii. Signature 
 
     
iv. Name of Researcher 
(Please Print) 
 v. Date   
Signature 
 
Thank you for your help with this research study 
 
 
 
 
 
  
 
f. Consultee information sheet 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
  
 
g. Consultee advice form 
                         
 
 
 
 
PIP-D Study Consultee Interview Form 
 
Name and contact details of Principal Investigator: 
Laurna Bullock, Research Institute for Primary Care & Health Sciences, Keele 
University, Staffordshire, ST5 5BG, 01782 734889, l.bullock@keele.ac.uk 
               Please initial 
1. I advise that ________ would in my view want to take part in the above  
study if they could decide……………………………………………………….……… 
 
2. I confirm that I have read and understand the information leaflet  
(version 1.1, dated 04/10/2017)................................................................................. 
 
3. ________ and I have had the opportunity to ask questions, and have had  
these answered to my satisfaction by the researcher..............................................  
 
4. I understand that the participation of the person about whom I am giving  
advice is voluntary, and that I am free to advise that they should be withdrawn  
at any time without implication to their care…………………………………………….… 
 
5. I understand that personal information provided will be made anonymous  
for research outputs and will remain confidential.………………………………………. 
 
  
 
 
 
 
 
 
Study ID Number 
 
 
 
 
 
 
  
 
6. I understand that the content of the interview will be recorded and written  
up for analysis and used to form results………………………………………………….. 
 
7. I agree to the researcher interviewing ____________………………................... 
 
8. I agree for the information that has been made anonymous to be stored and  
to be used for further analysis ………………………………….……………….……. 
 
9. I agree for anonymous quotes to be used in research results (e.g.  
publications, presentations)………………………………………………………..  
 
10. I wish to receive a copy of the results when the project is completed……………….. 
 
Please sign and date on the line below:  
 
13.1.1 Name of Participant 
(Please Print) 
 13.1.2 Date  13.1.3 Signature 
 
 
 
    
13.1.4 Name of Researcher 
(Please Print) 
 13.1.5 Date   
Signature 
 
Thank you for your help with this research study 
 
 
 
 
 
 
  
 
h. Healthcare professional invitation sheet 
  
 
i. Healthcare professional information sheet  
 
 
  
 
 
  
 
  
 
j. Healthcare professional consent form 
  
 
Appendix 9: Risk protocol 
 
 
  
 
 
  
 
 Appendix 10: Thematic analysis  
a. Overview of themes and codes 
Theme Description of theme Example codes Example quotes 
Gathering 
information to 
identify pain 
 
 
 
 
 
 
 
 
 
 
 
This theme captured the 
methods used to identify 
and assess the pain 
experienced by the 
person with dementia. 
Healthcare 
professionals and family 
caregivers gathered 
information using a 
variety of methods to 
build a picture of the 
pain experience. 
Multiple methods to 
identify pain 
“y'know... there's all sorts of things that you can pick up on.” Jenny, GP 
“I just look at the whole picture, at the whole medication, and the whole physical 
history, and just try to give provisional diagnosis of provisional reasoning, and try to 
tackle them one by one.” Rani, psychiatrist  
Narrowing approach “sometimes, you just have to sit and go through things, do blood tests, sometimes 
you have to do the x-rays, it starts with a careful history, the history mainly, and then 
a diligent examination, so you just have to be prepared for anything” Alan, GP 
“you've got an awful lot of information that actually is probably going to be 
channelling you, narrowing down your decision making” Jenny, GP 
Diagnosis by 
exclusion 
“I'm eliminating other things, like... um.... like infections, urine retention, or 
constipation, as I mentioned, before I'm thinking this is a long term pain that I 
potentially need to treat” Jessica, GP 
“you just rule out things, you- you- it's a diagnosis by exclusion” Alan, GP 
Subtheme: 
Disentangling 
the self-report of 
pain 
 
 
Health care 
professionals and family 
caregivers 
acknowledged the 
importance, yet 
sometimes difficulty of 
Communication 
implicating self-report 
“her ability to give factual information which is what the GP needs and wants is very 
poor now.” Charles, family caregiver 
“if it's kind of early dementia, they'd probably be able to give a relatively good 
history, if it's end stage dementia, y'know not so much...” Amy, GP 
“I would say that most people with mild to moderate dementia, you just treat them in 
the same way, the normal questioning, where's the pain? How severe is it? What 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
disentangling the self-
reported pain of the 
person with dementia. 
Disentangling the report 
become increasingly 
challenging as the 
condition progressed, 
and communication 
ability worsened. Some 
participants questioned 
the if self-reported pain 
reflected the experience 
of pain especially if the 
reports were 
inconsistent, or the 
person with dementia 
was perceived as ‘stoic’ 
does it stop you from doing? Etc. etc. etc... but it's- it's more the severe end that I’m 
talking about here, where it's difficult having a conversation with someone, and sort 
of answering those questions can sometimes be a tricky area...” Chris, GP 
‘Reliability’ of self-
report 
 
‘Accuracy’ of self-
report 
“there's a lot of "oh me back hurts" and "oo this hurts" and sometimes, I do wonder 
dad if it is in your mind with the greatest respect” David, caregiver 
“think it would be reliable, pretty reliable” Alan, GP 
“it is challenging to be honest to get an accurate history in patients that have 
dementia” Amy, GP 
“even if the patient will nod and say "no", you're not entirely confident that maybe 
that's accurate” Jenny, GP 
Stoicism 
 
Stoicism implicating 
self-report 
 
 
Inevitability of pain  
“As I say it's very difficult, because she very rarely admits to anything” John, 
caregiver 
Laurna: “How do you tell other people that you're in pain, Richard?” 
Richard: “I think I’m very lucky that I can put up with what pain or discomfort there is” 
“because if you don't ask if someone's got pain, they won’t necessarily tell you, they 
might just accept it” Jenny, GP 
But at the end of it, he said well I - I – I’m sorry, but there wasn't really anything 
[pause] there wasn't really anything... nothing new it was just- carry on living with it... 
sort of thing. Charles, husband family caregiver 
Inconsistency in 
reports 
“it's very difficult to judge, and the answers you will get y'know will be- could be quite 
diff- y'know different [pause] and again, there's nothing wrong with that dad, but 
that's y'know how- how things are.” David, caregiver 
“when- she's in bed, she's all glammed up, she's 90 and she's glamorous, isn't she? 
My mother, isn't she? Glammed up, nice young chap, chatting away, "I'm fine! 
Nothing the matter with me" "I hear you had a little fall?" "Did I? I don't remember?" 
Brenda, caregiver 
  
 
 
 
 
 
 
 
 
Subtheme: 
Observing 
changes 
 
“it's that inconsistent history that makes y'know the diagnosis... the assessment 
challenging.. sometimes in patients with dementia, y'know you can examine a joint, 
and they're screaming out in pain, but the joint looks fine” Amy, GP 
“I have seen patients with dementia if you ask them y'know "are you in pain?" "Oh 
yea, incredible pain" "where's it hurt?" "oh, everywhere" and actually in my 
perspective, in my clinical perspective, y'know they've not got any issues causing 
them pain” Ishann, GP 
Family caregivers and 
healthcare professionals 
observed changes 
(particularly, 
behavioural, 
psychological, and 
physical) in the person 
with dementia as a 
potential indication of 
pain. Despite 
acknowledging the link 
between behavioural 
and psychological 
symptoms and pain, 
there remained 
challenges determining 
Facial changes 
 
Behavioural changes 
 
Mood changes 
 
Change from 
“normal” 
“either ratty, or withdrawn. And just the look on her face and I know that y'know she- 
she's suffering.” John, caregiver 
“he didn't want to eat, and he wanted to lie down, he wasn't well” Carol, caregiver 
“Distress, y'know clear facial distress, um obvious things y'know like guarding a limb, 
not wanting to utilise an arm” Lisa, GP 
“if he got angry about something, or something like that, I would know- I would 
definitely know there was something wrong, because he never does that.” David, 
caregiver 
“body language cues, so they're rubbing their leg or whatever, ur... But I think a lot of 
it, and certainly as dementia progresses more I think a lot is much more non-verbal, 
urm... and just changes in pres- presentation and behaviour, urm... changes in 
appetite and sleep patterns, um... yea... agitation” Mel, psychiatrist 
“if they have dementia you can see it from facial expressions, you can see it from 
non-verbal expressions” Muhammed, GP.  
Vigilance “I'm watching Will a lot because I don't want anything to go wrong...” Carol, caregiver 
“When he goes quiet for a length of time I’m always asking if you're alright, aren't I?” 
Denise, caregiver 
  
 
the driver of this 
presentation.  
“keep an eye on things, and- I think- I think it was almost left to me… under the 
microscope... Aren't you?” Brenda, caregiver 
Changes in 
functionality  
“Do they get up to the shops, y'know? Has their daily routine changed? What 
activities can they do?” Amy, GP 
“so it's more about that- that deterioration of function rather than people presenting 
and saying "I’m in pain"” Chris, GP 
“it might be lack of engagement with activities, it might be sort of, not getting- not 
wanting to get out of bed, not wanting to get dressed, all sorts of signs really” Jenny, 
GP 
“People seem to go along steadily, and then um, it can cause a sudden decline in 
their capacity to carry out normal activities of daily living” Lisa, GP 
Link between BPSD 
and pain 
 
Recognising pain as 
a differential 
diagnosis 
 
BPSD overlooked as 
a symptom  
 
Determining the 
reason for BPSD 
“People don't consider the pain as being a cause, they just don't consider it…there's 
an old adage in medicine... if you don't think of the diagnosis, you won’t make the 
diagnosis, but you don't examine the patient diligently, and carefully, you won’t make 
the diagnosis either, and that gets missed, across the board it gets missed” Alan, GP 
“I definitely have it on my radar as one of the differential diagnoses, but I think any 
clinician would find it challenging... and always y'know there's room for 
improvement.” Amy, GP 
“BPSD can be caused by, and triggered by many things, it can be triggered by one 
thing, but maintained by another thing, or other things, y'know? So urm... usually 
these things are multifactorial, an important point is that pain should not be missed, 
and I don't think we have missed it.” Hayma, psychiatrist  
Physical observation 
 
“we wouldn't have needed to go to the loo with her before, but when she'd broke her 
foot she needed help and assistance, and that gave us the- that, it gave us the way 
  
 
Physical examination 
 
 
forward to begin to monitor... her body, her changes, and that particularly.” Brenda, 
caregiver 
“are they weeing okay, are they pooing okay? are they sort of, y'know physically 
examine someone as well, which sometimes is difficult with dementia patients, if 
they won’t allow it, or agitated” Jenny, GP 
The 
importance of 
familiarity  
This theme captures the 
importance of familiarity 
to determine the 
presence of pain for a 
person with dementia, 
and the potential lack of 
familiarity between the 
healthcare professional 
and the person with 
dementia. 
Familiarity of 
caregiver 
“If you live with somebody long enough, you're normally tuned with them, and you 
know if something is wrong or out of place... So if he goes quiet for a length of time, 
but I’m always asking if you're alright, aren't I?” Denise, caregiver 
“it's actually the carers that know, if you've been with somebody for 40 odd years, it- 
you are- you know that person inside out, y'know?” Brenda, caregiver 
Continuity of care 
 
Limited familiarity  
“I remembered her from Christmas time, when she- when she came urm... we had a 
similar problem then...” Alan, GP 
“if you know the patient before, and they seem pretty good, and suddenly they're 
not,  y'know it's about that” Chris, GP 
“that background history can vary completely, the assessment can vary completely, 
urm... and so it really is important that y'know having an allocated GP actually 
means that, and not just for your records” Amy, GP 
“there is a huge problem in terms on continuity, and I think what, y'know the old GP 
would have been able to pick up as a change in Mrs Blogs, maybe now won’t get 
noticed, so yea... so lost, isn't it?” Lisa, GP 
“If you see a different doctor each time, they don't notice” Michelle, caregiver 
  
 
“I think, in order to make that sort of assessment you really got to see the whole 
picture, rather than a snapshot [pause] which is what the health professionals get” 
Robert, caregiver 
Surrogate familiarity “You might be able to get that from the carer, or the spouse, or whoever is looking 
after that patient, and those people are in far more close contact with that patient, 
and will have a far better idea if they think they're agitated” Jenny, GP 
relatives, caregivers, would be the best source of information if the patient can't give 
it me... So finding out how they compare to their usual self, and what their ideas and 
concerns are about what would be affecting the person... Jessica, GP 
“so if they've come with someone, whoever it is, urm... who can urm, add a bit more 
picture to the story, give me a bit more, help with the examination, in terms of urm, if 
they know them best” Muhammed, GP 
“Relatives are better at picking up the changes- the subtle changes in their loved 
ones behaviour, because they're there 24/7.” Hayma, psychiatrist 
The use of pain 
assessment 
tools 
This theme captured the 
perspectives towards 
pain assessment tools, 
and their use for people 
with dementia. 
Unaware of 
behavioural 
observation scales 
“you're going to tell me that there's a dementia pain scale...” Chris, GP 
“I think if there was um... a... specific pain assessment tool of some description... 
urm... which you're probably going to tell me that there is that I don't know about” 
Lisa, GP 
Holistic assessment  “I think pain scores are available, and I think even the picture ones and things, 
depending on their level of cognition, but to be honest, I mean when I- I often go a 
lot in terms of what the carers are saying on that, and that's more how I find the most 
useful information” Ishaan, GP 
  
 
“Sometimes use the Abbey Pain Scale, that's one scale... that we sometimes use... 
urm... but in my practice, and y'know there are some, ur... visual scales, of y'know 
facial expression for example, there are some other scales available that we 
sometimes use, urm... so yea... But you tend to really go by, urm... the observations 
of carers, and the use of behaviour charts” Tom, GP 
“I don't know if it's a general doctor thing, I think my perception would be, maybe just 
anecdotal that doctors go much more on history urm, and nurses- and nursing staff 
are often very good at doing the more formalised assessments.” Mel, Psychiatrist 
Appropriateness of 
self-report scales 
“Yea, I mean, it- numbers don't really tell the story anyway do they?” John, caregiver 
“I’m not sure how effective our standard- on a scale of 1-10 are, in that sort of 
situation, because it's always a bit tricky to sort of discuss” Chris, GP 
“so we ask for the symptoms, and 1-10, y'know severity scores, and those sorts of 
things don't compute at all” Lisa, GP 
  
 
Non-drug 
management of 
pain 
Many people with 
dementia used a variety 
of non-drug treatments 
for their pain. 
Irrespective of the many 
considerations (and 
potential scepticism) 
associated with non-
drug treatments, there 
was a general support 
towards such 
approaches for pain, 
especially as a method 
to reduce 
pharmacological burden 
 
 
 
 
 
 
 
 
 
 
 
Comfort and 
relaxation for pain 
 
 
 
 
 
 
 
Positive regard for 
physiotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Rub some cream on it, or something, have a hot nice bath. Y'know, relax. Just get 
on with it.” Mary, caregiver 
“you will deal with that by measures that we have, that is putting gel on and giving 
paracetamol, hot water bottle calming her down...” Brenda, caregiver 
“I know one, that I tell you to do, and it's really good... a bowl of water, put your feet 
in” Michelle, caregiver 
“Relaxation, try to relax... We do recommend that, we do discuss it when we discuss 
the patient, what does he like to do? What makes him feel good?” Aska, psychiatrist 
“He tends to feel better when she's, urm... when she's been in a more relaxed 
state... so if she has managed to get some sleep or erm... [Pause] just be distracted 
by a simple activity” John, caregiver 
“Well, you can forget it sometimes if you're chatting, or doing something, ya know? 
You’re not worrying all of the time [pause] it's just there.” Patricia, person with 
dementia 
Laurna: “How did you find physio?” 
James: “Helped, yea… I do think that it helps. And... I won’t say [pause] it- it’s did 
enough to stop it, but it did help.” 
Laurna: “And how do you feel towards the physio?” 
Richard: “I think it has improved things...”  
“I mean I was already doing quite a few exercises, because I know I've done a lot of 
sports, so I've looked at a lot of sports physio as  well, so I know a fair few things to 
do myself without them telling me... a lot of the exercise I'm doing already, I'm doing 
them every morning.” Greg, person with dementia 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sceptical of 
alternative or 
complementary 
 
 
 
 
 
Evidence-based 
medicine 
“Physio might... I might send people for- for physio.” Alan, GP 
“you might regard them as quackery, I don't know but er... we've got erm... lavender 
oil, which I put... ur... on her forehead... and... And... What’s the other one? Oh yes, 
we've got a pot of this, erm... aloe vera cream...” John, caregiver 
Well… The reality is, unless- and there are- there are a few people who do have ur... 
reiki, is it called? To be fair these are used for better of patients...  they have 
reiki... [Hushed tone]I don't know what it is... I pretend I know what it is, but I don't... 
Alan, GP 
“I think as practitioners you have to practice evidence based medicine, so if there's 
not robust support for these things, then it's difficult...” Jenny, GP 
  
 
 
Self-management 
challenge 
“Which I wasn't very good at following was I?” James, person with dementia 
“but some of the sort of self-management problems can be a bit tricky, because they 
do need to be self-management” Chris, GP 
“Yes it can be quite challenging to tell somebody to do regular knee strengthening 
exercises” Amy, GP 
“you do wonder if they're actually going to do it, I'll be honest... it can be difficult to 
convince people, um, and I think in the elderly particularly, that if I've got arthritis I 
shouldn't be using the joint, for example, that's still out there as a, sort a myth, it can 
be quite hard to overcome.” Lisa, GP 
Lack of resources 
 
Financial burden 
“Ur... Indian head massage, I think it’s called y'know... and that just exacerbated the 
thing... she's had urm, facial massages and so on... I mean, we've thrown money at 
it.” John, caregiver 
“Well we never- we never... as doctors we can't prescribe those things, because 
they're not necessarily accessible on the NHS.” Jenny, GP 
Supportive of non-
drug 
“I would say "well try it if you want..." Alan, GP 
“guess this is not something that I back up with evidence or anything else, but my 
personal perspective I support it, I say yea, you can try it...” Ishann, GP 
“we certainly don't have a "no you can't have that" treatment approach” Jenny, GP 
“Urm... but certainly these things would not do any harm, urm, even if they're not 
evidence based, you're still encouraging urm, they may help because the evidence 
may not be there for populations, but it may help for that individual” Muhammed, GP 
  
 
Concerns 
related to 
analgesic 
medication 
This theme captured the 
number of concerns 
held by people with 
dementia, family 
caregivers, and 
healthcare professionals 
that contributed 
resistance to use 
analgesic medication  
Reluctance to use 
analgesia 
“Only as a last resort for me, I hate taking tablets at the best of times, so I've got to 
be getting pretty bad before I'll take them” Greg, person with dementia  
“I don't think pills solve anything, I think you need to go a little bit deeper and y'know, 
so I'm- [pause] I wouldn't advocate just having pills at all.” Mary, caregiver 
“You do see a lot of anxiety around tablets... from the caregivers point of view, they 
get really anxious about it” Lisa, GP 
Subtheme: 
Side effects 
People with dementia, 
family caregivers, and 
healthcare professionals 
each reflected upon the 
side effects associated 
with analgesic 
medications that are 
intensified by the 
presence and severity of 
dementia. Such 
concerns led to a 
preference for 
paracetamol, and 
caution towards NSAIDs 
and opioids. 
Side effects and 
adverse events 
 
Preference for simple 
analgesics 
 
Reluctance towards 
NSAIDs  
 
Reluctance towards 
opioids 
I mean- we manage without it... I'm not very keen on him taking a lot of pain killers, I 
think sometimes you're just adding on another problem, urm, I dare say the stuff the 
doctor could give him, but I dunno… [Sigh] you've got to be careful of some of this 
stuff. Carol, caregiver 
I think co-codamol, I will have to have a word with mum about that,  but there's 
definitely one that doesn't sort of agree, as in, the side effects and things... John, 
caregiver 
It's simple to say that... but there's a lot of adverse reaction to a lot of the analgesics 
available... um... and um... I can accept that in end of life care there's um... there's a 
lot of, there's a lot of common sense in the argument that- that you don't have to die 
of extreme pain- or you don't have to die in extreme pain... I accept that because the 
side effects etc. then aren't the issue that you're going to be bothered about... But I 
think for somebody that is expected to live, then I think you have a very different set 
of circumstances... Charles, caregiver 
“very strong pain medications have got significant side effects like, constipation and 
things like that. And we know anti-inflammatory’s can upset your stomach...” Brenda, 
caregiver 
  
 
“you've- this group of patients are particularly susceptible to... side effects of certain 
drugs so you have to be careful, so you go with a drug which is the simplest... with 
the lowest side effect profile” Alan, GP 
y'know some mild opiates, and then you think "oh god, that's going to constipate 
them", and they've probably already got constipation, or they've got some allergy to 
codeine, and then there's all this stuff, so there's no one size fits all, that's for 
certain” Lisa, GP 
Subtheme: 
Illness and 
treatment 
burden 
People with dementia 
had a number of 
conditions in addition to 
dementia and pain. 
Additionally, the person 
with dementia took 
numerous medications 
to treat their conditions. 
Each of these factors, 
again, created additional 
concerns when ‘adding 
in’ an analgesic 
medication. 
Comorbidities 
 
 
 
 
 
 
 
 
 
 
Amount of 
medications 
“He can only take paracetamol 'cause he's on warfarin he's very limited as to what 
other drugs he can take... he can't take things like ibuprofen... um... or aspirin... or 
so.” Carol, caregiver 
“and then things like y'know various groups, often with these patients there's going 
poly-pharmacy anyway, they'll have multiple comorbidities, so thinking about any 
medications that are contra-indicators urm, looking at their renal function, have they 
got any allergies” Amy, GP 
“often these people in the community with dementia are older adults, with other 
comorbidities, and then it may be vascular dementia as well, so if- if they have a 
history of heart problems, or a history of stomach ulcers, or bleeds in the gut, or if 
they have vascular dementia, we want to avoid anti-inflammatories” Jessica, GP 
“she's got... quite a lot of drugs to take so she doesn't really want extra...” John, 
caregiver 
“that's another one of my things, if you're taking medication for urm... y’know for 
memory problems, taking them- it for gout, and thing and another, suddenly have 
another load of pills thrust at you, plus y'know para- y'know even if we buy some day 
nurse they say at the counter, "are you having any paracetamol?" Goodness knows 
what all of these others things will have an effe- y'know sort of an effect, y'know 
on...” David, caregiver 
  
 
“he's on 10 tablets a day anyway, for his various conditions, so pain killers are over 
and above...” Denise, caregiver 
“do wonder sometimes, y'know we give them all for the right reasons, and guidelines 
tell us to give them all, what guidelines don't do, they don't account for multi 
morbidity, and they don't kind of say, the guideline for gout, and the guideline for 
high blood pressure, and it's all best practice, but when you put them all together, to 
tailor for the individual they're on 20 medications all of a sudden...” Chris, GP 
“the more medications we give to them, the more challenging it's going to be, the 
more likely they're going to be to fall, it's going to impair their dementia, impair their 
condition.” Ishann, GP 
Subtheme: 
Weighing up the 
concerns 
Healthcare 
professionals weighed 
up their concerns, 
“starting low and going 
slow” and trialling 
analgesic medication to 
identify the ‘most 
appropriate’ treatment 
when the options are 
perceived as limited. 
Weighing up 
 
 
 
 
 
 
 
Reaching the limit of 
treatment 
 
 
 
 
 
 
“say look, this is probably the best thing you can offer them, and there's still a risk 
associated with it, but shall we go for this, because we can't leave them like that...” 
Lisa, GP 
“you've got to balance things up, a lot of medication we use for pain is quite... bad for 
the elderly in lots of ways, so... it's risk, benefit, harm, and all the rest of it.” Jenny, 
GP 
“it's balancing the risks, do they urm... need the pain relief badly enough, urm versus 
do- how- how will this affect their dementia?” Jessica, GP 
“He can only take paracetamol 'cause he's on warfarin he's very limited as to what 
other drugs he can take... he can't take things like ibuprofen... um... or aspirin... or 
so...” Carol, caregiver 
“But at the end of it, he said well I - I – I’m sorry, but there wasn't really anything 
[pause] there wasn't really anything... nothing new it was just- carry on living with it... 
sort of thing [pause]. I can only imagine that there isn't any magic, y'know.” Robert, 
caregiver 
  
 
 
 
 
 
Starting low and 
going slow 
“you go round and round and round, so you try to keep away from- so if you look at 
it, in those terms, you're really really limited y'know can you go on to...” Alan, GP 
“So you really are... trying to tailor analgesia for somebody who's y'know... maybe 
got a million and one things that you can't give, and that can be really, you can be 
quite boxed in quite quickly” Lisa, GP 
“yea when it comes to prescribing it will be starting off at a very, very low dose, and 
then titrating, but slowly” Amy, GP 
“you always sort of go for the most straight forward, y'know lowest strength 
analgesia and work up” Ishaan, GP 
“I would be starting at the lowest possible dose, and monitoring them regularly.” 
Jessica, GP 
“you always sort of go for the most straight forward, y'know lowest strength 
analgesia and work up” Jenny, GP 
“What we want to do, is use the- is the minimum dose and minimum frequency that 
controls their pain, and it doesn't have to be completely gone, but sufficiently, that 
they're happy with that level of pain” Chris, GP 
Responsibility 
of the 
caregiver to 
manage pain 
This theme captured the 
role of caregivers to 
manage and monitor 
pain (both analgesic and 
non-drug) in the 
community for the 
person with dementia. 
This role was an 
important consideration 
Caregiver’s role to 
manage  
“She will ask me if I want to take something” Steven, person with dementia 
“I deal with the medications” Denise, caregiver 
“I mean occasionally she'll ask for a pain killer, but, ur I'm offering her pain killers 
before she asks for them” John, caregiver 
Reliance on the 
caregiver 
“so if it was somebody who for example lived with their daughter, who responded 
well to two paracetamol twice a day or three times a day, you'd leave it to that, 
because if they live with them then they- they- they- they- can do it” Alan, GP 
“If they have someone to prompt to give them the medications, you would be a bit 
more reassured” Amy, GP 
  
 
for healthcare 
professionals when 
choosing the pain 
management strategy 
for their patients with 
dementia.  
“you have to sort of, give permission for the caregiver to take on that role almost, to 
initiate those things, and maybe say "do you want some paracetamol?" "are you in 
pain?" and sort of ask, rather than... "hasn't asked for any therefore doesn't need 
any” Jenny, GP 
“it certainly influences the safety, doesn't it? If you've got no one actively monitoring 
them” Jessica, GP 
Burden of analgesic 
medication 
“people really like blister packs for that reason, because they almost feel that the 
responsibility is taken from them then, they're not the person who's going to have to 
dole it out, and get it wrong, potentially, and cause problems” Lisa, GP 
Caregiver to initiate 
non-drug treatment 
“if the caregiver is willing to do some gentle massage techniques...” Lisa, GP 
“because the carer can manage it, they can do gentle massage or warm baths, 
y'know any sort of behavioural things that can help with pain but if the carer is 
completely rung out themselves, which they often are, they haven't got the resources 
themselves to help manage so...” Mel Psychiatrist 
 
  
 
b. Final thematic map 
Final thematic map to highlight the interconnections between themes 
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Appendix 12: Comparison of community sensitivity cohort 
a. Incidence cohort 
In the methods chapter, the identification of participants in the dementia cohort and older 
adult cohort living in the community was discussed. Sensitivity analysis was conducted using 
additional, strict criteria to identify a restricted cohort of patients with a greater likelihood of 
living in the community. The application of the strict criteria allowed the sensitivity analysis to 
examine to what extent the main results reflect the restricted cohort of patients with a greater 
likelihood of living in the community. A total of n=4850 people with dementia, and n=3477 
older adults without dementia were identified using the strict criteria. Table A.1 compares the 
people with dementia, using the strict criteria included in the community sensitivity analysis 
(n=4850), to people with dementia that were not included (n=16,243). Additionally, Table A. 1 
compares the older adults using the strict criteria included in the community sensitivity 
analysis (n=3477) to older adults that were not included (n=17,616).  
  
 
Table A.1. Incidence cohort: Comparison between participants in the dementia cohort and older adult cohort in and out of the community sensitivity analysis 
 Dementia cohort (n=21,093) Older adult cohort (n=21,093) 
 Non- 
community  
Community  p Effect 
size 
Non-
community  
Community  p Effect  
size 
Total n 16,243 4850   17,616 3477   
Gender, female % (n) 59.8 (9709) 57.1 (2767) .001** V = .02 58.9 (10,372) 60.5 (2104) .07  V = .01 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.8 (138) 
13.0 (2115) 
3.6 (585) 
0.6 (93) 
81.9 (13,296) 
0.1 (24) 
 
1.3 (62) 
14.4 (699) 
3.9 (187) 
0.6 (27) 
79.8 (3870) 
0.1 (5) 
.01*  V = .03  
0.8 (142) 
12.5 (2199) 
3.4 (591) 
0.4 (65) 
82.9 (14595) 
0.1 (24) 
 
1.4 (47) 
13.8 (479) 
3.6 (126) 
0.8 (27) 
80.1 (2786) 
0.3 (12) 
<.001**  V = .04 
Year of birth Mean (SD) 1927.56 
(5.32) 
1929.84 (10.09) <.001**  g = 0.34 1928.01 (9.67) 1928.45 (9.94) .02*  g = 0.04 
Age at index  Mean (SD) 80.64 (8.06) 79.30 (8.56) <.001**  g = 0.16 80.34 (8.14) 80.28 (8.48) .71  g = 0.01 
Follow up (days) Median 
(IQR) 
624 (246, 
1205) 
564 (224, 1098.25) <.001**  g = 0.09 1255 (561, 
2321) 
1201 (532, 
2247) 
.001*  g = 0.01 
Practice IMD % (n) 
1 - Least 
2 
3 
 
15.8 (2569) 
19.2 (3120) 
21.1 (3424) 
 
16.3 (789) 
18.4 (893) 
18.6 (900) 
.003* r = .00  
15.6 (2756) 
19.5 (3435) 
21.0 (3699) 
 
17.3 (602) 
16.6 (578) 
18.0 (625) 
.003* r = .00 
  
 
4 
5 - Most 
21.4 (3482) 
22.5 (3648) 
20.2 (978) 
26.6 (1290) 
21.1 (3713) 
22.8 (4013) 
21.5 (747) 
26.6 (925) 
Morbidity (BNF) Median 
(IQR) £ 
9 (5, 15) 10 (5, 15) 0.43 g = 0.01 9 (5, 14) 9 (5, 14) .19  g = 0.03 
Consultation frequency£ 
Median (IQR) 
30 (16, 49) 30 (16, 50) 0.29  g = 0.02 25 (13, 42) 25 (12, 42) .62  g = 0.01 
CVD yes % (n) £ 7.1 (1155) 6.7 (327) .38  V= .01 5.6 (984) 5.8 (200) .70 V = .00 
Depression/bipolar yes % (n) 
£ 
7.3 (1192) 6.9 (334) .29 V= .01 2.1 (366) 2.6 (90) .06 V = .01 
Diabetes yes % (n) £ 15.2 (2470) 17.6 (852) <.001** V = .03 14.2 (2504) 14.2 (493) .96 V = 00 
Transfer out reason % (n) 
Death 
Data not entered 
Internal transfer  
New health authority 
Other 
 
36.4 (5914) 
27.7 (4494) 
8.4 (1364) 
7.5 (1215) 
20.0 (3256) 
 
29.8 (1446) 
33.3 (1613) 
7.3 (352) 
8.3 (402) 
21.4 (1037) 
<.001** V = .07  
26.8 (4713) 
59.8 (10536) 
3.0 (525) 
3.8 (663) 
6.7 (1179) 
 
26.0 (904) 
59.1 (2055) 
3.1 (107) 
4.6 (161) 
7.2 (250) 
.11 V = .02 
*p=<.05, **p=<.001  
£During the 2 years before index date 
SD Standard Deviation; CVD cardiovascular disease; IMD practice-level Indices of Multiple Deprivation; BNF British National Formulary 
Cramer’s V (V) Effect size for chi-square  
Hedges’ g (g) – Effect size for independent t-tests with different sample sizes 
Pearson’s r (r) Effect size for chi-square test for independence 
Participants identified for the community sensitivity analysis were identified on the basis of: 1) no evidence of a Read code indicative of formal care residence; 2) a family 
number frequency of equal to, or less than two, and 3) no evidence of consultation location occurring in a residential or nursing home during follow up. 
 
  
 
 
Descriptive comparison between people with dementia, using the strict criteria included in 
the community sensitivity analysis (n=4850), to people with dementia that were not included 
(n=16,243) indicated minimal, but significant differences in many characteristics. When 
exploring the effect sizes, only small effects were identified. When comparing older adults 
using the strict criteria included in the community sensitivity analysis (n=3477) to older adults 
that were not included (n=17,616) similar, significant differences were evident, however with 
a small effect size. These comparisons suggest marginal differences between the 
characteristics between people with dementia and older adults identified for the community 
sensitivity analyses, and those not.   
People with dementia (n=4850) and older adults (n=4850) identified using the strict 
“community” criteria were used as a sensitivity analysis to examine the potential impact on 
the incidence of musculoskeletal consultation.
  
 
b. Prevalence cohort 
Similarly to the incidence cohort (see above), sensitivity analysis was conducted using 
additional, strict criteria to identify a restricted cohort of patients with a greater likelihood of 
living in the community. A total of n=8875 people with dementia, and n=8349 older adults 
without dementia were identified using the strict criteria. Table A.2 compares the people with 
dementia, using the strict criteria included in the community sensitivity analysis (n=8875), to 
people with dementia that were not included (n=27,707). Additionally, Table A.2 compares 
the older adults using the strict criteria included in the community sensitivity analysis 
(n=8349) to older adults that were not included (n=28,233).  
  
 
Table A.2. Prevalence cohort: Comparison between participants in the dementia cohort and older adult cohort in and out of the 
community sensitivity analysis 
 Dementia cohort (n=36,582) Older adult cohort (n=36,582) 
 Non-
community 
Community  p Effect 
size 
Non- 
community  
Community p Effect 
size 
Total n 27,707 8875   28,233 8349   
Gender, female % (n) 60.4 (16,736) 57.7 (5124) <.001** V = .02 59.9 (16,912) 59.3 (4948) .30 V = .01 
Marital status % (n) 
Single 
Married  
Widowed 
Divorced 
Unknown 
Other 
 
0.8 (221) 
13.5 (3751) 
3.5 (975) 
0.5 (150) 
81.5 (22580) 
0.1 (30) 
 
1.2 (109) 
15.3 (15.3) 
3.6 (322) 
0.8 (74) 
78.8 (6996) 
0.2 (14) 
<.001** V = .05  
0.8 (223) 
13.0 (3668) 
3.4 (951) 
0.4 (103) 
82.3 (23247) 
0.1 (41) 
 
1.2 (103) 
14.9 (1244) 
3.6 (297) 
0.9 (71) 
79.1 (6604) 
0.4 (30) 
<.001** V = .05 
Year of birth  
Mean (SD) 
1928.07 (9.59) 1930.81 
(10.18) 
<.001**  
 
g = .28 1928.32 
(9.62) 
1930.14 (10.29) <.001**  
 
g = .19 
Age at index  
Mean (SD) 
80.33 (8.10) 78.72 (8.65) <.001**  
 
g = .20 80.17 (8.1) 79.16 (8.74) <.001**  
 
g = .12 
Follow up (days)  
Median (IQR)  
636 (256, 
1219) 
576 (232, 
1102) 
<.001**  g = .09 1259 (567, 
2306) 
1105 (500, 2050) <.001**  g = .13 
Morbidity (BNF) Median 
(IQR) £ 
10 (6, 16) 11 (6, 16) .001** g = .03 10 (6, 15) 10 (6, 15) .31 g = .05 
Consultation freq Median 
(IQR) £ 
33 (19, 55) 28 (15, 46) .02* g = .03 28 (15, 47) 34 (19, 56) .37 g = .02 
  
 
CVD yes % (n) £ 7.6 (2097) 6.9 (608) .03 V = .01 6.1 (1724) 5.6 (470) .11 V = .01 
Depression/bipolar yes % 
(n) £ 
8.2 (2264) 7.9 (698) .36 V = .01 2.6 (746) 2.6 (219) .92 V = .001 
Diabetes yes % (n) £ 16.0 (4427) 19 (1688) <.001** V = .04 14.7 (4147) 15.7 (1312) .02* V = .01 
Practice IMD % (n) 
1 - Least 
2 
3 
4 
5 - Most 
 
16.1 (4465) 
19.6 (5423) 
20.1 (5572) 
21.2 (5883) 
23.0 (6364) 
 
16.8 (1493) 
17.9 (1587) 
19.0 (1687) 
21.0 (1860) 
25.3 (2248) 
.006* r = .00  
16.1 (4512) 
19.4 (5473) 
20.4 (5750) 
21.0 (5937) 
23.1 (6531) 
 
17.0 (1416) 
18.4 (1537) 
18.1 (1509) 
21.6 (1806) 
24.9 (2081) 
.05 r = .00 
Transfer out reason % (n) 
Death 
Data not entered 
Internal transfer  
Removal to new health 
authority 
Other 
 
26.9 (2391) 
37.2 (3301) 
7.1 (626) 
16.8 (1491) 
8.1 (715) 
4.0 (351) 
 
35.1 (9719) 
29.8 (8270) 
7.9 (2192) 
16.6 (4606) 
7.3 (2011) 
3.3 (909) 
<.001** V = .09  
25.6 (7239) 
61.3 (17311) 
2.9 (815) 
5.1 (1433) 
3.8 (1063) 
1.3 (372) 
 
22.2 (1851) 
63.9 (5333) 
3.1 (256) 
4.6 (385) 
4.2 (350) 
2.1 (174) 
<.001** V = .04 
*p=<.05, **p=<.001  
£During the 2 years before index date 
SD Standard Deviation; CVD cardiovascular disease; IMD practice-level Indices of Multiple Deprivation; BNF British National Formulary 
Cramer’s V (V) Effect size for chi-square  
Hedges’ g (g) – Effect size for independent t-tests with different sample sizes 
Pearson’s r (r) Effect size for chi-square test for independence 
Participants identified for the community sensitivity analysis were identified on the basis of: 1) no evidence of a Read code indicative of formal care 
residence; 2) a family number frequency of equal to, or less than two, and 3) no evidence of consultation location occurring in a formal residence during 
follow up. 
 
  
 
Descriptive comparison between people with dementia, using the strict criteria included in 
the community sensitivity analysis (n=8875), to people with dementia that were not included 
(n=27,707) indicated minimal, but significant difference in many characteristics. However, 
when exploring the effect sizes, only small effects were identified. When comparing older 
adults using the strict criteria included in the community sensitivity analysis (n=8349) to older 
adults that were not included (n=28,233) similar, significant differences were evident, 
however with a small effect size. These comparisons suggest marginal differences in the 
characteristics between people with dementia and older adults identified for the community 
sensitivity analyses, and those not.   
People with dementia (n=8875) and older adults (n=8349) identified using the strict 
“community” criteria were used as a sensitivity analysis to examine the potential impact on 
the prevalence of musculoskeletal consultation and analgesic prescription. 
 
 
 
  
 
Appendix 13: Sensitivity analysis 
a. Proportional Hazards Models: Not stratified by matched-pairs 
Table A.3: Univariate and multivariable Cox Regression to examine the association 
between cohort status (dementia cohort and older adult cohort) for incident musculoskeletal 
consultation 
Univariate Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.35 (.02)** .68 .70 .73 
Model χ 2(1) = 437.88, p=<.001.  
*p<.05, **p<.001 
 
Multivariable Cox Proportional Hazards Model 
Covariate  B (SE) 95% CI for Adjusted Hazard Ratio 
  Lower Hazard 
Ratio 
Upper 
Cohort (dementia cohort=1) -.37 (.02)** .67 .69 .72 
Gender (female=1) .12 (.02)** 1.10 1.13 1.17 
IMD 1 – Least deprived - - - - 
2 -.07 (.03)* .88 .93 .98 
3 -.16 (.03)** .81 .86 .90 
4 -.10 (.03)** .86 .90 .95 
5 – Most deprived -.13 (.03)** .84 .88 .93 
CVD (yes=1) .04 (.03) .97 1.04 1.11 
Depression (yes=1) .06 (.04) .98 1.06 1.14 
Diabetes (yes=1) -.19 (.03)** .79 .83 .87 
BNF frequency£  .03 (.00)** 1.02 1.03 1.03 
Follow up (days)£ .00 (.00)** 1.00 1.00 1.00 
Year of index date£ -.01 (.00)** .99 1.00 1.00 
Consultation frequency£ .00 (.00)** 1.00 1.00 1.01 
Age at index date£ -.01 (.00)** .99 .99 .99 
Model χ2(14) = 1540.47, p=<.001.  
*p<.05, **p<.001 
£Continuous covariates 
Categorical reference categories = 0 
 
  
 
b. Conditional logistic regression sensitivity: Association between dementia and 
musculoskeletal consultation 
i. Community sensitivity analysis (Table A.4) 
ii. Healthy cohort sensitivity analysis 
iii. Logistic regression analysis (Table A.5) 
 
 
  
  
 
i. Community sensitivity analysis: Conditional logistic regression to examine the 
association between dementia cohort and musculoskeletal consultation 
 
Table A.4. Crude and adjusted odds ratio (OR) stratified into year time periods: 
Community sensitivity  
Time (yrs) OR (95% CI) Adjusted OR (95% CI) 
0 to 5 .78 (.59 to 1.03) .72 (.53 to .98) 
0 to 1 .83 (.73 to .94) .86 (.74 to .99) 
1 to 2 .77 (.65 to .92) .73 (.60 to .90) 
2 to 3 .65 (.52 to .83) .61 (.46 to .80) 
3 to 4 .59 (.43 to .82) .56 (.39 to .81) 
4 to 5 .49 (.32 to .77) .44 (.26 to .73) 
0 is index date; dementia diagnosis or equivalent for older adults.  
Multivariable model adjusted for: evidence of cardiovascular-related conditions, diabetes, 
depression, morbidity (BNF), follow up (days), and consultation frequency 
  
 
ii. Healthy cohort sensitivity analysis: Conditional logistic regression to examine the 
Association between dementia cohort and musculoskeletal consultation (index date 
to five years after index date). 
Univariate analysis: 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-
square df Sig. 
Chi-
square df Sig. 
Chi-
square df Sig. 
8847.971 11.833 1 .001 11.837 1 .001 11.837 1 .001 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
casecontrol -.086 .025 11.826 1 .001 .917 .874 .964 
 
Multivariable analysis: 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-
square df Sig. 
Chi-
square df Sig. 
Chi-
square df Sig. 
8319.169 520.005 11 .000 540.638 11 .000 540.638 11 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equationb 
 B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
casecontrol -.120 .029 16.858 1 .000 .887 .837 .939 
CVD_covariate .104 .073 2.039 1 .153 1.109 .962 1.279 
depression_covariate .013 .075 .030 1 .863 1.013 .875 1.173 
diabetes_covariate .147 .054 7.506 1 .006 1.159 1.043 1.287 
splitBNF   455.779 4 .000    
splitBNF(1) -1.292 .066 382.703 1 .000 .275 .241 .313 
splitBNF(2) -.659 .062 113.201 1 .000 .517 .458 .584 
splitBNF(3) -.426 .058 54.480 1 .000 .653 .583 .731 
splitBNF(4) -.145 .058 6.166 1 .013 .865 .772 .970 
followupsplit   2.451 2 .294    
followupsplit(1) -.057 .072 .641 1 .423 .944 .820 1.087 
  
 
followupsplit(2) .047 .054 .744 1 .388 1.048 .942 1.165 
yearofdiagnosissplit   . 0a .    
Consultationfrequ .000 .001 .165 1 .685 1.000 .999 1.001 
IMD   . 0a .    
gender   . 0a .    
agesplit   . 0a .    
a. Degree of freedom reduced because of constant or linearly dependent covariates 
b. Constant or Linearly Dependent Covariates S = Stratum effect. yearofdiagnosissplit(1) = .0477 + S ;  
yearofdiagnosissplit(2) = .0857 + S ;  yearofdiagnosissplit(3) = .1682 + S ;  yearofdiagnosissplit(4) = .2196 + S ;  
yearofdiagnosissplit(5) = .2634 + S ;  yearofdiagnosissplit(6) = .1948 + S ;  IMD(1) = .1668 + S ;  IMD(2) = .1963 
+ S ;  IMD(3) = .1814 + S ;  IMD(4) = .2085 + S ;  gender = .3564 + S ;  agesplit(1) = .028 + S ;  agesplit(2) = 
.1043 + S ;  agesplit(3) = .3931 + S ;  agesplit(4) = .4216 + S ; 
 
 
  
 
iii. Logistic Regression analysis  
Table A.5. Crude and adjusted odds ratio (OR) stratified into year time periods: Logistic 
regression sensitivity analysis 
Time 
(yrs) 
Dementia cohort 
prevalence 
Older adult cohort 
prevalence 
OR (95% CI) Adjusted OR 
(95% CI) 
0 to 5 58.54% 70.76% .58 (.54 to .63) .54 (.50 to .59) 
0 to 1 24.46% 30.79% .73 (.70 to .76) .72 (.69 to .75) 
1 to 2 22.26% 30.55% .65 (.62 to .68) .66 (.63 to .69) 
2 to 3 19.94% 30.56% .57 (.54 to .60) .58 (.54 to .61) 
3 to 4 19.27% 31.71% .51 (48 to .55) .53 (.49 to .56) 
4 to 5 19.52% 31.04% .54 (.49 to .59) .53 (.48 to .58) 
0 is index date; dementia diagnosis or equivalent for older adults.  
Predictor: Dementia cohort vs. older adult cohort 
Outcome: Musculoskeletal consultation: yes/no 
Multivariable models adjusted for: gender, deprivation (IMD), evidence of cardiovascular-related 
conditions, diabetes, depression, age at index, morbidity (BNF), follow up, year of index date, and 
consultation frequency 
*Consultation frequency entered as a continuous covariate. All other covariates were categorical. 
  
 
c. Annual prevalence of analgesic prescription stratified by pre-index date analgesic prescription for each analgesic classification 
 
Table A.6: No analgesic during the one year before index date 
 Any  
% (95% CI) 
Basic 
% (95% CI) 
Weak 
% (95% CI) 
Moderate 
% (95% CI) 
Strong 
% (95% CI) 
Very strong 
% (95% CI) 
NSAID 
% (95% CI) 
0-1  
Dementia cohort 10.15  
(9.68 to 10.71) 
6.84 
(6.39 to 7.31) 
2.66 
(2.39 to 2.97) 
0.95 
(0.79 to 1.14) 
1.29 
(1.10 to 1.51) 
0.10 
(0.06 to 0.18) 
1.83 
(1.61 to 2.09) 
Older adult 
cohort 
12.56 
(12.02 to 13.11) 
7.17 
(6.76 to 7.61) 
3.17 
(2.89 to 3.47) 
1.39 
(1.21 to 1.60) 
2.04 
(1.82 to 2.28) 
0.10 
(0.06 to 0.17) 
3.08 
(2.81 to 3.38) 
1 – 2 
Dementia 
cohort 
11.04  
(10.36 to 11.75) 
7.76 
(7.19 to 8.37) 
2.73 
(2.39 to 3.11) 
1.16 
(0.95 to 1.42) 
1.29 
(1.06 to 1.56) 
0.09 
(0.04 to 0.18) 
1.71 
(1.44 to 2.02) 
Older adult 
cohort 
13.52 
(12.91 to 14.15) 
7.82 
(7.35 to 8.33) 
3.46 
(3.14 to 3.81) 
1.45 
(1.25 to 1.69) 
2.69 
(2.41 to 3.00) 
0.16 
(0.10 to 0.26) 
3.49 
(3.17 to 3.83) 
2 – 3 
Dementia 
cohort 
11.05  
(10.22 to 11.93) 
7.86 
(7.16 to 8.62) 
3.17 
(2.73 to 3.69) 
1.22 
(0.95 to 1.56) 
1.35 
(1.07 to 1.71) 
0.12 
(0.05 to 0.25) 
1.65 
(1.33 to 2.03) 
Older adult 
cohort 
14.58 
(13.88 to 15.31) 
8.42 
(7.87 to 8.99) 
3.97 
(3.60 to 4.38) 
1.50 
(1.28 to 1.77) 
2.46 
(2.16 to 2.79) 
0.17 
(0.10 to 0.28) 
3.46 
(3.11 to 3.85) 
3 – 4  
Dementia 
cohort 
9.96  
(8.98 to 11.03) 
7.03 
(6.20 to 7.95) 
2.66 
(2.16 to 3.27) 
0.95 
(0.67 to 1.34) 
1.89 
(1.48 to 2.42) 
0.06 
(0.02 to 0.22) 
1.68 
(1.29 to 2.18) 
  
 
Older adult 
cohort 
15.58 
(14.78 to 16.42) 
9.74 
(9.09 to 10.43) 
4.32 
(3.89 to 4.80) 
1.81 
(1.53 to 2.14) 
2.68 
(2.34 to 3.07) 
0.19 
(0.11 to 0.31) 
3.38 
(3.00 to 3.82) 
4 – 5   
Dementia 
cohort 
11.69  
(10.34 to 13.19) 
8.05 
(6.92 to 9.34) 
2.77 
(2.13 to 3.59) 
1.54 
(1.08 to 2.19) 
1.49 
(1.04 to 2.13) 
0.21 
(0.08 to 0.53) 
2.00 
(1.47 to 2.72) 
Older adult 
cohort 
16.12 
(15.21 to 17.08) 
10.46 
(9.71 to 11.26) 
4.28 
(3.79 to 4.82) 
1.69 
(1.39 to 2.05) 
3.36 
(2.93 to 3.85) 
0.20 
(0.11 to 0.35) 
3.43 
(2.99 to 3.92) 
CI Confidence Interval  
  
 
Table A.7: Any analgesic during the one year before index date 
 Any  
% (95% CI) 
Basic 
% (95% CI) 
Weak 
% (95% CI) 
Moderate 
% (95% CI) 
Strong 
% (95% CI) 
Very strong 
% (95% CI) 
NSAID 
% (95% CI) 
0-1  
Dementia cohort 31.22 
(30.41 to 32.03) 
22.08 
(21.37 to 22.82) 
8.75 
(8.27 to 9.26) 
4.80 
(4.44 to 5.19) 
8.45 
(7.98 to 8.95) 
1.11 
(0.94 to 1.30) 
5.47 
(5.09 to 5.88) 
Older adult 
cohort 
36.79 
(36.05 to 37.53) 
24.56 
(23.90 to 25.23) 
11.07 
(10.59 to 11.56) 
6.51 
(6.14 to 6.90) 
11.07 
(10.59 to 11.56) 
1.13 
(0.97 to 1.30) 
9.00 
(8.56 to 9.45) 
1 – 2 
Dementia cohort 26.19 
(25.25 to 27.15) 
18.72 
(17.90 to 19.58) 
7.15 
(6.62 to 7.73) 
4.07 
(3.66 to 4.51) 
7.68 
(7.13 to 8.28) 
0.99 
(0.80 to 1.23) 
4.39 
(3.97 to 4.86) 
Older adult 
cohort 
35.58 
(34.76 to 36.40) 
23.99 
(23.27 to 24.73) 
11.02 
(10.50 to 11.57) 
6.14 
(5.74 to 6.56) 
10.78 
(10.26 to 11.32) 
1.33 
(1.15 to 1.54) 
8.21 
(7.76 to 8.70) 
2 - 3 
Dementia cohort 22.62 
(21.49 to 23.78) 
16.15 
(15.17 to 17.18) 
6.04 
(5.42 to 6.73) 
3.32 
(2.87 to 3.85) 
6.35 
(5.72 to 7.05) 
1.09 
(0.84 to 1.41) 
3.65 
(3.17 to 4.20) 
Older adult 
cohort 
35.27 
(34.35 to 36.19) 
24.27 
(23.46 to 25.10) 
10.82 
(10.24 to 11.43) 
6.03 
(5.59 to 6.50) 
10.67 
(10.09 to 11.28) 
1.13 
(0.95 to 1.36) 
7.49 
(7.00 to 8.01) 
3 – 4  
Dementia cohort 21.48 
(20.09 to 22.93) 
15.35 
(14.14 to 16.64) 
6.00 
(5.23 to 6.88) 
3.38 
(2.80 to 4.06) 
6.78 
(5.96 to 7.71) 
1.00 
(0.71 to 1.41) 
3.59 
(3.00 to 4.30) 
Older adult 
cohort 
36.22 
(35.18 to 37.27) 
24.89 
(23.96 to 25.84) 
11.44 
(10.76 to 12.15) 
6.04 
(5.54 to 6.58) 
11.13 
(10.46 to 11.83) 
1.12 
(0.92 to 1.38) 
7.65 
(7.09 to 8.25) 
  
 
4 – 5   
Dementia cohort 21.78 
(20.00 to 23.67) 
15.09 
(13.56 to 16.75) 
6.33 
(5.33 to 7.51) 
3.71 
(2.95 to 4.64) 
6.44 
(5.43 to 7.62) 
0.88 
(0.55 to 1.40) 
4.12 
(3.32 to 5.10) 
Older adult 
cohort 
35.70 
(34.53 to 36.89) 
25.23 
(24.17 to 26.31) 
11.35 
(10.59 to 12.16) 
5.66 
(5.12 to 6.26) 
11.02 
(10.27 to 11.81) 
1.19 
(0.95 to 1.49) 
7.11 
(6.50 to 7.77) 
CI Confidence Interval
  
 
d. Conditional logistic regression sensitivity: Association between dementia and 
analgesic prescription 
i) Community sensitivity analysis (Table A.8) 
ii) Healthy cohort sensitivity analysis (Table A.9) 
iii) All analgesic prescriptions sensitivity analysis (Table A.10) 
iv) Logistic regression sensitivity analysis (Table A.11)
  
 
i. Community sensitivity analysis 
Table A.8. Community sensitivity analysis: Conditional logistic regression  
 0 - 1 1 - 2 2 - 3 3 - 4 4 - 5 0 – 5 
Analgesic category OR (95% CI) 
Any analgesic  .88 (.76 to 1.01) .79 (.65 to .95) .60 (.46 to .78) .56 (.39 to .80) .47 (.29 to .76) .78 (.58 to 1.06) 
Basic analgesic .91 (.77 to 1.08) .83 (.66 to 1.04) .67 (.49 to .92) .58 (.37 to .92) .52 (.28 to .94) .77 (.54 to 1.10) 
Weak analgesic .93 (.71 to 1.21) .76 (.53 to 1.09) .50 (.30 to .84) .40 (.19 to .83) .64 (.25 to 1.64) .74 (.46 to 1.17) 
Moderate analgesic .88 (.60 to 1.28) 1.03 (.63 to 1.68) .64 (.28 to 1.49) .53 (.22 to 1.35) .29 (.06 to 1.38) .68 (.34 to 1.39) 
Strong analgesic .71 (.54 to .92) .56 (.40 to .82) .70 (.43 to 1.16) .63 (.31 to 1.30) .82 (.34 to 1.97) .66 (.39 to 1.11) 
Very strong analgesic  1.67 (.82 to 3.41) 2.00 (.50 to 8.00) 4.00 (.85 to 18.84) .50 (.13 to 2.00) .33 (.04 to 3.21) .83 (.25 to 2.73) 
NSAID .71 (.53 to .96) .58 (.37 to .90) .36 (.19 to .68) .39 (.18 to .85) .33 (.13 to .84) .62 (.38 to 1.01) 
Predictor: Dementia cohort vs. older adult cohort 
Outcome: Analgesic category: yes/no 
Multivariable model could not be computed due to the small numbers in each cell  
 
 
  
 
ii. Healthy cohort sensitivity analysis 
Table A.9. Healthy cohort sensitivity analysis: from index date to five years after index 
date 
Analgesic category OR (95% CI) Adjusted OR (95% CI) 
Any analgesic  .77 (.74 to .80) .81 (.77 to .84) 
Basic analgesic .83 (.77 to .84) .85 (.81 to .89) 
Weak analgesic .68 (.64 to 72) .73 (.67 to .78) 
Moderate analgesic .69 (.64 to .76) .71 (.64 to .79) 
Strong analgesic .63 (.59 to .67) .60 (.56 to .66) 
Very strong analgesic  .77 (.64 to .93) .70 (.55 to .91) 
NSAID .54 (.50 to .58) .58 (.53 to .64) 
Predictor: Dementia cohort vs. older adult cohort 
Outcome: Analgesic category: yes/no 
Multivariable models adjusted for: evidence of cardiovascular-related conditions, evidence of 
diabetes, evidence of depression, morbidity (BNF), follow up (days), consultation frequency 
 
 
 
 
  
 
iii. All analgesic prescriptions: not matched to a musculoskeletal consultation 
Table A.10. All analgesic prescriptions (not matched to a musculoskeletal consultation): Conditional logistic regression sensitivity analysis 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
Any Analgesic Classification 
OR (95% CI) 97 (.94 to .99) .94 (.92 to .98) .94 (.90 to .98) .91 (.86 to .96) .91 (.85 to .98) .98 (.93 to 1.05) 
Adj OR (95% CI) .96 (.93 to .99) .93 (.90 to .97) .92 (.88 to .96) .90 (.85 to .96) .89 (.83 to .97) .97 (.91 to 1.03) 
Basic Analgesic 
OR (95% CI) 1.06 (1.03 to 
1.09) 
1.05 (1.01 to 
1.09) 
1.05 (1.00 to 
1.11) 
1.03 (.96 to 1.10) .97 (.89 to 1.05) 1.05 (.99 to 1.13) 
Adj OR (95% CI) 1.05 (1.02 to 
1.09) 
1.03 (.98 to 1.08) 1.04 (.98 to 1.11) 1.01 (.93 to 1.09) .95 (.87 to 1.05) 1.03 (.96 to 1.11) 
Weak Analgesic 
OR (95% CI) .91 (.86 to .95) .87 (.81 to .92) .85 (.78 to .92) .72 (.64 to .80) .72 (.63 to .84) .88 (.81 to .97) 
Adj OR (95% CI) .90 (.85 to .96) .87 (.80 to .93) .85 (.77 to .93) .77 (.68 to .88) .73 (.62 to .85) .86 (.78 to .95) 
Moderate Analgesic 
OR (95% CI) .86 (.80 to .92) .81 (.74 to 89) .84 (.74 to .94) .73 (.63 to .85) .84 (.69 to 1.03) .79 (.70 to .89) 
Adj OR (95% CI) .86 (80 to .94) .78 (.70 to .87) .82 (.71 to .94) .72 (.60 to .85) .77 (.61 to .97) .74 (.65 to .85) 
Strong Analgesic 
OR (95% CI) .84 (.80 to .89) .76 (.71 to .81) .73 (.67 to .80) .72 (.64 to .81) .71 (.61 to 83) .77 (.70 to .86) 
Adj OR (95% CI) .77 (.72 to .82) .71 (.65 to .77) .64 (.58 to .72) .65 (.57 to .74) .61 (.51 to .73) .70 (.62 to .78) 
Very Strong Analgesic 
  
 
OR (95% CI) 1.00 (.85 to 1.17) 1.03 (.84 to 1.26) 1.14 (.88 to 1.47) .83 (.60 to 1.16) .93 (.61 to 1.43) .84 (.63 to 1.13) 
Adj OR (95% CI) .78 (.63 to .97) .91 (.70 to 1.18) .94 (.66 to 1.34) .75 (.49 to 1.13) 1.03 (.55 to 1.94) .83 (.57 to 1.22) 
NSAIDs 
OR (95% CI) .64 (.60 to .68) .56 (.54 to .64) .54 (.48 to .60) .54 (.46 to .62) .64 (.53 to .78) .68 (.61 to .76) 
Adj OR (95% CI) .66 (.62 to .71) .59 (.54 to .65) .54 (.48 to .61) .57 (.48 to .67) .61 (.80 to .76) .68 (.61 to .76) 
Predictor: Dementia cohort vs. older adult cohort. Outcome: Analgesic category: yes/no. 
Multivariable models adjusted for: evidence of cardiovascular-related conditions, evidence of diabetes, evidence of depression, morbidity (BNF), follow up 
(days), consultation frequency.  
Consultation frequency entered as a continuous covariate. All other covariates were categorical. 
  
  
  
 
iv. Logistic regression analysis 
Table A.11 Association between dementia cohort/older adult cohort and analgesic prescription, stratified by analgesic potency and time 
period from index date: Logistic regression (rather than conditional) sensitivity analysis 
 0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 0 to 5 
Any Analgesic Classification 
OR (95% CI) .78 (.75 to .81) .69 (.65 to .72) .59 (.56 to .63) .52 (.48 to .56) .57 (.51 to .62) .64 (.60 to .69) 
Adj OR (95% CI) .74 (.71 to .77) .65 (.62 to .69) .57 (.54 to .61) .50 (.47 to .55) .54 (.49 to .59) .59 (.55 to .64) 
Basic Analgesic 
OR (95% CI) .88 (.84 to .92) .89 (.75 to .83) .68 (.63 to .73) .59 (.54 to .64) .59 (.53 to .66) .73 (.67 to .78) 
Adj OR (95% CI) .84 (.80 to .88) .75 (.71 to .80) .65 (.60 to .70) .57 (.52 to .63) .56 (.50 to .63) .70 (.65 to .76) 
Weak Analgesic 
OR (95% CI) .78 (.73 to .83) .65 (.60 to .71) .59 (.53 to .66) .52 (.45 to .59) .56 (.47 to .65) .67 (.61 to .74) 
Adj OR (95% CI) .76 (.71 to .81) .64 (.59 to .70) .59 (.53 to .66) .52 (.46 to .60) .56 (.47 to .66) .66 (.60 to .72) 
Moderate Analgesic 
OR (95% CI) .71 (.64 to .78) .66 (.59 to .75) .58 (.50 to .67) .53 (.44 to .64) .70 (.56 to .87) .67 (.59 to .76) 
Adj OR (95% CI) .69 (.63 to .76) .66 (.58 to .74) .57 (.49 to .66) .53 (.44 to .64) .69 (.55 to .86) .67 (.59 to .76) 
Strong Analgesic 
OR (95% CI) .72 (.67 to .77) .64 (.58 to .70) .55 (.49 to .62) .59 (.52 to .68) .52 (.44 to .63) .67 (.60 to .74) 
Adj OR (95% CI) .64 (.59 to .69) .59 (.54 to .65) .51 (.45 to .58) .55 (.48 to .64) .48 (.40 to .57) .57 (.52 to .64) 
Very Strong Analgesic 
OR (95% CI) .96 (.78 to 1.19) .71 (.55 to .91) .89 (.66 to 1.20) .78 (.53 to 1.15) .76 (.47 to 1.23) .83 (.63 to 1.10) 
Adj OR (95% CI) .80 (.65 to 1.00) .63 (.49 to .82) .81 (.60 to 1.11) .74 (.50 to 1.09) .69 (.42 to 1.13) .69 (.52 to .93) 
  
 
NSAIDs 
OR (95% CI) .58 (.54 to .63) .50 (.45 to .55) .46 (.40 to .53) .46 (.39 to .54) .56 (.46 to .69) .59 (.54 to .66) 
Adj OR (95% CI) .55 (.50 to .59) .50 (.45 to .55) .47 (.41 to .54) .46 (.39 to .55) .56 (.46 to .69) .54 (.49 to .61) 
OR Odds Ratio; Adj OR Adjusted Odds Ratio; NSAID Non-Steroidal Anti-Inflammatory Drugs; CI confidence interval 
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